{
  "dataset": "ist3",
  "total_mechanisms_analyzed": 33,
  "total_abstracts_retrieved": 453,
  "overall_support_count": 11,
  "overall_conflict_count": 14,
  "overall_neutral_count": 428,
  "mechanism_results": [
    {
      "feature_name": "gender",
      "mechanism": {
        "mechanism_type": "biological",
        "description": "Estrogen is known to have protective vascular effects, promoting repair and remodeling of damaged cerebral vessels, which might enhance recovery post-thrombolysis.",
        "evidence_level": "moderate"
      },
      "query": "(stroke OR alteplase OR thrombolysis OR \"ischemic stroke\") AND \"gender\" AND (\"pathophysiology\" OR \"mechanism\" OR \"causal\" OR \"etiology\" OR \"interaction\") AND (\"thrombolysis\" OR \"remodeling\" OR \"protective\") AND (Clinical Trial[PT] OR Review[PT] OR Meta-Analysis[PT])",
      "total_abstracts": 20,
      "support_count": 0,
      "conflict_count": 0,
      "neutral_count": 20,
      "support_percentage": 0.0,
      "conflict_percentage": 0.0,
      "support_ratio": 0.0,
      "abstracts_analyzed": [
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract notes that sex hormones affect vascular function and that diabetes attenuates the protective effect of the female sex on cardiovascular outcomes, but it does not specifically address estrogen-mediated repair/remodeling of damaged cerebral vessels or outcomes post-thrombolysis. Thus it neither directly supports nor contradicts the proposed mechanism.",
          "key_findings": "Sex hormones are said to have a great impact on vascular function and inflammatory responses; diabetes appears to attenuate the protective effect of the female sex in development of cardiac diseases and nephropathy; women with diabetes have greater increases in cardiovascular risk, myocardial infarction, and stroke mortality than men compared with nondiabetic subjects. No data are provided on cerebral vascular repair, remodeling, or post-thrombolysis recovery.",
          "pmid": "27159875",
          "title": "Sex and Gender Differences in Risk, Pathophysiology and Complications of Type 2 Diabetes Mellitus.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract discusses epidemiology and risk factors for atrial fibrillation and mentions structural and electrical atrial remodeling, but it does not address estrogen, sex hormones, cerebral vessels, thrombolysis, or vascular repair mechanisms. Therefore, it provides no evidence for or against the proposed estrogen-mediated vascular repair mechanism.",
          "key_findings": "Old age, male gender, European descent, sedentary lifestyle, smoking, obesity, diabetes, obstructive sleep apnea, and hypertension are identified as risk factors for atrial fibrillation, with these factors inducing structural and electrical atrial remodeling; no discussion of estrogen or cerebral vascular repair/remodeling is included.",
          "pmid": "36434795",
          "title": "Atrial fibrillation: Epidemiology, pathophysiology, and clinical complications (literature review).",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract discusses caffeine consumption, sex differences, and its role as a risk or protective factor for neurological and psychiatric disorders, but it does not mention estrogen, vascular effects, cerebral vessel repair/remodeling, or post-thrombolysis recovery. Therefore, it neither supports nor contradicts the proposed estrogen-mediated vascular repair mechanism.",
          "key_findings": "The review focuses on how caffeine consumption affects risk for various neurological and psychiatric disorders, considering sex/gender differences, and aims to inform sex-specific caffeine therapies; no mechanisms involving estrogen or cerebral vascular repair are described.",
          "pmid": "33050315",
          "title": "Effect of Caffeine Consumption on the Risk for Neurological and Psychiatric Disorders: Sex Differences in Human.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract discusses sex differences in stroke, hormone replacement therapy increasing thromboembolic risk, and comparable efficacy of thrombolysis and thrombectomy in women and men, but it does not address estrogen\u2019s vascular repair/remodeling effects or its role in enhancing recovery post-thrombolysis.",
          "key_findings": "1) Hormone replacement therapy in older women is no longer recommended due to increased thromboembolic risk. 2) Intravenous thrombolysis with rtPA and mechanical thrombectomy are as efficacious in women as in men. 3) The abstract notes sex-specific epidemiology and outcomes but does not examine estrogen-mediated vascular protection or post-thrombolysis recovery mechanisms.",
          "pmid": "34172293",
          "title": "Stroke in women: When gender matters.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract discusses sex differences in cardiac electrophysiology and arrhythmia outcomes but does not mention estrogen, vascular protection, cerebrovascular repair/remodeling, stroke recovery mechanisms, or thrombolysis. It focuses on arrhythmia epidemiology, QT interval, stroke risk in atrial fibrillation, sudden cardiac death, and response to device therapy, which are not directly tied to estrogen-mediated vascular repair in cerebral vessels post-thrombolysis.",
          "key_findings": "Women have higher resting heart rates, longer QT intervals (higher risk of drug-induced torsades de pointes), higher stroke risk in atrial fibrillation, lower risk of sudden cardiac death, less known coronary artery disease at time of event, equal survival benefit from ICDs and CRT but underutilization in women, and better response to CRT (fewer hospitalizations and more robust reverse ventricular remodeling). No mention of estrogen, vascular protection, cerebrovascular remodeling, or thrombolysis.",
          "pmid": "22389121",
          "title": "Arrhythmias in women.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract evaluates the overall efficacy and timing of endovascular thrombectomy versus medical management in acute ischemic stroke and examines subgroup effects by gender, age, severity, imaging, and IV tPA use. It does not measure estrogen levels, hormonal status, vascular repair/remodeling, or sex-hormone\u2013mediated differences in recovery. The note that benefits did not differ by gender does not directly test or address an estrogen-mediated vascular repair mechanism, so the results neither support nor contradict the proposed mechanism.",
          "key_findings": "Endovascular therapy with stent-retrievers improved 90-day functional outcomes compared with medical therapy (OR 2.22) without affecting mortality or symptomatic intracerebral hemorrhage; earlier treatment was associated with better outcomes; and no significant differences in treatment benefit were found across gender, age, stroke severity, CT ischemic changes, or IV tPA administration.",
          "pmid": "26807742",
          "title": "Endovascular Treatment with Stent-Retriever Devices for Acute Ischemic Stroke: A Meta-Analysis of Randomized Controlled Trials.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract focuses on sex differences in stroke incidence, age of occurrence, symptom presentation, and resulting treatment delays. It does not address estrogen, vascular repair/remodeling, or recovery outcomes post-thrombolysis, so it neither supports nor contradicts the proposed estrogen-mediated protective vascular mechanism.",
          "key_findings": "Women experience stroke at older ages, have slightly higher lifetime risk due to longer life expectancy, and more often present with non-traditional stroke symptoms (e.g., impaired consciousness, altered mental status), which are associated with delayed recognition and delayed or missed reperfusion treatments such as thrombolysis and thrombectomy.",
          "pmid": "28364868",
          "title": "Sex differences in the presentation of stroke.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract discusses estrogen deficiency as a factor in the pathophysiology of microvascular angina in women but does not present data about estrogen\u2019s protective vascular effects on cerebral vessels, nor about repair/remodeling or recovery after thrombolysis. It is about coronary microvascular disease and chest pain, not cerebral vasculature or post-thrombolysis recovery.",
          "key_findings": "Endothelial dysfunction, estrogen deficiency, and abnormal nociception are cited as contributors to microvascular angina in women; diagnostic and treatment considerations for gender differences in chest pain are discussed. No mention is made of cerebral vessels, thrombolysis, or vascular repair/remodeling.",
          "pmid": "20419338",
          "title": "Gender and microvascular angina.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "medium",
          "reasoning": "The abstract notes a generally protective role of female sex hormones on stroke incidence and suggests hormones influence physiology, disease, and recovery, but it does not specifically discuss estrogen-mediated vascular repair/remodeling of cerebral vessels, nor does it address recovery post-thrombolysis. Thus it is related conceptually but does not provide direct mechanistic or treatment-context evidence for the proposed pathway.",
          "key_findings": "1) Incidence of stroke is higher in men across all ages, suggesting a protective role of sex hormones in women. 2) The sex difference in stroke incidence and prevalence decreases as women age, which is interpreted as evidence that hormones play a pivotal role in normal physiology, disease, and recovery. 3) The review mentions sex-based differences in response to therapy in acute management and prevention but without mechanistic detail about vascular repair or post-thrombolysis recovery.",
          "pmid": "18991796",
          "title": "Stroke in women.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract discusses sex and gender differences in stroke epidemiology, outcomes, and care pathways in a broad, review-style manner but does not present specific mechanistic or clinical evidence about estrogen\u2019s vascular protective effects, cerebral vessel repair/remodeling, or recovery post-thrombolysis. Therefore, it neither supports nor contradicts the proposed mechanism.",
          "key_findings": "The review notes that sex and gender influence acute stroke epidemiology, diagnosis, access to care, treatment outcomes, and post-acute care, and that baseline functional differences between women and men account for much of the outcome differences. It emphasizes confounding and methodological issues in sex- and gender-stratified analyses but does not mention estrogen, vascular remodeling, or post-thrombolysis recovery mechanisms.",
          "pmid": "36746379",
          "title": "Sex and Gender Differences in Stroke and Their Practical Implications in Acute Care.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract discusses post-thrombotic syndrome after deep vein thrombosis, its risk factors, diagnosis, and management, including thrombolysis and compression therapy. It does not mention estrogen, sex hormones, cerebral vessels, vascular repair/remodeling, or recovery post-thrombolysis, so it neither supports nor contradicts the proposed estrogen-related vascular recovery mechanism.",
          "key_findings": "Recurrent thrombosis, thrombus location, and obesity are identified as major risk factors for post-thrombotic syndrome; gender and age effects are uncertain. Adequate anticoagulation and elastic compression stockings reduce PTS incidence. Catheter-directed thrombolysis and mechanical thrombectomy may preserve valvular function and reduce PTS. No data on estrogen or hormone-related vascular repair are presented.",
          "pmid": "23433231",
          "title": "Post-thrombotic syndrome: a clinical review.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract evaluates long-term risk of venous thromboembolism after COVID-19 and notes higher risk among females, but it does not examine estrogen levels, vascular repair/remodeling, thrombolysis, or post-thrombolysis recovery. The observed sex difference is not mechanistically linked to estrogen\u2019s vascular effects in this study, so it neither supports nor contradicts the proposed estrogen-mediated protective vascular mechanism.",
          "key_findings": "Recovered COVID-19 patients had increased risk of pulmonary embolism (HR 3.16) and deep vein thrombosis (HR 2.55) compared with non-infected controls over a mean follow-up of 8.5 months; risk of PE and DVT increased with age and female sex, and decreased with longer follow-up.",
          "pmid": "36652137",
          "title": "Risk of venous thromboembolic events after COVID-19 infection: a systematic review and meta-analysis.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract examines gender differences in risk factors for cerebral microbleeds in acute ischemic stroke patients but does not measure estrogen levels, vascular repair/remodeling, thrombolysis outcomes, or recovery post-thrombolysis. Although it compares male and female patients, it does not attribute differences to estrogen or evaluate any protective vascular effect or post-thrombolysis recovery, so it neither supports nor contradicts the proposed mechanism.",
          "key_findings": "In a retrospective cohort of 482 acute ischemic stroke patients, females were older and had higher lipid and fibrinogen levels and higher NIHSS scores, with lower rates of smoking and alcohol use than males. No significant gender differences were found in the incidence or severity of cerebral microbleeds. In females, age and old lacunar infarcts were independent risk factors and blood glucose was an independent protective factor for cerebral microbleeds; these associations were not seen in males. The study did not assess estrogen, vascular remodeling, or post-thrombolysis recovery.",
          "pmid": "37259500",
          "title": "Gender heterogeneity in the influencing factors for cerebral microbleeds in acute ischemic stroke patients.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract states that women are relatively protected from cerebrovascular disease and attributes this commonly to estrogen and progesterone, but it does not specifically discuss vascular repair/remodeling of cerebral vessels or recovery post-thrombolysis. It remains at a high-level discussion of sex steroids in ischemic cell death and neuroprotection without detailing the proposed vascular mechanism.",
          "key_findings": "Women are relatively protected from cerebrovascular disease compared with men; this is commonly attributed to protective effects of female sex hormones (estrogen and progesterone). Sex differences in brain injury persist beyond menopause and in pediatric populations, suggesting reproductive steroids do not fully explain sexual dimorphism. The review focuses on sex steroids (estradiol, progesterone, testosterone) in ischemic cell death and neuroprotection, but does not specify estrogen-mediated vascular repair/remodeling or post-thrombolysis recovery.",
          "pmid": "19531872",
          "title": "Mechanisms of gender-linked ischemic brain injury.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract evaluates the efficacy and safety of intravenous thrombolysis in internal carotid artery occlusion but does not analyze estrogen levels, sex-specific differences, vascular repair/remodeling mechanisms, or hormonal influences on recovery. Therefore, it neither supports nor contradicts the proposed estrogen-mediated vascular protection mechanism.",
          "key_findings": "Intravenous rt-PA within 4.5 hours in ICA occlusion improved favorable functional outcome at 90 days (28.9% vs 20.6%; adjusted OR 1.80) but increased mortality (25.7% vs 15.4%; adjusted OR 2.28) and intracranial bleeding. No data on estrogen, sex-hormone status, or vascular repair mechanisms were reported.",
          "pmid": "22034003",
          "title": "Systemic thrombolysis in patients with acute ischemic stroke and Internal Carotid ARtery Occlusion: the ICARO study.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract examines risk factors for cardiac rupture after acute myocardial infarction, including female sex and thrombolysis, but it does not analyze estrogen levels, vascular repair/remodeling, cerebral vessels, or recovery post-thrombolysis. Female gender being a risk factor for cardiac rupture does not directly test or address the proposed estrogen-mediated protective vascular mechanism in cerebral circulation after thrombolysis.",
          "key_findings": "Female gender, older age, new-onset MI, LAD infarction, anterior wall infarction, and single-vessel disease increase risk of cardiac rupture after AMI; history of MI, smoking, multivessel disease, and primary PCI reduce risk; thrombolysis increases risk of cardiac rupture.",
          "pmid": "30487185",
          "title": "Risk factors for cardiac rupture complicating myocardial infarction: a PRISMA meta-analysis and systematic review.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract discusses gender differences in thromboembolic risk in atrial fibrillation and mentions estrogen hormone replacement therapy as a proposed contributor to increased thrombogenicity in women, but it does not address estrogen\u2019s potential protective vascular effects, repair/remodeling of cerebral vessels, or recovery post-thrombolysis. No data are presented regarding cerebral vascular repair, remodeling, or post-thrombolysis outcomes, so the proposed mechanism is neither supported nor contradicted.",
          "key_findings": "Female sex is described as an independent stroke risk factor in atrial fibrillation; biological contributors such as hypertension, renal dysfunction, hyperthyroidism, cardiovascular remodeling, increased hypercoagulability, and estrogen hormone replacement therapy are proposed as reasons for increased thrombogenicity in women. The review also notes that women have higher thromboembolic risk when not anticoagulated but may experience greater risk reduction with anticoagulation. No evidence is presented regarding estrogen-mediated vascular repair or post-thrombolysis recovery.",
          "pmid": "26923085",
          "title": "Gender Differences of Thromboembolic Events in Atrial Fibrillation.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract focuses on HbA1c, glycemic control, and their impact on mortality and stroke outcomes in patients with ischemic stroke and paroxysmal atrial fibrillation. It does not discuss estrogen, sex hormones, vascular repair/remodeling mechanisms, or post-thrombolysis recovery, so it neither supports nor contradicts the proposed estrogen-mediated vascular protection mechanism.",
          "key_findings": "Elevated HbA1c is associated with higher mortality and adverse outcomes in ischemic stroke and paroxysmal atrial fibrillation; the review synthesizes multiple study designs to link poor glycemic control to mortality, functional recovery, and complications, and emphasizes individualized strict glycemic control with targets often <7%.",
          "pmid": "39830535",
          "title": "Role of HbA1c in Mortality Among Patients With a Medical History of Ischemic Stroke and Paroxysmal Atrial Fibrillation: A Systematic Review.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract evaluates sex differences in venous thromboembolism risk after hip and knee arthroplasty, not recovery after thrombolysis, cerebral vessels, or estrogen-mediated vascular repair/remodeling. It reports higher VTE risk in women but does not investigate hormonal status, estrogen levels, vascular protective mechanisms, or post-thrombolysis outcomes, so it neither supports nor contradicts the proposed mechanism.",
          "key_findings": "Meta-analysis of 20 studies (7,892,585 patients) found female patients have a slightly higher risk of venous thromboembolism than male patients after total hip and total knee arthroplasty (pooled OR 1.184, 95% CI 1.070\u20131.310). No association with THA vs TKA incidence; no significant publication bias.",
          "pmid": "26446589",
          "title": "Gender differences of venous thromboembolism risk after total hip and total knee arthroplasty: a meta-analysis.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract analyzes risk and protective factors for stroke in type 2 diabetes (e.g., age, gender, vascular risk factors, medications like metformin/pioglitazone, lipid levels, microvascular complications), but does not examine estrogen, sex hormones, vascular repair/remodeling, or post-thrombolysis recovery. Therefore it neither supports nor contradicts the proposed estrogen-mediated vascular repair mechanism.",
          "key_findings": "Female gender is reported as a risk factor category along with age and other clinical variables, but no data on estrogen levels, hormone status, or vascular repair mechanisms are provided. The study focuses on epidemiologic associations (e.g., hypertension, BMI, HbA1c, eGFR, albuminuria, lipids, CHD, AF, DR, PVD, carotid plaque, exercise, and certain hypoglycemic agents) with stroke in T2DM, without mechanistic analysis of estrogen or thrombolysis outcomes.",
          "pmid": "38913694",
          "title": "Influencing factors of stroke in patients with type 2 diabetes: A systematic review and meta-analysis.",
          "analysis_method": "llm"
        }
      ]
    },
    {
      "feature_name": "gender",
      "mechanism": {
        "mechanism_type": "biological",
        "description": "Previous research indicates sex-related differences in platelet reactivity and thrombus dynamics, possibly affecting thrombolytic efficacy.",
        "evidence_level": "moderate"
      },
      "query": "(stroke OR alteplase OR thrombolysis OR \"ischemic stroke\") AND \"gender\" AND (\"pathophysiology\" OR \"mechanism\" OR \"causal\" OR \"etiology\" OR \"interaction\") AND (\"thrombolytic\" OR \"differences\" OR \"reactivity\") AND (Clinical Trial[PT] OR Review[PT] OR Meta-Analysis[PT])",
      "total_abstracts": 20,
      "support_count": 0,
      "conflict_count": 1,
      "neutral_count": 19,
      "support_percentage": 0.0,
      "conflict_percentage": 5.0,
      "support_ratio": 0.0,
      "abstracts_analyzed": [
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract discusses sex and gender differences in risk, pathophysiology, and complications of type 2 diabetes, with emphasis on hormones, metabolism, vascular function, inflammation, and cardiovascular outcomes. It does not mention platelets, thrombus formation, or thrombolytic therapy, nor does it assess sex-related differences in platelet reactivity or thrombus dynamics. Therefore it neither supports nor contradicts the proposed mechanism.",
          "key_findings": "The abstract reports sex differences in: (1) age and BMI at T2DM diagnosis; (2) prevalence of obesity; (3) genetic, epigenetic, nutritional, and lifestyle influences on risk and complications; (4) effects of sex hormones on energy metabolism, body composition, vascular function, and inflammatory responses; (5) psychosocial stress impact (greater in women); (6) increases in cardiovascular risk, myocardial infarction, and stroke mortality (greater in women with diabetes); and (7) attenuation of female cardiovascular and renal protection by diabetes. No data on platelet reactivity, thrombus dynamics, or thrombolytic efficacy are presented.",
          "pmid": "27159875",
          "title": "Sex and Gender Differences in Risk, Pathophysiology and Complications of Type 2 Diabetes Mellitus.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract reports sex-stratified differences in bleeding reduction between treatment strategies (greater bleeding reduction among men) but does not examine or discuss underlying biological mechanisms such as sex-related differences in platelet reactivity, thrombus dynamics, or thrombolytic efficacy. The findings are clinical and observational with respect to sex, without mechanistic interpretation linking them to platelet biology.",
          "key_findings": "In a meta-analysis of 4 RCTs of patients with atrial fibrillation and stable coronary artery disease, oral anticoagulation monotherapy vs oral anticoagulation plus single antiplatelet therapy reduced major bleeding (HR 0.59; 95% CI 0.44-0.79) without increasing ischemic events. Subgroup analyses suggested the magnitude of bleeding reduction may be greater among men (P_interaction = 0.03), but no specific data on sex-related platelet reactivity, thrombus dynamics, or thrombolytic efficacy were presented.",
          "pmid": "39918465",
          "title": "Anticoagulation and Antiplatelet Therapy\u00a0for Atrial Fibrillation and Stable Coronary Disease: Meta-Analysis of Randomized Trials.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract examines loneliness and social isolation as risk factors for coronary heart disease and stroke but does not assess platelet reactivity, thrombus dynamics, sex-related biological differences, or thrombolytic efficacy. It only notes that subgroup analyses did not find gender differences in the *associations* between social factors and outcomes, which is not evidence about sex-specific platelet or thrombus mechanisms.",
          "key_findings": "Poor social relationships (loneliness and social isolation) were associated with a 29% increased risk of incident CHD (RR 1.29, 95% CI 1.04\u20131.59) and a 32% increased risk of stroke (RR 1.32, 95% CI 1.04\u20131.68), with no differences in these associations by gender. The study is a systematic review and meta-analysis of longitudinal observational studies in high-income countries and does not address platelet biology or thrombolytic treatment response.",
          "pmid": "27091846",
          "title": "Loneliness and social isolation as risk factors for coronary heart disease and stroke: systematic review and meta-analysis of longitudinal observational studies.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract discusses sex differences in the effects of caffeine consumption on neurological and psychiatric disorders. It does not address platelets, thrombosis, thrombolysis, or platelet reactivity, and therefore provides no direct evidence for or against sex-related differences in platelet reactivity and thrombus dynamics affecting thrombolytic efficacy.",
          "key_findings": "The review focuses on how caffeine consumption may act as a risk or protective factor for various neurological and psychiatric disorders, with attention to sex differences, and aims to inform sex-specific caffeine therapies. No mention is made of platelets, thrombus dynamics, or thrombolytic treatment.",
          "pmid": "33050315",
          "title": "Effect of Caffeine Consumption on the Risk for Neurological and Psychiatric Disorders: Sex Differences in Human.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract discusses sex and gender differences in migraine epidemiology, symptomatology, hormone influences (especially estrogen), CGRP, and stroke risk with estrogen use, but does not mention platelets, thrombus dynamics, or thrombolytic efficacy. Therefore it neither supports nor contradicts the proposed mechanism about sex-related differences in platelet reactivity and thrombus dynamics affecting thrombolytic efficacy.",
          "key_findings": "Sex hormones, particularly estrogen, influence migraine pathophysiology and the natural course of migraine; migraine is more prevalent and disabling in women; estrogen dose and aura frequency are linked to ischemic stroke risk; hormone-containing therapies and gender affirming hormone therapy have nuanced effects and risks (including ischemic stroke), but no data are presented on platelet reactivity, thrombosis, or thrombolytic response.",
          "pmid": "35679008",
          "title": "Sex and Gender Considerations in Episodic Migraine.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract investigates clinical and demographic risk factors for recurrence of benign paroxysmal positional vertigo (including female sex) but does not assess platelet reactivity, thrombus dynamics, or thrombolytic efficacy. The mention of female gender as a risk factor is not linked to any platelet- or thrombosis-related mechanism, so it neither supports nor contradicts the proposed biological mechanism.",
          "key_findings": "Female gender, age \u226565, hyperlipidemia, diabetes, hypertension, migraine, cervical spondylosis, osteopenia/osteoporosis, head trauma, otitis media, abnormal vestibular evoked myogenic potential, and long computer use were associated with higher BPPV recurrence risk, while factors like smoking, alcohol, stroke, and others were not. No data on platelet function, thrombus dynamics, or thrombolytic treatment were reported.",
          "pmid": "32776833",
          "title": "Risk Factors for the Recurrence of Benign Paroxysmal Positional Vertigo: A Systematic Review and Meta-Analysis.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract discusses sex differences in heart failure phenotypes, pathophysiology, and therapeutic responses broadly, but does not address platelet reactivity, thrombus dynamics, or thrombolytic efficacy. Therefore it neither supports nor contradicts the proposed platelet/thrombus-related mechanism.",
          "key_findings": "Men are more prone to HFrEF and women to HFpEF; sex differences exist in genetic cardiomyopathy penetrance, risk factors, and conditions such as peripartum and Takotsubo cardiomyopathy; coronary macrovascular disease is hypothesized to underlie higher HFrEF risk in men, while coronary microvascular dysfunction/endothelial inflammation is implicated in female-predominant HF syndromes; women are under-represented in HF clinical trials. No data are presented on platelets, thrombus dynamics, or thrombolytic therapy.",
          "pmid": "31800034",
          "title": "Sex differences in heart failure.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract compares radial extracorporeal shock wave therapy and TENS for post\u2011stroke upper limb spasticity and reports outcomes by treatment over time. It does not measure platelet function, thrombus dynamics, sex-related differences in these factors, or thrombolytic efficacy, nor does it analyze treatment effects stratified by mechanisms related to platelet reactivity or thrombosis.",
          "key_findings": "rESWT was superior to TENS in reducing spasticity and improving voluntary control and hand function in chronic post\u2011stroke hemiplegia; outcomes were assessed at baseline, immediately post\u2011treatment, and after four weeks. Although gender and stroke type were recorded, no mechanistic data on platelet reactivity or thrombus dynamics, or sex-related differences in these, were presented.",
          "pmid": "37235581",
          "title": "The effectiveness of radial extracorporeal shock wave therapy vs transcutaneous electrical nerve stimulation in the management of upper limb spasticity in chronic-post stroke hemiplegia-A randomized controlled trial.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract discusses sex and gender differences in susceptibility and immunologic responses to neuroinfectious diseases (HIV-related cerebrovascular disease and Zika), but does not mention platelets, thrombus dynamics, or thrombolytic efficacy. Therefore it neither supports nor contradicts the proposed mechanism about sex-related differences in platelet reactivity affecting thrombolysis.",
          "key_findings": "Sex and gender have major impact on susceptibility and immune responses in infectious diseases, with examples including heightened cerebrovascular disease risk in women with HIV and sex-specific implications of Zika virus infection for reproductive health and vaccine development.",
          "pmid": "29270943",
          "title": "Sex Matters in Neuroinfectious Diseases.",
          "analysis_method": "llm"
        },
        {
          "stance": "conflict",
          "confidence": "medium",
          "reasoning": "The proposed mechanism suggests that sex-related differences in platelet reactivity and thrombus dynamics may affect thrombolytic efficacy. The abstract explicitly states that venous thrombolysis with rtPA and mechanical thrombectomy are now proven to be as efficacious in women as in men. This directly argues against a meaningful sex-based difference in thrombolytic treatment efficacy attributable to underlying biological differences such as platelet reactivity or thrombus dynamics, thereby conflicting with the proposed mechanism\u2019s implication that these differences impact efficacy.",
          "key_findings": "The abstract reports that venous thrombolysis with rtPA and mechanical thrombectomy are proven to be equally efficacious in women and men, despite acknowledging broader sex-related differences in stroke characteristics.",
          "pmid": "34172293",
          "title": "Stroke in women: When gender matters.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract discusses smoking as a cardiovascular and cerebrovascular risk factor and mentions possible gender-dependent differences in atherosclerotic complications related to hormonal status, but it does not address platelet reactivity, thrombus dynamics, or thrombolytic efficacy specifically. It only broadly proposes that mechanisms of tobacco-induced atherosclerotic damage and gender-related differences will be reviewed, without providing mechanistic data relevant to platelet behavior or thrombolysis.",
          "key_findings": "Smoking is a major risk factor for coronary, cerebrovascular, and peripheral artery disease in both men and women; risk declines after smoking cessation. Hormonal status may affect atherosclerotic plaque development and stability, and smoking habits could influence clinical complications of atherosclerosis in a gender-dependent manner. The review aims to describe mechanisms of tobacco-induced atherosclerotic damage and potential gender-related differences, but no specific findings on platelet reactivity, thrombus dynamics, or thrombolytic efficacy are presented in the abstract.",
          "pmid": "11861027",
          "title": "Smoking and gender.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract discusses sex differences in cerebrovascular hemodynamics in general and mentions that sex differences in vascular physiology may influence treatment response, but it does not specifically address platelet reactivity, thrombus dynamics, or thrombolytic efficacy. Therefore, it neither supports nor contradicts the proposed platelet/thrombus-based mechanism.",
          "key_findings": "The review highlights that sex and gender influence vascular physiology and cerebrovascular hemodynamics, potentially contributing to differences in clinical presentation, treatment response, and outcomes, and identifies a knowledge gap in understanding sex-specific mechanisms as therapeutic targets.",
          "pmid": "29270941",
          "title": "Cerebrovascular Hemodynamics in Women.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract discusses sex differences in stroke risk factors (hypertension, atrial fibrillation, diabetes, obesity, hormonal factors, etc.) but does not mention platelet reactivity, thrombus dynamics, or thrombolytic efficacy. Therefore it neither supports nor contradicts the proposed mechanism about sex-related differences in platelet function affecting thrombolysis.",
          "key_findings": "Women have different incidence and significance of various stroke risk factors compared with men, including higher prevalence of hypertension, atrial fibrillation, diabetes mellitus, abdominal obesity, migraine with aura, emotional stress and depression, as well as unique female-specific factors such as menarche timing, pregnancy-related conditions, hormonal disturbances, and use of hormonal therapies.",
          "pmid": "32207719",
          "title": "[Gender differences in stroke risk factors].",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract discusses sex differences in cardiac electrophysiology, arrhythmia epidemiology, and response to device therapy, but does not mention platelets, thrombus formation, thrombolysis, or thrombolytic efficacy. Therefore it neither supports nor contradicts the proposed mechanism about sex-related differences in platelet reactivity and thrombus dynamics.",
          "key_findings": "Women have higher resting heart rates, longer QT intervals with greater risk of drug-induced torsades de pointes, higher stroke risk in atrial fibrillation, lower risk of sudden cardiac death, and differences in utilization and response to anticoagulation, ablation, ICDs, and CRT compared with men. No data are presented on platelet function, thrombus dynamics, or thrombolytic response.",
          "pmid": "22389121",
          "title": "Arrhythmias in women.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract discusses sex differences in stroke incidence, age at occurrence, symptom presentation, and treatment delays, but it does not address platelet reactivity, thrombus dynamics, or thrombolytic efficacy. Therefore it neither supports nor contradicts the proposed biological mechanism.",
          "key_findings": "Women experience stroke at an older age, have slightly higher lifetime risk, and more often present with non-traditional stroke symptoms (e.g., impaired consciousness, altered mental status), which are associated with delayed recognition and treatment. Thrombolysis and thrombectomy are noted as time-sensitive, but no sex-related differences in biological response or efficacy are examined.",
          "pmid": "28364868",
          "title": "Sex differences in the presentation of stroke.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract discusses gender differences in stroke incidence, age at first stroke, case-fatality rate, functional outcome, risk factor profiles, and overall treatment response, but it does not address platelet reactivity, thrombus dynamics, or thrombolytic efficacy specifically. The statement that gender differences in treatment response appear to be weak is non-specific and not linked to platelet biology or thrombolysis mechanisms.",
          "key_findings": "Incidence of stroke is higher in men than women across age classes; women are older at first stroke; prevalence is higher in men until ~80 years, then higher in women; case-fatality rate is generally higher in women; some weak evidence of better functional outcome in men; gender differences in risk factor profiles and treatment response appear weak; caregiver burden predominantly affects women.",
          "pmid": "11252851",
          "title": "Stroke and gender.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract reports that the beneficial effect of endovascular treatment on functional outcomes does not differ by gender, but it does not measure or analyze platelet reactivity, thrombus dynamics, or thrombolytic efficacy. Therefore it neither supports nor contradicts the proposed sex-related biological mechanism.",
          "key_findings": "Meta-analysis of five RCTs (1,287 patients) found endovascular therapy improved functional outcome (OR 2.22) without affecting mortality or symptomatic ICH; meta-regression showed better outcomes with shorter onset-to-groin puncture and onset-to-reperfusion times; no significant differences in treatment benefit across gender, age, stroke severity, CT ischemic changes, or IV tPA use.",
          "pmid": "26807742",
          "title": "Endovascular Treatment with Stent-Retriever Devices for Acute Ischemic Stroke: A Meta-Analysis of Randomized Controlled Trials.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract discusses sex- and gender-related differences in heart\u2013brain interactions and their influence on pathogenesis and treatment responses in cardiac and brain diseases, but it does not mention platelets, thrombus dynamics, or thrombolytic efficacy. Thus it is related to sex differences and cardiovascular/brain disorders in general, but does not address the specific mechanistic pathway proposed.",
          "key_findings": "The review summarizes evidence that: (1) the heart and brain have intimate crosstalk through physiological and neurohumoral circuits; (2) they share common risk factors and are both influenced by systemic inflammation, atherosclerosis, and neuroendocrine dysfunction; (3) sex- and gender-related differences modify heart\u2013brain interactions over the lifespan and affect pathogenesis, clinical manifestations, and treatment responses. No specific data on platelet reactivity, thrombus dynamics, or thrombolytic therapy are presented.",
          "pmid": "35194633",
          "title": "Heart-brain interactions in cardiac and brain diseases: why sex matters.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract discusses gender differences in chest pain, microvascular angina, and related mechanisms such as endothelial dysfunction, estrogen deficiency, and abnormal nociception. It does not mention platelets, thrombus dynamics, or thrombolytic efficacy, nor does it provide data on sex-related differences in these factors. Thus it neither supports nor contradicts the proposed mechanism about platelet reactivity and thrombolysis.",
          "key_findings": "Women more often present with atypical chest pain and may have ischemia on stress testing without obstructive coronary artery disease; microvascular angina is proposed as an under-recognized mechanism involving endothelial dysfunction, estrogen deficiency, and abnormal nociception, with treatments aimed at these pathways.",
          "pmid": "20419338",
          "title": "Gender and microvascular angina.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract discusses sex differences in stroke incidence, outcomes, symptom presentation, carotid plaque characteristics, and response to carotid revascularization versus medical therapy, but it does not mention platelet reactivity, thrombus dynamics, or thrombolytic efficacy. Thus it neither supports nor contradicts the specific proposed mechanism about sex-related differences in platelet function affecting thrombolysis.",
          "key_findings": "Women have higher mortality and disability after stroke than men; they often present with atypical stroke symptoms leading to delays in diagnosis and treatment; carotid plaques in women differ in morphology and composition from those in men; women derive less benefit from carotid revascularization but more from medical management compared with men; women are less likely to receive medical therapy for cardiovascular risk factors.",
          "pmid": "34849703",
          "title": "Importance of sex and gender in ischaemic stroke and carotid atherosclerotic disease.",
          "analysis_method": "llm"
        }
      ]
    },
    {
      "feature_name": "gender",
      "mechanism": {
        "mechanism_type": "biological",
        "description": "Hormonal differences may impact inflammation and immune responses post-stroke, influencing recovery trajectories differently between men and women.",
        "evidence_level": "moderate"
      },
      "query": "(stroke OR alteplase OR thrombolysis OR \"ischemic stroke\") AND \"gender\" AND (\"pathophysiology\" OR \"mechanism\" OR \"causal\" OR \"etiology\" OR \"interaction\") AND (\"trajectories\" OR \"inflammation\" OR \"differently\") AND (Clinical Trial[PT] OR Review[PT] OR Meta-Analysis[PT])",
      "total_abstracts": 20,
      "support_count": 0,
      "conflict_count": 1,
      "neutral_count": 19,
      "support_percentage": 0.0,
      "conflict_percentage": 5.0,
      "support_ratio": 0.0,
      "abstracts_analyzed": [
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract discusses sex hormones influencing energy metabolism, vascular function, and inflammatory responses, and notes sex differences in stroke risk and mortality in people with type 2 diabetes. However, it does not examine post-stroke inflammation or immune responses, nor does it assess how hormonal differences affect stroke recovery trajectories specifically. Thus, it is related in theme but does not provide direct mechanistic evidence for or against the proposed post-stroke recovery mechanism.",
          "key_findings": "Sex hormones are reported to have a great impact on energy metabolism, body composition, vascular function, and inflammatory responses; endocrine imbalances relate to unfavorable cardiometabolic traits; women with diabetes experience greater increases in cardiovascular risk, myocardial infarction, and stroke mortality than men. These findings concern risk and systemic pathophysiology, not post-stroke immune/inflammatory responses or recovery trajectories.",
          "pmid": "27159875",
          "title": "Sex and Gender Differences in Risk, Pathophysiology and Complications of Type 2 Diabetes Mellitus.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract discusses sex differences in heart failure types, risk factors, pathophysiology, and therapeutic responses, but it does not address post-stroke recovery, nor does it specifically examine how hormonal differences modulate inflammation or immune responses after stroke. Any mention of endothelial inflammation is in the context of heart failure pathophysiology, not stroke or stroke recovery trajectories.",
          "key_findings": "Men are more predisposed to heart failure with reduced ejection fraction, while women predominate in heart failure with preserved ejection fraction; sex differences exist in genetic cardiomyopathy penetrance, risk factors such as breast cancer treatment, and sex-specific conditions like peripartum cardiomyopathy; coronary microvascular dysfunction and endothelial inflammation are postulated mechanisms particularly relevant to women\u2019s heart failure phenotypes; there are sex disparities in clinical trial enrollment and gaps in sex-specific heart failure mechanisms and treatments.",
          "pmid": "31800034",
          "title": "Sex differences in heart failure.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract is about methodological guidelines for autophagy assays and does not address sex or gender differences, hormonal influences, inflammation, immune response, stroke, or recovery trajectories.",
          "key_findings": "The abstract provides guidance on the use and interpretation of assays for monitoring autophagy; it does not present data on hormonal effects, sex differences, or post-stroke inflammatory/immune mechanisms.",
          "pmid": "26799652",
          "title": "Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition).",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract discusses sex/gender differences in cardiopulmonary diseases and mentions inflammation and early vascular aging as shared pathophysiology, but it does not address post-stroke populations, stroke recovery trajectories, or explicitly link hormonal differences to inflammation or immune responses after stroke. Thus it neither supports nor contradicts the specific proposed mechanism.",
          "key_findings": "The review highlights that: (1) sex and gender influence disease manifestation, treatment response, and outcomes in cardiovascular and pulmonary diseases; (2) heart disease in females may have different pathophysiology compared to males; (3) there is higher prevalence of pulmonary disorders in females; and (4) early vascular aging and inflammation are presented as potential shared pathophysiological links in the cardiopulmonary continuum, with interactions involving chronic kidney disease. Stroke, post-stroke inflammation, immune response, and hormone-specific mechanisms are not directly discussed.",
          "pmid": "36003909",
          "title": "Gender dimension in cardio-pulmonary continuum.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract discusses methodological guidelines for monitoring autophagy across organisms and experimental systems. It does not address sex or gender differences, hormones, stroke, inflammation, immune responses, or recovery trajectories, so it neither supports nor contradicts the proposed mechanism.",
          "key_findings": "The paper outlines updated guidelines for selecting and interpreting assays to monitor autophagy, emphasizing the need for multiple techniques, caution with genetic approaches targeting autophagy-related genes, and the nonspecific nature of some autophagy markers due to their roles in other pathways such as apoptosis.",
          "pmid": "33634751",
          "title": "Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition)<sup>1</sup>.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract discusses platelet-leukocyte interactions, inflammation, and vascular diseases including ischemic stroke, and it mentions gender as a vascular risk factor. However, it does not address hormonal differences, nor does it analyze sex-specific or hormone-mediated differences in post-stroke inflammation, immune responses, or recovery trajectories. Therefore it neither supports nor contradicts the proposed hormone-based mechanism.",
          "key_findings": "The review describes how unhealthy lifestyle and endogenous factors (including gender) contribute to a pro-inflammatory and pro-thrombotic milieu leading to vascular disease; it details platelet-leukocyte crosstalk as a regulator of immune responses and inflammation in chronic and acute vascular diseases such as ischemic stroke. No data or discussion are provided on hormonal mechanisms or sex-specific post-stroke immune or recovery differences.",
          "pmid": "32439204",
          "title": "Platelet-leukocyte interplay during vascular disease.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract discusses sex- and gender-related differences in heart\u2013brain interactions and mentions systemic inflammation and neuroendocrine system dysfunction in general, but it does not specifically address post-stroke inflammation or immune responses, nor does it directly link hormonal differences to recovery trajectories after stroke.",
          "key_findings": "The review summarizes evidence that: (1) the heart and brain share common risk factors and are affected by systemic inflammation and neuroendocrine dysfunction; (2) physiological interactions between heart and brain influence disease pathogenesis, clinical manifestations, and treatment responses; and (3) sex- and gender-related differences modify heart\u2013brain interactions over the lifespan. Stroke, post-stroke immune response, and hormone-specific mechanisms are not specifically detailed in the abstract.",
          "pmid": "35194633",
          "title": "Heart-brain interactions in cardiac and brain diseases: why sex matters.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract discusses stroke risk factors, including gender as a nonmodifiable marker and inflammation as a putative risk factor, but it does not address post-stroke recovery, hormonal differences, or sex-specific immune/inflammatory responses after stroke. Therefore, it neither supports nor contradicts the proposed mechanism.",
          "key_findings": "Gender is listed as a nonmodifiable risk marker for stroke, and inflammation is mentioned as a putative risk factor, but no data are presented on hormonal influences, post-stroke inflammation, immune responses, or differential recovery trajectories between men and women.",
          "pmid": "9932614",
          "title": "Stroke risk factors and stroke prevention.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract notes that gender differences are among many factors affecting stroke outcome, but it does not mention hormones, hormonal modulation, or sex-specific inflammatory/immune mechanisms, nor does it present data comparing post-stroke inflammation or recovery trajectories between men and women.",
          "key_findings": "The review discusses inflammation and immune responses in stroke, and lists \u2018gender differences\u2019 as one of several factors affecting stroke outcome (along with aging, comorbidities, lifestyle factors, and infections), but provides no mechanistic or empirical detail on how hormonal differences influence post-stroke inflammation or immune responses.",
          "pmid": "33017613",
          "title": "Filling the gaps on stroke research: Focus on inflammation and immunity.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract discusses endothelial dysfunction, oxidative stress, inflammation, and stroke risk in the context of urolithiasis and cardiovascular disease, but it does not examine sex differences, hormonal influences, or differential post\u2011stroke immune/inflammatory responses between men and women. Therefore it neither supports nor contradicts the proposed hormone\u2011based, sex\u2011specific post\u2011stroke mechanism.",
          "key_findings": "1) Urolithiasis is epidemiologically associated with higher incidence of cardiovascular disease, including stroke (relative risk ~1.20\u20131.24). 2) Endothelial dysfunction is described as an early pathogenic event linked to oxidative stress and low\u2011grade chronic inflammation in several cardiovascular conditions. 3) Endothelial dysfunction is strongly associated with urolithiasis, and experimental hyperoxaluria models show elevated serum endothelial dysfunction markers. 4) Subgroup analyses for gender or age in the urolithiasis\u2013CVD relationship are reported as inconclusive. 5) No systemic serum markers of endothelial dysfunction, inflammation, or oxidative stress are clearly related in clinical studies. None of these findings address hormonal or sex\u2011specific modulation of post\u2011stroke inflammation or immune responses.",
          "pmid": "35055099",
          "title": "Endothelial Dysfunction: An Intermediate Clinical Feature between Urolithiasis and Cardiovascular Diseases.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract discusses inflammation (measured by hs-CRP) as a cardiovascular risk marker across countries and ethnicities and mentions gender only as a search term. It does not present data on hormonal differences, sex-specific immune responses, or post-stroke recovery trajectories, so it neither supports nor contradicts the proposed hormone-based mechanism.",
          "key_findings": "Inflammation is recognized as a common pathway for complications of atherosclerosis, stroke, and ischemic heart disease; hs-CRP adds prognostic information about cardiovascular risk and mortality across diverse countries and ethnicities, independent of ancestry or geographic region.",
          "pmid": "27166776",
          "title": "High-Sensitivity C-Reactive Protein and Cardiovascular Disease Across Countries and Ethnicities.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract mentions gender as a classical risk factor for vascular disease and dementia, and also mentions inflammation as a putative risk factor, but it does not discuss post-stroke recovery, hormonal differences, or sex-specific inflammatory/immune responses after stroke. There is no mechanistic or outcome-based evidence about how hormonal differences influence post-stroke inflammation or recovery trajectories between men and women.",
          "key_findings": "The paper reviews relationships between risk factors for vascular disease/stroke and Alzheimer's disease, including age, gender, socioeconomic status, diabetes, cholesterol, cardiovascular disease, atrial fibrillation, smoking, alcohol, APOE, homocysteine, hemostatic/thrombotic abnormalities, and inflammation. It does not address hormonal mechanisms, immune responses, or sex-specific post-stroke recovery.",
          "pmid": "10420064",
          "title": "Risk factors for vascular disease and dementia.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract discusses protein biomarkers related to inflammation, coagulation, adhesion, senescence, and their relationship to stroke outcomes, and briefly notes gender as one of several predictors of stroke outcome. However, it does not examine hormonal differences, sex-specific immune or inflammatory responses, or differential recovery trajectories between men and women. Therefore, it neither supports nor contradicts the proposed hormone-based sex difference mechanism.",
          "key_findings": "The study reviews protein biomarkers in blood (e.g., inflammatory, coagulation-related, adhesion-related, senescence-related) that predict long-term outcome after ischemic stroke and shows they form an interacting network of molecular processes influencing stroke outcome. It notes that age and stroke severity are the strongest predictors, with gender, genetics, and lifestyle also contributing, but does not analyze or attribute these gender differences to hormonal effects or sex-specific immune/inflammatory responses.",
          "pmid": "35953740",
          "title": "Protein Biomarkers in Blood Reflect the Interrelationships Between Stroke Outcome, Inflammation, Coagulation, Adhesion, Senescence and Cancer.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract focuses on stroke characteristics in patients with familial Mediterranean fever, comparing infarct patterns and vascular status to controls. It does not analyze sex-based differences, hormonal influences, or differential post-stroke inflammation/immune responses between men and women, so it neither supports nor contradicts the proposed hormonal mechanism.",
          "key_findings": "In FMF patients with acute neurovascular events, most ischemic strokes were cryptogenic; distal cerebral artery and midbrain deep perforator involvement were more frequent than in age- and gender-matched controls; vascular risk factors and angiographic disease did not differ from controls; long-term prognosis under antiplatelets and colchicine was favorable. No data on hormonal status, sex-specific immune/inflammatory responses, or recovery differences between men and women are presented.",
          "pmid": "36744553",
          "title": "Acute stroke in familial Mediterranean fever: An analysis of 23 new cases and systematic review of the literature.",
          "analysis_method": "llm"
        },
        {
          "stance": "conflict",
          "confidence": "medium",
          "reasoning": "The proposed mechanism suggests that hormonal (sex-related) differences may alter inflammation and immune responses post-stroke, leading to different recovery trajectories between men and women. This abstract explicitly reports that no gender differences were evident in cognitive assessments post-stroke, despite discussing inflammation-centered comorbidity burden as relevant to cognitive decline. While inflammation is mentioned, the key sex-based prediction of the mechanism (different outcomes between men and women) is not observed in this sample, which mildly contradicts the proposed mechanism as stated.",
          "key_findings": "Among 97 community-dwelling stroke survivors, total comorbidity burden (SPI-II score) was negatively correlated with cognitive performance (MoCA, MMSE), and inflammation is suggested as an important component of this burden. However, the study found no gender differences in cognitive assessments, indicating no observable sex-based difference in post-stroke cognitive outcomes in this cohort.",
          "pmid": "36294026",
          "title": "Examining the Associations between Post-Stroke Cognitive Function and Common Comorbid Conditions among Stroke Survivors.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract discusses sex differences, sex hormones, microglia, and brain injury, but in the context of traumatic brain injury (TBI), not stroke. It also states that evidence about sex hormone-related differences is contradictory and inconclusive. It does not provide specific data on how hormonal differences impact post-stroke inflammation or immune responses, nor on recovery trajectories in men vs. women after stroke, so it neither supports nor contradicts the proposed mechanism.",
          "key_findings": "1) Sex differences are recognized in several neurologic disorders, including stroke and TBI. 2) Microglia have sexually dimorphic roles in CNS development and other neurologic conditions. 3) Existing evidence for sex differences in TBI mainly centers on sex hormones, but the findings are contradictory and do not allow firm conclusions. 4) The relationship among sex, sex hormones, and microglia in TBI is emphasized as important but remains insufficiently understood.",
          "pmid": "27870453",
          "title": "Do microglia play a role in sex differences in TBI?",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "medium",
          "reasoning": "The abstract discusses that stroke pathophysiology and immune\u2011neurovascular crosstalk depend on brain maturation stage and notes that age-specific and gender differences should be considered for treatment strategies. However, it does not present data or mechanistic discussion specifically linking hormonal differences between men and women to post-stroke inflammation or immune responses, nor to differing recovery trajectories. Gender is only mentioned as a consideration, without mechanistic or evidentiary detail about hormones.",
          "key_findings": "1) Immune-neurovascular interactions and the influence of inflammatory mediators vary with brain maturation stage in neonatal and childhood stroke. 2) Resident and peripheral immune populations modulate stroke outcome. 3) Future prophylactic and therapeutic strategies should be age-specific and consider gender differences. The abstract does not specify hormonal mechanisms or differential inflammatory/immune responses by sex.",
          "pmid": "36705821",
          "title": "Brain Maturation as a Fundamental Factor in Immune-Neurovascular Interactions in Stroke.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "medium",
          "reasoning": "The abstract discusses sex steroid (estrogen, progesterone) neuroprotective effects and mentions sex differences in TBI outcomes, but it does not specifically describe differential post-injury inflammation or immune responses between men and women, nor how these hormonal differences modulate post-stroke (or post-TBI) immune/inflammatory pathways to shape recovery trajectories by sex. The focus is on neuroprotection and clinical trial design, not on mechanistic immune/inflammatory sex differences in recovery.",
          "key_findings": "1) Females have less harmful outcomes after brain damage including TBI than males. 2) Experimental studies report reduced secondary brain damage and improved neurologic outcomes after TBI with progesterone and estrogen administration. 3) Some clinical trials with progesterone showed useful features, but later phase III trials were unsuccessful. 4) The review emphasizes secondary injury mechanisms and neuroprotective effects of estrogen and progesterone, and the need to consider endogenous hormone levels, therapeutic window, dosage, responsive population, gender, and age in future TBI studies.",
          "pmid": "29151229",
          "title": "Effects of Female Sex Steroids Administration on Pathophysiologic Mechanisms in Traumatic Brain Injury.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract discusses sex (male vs female) differences in liver fibrogenesis in a NASH rat model and links them to differences in hepatic detoxification (phase II drug-metabolizing) enzymes, not to hormonal modulation of inflammation or immune responses after stroke. The proposed mechanism concerns post-stroke recovery and sex hormone\u2013mediated immune/inflammatory responses, which is not addressed here.",
          "key_findings": "In SHRSP5/Dmcr NASH rat models, sex and strain differences in fibrogenesis under a high-fat, high-cholesterol diet are associated with decreased levels of UGP-glucuronosyltransferase, sulfotransferase, and their regulating nuclear receptors only in male SHRSP5/Dmcr rats, suggesting a role for phase II drug-metabolizing enzymes in NASH progression; age and gender are noted as associated with NASH/NAFLD development, but the mechanisms are not linked to hormonal modulation of inflammation or immune responses post-stroke.",
          "pmid": "26411937",
          "title": "[Mechanism Analysis and Prevention of Pathogenesis of Nonalcoholic Steatohepatitis].",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract notes gender differences and mentions hormonal shifts in women as part of HFpEF pathophysiology, but it does not discuss inflammation, immune responses, post-stroke context, or recovery trajectories. Thus, it neither supports nor contradicts the specific mechanism of hormonal effects on post-stroke inflammatory/immune responses and recovery.",
          "key_findings": "The abstract states that HFpEF patients are more commonly women and that gender differences involve changes due to smaller heart size and hormonal shifts, among other phenotype-specific mechanisms. No mention is made of stroke, post-stroke inflammation, immune response, or recovery differences between men and women.",
          "pmid": "40472932",
          "title": "Primary heart failure with preserved ejection fraction: The intertwined pathophysiology and treatment of some of the most relevant phenotypes.",
          "analysis_method": "llm"
        }
      ]
    },
    {
      "feature_name": "age",
      "mechanism": {
        "mechanism_type": "biological",
        "description": "Neuroplasticity and the brain's ability to recover from ischemic insult decrease with increasing age, which likely enhances the therapeutic effects of early reperfusion in younger patients.",
        "evidence_level": "moderate"
      },
      "query": "(stroke OR alteplase OR thrombolysis OR \"ischemic stroke\") AND \"age\" AND (\"pathophysiology\" OR \"mechanism\" OR \"causal\" OR \"etiology\" OR \"interaction\") AND (\"neuroplasticity\" OR \"therapeutic\" OR \"reperfusion\") AND (Clinical Trial[PT] OR Review[PT] OR Meta-Analysis[PT])",
      "total_abstracts": 20,
      "support_count": 0,
      "conflict_count": 2,
      "neutral_count": 18,
      "support_percentage": 0.0,
      "conflict_percentage": 10.0,
      "support_ratio": 0.0,
      "abstracts_analyzed": [
        {
          "stance": "conflict",
          "confidence": "medium",
          "reasoning": "The proposed mechanism suggests that older age reduces neuroplasticity and recovery, thereby implying that early reperfusion (endovascular thrombectomy) should have *greater* therapeutic impact in younger patients than in older ones. The meta-analysis, however, reports no heterogeneity of treatment effect across age subgroups and highlights a strong beneficial effect even in patients aged 80 years or older, with no indication that benefit is diminished in older patients. This contradicts the age-dependent reduction in therapeutic effect implied by the mechanism, though the abstract does not directly measure neuroplasticity itself.",
          "key_findings": "1) Subgroup analysis showed no heterogeneity of treatment effect across prespecified subgroups, including age (p_interaction = 0.43). 2) Endovascular thrombectomy significantly reduced disability overall at 90 days versus control (adjusted cOR 2.49, 95% CI 1.76\u20133.53). 3) Effect sizes favoring thrombectomy were present in patients aged 80 years or older (cOR 3.68, 95% CI 1.95\u20136.92), suggesting preserved or even strong benefit in the very elderly rather than a reduced therapeutic effect with age.",
          "pmid": "26898852",
          "title": "Endovascular thrombectomy after large-vessel ischaemic stroke: a meta-analysis of individual patient data from five randomised trials.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The trial compares clinical efficacy and safety of tenecteplase versus alteplase in acute ischemic stroke but does not analyze outcomes by age strata or investigate neuroplasticity, recovery capacity, or age-related differences in benefit from early reperfusion. Therefore it neither supports nor contradicts the proposed age-dependent neuroplasticity mechanism.",
          "key_findings": "In 1577 randomized acute ischemic stroke patients (median age 74), tenecteplase 0.25 mg/kg was non-inferior to alteplase 0.9 mg/kg for achieving mRS 0\u20131 at 90\u2013120 days (36.9% vs 34.8%; risk difference 2.1%, 95% CI -2.6 to 6.9). Symptomatic intracerebral hemorrhage (3.4% vs 3.2%) and 90-day mortality (15.3% vs 15.4%) were similar. No age-specific analyses or measures of neuroplasticity or age-related modulation of reperfusion benefit are reported.",
          "pmid": "35779553",
          "title": "Intravenous tenecteplase compared with alteplase for acute ischaemic stroke in Canada (AcT): a pragmatic, multicentre, open-label, registry-linked, randomised, controlled, non-inferiority trial.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract focuses on ischemic stroke mimics, their prevalence, characteristics, and outcomes, including thrombolysis safety. It does not analyze age-related neuroplasticity, age-dependent brain recovery after ischemia, or differential benefit of early reperfusion by age. Any mention of age is in the context of stroke mimics having younger age than true strokes, not mechanistic recovery or reperfusion efficacy.",
          "key_findings": "Ischemic stroke mimics account for about 24.8% of suspected acute strokes; mimic patients tend to have younger age, fewer vascular risk factors, less severe symptoms, and better outcomes than true ischemic stroke patients. Thrombolysis is given less often to mimics (26.3%) than strokes (61.7%), with much lower intracranial hemorrhage and mortality in mimics. The review does not examine neuroplasticity, age-related recovery capacity after ischemic insult, or how age modifies the therapeutic effect of early reperfusion.",
          "pmid": "34656244",
          "title": "Ischemic stroke mimics: A comprehensive review.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract discusses general stroke epidemiology, recanalization therapy, and neuroprotective strategies, but does not address age-related differences in neuroplasticity, age-modified recovery from ischemic insult, or differential benefit of early reperfusion in younger versus older patients.",
          "key_findings": "The review notes increasing stroke incidence, including in younger groups, describes advances in pharmacologic and mechanical recanalization, and outlines efforts to develop neuroprotective agents and combinational strategies, but provides no data or claims about how age affects neuroplasticity, brain recovery, or the therapeutic impact of early reperfusion.",
          "pmid": "33144066",
          "title": "Emerging neuroprotective strategies for the treatment of ischemic stroke: An overview of clinical and preclinical studies.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract evaluates fibrinolytic therapy versus placebo in intermediate-risk pulmonary embolism and reports outcomes of hemodynamic decompensation, bleeding, and stroke. It does not analyze age-related differences in neuroplasticity, brain recovery from ischemia, or age-modified therapeutic effects of reperfusion or fibrinolysis. No mechanistic or subgroup data related to age and neuroplastic recovery are presented.",
          "key_findings": "Tenecteplase plus heparin reduced death or hemodynamic decompensation within 7 days compared with placebo plus heparin (2.6% vs. 5.6%), but increased major extracranial bleeding (6.3% vs. 1.2%) and stroke (2.4% vs. 0.2%). Mortality at 7 and 30 days did not differ significantly between groups. No age-stratified outcomes or data on neuroplasticity or ischemic brain recovery are reported.",
          "pmid": "24716681",
          "title": "Fibrinolysis for patients with intermediate-risk pulmonary embolism.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract compares pediatric and adult stroke in terms of epidemiology, aetiology, and evidence level for interventions, but it does not discuss age-related differences in neuroplasticity, recovery from ischemia, or differential benefit of early reperfusion between younger and older patients.",
          "key_findings": "Childhood strokes are a major cause of long-term neurological morbidity; approximately half are hemorrhagic and half ischemic; causes differ from adults; urgent imaging is needed to guide hyperacute therapies; evidence for rapid reperfusion therapies in children remains low; time delays in diagnosis and treatment are common; effective primary prevention exists for sickle cell disease-related stroke. No data are presented on neuroplasticity, age-related recovery capacity, or age-dependent therapeutic effects of early reperfusion.",
          "pmid": "35210461",
          "title": "Childhood stroke.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract compares clinical outcomes of balloon angioplasty plus medical management vs medical management alone in symptomatic intracranial stenosis but does not analyze results by age, discuss neuroplasticity, or address age-related differences in recovery from ischemic insult. Therefore, it neither supports nor contradicts the proposed age-dependent neuroplasticity mechanism.",
          "key_findings": "Balloon angioplasty plus aggressive medical management reduced the 12\u2011month composite outcome of stroke/death or revascularization compared to aggressive medical management alone (4.4% vs 13.5%; HR 0.32). Procedural complication and dissection rates were relatively high. Mean age was 58 years, but no age-stratified outcomes or mechanistic neuroplasticity data were reported.",
          "pmid": "39235816",
          "title": "Balloon Angioplasty vs Medical Management for Intracranial Artery Stenosis: The BASIS Randomized Clinical Trial.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract evaluates adjunctive intra-arterial tenecteplase after successful endovascular thrombectomy and reports overall clinical and safety outcomes, but it does not analyze results by age, nor does it address neuroplasticity, age-dependent recovery potential, or differential benefit of early reperfusion in younger vs older patients. Therefore it neither supports nor contradicts the proposed age-related neuroplasticity mechanism.",
          "key_findings": "In 540 patients (median age 69 years) with large vessel occlusion stroke and near-complete to complete reperfusion after EVT, adjunctive intra-arterial tenecteplase did not significantly increase the rate of freedom from disability (mRS 0\u20131 at 90 days: 49.1% vs 44.1%; adjusted RR 1.15, 95% CI 0.97\u20131.36; P=0.11), nor did it significantly affect 90-day mortality or symptomatic intracranial hemorrhage. No age-stratified outcomes or mechanistic analyses on neuroplasticity or age-related recovery were reported.",
          "pmid": "39804681",
          "title": "Intra-Arterial Tenecteplase Following Endovascular Reperfusion for Large Vessel Occlusion Acute Ischemic Stroke: The POST-TNK Randomized Clinical Trial.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract evaluates the effect of intravenous tirofiban before endovascular thrombectomy on 90-day functional outcome and hemorrhage risk in large vessel occlusion stroke. It does not analyze age-related differences, neuroplasticity, or differential benefit of early reperfusion by age group, nor does it address mechanisms of recovery capacity after ischemia. Therefore, it neither supports nor contradicts the proposed age-dependent neuroplasticity mechanism.",
          "key_findings": "In 948 patients (mean age 67 years) with large vessel occlusion stroke undergoing endovascular thrombectomy, pre-procedural intravenous tirofiban did not significantly improve 90-day disability (median mRS 3 vs 3; adjusted common OR 1.08, 95% CI 0.86\u20131.36) and increased symptomatic intracranial hemorrhage numerically (9.7% vs 6.4%). No age-stratified outcomes or mechanistic data about neuroplasticity or age-related recovery were reported.",
          "pmid": "35943471",
          "title": "Effect of Intravenous Tirofiban vs Placebo Before Endovascular Thrombectomy on Functional Outcomes in Large Vessel Occlusion Stroke: The RESCUE BT Randomized Clinical Trial.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract discusses epidemiology, risk factors, and management questions for ischemic stroke in patients \u226460 years old, but it does not address age-related differences in neuroplasticity, brain recovery after ischemia, or differential benefit of early reperfusion by age. Therefore, it neither supports nor contradicts the proposed mechanism.",
          "key_findings": "Focuses on causes and management issues in young stroke patients, including genetic thrombophilia, patent foramen ovale, cerebral vein thrombosis, carotid dissection, antiphospholipid syndrome, anticoagulation strategies, and COVID-19-related large vessel stroke; does not discuss neuroplasticity, recovery capacity, or age-modified effects of reperfusion therapy.",
          "pmid": "33870763",
          "title": "Ischemic Stroke in the Young.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract evaluates different post-thrombectomy blood pressure targets and their impact on functional outcome but does not analyze age-related differences, neuroplasticity, or differential benefit of early reperfusion by age. No mechanistic or subgroup data are presented that relate outcomes to age-dependent brain recovery or plasticity.",
          "key_findings": "In 305 eligible patients (mean age 73 years) after successful endovascular thrombectomy, intensive systolic BP lowering (<140 mm Hg) during the first 24 hours resulted in a lower rate of functional independence at 3 months (39.4%) compared with conventional BP management (140\u2013180 mm Hg; 54.4%), without significant differences in symptomatic intracerebral hemorrhage or stroke-related mortality. Age-related effects or mechanisms of neuroplastic recovery were not examined.",
          "pmid": "37668619",
          "title": "Intensive vs Conventional Blood Pressure Lowering After Endovascular Thrombectomy in Acute Ischemic Stroke: The OPTIMAL-BP Randomized Clinical Trial.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract analyzes predictors of hemorrhagic transformation and symptomatic intracranial hemorrhage after endovascular thrombectomy, focusing on alteplase use, NIHSS score, glucose, anticoagulant history, and number of device passes. It does not examine age-related differences in neuroplasticity, recovery potential, or how age modifies the therapeutic effect of early reperfusion, so it neither supports nor contradicts the proposed mechanism.",
          "key_findings": "In a randomized trial of EVT alone versus EVT plus alteplase in acute ischemic stroke, symptomatic intracranial hemorrhage was associated with higher baseline NIHSS and higher admission glucose; alteplase treatment did not increase the risk of hemorrhagic transformation, symptomatic intracranial hemorrhage, or parenchymal hematoma. Age is reported only as a median descriptive variable and is not analyzed as a modifier of treatment effect or recovery, nor is neuroplasticity assessed.",
          "pmid": "34872341",
          "title": "Clinical and Imaging Indicators of Hemorrhagic Transformation in Acute Ischemic Stroke After Endovascular Thrombectomy.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract examines how the benefit of IV thrombolysis plus thrombectomy declines with increasing time from stroke onset, but it does not analyze differences by patient age, nor does it address neuroplasticity or age-related capacity for recovery. The observed time dependence of treatment effect is consistent with general principles of ischemic injury progression but does not specifically test or discuss age-dependent neuroplasticity or whether earlier reperfusion preferentially benefits younger patients.",
          "key_findings": "In an individual participant data meta-analysis of 6 RCTs (n=2313) of IV thrombolysis plus thrombectomy vs thrombectomy alone, the benefit of combination therapy on 90-day functional outcome decreased with longer onset-to-IVT time (interaction ratio of adjusted common OR per 1-hour delay, 0.84 [95% CI, 0.72-0.97]). Adjusted common ORs for improved mRS with IVT plus thrombectomy vs thrombectomy alone were 1.49 at 1 hour, 1.25 at 2 hours, and 1.04 at 3 hours; predicted absolute risk differences for mRS 0\u20132 were 9%, 5%, and 1% at those times, respectively. Benefit was no longer statistically significant after approximately 2 hours 20 minutes. Age is only reported descriptively (median 71 years) and is not analyzed as an effect modifier.",
          "pmid": "38324409",
          "title": "Time to Treatment With Intravenous Thrombolysis Before Thrombectomy and Functional Outcomes in Acute Ischemic Stroke: A Meta-Analysis.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The trial evaluates the efficacy and safety of remote ischemic conditioning in acute stroke but does not analyze outcomes by age, neuroplasticity, or differential benefit of early reperfusion/conditioning in younger vs older patients. No mechanistic data about age-related recovery capacity or neuroplasticity are presented, so it neither supports nor contradicts the proposed age-dependent mechanism.",
          "key_findings": "In 1500 patients with suspected acute stroke (<4 hours from symptom onset), remote ischemic conditioning started prehospital and continued in-hospital did not significantly improve 90-day functional outcome compared with sham (mRS shift OR 0.95, 95% CI 0.75\u20131.20). Serious adverse events were similar between groups. The abstract does not report age-stratified effects or measures related to neuroplasticity or age-dependent recovery.",
          "pmid": "37787796",
          "title": "Remote Ischemic Conditioning for Acute Stroke: The RESIST Randomized Clinical Trial.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract compares tenecteplase versus alteplase for thrombolysis after ischemic stroke and reports imaging and clinical outcomes, but it does not analyze results by age, neuroplasticity, or differential benefit of early reperfusion in younger versus older patients. No mechanistic discussion of age-related brain recovery or plasticity is provided.",
          "key_findings": "Tenecteplase and alteplase showed no significant differences in percentage of penumbra salvaged, intracerebral hemorrhage rates, serious adverse events, or neurological and radiological outcomes in adults treated within 4.5 hours of stroke onset, without stratification or analysis based on patient age or neuroplasticity-related factors.",
          "pmid": "25726502",
          "title": "Alteplase versus tenecteplase for thrombolysis after ischaemic stroke (ATTEST): a phase 2, randomised, open-label, blinded endpoint study.",
          "analysis_method": "llm"
        },
        {
          "stance": "conflict",
          "confidence": "medium",
          "reasoning": "The proposed mechanism suggests that decreased neuroplasticity and recovery potential with age should make early reperfusion more beneficial in younger patients than in older ones. However, the abstract reports that participants aged over 80 years benefited equally to those aged under 80 years, particularly if treated within three hours. This equal benefit across age groups, given similar treatment timing, conflicts with the idea that younger patients have enhanced therapeutic effects from early reperfusion due to greater neuroplasticity.",
          "key_findings": "1) Thrombolytic therapy within three hours of stroke was more effective than later treatment overall (OR 0.66 for death or dependency), indicating a strong time-dependent benefit. 2) The abstract specifically states: 'Participants aged over 80 years benefited equally to those aged under 80 years, particularly if treated within three hours of stroke.' 3) No differential advantage of early reperfusion in younger versus older patients is reported, despite age-related concerns and prior upper age limits in some countries.",
          "pmid": "25072528",
          "title": "Thrombolysis for acute ischaemic stroke.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract evaluates the clinical efficacy and safety of adjunct intra-arterial urokinase after successful endovascular reperfusion but does not analyze outcomes by age, neuroplasticity, or differential benefit of early reperfusion in younger versus older patients. No mechanistic or subgroup data related to age-dependent brain recovery or plasticity are provided.",
          "key_findings": "In 535 acute ischemic stroke patients with large vessel occlusion who achieved near-complete/complete reperfusion via thrombectomy, adjunct intra-arterial urokinase did not significantly increase survival without disability at 90 days (45.1% vs 40.2%; adjusted RR 1.13, 95% CI 0.94-1.36; P=0.19) and did not significantly affect mortality or symptomatic intracranial hemorrhage. Age is only reported as a median (69 years) without analysis of age-related differences in treatment effect.",
          "pmid": "39804674",
          "title": "Intra-Arterial Urokinase After Endovascular Reperfusion for Acute Ischemic Stroke: The POST-UK Randomized Clinical Trial.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The trial compares alteplase vs aspirin in minor, nondisabling stroke and reports functional outcomes and hemorrhage risk, stratifying analyses by age among other factors. However, the abstract does not present age-specific results, does not analyze differential benefit of early reperfusion by age, and does not discuss neuroplasticity or age-related recovery capacity. Therefore it neither supports nor contradicts the proposed mechanism about decreased neuroplasticity with age enhancing early reperfusion benefit in younger patients.",
          "key_findings": "In 313 patients with minor nondisabling acute ischemic stroke (mean age 62 years) treated within 3 hours, alteplase did not increase the likelihood of favorable 90-day functional outcome compared with aspirin (78.2% vs 81.5%; adjusted risk difference -1.1%; 95% CI -9.4% to 7.3%) but increased symptomatic intracranial hemorrhage (3.2% vs 0%). Analyses were adjusted for age, NIHSS, and time to treatment, but no age-stratified outcomes or mechanistic neuroplasticity data are reported.",
          "pmid": "29998337",
          "title": "Effect of Alteplase vs Aspirin on Functional Outcome for Patients With Acute Ischemic Stroke and Minor Nondisabling Neurologic Deficits: The PRISMS Randomized Clinical Trial.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract discusses clinical characteristics, pathology, and treatment of Sneddon syndrome, including age at diagnosis and prognosis, but it does not address age-related differences in neuroplasticity, brain recovery from ischemia, or differential therapeutic benefit of early reperfusion by age.",
          "key_findings": "Sneddon syndrome involves noninflammatory thrombotic vasculopathy of cerebral and dermal arteries, predominantly affects women with median diagnosis age of 40 years, can have childhood onset, is associated with recurrent strokes and early-onset dementia, and is treated primarily with antiplatelet/antithrombotic agents. No data are provided on neuroplasticity, age-modified recovery from ischemia, or age-dependent efficacy of early reperfusion therapies.",
          "pmid": "31160219",
          "title": "Sneddon Syndrome: A Comprehensive Overview.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract evaluates timing of initiation of dual antiplatelet therapy (clopidogrel plus aspirin) between 0\u201372 hours after mild ischemic stroke/TIA and its effect on recurrent stroke and bleeding. It does not analyze outcomes by patient age, nor does it examine neuroplasticity, recovery capacity, or differential therapeutic effects of early reperfusion in younger vs older patients. The study\u2019s timing dimension is about antithrombotic treatment window, not age\u2011related brain recovery mechanisms.",
          "key_findings": "Dual antiplatelet therapy started within 72 hours reduced 90\u2011day new stroke risk compared with aspirin alone, with consistent benefit across three initiation windows (\u226424 h, >24\u201348 h, >48\u201372 h), and similar relative increase in moderate\u2011to\u2011severe bleeding across these windows. Median age was 65, but no age-stratified efficacy or mechanistic neuroplasticity analysis was reported.",
          "pmid": "39240565",
          "title": "Clopidogrel and Aspirin Initiated Between 24 to 72 Hours for Mild Ischemic Stroke: A Subgroup Analysis of the INSPIRES Randomized Clinical Trial.",
          "analysis_method": "llm"
        }
      ]
    },
    {
      "feature_name": "age",
      "mechanism": {
        "mechanism_type": "biological",
        "description": "Studies have shown a decreasing benefit-to-risk ratio of alteplase with increasing age beyond 80 years, potentially due to higher risk of hemorrhagic complications in older adults.",
        "evidence_level": "moderate"
      },
      "query": "(stroke OR alteplase OR thrombolysis OR \"ischemic stroke\") AND \"age\" AND (\"pathophysiology\" OR \"mechanism\" OR \"causal\" OR \"etiology\" OR \"interaction\") AND (\"complications\" OR \"hemorrhagic\" OR \"potentially\") AND (Clinical Trial[PT] OR Review[PT] OR Meta-Analysis[PT])",
      "total_abstracts": 20,
      "support_count": 0,
      "conflict_count": 0,
      "neutral_count": 20,
      "support_percentage": 0.0,
      "conflict_percentage": 0.0,
      "support_ratio": 0.0,
      "abstracts_analyzed": [
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract discusses epidemiology, risk factors, and outcomes of premature (young) stroke, but does not mention alteplase, thrombolytic therapy, age over 80, benefit-to-risk ratios, or hemorrhagic complication rates by age. It neither supports nor contradicts the specific mechanism regarding alteplase risk-benefit in very elderly patients.",
          "key_findings": "The abstract reports rising incidence of ischemic and hemorrhagic strokes in young patients, heterogeneity and frequent cryptogenic etiology, shifting sex distribution and vascular risk factors with age within younger groups, higher incidence in minority and socioeconomically disadvantaged populations, and concerns about misdiagnosis and need for special diagnostic work-up in premature stroke. No data on alteplase use or age-related hemorrhagic risk is provided.",
          "pmid": "36374365",
          "title": "A Contemporary Review of Epidemiology, Risk Factors, Etiology, and Outcomes of Premature Stroke.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract discusses post-stroke movement disorders, their clinical spectrum, pathophysiological mechanisms, and lack of management guidelines. It does not mention alteplase, thrombolysis, age-stratified treatment effects, hemorrhagic complications, or benefit-to-risk ratios in older adults. Therefore it neither supports nor contradicts the proposed age-related risk mechanism for alteplase.",
          "key_findings": "Involuntary movements occur in 1\u20134% of strokes, with hemichorea-hemiballism most common in adults and dystonia in children; other movement disorders include tremor, myoclonus, asterixis, stereotypies, and vascular parkinsonism. Pathophysiological mechanisms proposed include neuronal plasticity, functional diaschisis, and age-related differences in brain metabolism. No treatment guidelines exist due to heterogeneity of post-stroke movement disorders.",
          "pmid": "33904435",
          "title": "Post-stroke Movement Disorders: Clinical Spectrum, Pathogenesis, and Management.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The proposed mechanism concerns a decreasing benefit-to-risk ratio of alteplase in patients over 80, due to higher hemorrhagic risk. This abstract focuses on endovascular thrombectomy versus standard care, with alteplase use only as an adjustment covariate. It reports no difference in hemorrhage or mortality between thrombectomy and control groups and shows benefit of thrombectomy in patients \u226580, but it does not analyze alteplase-specific risks, age-related alteplase effects, or changing benefit-to-risk ratios of alteplase itself.",
          "key_findings": "Endovascular thrombectomy reduced disability at 90 days versus control (adjusted cOR 2.49, 95% CI 1.76\u20133.53) with no heterogeneity of treatment effect across subgroups, including patients aged \u226580 years (cOR 3.68, 95% CI 1.95\u20136.92). Mortality and risks of parenchymal hematoma and symptomatic intracranial hemorrhage did not differ between thrombectomy and control groups. Intravenous alteplase use (yes/no) was included as an adjustment factor but alteplase-specific age-related benefit\u2013risk patterns were not reported.",
          "pmid": "26898852",
          "title": "Endovascular thrombectomy after large-vessel ischaemic stroke: a meta-analysis of individual patient data from five randomised trials.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The trial compares tenecteplase vs alteplase for acute ischaemic stroke and reports overall safety and efficacy outcomes, but it does not analyze age-stratified benefit-risk profiles, nor does it examine whether alteplase risk (particularly hemorrhagic complications) increases disproportionately beyond age 80. Therefore it neither supports nor contradicts the proposed age-related decline in alteplase benefit-to-risk ratio.",
          "key_findings": "In 1,577 patients (median age 74, IQR 63\u201383) randomized to tenecteplase or alteplase within 4.5 hours of stroke onset, tenecteplase was non-inferior to alteplase for functional outcome (mRS 0\u20131 at 90\u2013120 days: 36.9% vs 34.8%; risk difference 2.1%, 95% CI -2.6 to 6.9). Symptomatic intracerebral hemorrhage rates were similar (3.4% vs 3.2%), as were 90-day mortality rates (15.3% vs 15.4%). No age-stratified risk or outcome data, particularly for patients >80 years, are presented.",
          "pmid": "35779553",
          "title": "Intravenous tenecteplase compared with alteplase for acute ischaemic stroke in Canada (AcT): a pragmatic, multicentre, open-label, registry-linked, randomised, controlled, non-inferiority trial.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract discusses stroke epidemiology, recanalization therapy in general, and the development of neuroprotective strategies, but it does not mention alteplase specifically, age-related differences in its benefit-risk profile, or hemorrhagic complication rates in older adults. Therefore it neither supports nor contradicts the proposed mechanism.",
          "key_findings": "The review describes (1) the growing global burden of stroke, (2) advances in pharmacological and mechanical recanalization therapies, and (3) efforts to develop neuroprotective agents (including SPAN and various molecular mechanisms). It does not provide data or discussion on alteplase outcomes stratified by age or on hemorrhagic risks in patients over 80.",
          "pmid": "33144066",
          "title": "Emerging neuroprotective strategies for the treatment of ischemic stroke: An overview of clinical and preclinical studies.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract evaluates tenecteplase versus placebo in intermediate-risk pulmonary embolism but does not stratify outcomes by age, address patients over 80 specifically, or analyze how hemorrhagic risk or benefit\u2013risk ratio changes with increasing age. Thus it does not directly support or contradict the proposed age-related alteplase mechanism.",
          "key_findings": "In intermediate-risk PE, tenecteplase plus heparin reduced death or hemodynamic decompensation compared with placebo (2.6% vs 5.6%; OR 0.44) but increased major extracranial bleeding (6.3% vs 1.2%) and stroke, mostly hemorrhagic (2.4% vs 0.2%), with no significant difference in 7- or 30-day mortality. No age-related analyses or data specific to patients over 80 years were reported.",
          "pmid": "24716681",
          "title": "Fibrinolysis for patients with intermediate-risk pulmonary embolism.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract evaluates intra-arterial tenecteplase after endovascular thrombectomy and reports overall efficacy and hemorrhage outcomes, but it does not analyze differential benefit or hemorrhagic risk by age, nor does it address alteplase specifically or patients >80 years as a subgroup. Therefore it neither supports nor contradicts the proposed age-dependent benefit\u2013risk mechanism for alteplase.",
          "key_findings": "In 540 patients (median age 69) with large vessel occlusion stroke and near-complete/complete reperfusion after EVT, adjunctive intra-arterial tenecteplase vs no intra-arterial thrombolysis showed: (1) no statistically significant increase in freedom from disability at 90 days (49.1% vs 44.1%; adjusted RR 1.15, 95% CI 0.97\u20131.36; P=0.11); (2) similar 90-day mortality (16.0% vs 19.3%; adjusted HR 0.75, 95% CI 0.50\u20131.13; P=0.16); (3) numerically higher but not significantly increased symptomatic intracranial hemorrhage (6.3% vs 4.4%; adjusted RR 1.43, 95% CI 0.68\u20132.99; P=0.35). No age-stratified or >80-year analyses were reported.",
          "pmid": "39804681",
          "title": "Intra-Arterial Tenecteplase Following Endovascular Reperfusion for Large Vessel Occlusion Acute Ischemic Stroke: The POST-TNK Randomized Clinical Trial.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract focuses on patent foramen ovale, cryptogenic stroke, and outcomes of PFO closure versus medical therapy, mainly in patients \u226460 years. It does not discuss alteplase (tPA), thrombolytic therapy, age-related differences in benefit\u2013risk, or hemorrhagic complications. Therefore, it neither supports nor contradicts the proposed mechanism about decreasing benefit-to-risk of alteplase in those >80 years.",
          "key_findings": "PFO is present in ~25% of adults; it is common in younger and middle-aged patients with cryptogenic stroke. PFO closure reduces recurrent ischemic stroke in well-selected patients \u226460 years, particularly those classified as PASCAL 'probable.' In PASCAL 'unlikely' patients (often older with vascular risk factors and without high-risk PFO features), PFO closure does not reduce recurrent stroke and is associated with higher risk of procedure- and device-related adverse events such as atrial fibrillation. No data are presented on alteplase, thrombolysis, or age-related hemorrhagic risk.",
          "pmid": "40720119",
          "title": "Patent Foramen Ovale and Stroke: A Review.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract focuses on ischemic stroke in younger patients (\u226460 years), addressing topics like thrombophilia, PFO, cerebral vein thrombosis, carotid dissection, antiphospholipid syndrome, DOACs, and COVID-19-related stroke. It does not discuss alteplase use, benefit-to-risk ratios, hemorrhagic complications, or age >80, so it neither supports nor contradicts the proposed age-related mechanism of alteplase risk-benefit.",
          "key_findings": "Narrative review of ischemic stroke in young adults covering genetic thrombophilia, patent foramen ovale closure, treatment of cerebral vein thrombosis, carotid dissection, antiphospholipid syndrome, DOAC use, and mechanisms of large vessel stroke in COVID-19; no data on alteplase, thrombolysis outcomes, or age >80.",
          "pmid": "33870763",
          "title": "Ischemic Stroke in the Young.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The proposed mechanism concerns age-related changes in the benefit\u2011to\u2011risk ratio of alteplase in patients over 80, specifically due to higher hemorrhagic risk with increasing age. The abstract evaluates whether alteplase increases hemorrhagic transformation risk after endovascular thrombectomy overall, identifies predictors of hemorrhage, and reports no association between alteplase treatment and HT/sICH/PH. However, it does not analyze age subgroups, does not focus on patients >80, and does not examine how hemorrhagic risk with alteplase varies by age. Therefore it neither supports nor contradicts the specific age\u2011dependent mechanism.",
          "key_findings": "In the DIRECT\u2011MT trial (EVT alone vs IV alteplase plus EVT; n=633, median age 69), alteplase treatment was not associated with increased risk of hemorrhagic transformation, symptomatic intracranial hemorrhage, or parenchymal hematoma. Independent predictors of sICH included higher baseline NIHSS and higher admission glucose (overall and in specific treatment groups), as well as history of anticoagulant use and >3 device passes in the combination\u2011therapy group. No age\u2011stratified hemorrhagic risk or data specific to patients >80 years were reported.",
          "pmid": "34872341",
          "title": "Clinical and Imaging Indicators of Hemorrhagic Transformation in Acute Ischemic Stroke After Endovascular Thrombectomy.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The proposed mechanism concerns age-related changes in the benefit\u2011to\u2011risk ratio of alteplase beyond age 80, particularly due to higher hemorrhagic risk. The abstract analyzes time-to-treatment effects of IV thrombolysis plus thrombectomy versus thrombectomy alone on functional outcomes, without stratifying by age (especially >80) or reporting hemorrhagic complication rates by age. It focuses on time dependency, not on age-related bleeding risk or benefit\u2011to\u2011risk ratios, so it neither supports nor contradicts the specific age-based mechanism.",
          "key_findings": "In a meta-analysis of 6 randomized trials (n=2313, median age 71), the benefit of IV thrombolysis plus thrombectomy versus thrombectomy alone declined with increasing time from symptom onset to expected IVT administration. There was a significant time-by-treatment interaction (ratio of adjusted common OR per 1-hour delay 0.84, 95% CI 0.72\u20130.97). Benefit was significant at earlier times (e.g., adjusted common OR 1.49 at 1 hour; 1.25 at 2 hours) and not statistically significant beyond about 2 hours 20 minutes, with the point estimate crossing the null around 3 hours 14 minutes. No age-stratified outcomes or hemorrhage data were reported.",
          "pmid": "38324409",
          "title": "Time to Treatment With Intravenous Thrombolysis Before Thrombectomy and Functional Outcomes in Acute Ischemic Stroke: A Meta-Analysis.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract discusses epidemiology, etiology, and management gaps in stroke among young patients, but does not mention alteplase, thrombolysis, age-related benefit-risk, or hemorrhagic complications. It therefore neither supports nor contradicts the proposed age-related change in alteplase benefit-to-risk ratio in those over 80.",
          "key_findings": "Focus on stroke in the young, with increased prevalence, distinct etiologies (e.g., cardioembolism with PFO/atrial septal aneurysm, non-atherosclerotic vasculopathies, thrombophilia), and lack of evidence-based management guidelines for these uncommon causes; no data on alteplase use or age-related treatment risks.",
          "pmid": "31768660",
          "title": "Stroke in the Young: a Global Update.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The study compares tenecteplase versus alteplase for acute ischemic stroke and reports hemorrhage and adverse event rates, but it does not analyze outcomes by age, does not focus on patients >80 years, and does not evaluate how age modifies alteplase benefit\u2013risk or hemorrhagic risk. Therefore it neither supports nor contradicts the proposed age-related decline in alteplase benefit\u2013risk beyond 80.",
          "key_findings": "Adults with supratentorial ischemic stroke within 4.5 hours were randomized to tenecteplase or alteplase. Symptomatic intracerebral hemorrhage rates and total intracerebral hemorrhage events did not significantly differ between treatment groups. Age was included in the randomization/minimization algorithm, but no age-stratified safety or efficacy results are reported, and there is no specific analysis of patients older than 80 years.",
          "pmid": "25726502",
          "title": "Alteplase versus tenecteplase for thrombolysis after ischaemic stroke (ATTEST): a phase 2, randomised, open-label, blinded endpoint study.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract examines age as a risk factor for post\u2011stroke dysphagia, not the benefit\u2011to\u2011risk ratio of alteplase, nor hemorrhagic complications or thrombolytic therapy outcomes by age. It does not address alteplase use, treatment effects, or bleeding risk, so it neither supports nor contradicts the proposed mechanism.",
          "key_findings": "Elder age (SMD = 0.42, 95% CI: 0.34\u20130.50), hypertension (OR = 1.96), diabetes (OR = 1.83), and brainstem stroke (OR = 2.12) are associated with increased risk of dysphagia after ischemic stroke; gender showed no significant association. No data on alteplase, hemorrhagic complications, or age-related thrombolysis outcomes are reported.",
          "pmid": "35709228",
          "title": "Risk factors of dysphagia in patients with ischemic stroke: A meta-analysis and systematic review.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The proposed mechanism concerns age-related changes in the benefit\u2011risk profile of alteplase (a thrombolytic), specifically in adults over 80 and their risk of hemorrhagic complications. The abstract instead evaluates hemorrhagic stroke risk associated with lipid\u2011lowering therapies (statins, PCSK9 inhibitors, ezetimibe, triglyceride\u2011lowering agents) and includes age subgroups only within that context. It does not study alteplase, thrombolysis, or benefit\u2011risk tradeoffs of reperfusion therapy in older adults, so it neither supports nor contradicts the specific alteplase mechanism.",
          "key_findings": "The meta-analysis of 37 LDL-C\u2013lowering and 11 triglyceride\u2011lowering trials (\u22651000 patients, \u22652 years follow\u2011up) found a modestly increased risk of hemorrhagic stroke with LDL\u2011C lowering overall (RR 1.16, 95% CI 1.01\u20131.32), particularly with statins (RR 1.17, 95% CI 1.01\u20131.36), including higher risk in statin trials with mean age \u226565 years (RR 1.34, 95% CI 1.04\u20131.73). PCSK9 inhibitors and ezetimibe had wide confidence intervals, and triglyceride\u2011lowering therapies did not show clear increased risk (RR 1.05, 95% CI 0.86\u20131.30). No data on alteplase or thrombolytic therapy were presented.",
          "pmid": "38323514",
          "title": "Lipid-Lowering Therapy and Risk of Hemorrhagic Stroke: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The proposed mechanism concerns age-dependent changes in the benefit\u2013risk ratio of alteplase (an IV thrombolytic), particularly increased hemorrhagic risk in those over 80. The abstract evaluates intra-arterial urokinase given after successful thrombectomy, in patients who did not receive IV thrombolysis, and does not analyze outcomes or hemorrhagic risk by age strata or specifically in patients >80. It also studies a different drug (urokinase) and route (intra-arterial), so it neither supports nor contradicts the specific age-related alteplase mechanism.",
          "key_findings": "In a randomized trial of 535 patients (median age 69) with large vessel occlusion and near-complete/complete reperfusion after thrombectomy, adjunct intra-arterial urokinase (100,000 IU) did not significantly improve survival without disability at 90 days compared with no intra-arterial thrombolysis (45.1% vs 40.2%; adjusted RR 1.13, 95% CI 0.94\u20131.36). Mortality at 90 days and symptomatic intracranial hemorrhage within 48 hours were similar between groups. No age-specific or >80 subgroup analyses were reported, and the study did not involve IV alteplase.",
          "pmid": "39804674",
          "title": "Intra-Arterial Urokinase After Endovascular Reperfusion for Acute Ischemic Stroke: The POST-UK Randomized Clinical Trial.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The proposed mechanism concerns age-related changes in the benefit\u2011risk ratio of alteplase in patients >80 years, specifically due to higher hemorrhagic risk. This trial reports overall efficacy and symptomatic intracranial hemorrhage rates for alteplase vs aspirin in mostly younger patients with minor, nondisabling stroke; although age was a stratification/adjustment factor in analysis, the abstract does not present age\u2011specific results or compare outcomes in older versus younger patients. Therefore, it does not directly address whether benefit\u2011risk decreases beyond age 80.",
          "key_findings": "In 313 patients with minor, nondisabling acute ischemic stroke (mean age 62 years), alteplase did not increase the likelihood of favorable functional outcome at 90 days compared with aspirin (78.2% vs 81.5%; adjusted risk difference \u22121.1%, 95% CI \u22129.4% to 7.3%). Symptomatic intracranial hemorrhage occurred in 3.2% (5/156) of alteplase-treated patients and 0% of aspirin-treated patients (risk difference 3.3%, 95% CI 0.8%\u20137.4%). No age-stratified efficacy or safety outcomes, particularly for patients >80 years, are reported.",
          "pmid": "29998337",
          "title": "Effect of Alteplase vs Aspirin on Functional Outcome for Patients With Acute Ischemic Stroke and Minor Nondisabling Neurologic Deficits: The PRISMS Randomized Clinical Trial.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract compares transport strategies (direct to thrombectomy-capable center vs closest local stroke center) and reports overall age distribution and outcomes, but it does not stratify alteplase (IV tPA) benefit or hemorrhagic risk by age, nor does it assess changing benefit-to-risk ratios of alteplase in patients over 80 years. No data on age-specific hemorrhagic complications are presented.",
          "key_findings": "In this nonurban stroke systems-of-care trial, patients directly transported to thrombectomy-capable centers received less IV alteplase and more thrombectomy, with no significant difference in 90-day disability or mortality between transport strategies. The median age was 75 years (IQR 65\u201383), but outcomes and complications were not analyzed by age group or focused on alteplase-related hemorrhagic risk.",
          "pmid": "35510397",
          "title": "Effect of Direct Transportation to Thrombectomy-Capable Center vs Local Stroke Center on Neurological Outcomes in Patients With Suspected Large-Vessel Occlusion Stroke in Nonurban Areas: The RACECAT Randomized Clinical Trial.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract evaluates efficacy and safety of Ginkgo diterpene lactone meglumine in acute ischemic stroke and excludes patients over 80 years, with no use of alteplase or other thrombolysis allowed. It does not analyze age-related risk\u2013benefit profiles of alteplase or hemorrhagic complications, so it neither supports nor contradicts the proposed mechanism.",
          "key_findings": "Randomized, double-blind trial of 3448 AIS patients aged 18\u201380 comparing GDLM vs placebo showed improved 90-day mRS 0\u20131 in the GDLM group and similar adverse event rates; thrombolysis and thrombectomy were not permitted, and there was no analysis of alteplase, age >80, or hemorrhagic risk.",
          "pmid": "37578791",
          "title": "Efficacy and Safety of Ginkgo Diterpene Lactone Meglumine in Acute Ischemic Stroke: A Randomized Clinical Trial.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The proposed mechanism concerns age-related changes in the benefit-to-risk ratio of alteplase (IV thrombolysis) in patients over 80, driven by hemorrhagic risk. The abstract instead evaluates timing of initiation of direct oral anticoagulants after atrial fibrillation\u2013related ischemic stroke, with a median age of 75 and no age-stratified analyses, and does not involve alteplase use or age-related hemorrhagic risk patterns. Therefore, it neither supports nor contradicts the specific mechanism.",
          "key_findings": "In a response-adaptive randomized trial of 200 patients with AF-related ischemic stroke, patients were randomized to start a direct oral anticoagulant on day 3\u20134, 6, 10, or 14 after stroke. Ischemic events within 30 days were 0 (group 1), 3 (group 2), 2 (group 3), and 2 (group 4); hemorrhagic events were 1, 1, 1, and 0, respectively. Earlier initiation appeared favorable, but no clearly superior day was identified. No data on alteplase, no explicit analysis of patients >80 years, and no mechanistic evaluation of age-related hemorrhagic risk from thrombolysis were reported.",
          "pmid": "40163159",
          "title": "Optimal Delay Time to Initiate Anticoagulation After Ischemic Stroke in Atrial Fibrillation: A Pragmatic, Response-Adaptive Randomized Clinical Trial.",
          "analysis_method": "llm"
        }
      ]
    },
    {
      "feature_name": "age",
      "mechanism": {
        "mechanism_type": "biological",
        "description": "Younger patients often have fewer comorbid conditions and better physiological reserves, which can result in more effective recovery following reperfusion therapy.",
        "evidence_level": "moderate"
      },
      "query": "(stroke OR alteplase OR thrombolysis OR \"ischemic stroke\") AND \"age\" AND (\"pathophysiology\" OR \"mechanism\" OR \"causal\" OR \"etiology\" OR \"interaction\") AND (\"physiological\" OR \"reperfusion\" OR \"conditions\") AND (Clinical Trial[PT] OR Review[PT] OR Meta-Analysis[PT])",
      "total_abstracts": 20,
      "support_count": 0,
      "conflict_count": 0,
      "neutral_count": 20,
      "support_percentage": 0.0,
      "conflict_percentage": 0.0,
      "support_ratio": 0.0,
      "abstracts_analyzed": [
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract compares tenecteplase with alteplase for acute ischaemic stroke and reports overall functional outcomes, safety, and mortality. It does not analyze outcomes by patient age, comorbidity burden, or physiological reserve, nor does it evaluate recovery differences between younger and older patients after reperfusion therapy. Therefore, it neither supports nor contradicts the proposed mechanism about younger patients having better recovery due to fewer comorbidities and greater physiological reserve.",
          "key_findings": "In a randomized, multicentre Canadian trial of 1600 acute ischaemic stroke patients (median age 74), tenecteplase was non-inferior to alteplase for achieving mRS 0\u20131 at 90\u2013120 days (36.9% vs 34.8%; risk difference 2.1%, 95% CI -2.6 to 6.9). Symptomatic intracerebral haemorrhage at 24 h and 90-day mortality were similar between groups. No results were stratified by age or comorbidity, and no analyses of the impact of patient age or physiological reserve on recovery were reported.",
          "pmid": "35779553",
          "title": "Intravenous tenecteplase compared with alteplase for acute ischaemic stroke in Canada (AcT): a pragmatic, multicentre, open-label, registry-linked, randomised, controlled, non-inferiority trial.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract reports overall clinical outcomes of Tongxinluo as adjunct therapy in STEMI patients but does not analyze age-related differences, comorbidity burden, physiological reserve, or differential recovery after reperfusion by age or health status. Therefore it neither supports nor contradicts the mechanism that younger, less comorbid patients recover more effectively following reperfusion therapy.",
          "key_findings": "In a randomized, double-blind, placebo-controlled trial of 3777 STEMI patients (mean age 61 years), Tongxinluo plus guideline-directed therapy reduced 30-day MACCEs (3.4% vs 5.2%; RR 0.64, 95% CI 0.47-0.88) and 1-year MACCEs (5.3% vs 8.3%; HR 0.64, 95% CI 0.49-0.82), as well as cardiac death at 30 days and 1 year, but increased adverse drug reactions, mainly gastrointestinal. No subgroup analysis by age, comorbidities, or measures of physiological reserve was reported.",
          "pmid": "37874574",
          "title": "Traditional Chinese Medicine Compound (Tongxinluo) and Clinical Outcomes of Patients With Acute Myocardial Infarction: The CTS-AMI Randomized Clinical Trial.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract discusses pediatric stroke epidemiology, types, causes, imaging, prevention, and the limited evidence for rapid reperfusion therapies in children, but it does not compare outcomes by age, comorbidity burden, or physiological reserve, nor does it analyze recovery following reperfusion therapy as a function of patient age or health status.",
          "key_findings": "Childhood stroke is a major cause of neurological morbidity; about half of pediatric strokes are hemorrhagic and half ischemic; causes differ from adults; urgent imaging is essential; evidence for rapid reperfusion therapies in children is low; there are substantial delays in diagnosis and treatment; effective primary prevention exists for children with sickle cell disease. None of these findings address whether younger patients recover more effectively from reperfusion therapy because of fewer comorbidities or better physiological reserves.",
          "pmid": "35210461",
          "title": "Childhood stroke.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract discusses epidemiology, risk factors, and outcomes of atrial fibrillation, but does not address age-related differences in comorbidities, physiological reserve, or recovery following reperfusion therapy. No data are presented on reperfusion, recovery, or treatment response by age, so it neither supports nor contradicts the proposed mechanism.",
          "key_findings": "Advanced age, male sex, and various comorbidities (e.g., obesity, diabetes, hypertension, heart failure, myocardial infarction) are identified as AF risk factors; AF-related outcomes such as stroke and thromboembolism are discussed, as is the role of anticoagulation. There is no mention of reperfusion therapy or age-related recovery capacity.",
          "pmid": "28450367",
          "title": "Atrial Fibrillation: Epidemiology, Pathophysiology, and Clinical Outcomes.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract evaluates the efficacy and safety of adjunctive intra-arterial tenecteplase after successful endovascular reperfusion in acute ischemic stroke. It does not analyze outcomes by age, comorbidity burden, or physiological reserve, nor does it discuss differential recovery in younger versus older patients. Therefore, it neither supports nor contradicts the proposed mechanism about younger patients recovering more effectively after reperfusion due to fewer comorbidities and better physiological reserves.",
          "key_findings": "In 540 stroke patients (median age 69) with near-complete to complete reperfusion after EVT, adjunctive intra-arterial tenecteplase did not significantly increase freedom from disability at 90 days compared with control (49.1% vs 44.1%; adjusted RR 1.15, 95% CI 0.97-1.36; P=0.11). Ninety-day mortality and symptomatic intracranial hemorrhage rates were similar between groups. No data are presented on age-stratified outcomes, comorbidity profiles, or physiological reserve.",
          "pmid": "39804681",
          "title": "Intra-Arterial Tenecteplase Following Endovascular Reperfusion for Large Vessel Occlusion Acute Ischemic Stroke: The POST-TNK Randomized Clinical Trial.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract reviews reversible cerebral vasoconstriction syndrome, its clinical features, outcomes, and management, but it does not analyze age-related differences, comorbidity burden, physiological reserve, or response to reperfusion therapy. Therefore it neither supports nor contradicts the proposed mechanism about younger patients recovering better after reperfusion.",
          "key_findings": "RCVS predominantly affects women; presents with thunderclap headaches; 1/3\u20131/2 develop complications like hemorrhage, ischemic strokes, and reversible edema; vasoconstriction evolves from distal to proximal arteries; management is mostly symptomatic with calcium-channel blockers and removal of triggers; glucocorticoids worsen outcome; intra-arterial vasodilators have variable success; 90\u201395% of admitted patients have complete or major symptom resolution within days to weeks; recurrence is rare. No mention of age-stratified outcomes or reperfusion therapy response.",
          "pmid": "37246916",
          "title": "Reversible cerebral vasoconstriction syndrome: A review of pathogenesis, clinical presentation, and treatment.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract evaluates the efficacy and safety of DOACs versus no anticoagulation in predominantly elderly survivors of intracerebral haemorrhage with atrial fibrillation. It does not analyze age-related differences in recovery, comorbid burden, or physiological reserve, nor does it examine outcomes stratified by age or comorbidity. Therefore, it neither supports nor contradicts the proposed mechanism that younger patients recover more effectively after reperfusion therapy due to fewer comorbidities and better physiological reserves.",
          "key_findings": "Median patient age was 79 years; the trial compared DOACs to no anticoagulation and found reduced ischaemic stroke but increased recurrent intracerebral haemorrhage risk with DOACs. Outcomes were not reported by age groups, comorbidity burden, or measures of physiological reserve, and the study did not involve reperfusion therapy.",
          "pmid": "40023176",
          "title": "Direct oral anticoagulants versus no anticoagulation for the prevention of stroke in survivors of intracerebral haemorrhage with atrial fibrillation (PRESTIGE-AF): a multicentre, open-label, randomised, phase 3 trial.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract discusses dysphagia, its prevalence in elderly populations, associated complications, and the benefits of swallowing rehabilitation, but it does not compare younger versus older patients, nor does it address comorbid burden, physiological reserve, or recovery following reperfusion therapy. Therefore, it neither supports nor contradicts the proposed age-related recovery mechanism.",
          "key_findings": "Dysphagia is common in aging adults, particularly in those with stroke and dementia, and is associated with nutritional deficits and pneumonia risk. Swallowing rehabilitation can improve safe oral intake, nutritional status, and reduce pneumonia rates in elderly individuals with or at risk for dysphagia.",
          "pmid": "22956864",
          "title": "Dysphagia in the elderly: management and nutritional considerations.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract reports overall effects of remote ischemic conditioning on stroke outcomes and safety but does not analyze outcomes by age, comorbidity burden, or physiological reserve, nor does it discuss differential recovery between younger and older patients. Therefore, it provides no direct evidence for or against the proposed mechanism that younger patients recover more effectively following reperfusion therapy due to fewer comorbidities and better physiological reserves.",
          "key_findings": "In a randomized clinical trial of 1500 patients with suspected acute stroke, remote ischemic conditioning (RIC) initiated prehospital and continued in-hospital did not significantly improve 90-day functional outcome compared with sham (mRS OR 0.95, 95% CI 0.75\u20131.20). Serious adverse event rates were similar between RIC and sham groups. The abstract does not present subgroup analyses by age or comorbidity status and does not address mechanisms related to younger patients\u2019 physiological reserves or differential recovery following reperfusion therapy.",
          "pmid": "37787796",
          "title": "Remote Ischemic Conditioning for Acute Stroke: The RESIST Randomized Clinical Trial.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract focuses on comparing intensive vs conventional blood pressure targets after endovascular thrombectomy and their impact on functional outcomes and safety. It does not analyze age, comorbidity burden, or physiological reserve, nor does it evaluate differential recovery among younger vs older patients. Therefore, it provides no direct evidence for or against the proposed age-related recovery mechanism.",
          "key_findings": "In a randomized trial of 305 patients (mean age 73 years) after successful EVT, intensive BP control (systolic <140 mm Hg) resulted in lower functional independence at 3 months (39.4%) compared with conventional management (140\u2013180 mm Hg; 54.4%), without significant differences in symptomatic intracerebral hemorrhage or stroke-related mortality. No stratified results by age, comorbidities, or physiological reserve were reported.",
          "pmid": "37668619",
          "title": "Intensive vs Conventional Blood Pressure Lowering After Endovascular Thrombectomy in Acute Ischemic Stroke: The OPTIMAL-BP Randomized Clinical Trial.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract focuses on statin safety, adverse events, and tolerability across different demographic and clinical subgroups. It does not address reperfusion therapy, recovery after reperfusion, or the role of age-related comorbidities and physiological reserve in recovery outcomes, so it neither supports nor contradicts the proposed mechanism.",
          "key_findings": "The statement reviews statin safety, reporting low absolute risks of serious muscle injury, hepatotoxicity, and diabetes, no convincing links to several other adverse outcomes, and differences between clinical practice and trial-reported muscle symptoms. It also notes subgroup considerations (elderly, children, pregnant women, certain comorbid conditions). None of these findings pertain to recovery following reperfusion therapy or age-related physiological reserve.",
          "pmid": "30580575",
          "title": "Statin Safety and Associated Adverse Events: A Scientific Statement From the American Heart Association.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract discusses factors affecting venous leg ulcer healing (including advanced age and comorbid conditions such as obesity, nutritional deficiencies, venous disease, and deep venous thrombosis) but does not address reperfusion therapy or compare recovery or treatment response specifically between younger and older patients. Therefore, it neither supports nor contradicts the proposed mechanism about younger patients\u2019 better recovery following reperfusion therapy.",
          "key_findings": "Recalcitrant venous leg ulcers show prolonged healing time with advanced age, obesity, nutritional deficiencies, preexisting venous disease, deep venous thrombosis, larger wound area, and environmental factors like colder temperature. The abstract details molecular and cellular processes of wound healing and treatments such as compression therapy and venous interventions, but does not analyze age-related differences in response to reperfusion therapy.",
          "pmid": "33374372",
          "title": "Why Venous Leg Ulcers Have Difficulty Healing: Overview on Pathophysiology, Clinical Consequences, and Treatment.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract evaluates the efficacy and safety of adjunct intra-arterial urokinase after successful endovascular thrombectomy in acute ischemic stroke. It does not analyze outcomes by age, comorbidity burden, or physiological reserve, nor does it compare recovery between younger and older patients. Therefore, it provides no direct evidence regarding whether younger patients have better recovery following reperfusion therapy due to fewer comorbidities and better physiological reserves.",
          "key_findings": "In a randomized clinical trial of 535 patients (median age 69) with large vessel occlusion stroke who achieved near-complete or complete reperfusion by thrombectomy, adjunct intra-arterial urokinase did not significantly increase the proportion of patients with survival without disability (mRS 0\u20131 at 90 days: 45.1% vs 40.2%; adjusted RR 1.13, 95% CI 0.94\u20131.36; P=0.19). Mortality and symptomatic intracranial hemorrhage were similar between groups. No analyses by age, comorbidity status, or physiological reserve are reported.",
          "pmid": "39804674",
          "title": "Intra-Arterial Urokinase After Endovascular Reperfusion for Acute Ischemic Stroke: The POST-UK Randomized Clinical Trial.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract discusses age-related patterns in clinical manifestations of patent foramen ovale and missing mechanistic explanations for the impact of age on right-to-left shunting, but it does not address reperfusion therapy, recovery after reperfusion, comorbidities, or physiological reserve. Therefore it neither supports nor contradicts the proposed mechanism about younger patients recovering better after reperfusion therapy.",
          "key_findings": "The abstract states that PFO-related conditions (e.g., migraine, stroke/TIA, platypnea-orthodeoxia) are more common in specific age ranges and notes that mechanistic explanations for the impact of age on right-to-left shunting are lacking. It focuses on flow dynamics and pathophysiological sequelae of PFO, without discussing treatment response, reperfusion therapy, or recovery differences by age.",
          "pmid": "39134216",
          "title": "The pathophysiology of patent foramen ovale and its related complications.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract discusses venous thromboembolism risk, diagnosis, and treatment in pregnant and postpartum patients, including use of reperfusion therapies for limb- or life-threatening events, but it does not compare outcomes by age, comorbidity burden, or physiological reserve. Therefore, it does not provide evidence for or against the claim that younger patients recover more effectively following reperfusion therapy due to fewer comorbidities and better physiological reserves.",
          "key_findings": "Pregnancy and postpartum periods are associated with increased VTE risk, peaking shortly after delivery. Major risk factors include thrombophilia, cesarean delivery, postpartum infection, and obesity with immobilization. Most VTE cases are treated with low molecular weight heparin; limb- or life-threatening cases may require thrombolysis and other reperfusion therapies, with emphasis on multispecialty coordination to optimize maternal and fetal outcomes. No age-stratified or comorbidity-stratified recovery or outcome data following reperfusion therapy are reported.",
          "pmid": "35792687",
          "title": "Venous Thromboembolism During Pregnancy and the Postpartum Period: Risk Factors, Diagnostic Testing, and Treatment.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract evaluates work stress as a risk factor for cardiovascular disease and its consistency across age, sex, and socioeconomic groups. It does not address reperfusion therapy, recovery after reperfusion, physiological reserve, comorbidities, or age-related differences in treatment response or recovery. Therefore it neither supports nor contradicts the proposed mechanism about younger patients recovering more effectively following reperfusion therapy.",
          "key_findings": "Work stressors like job strain and long working hours are associated with a moderately elevated risk (10\u201340%) of incident coronary heart disease and stroke in over 600,000 individuals across 27 cohort studies. The association is similar between men and women, younger and older employees, and across socioeconomic groups. There is also an association with type 2 diabetes but not with common cancers or COPD. The abstract notes limited interventional evidence on whether reducing work stress lowers cardiovascular risk.",
          "pmid": "26238744",
          "title": "Work Stress as a Risk Factor for Cardiovascular Disease.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract compares two mechanical thrombectomy techniques and reports angiographic and reperfusion outcomes, but does not analyze age-related differences, comorbidity burden, physiological reserve, or recovery patterns by age. Therefore, it neither supports nor contradicts the proposed mechanism about younger patients recovering more effectively after reperfusion therapy.",
          "key_findings": "In 405 acute ischemic stroke patients (mean age 73 years), combined contact aspiration plus stent retriever did not significantly improve final near-total/total reperfusion (eTICI 2c/3) compared with stent retriever alone, though some secondary angiographic outcomes favored the combined technique. No age-stratified outcomes or analyses of comorbidities/physiological reserve were reported.",
          "pmid": "34581737",
          "title": "Effect of Thrombectomy With Combined Contact Aspiration and Stent Retriever vs Stent Retriever Alone on Revascularization in Patients With Acute Ischemic Stroke and Large Vessel Occlusion: The ASTER2 Randomized Clinical Trial.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The mechanism concerns younger patients having fewer comorbidities and better physiological reserve leading to better recovery after reperfusion therapy. This abstract focuses on frail, elderly patients (\u226575 years) with atrial fibrillation, comparing outcomes on DOACs vs warfarin. It does not analyze age gradients, younger cohorts, physiological reserve, or recovery after reperfusion therapy, nor does it compare older to younger patients in a way that tests this mechanism.",
          "key_findings": "In frail, elderly, VKA-experienced AF patients, standard-dose DOACs vs warfarin showed similar major bleeding and net clinical outcomes but significant reductions in stroke/systemic embolism, fatal and intracranial bleeding, and death; gastrointestinal bleeding was increased. Treatment effects were compared between frail elderly VKA-experienced vs those without all three criteria, but not along a younger vs older or physiological reserve axis, and no reperfusion therapy or recovery mechanisms were evaluated.",
          "pmid": "40769671",
          "title": "Outcomes in Older Patients After Switching to a Newer Anticoagulant or Remaining on Warfarin: The COMBINE-AF Substudy.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract evaluates the efficacy and safety of nerinetide adjunctive to endovascular thrombectomy but does not analyze outcomes by age, comorbidity burden, or physiological reserve, nor does it compare recovery between younger and older patients. Therefore it does not provide evidence for or against the proposed mechanism that younger patients recover more effectively following reperfusion therapy due to fewer comorbidities and better physiological reserves.",
          "key_findings": "The trial randomized 1105 adults (\u226518 years) with acute ischemic stroke due to large vessel occlusion to nerinetide or placebo, all undergoing endovascular thrombectomy. The primary outcome (mRS 0\u20132 at 90 days) was similar between nerinetide and placebo (61.4% vs 59.2%; adjusted RR 1.04, 95% CI 0.96\u20131.14; p=0.35). Secondary outcomes and serious adverse events were also similar, with evidence of treatment effect modification by alteplase use. No age-stratified or comorbidity-related analyses are reported.",
          "pmid": "32087818",
          "title": "Efficacy and safety of nerinetide for the treatment of acute ischaemic stroke (ESCAPE-NA1): a multicentre, double-blind, randomised controlled trial.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract discusses neuroendocrine changes with ageing, their role in premature ageing, and related disease risk, but does not address reperfusion therapy, recovery after reperfusion, or explicitly compare recovery or physiological reserve between younger and older patients in that context. Thus it neither supports nor contradicts the specific mechanism about better recovery following reperfusion therapy in younger patients.",
          "key_findings": "Ageing is associated with involution of neuroendocrine functions (decreased sex steroids and growth hormone, altered cortisol regulation) leading to changes in energy, body composition, insulin resistance, and increased risk of cardiovascular disease, diabetes, and stroke; psychosocial and environmental factors may contribute to premature ageing; hormonal substitution therapy shows promising preventive and therapeutic potential.",
          "pmid": "7595179",
          "title": "Neuroendocrine ageing.",
          "analysis_method": "llm"
        }
      ]
    },
    {
      "feature_name": "glucose",
      "mechanism": {
        "mechanism_type": "biological",
        "description": "Hyperglycemia in acute ischemic stroke is associated with increased risk of hemorrhagic transformation, potentially due to osmotic effects leading to blood-brain barrier disruption.",
        "evidence_level": "moderate"
      },
      "query": "(stroke OR alteplase OR thrombolysis OR \"ischemic stroke\") AND \"glucose\" AND (\"pathophysiology\" OR \"mechanism\" OR \"causal\" OR \"etiology\" OR \"interaction\") AND (\"transformation\" OR \"hyperglycemia\" OR \"potentially\") AND (Clinical Trial[PT] OR Review[PT] OR Meta-Analysis[PT])",
      "total_abstracts": 18,
      "support_count": 1,
      "conflict_count": 0,
      "neutral_count": 17,
      "support_percentage": 5.555555555555555,
      "conflict_percentage": 0.0,
      "support_ratio": 0.05555555555555555,
      "abstracts_analyzed": [
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract discusses stress hyperglycaemia broadly, its risks, mechanisms of harm, and management, but does not mention acute ischemic stroke, hemorrhagic transformation, blood-brain barrier disruption, or osmotic effects. Therefore it does not directly support or refute the proposed stroke-specific mechanistic pathway.",
          "key_findings": "Stress hyperglycaemia (often in patients without known diabetes) is associated with higher risk of adverse consequences than pre-existing diabetes in hospitalized patients; mechanisms of harm and classification are discussed in general terms, not in the context of ischemic stroke or hemorrhagic transformation.",
          "pmid": "19465235",
          "title": "Stress hyperglycaemia.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract discusses hyperglycemia and diabetes in the context of vascular homeostasis, oxidative stress, inflammation, atherothrombosis, and myocardial dysfunction, but it does not address acute ischemic stroke, hemorrhagic transformation, blood-brain barrier integrity, or osmotic mechanisms. Therefore it neither supports nor contradicts the proposed mechanism.",
          "key_findings": "Hyperglycemia, hyperinsulinemia, and insulin resistance are said to alter vascular homeostasis, with reduced nitric oxide and increased reactive oxygen species promoting inflammation and atherothrombotic progression leading to myocardial dysfunction and heart failure. No mention is made of stroke, hemorrhagic transformation, or blood-brain barrier disruption.",
          "pmid": "33813813",
          "title": "Epidemiology, Pathophysiology, Diagnosis and Treatment of Heart Failure in Diabetes.",
          "analysis_method": "llm"
        },
        {
          "stance": "support",
          "confidence": "medium",
          "reasoning": "The proposed mechanism links hyperglycemia in acute ischemic stroke to increased risk of hemorrhagic transformation via blood-brain barrier disruption. This abstract reports that higher glucose level at hospital arrival is an independent predictor of symptomatic intracranial hemorrhage after endovascular thrombectomy, both overall and specifically in the combination-therapy group. While the study does not test osmotic BBB-disruption mechanisms directly, it provides outcome-level evidence that hyperglycemia is associated with increased risk of hemorrhagic complications in acute ischemic stroke, which is consistent with the proposed mechanism.",
          "key_findings": "In 633 acute ischemic stroke patients undergoing endovascular thrombectomy, higher glucose level at hospital arrival was independently associated with symptomatic intracranial hemorrhage (overall adjusted OR 1.14 [95% CI, 1.00\u20131.29]; in the combination-therapy group adjusted OR 1.19 [95% CI, 1.03\u20131.38]). The study identifies admission hyperglycemia as a predictor of hemorrhagic complications (sICH), supporting a link between elevated glucose and hemorrhagic transformation risk, although it does not examine the specific osmotic/blood\u2013brain barrier mechanism.",
          "pmid": "34872341",
          "title": "Clinical and Imaging Indicators of Hemorrhagic Transformation in Acute Ischemic Stroke After Endovascular Thrombectomy.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract discusses diabetes, its diagnosis, treatment, and complications including stroke in general terms, but does not address acute ischemic stroke, hyperglycemia during stroke, hemorrhagic transformation, or blood-brain barrier disruption or osmotic mechanisms. Therefore it neither supports nor contradicts the proposed mechanism.",
          "key_findings": "The paper reviews prevalence, diagnosis, and treatment of diabetes and pre-diabetes, classifies diabetic complications into microvascular and macrovascular (including stroke), and notes the role of genetic and epigenetic factors in T2DM. No mechanistic data are presented on hyperglycemia\u2019s effect on hemorrhagic transformation or blood-brain barrier integrity in acute ischemic stroke.",
          "pmid": "31470636",
          "title": "From Pre-Diabetes to Diabetes: Diagnosis, Treatments and Translational Research.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract notes that stress-induced hyperglycemia negatively impacts acute illnesses including ischemic stroke, but it does not mention hemorrhagic transformation, blood\u2013brain barrier integrity, or osmotic mechanisms. It addresses clinical consequences of hyperglycemia in stroke only in broad terms, without mechanistic detail relevant to BBB disruption or hemorrhagic conversion.",
          "key_findings": "Stress-induced hyperglycemia is common in critically ill patients, is associated with increased mortality, and has a \"dire impact\" on acute illnesses such as myocardial infarction and ischemic stroke. The article reviews development, consequences, and management of SIH, but provides no specific data on hemorrhagic transformation or osmotic blood\u2013brain barrier disruption in stroke.",
          "pmid": "35959169",
          "title": "Stress-Induced Hyperglycemia: Consequences and Management.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract discusses chronic diabetes-associated hyperglycemia causing vascular damage, mitochondrial dysfunction, and oxidative stress, and mentions stroke in this general context. It does not address acute ischemic stroke, hemorrhagic transformation, blood\u2013brain barrier integrity, or osmotic effects as a mechanism, so it neither supports nor contradicts the proposed specific mechanism.",
          "key_findings": "Overloaded glucose in metabolic diseases like type 2 diabetes leads to mitochondrial dysfunction and increased ROS; diabetes-associated hyperglycemia and dyslipidemia can directly damage blood vessels and contribute to coronary artery disease or stroke; SGLT2 inhibitors and GLP-1 receptor agonists improve metabolism and cardiovascular/cardiorenal outcomes, potentially via effects on oxidative stress and mitochondrial function.",
          "pmid": "38220031",
          "title": "Cardiovascular benefits of SGLT2 inhibitors and GLP-1 receptor agonists through effects on mitochondrial function and oxidative stress.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract reports that diabetes and acute hyperglycemia are associated with poorer outcomes after ischemic or hemorrhagic stroke, but it does not specifically examine hemorrhagic transformation of ischemic stroke or mechanisms such as osmotic effects and blood\u2013brain barrier disruption. Therefore it does not directly support or contradict the proposed mechanistic pathway.",
          "key_findings": "Meta-analysis of 39 studies (n=359,783) found diabetes prevalence of 28% among stroke inpatients, higher in ischemic than hemorrhagic stroke. Most included studies showed that acute hyperglycemia and diabetes were associated with poorer outcomes (higher mortality, worse functional/neurological outcomes, longer stay, higher readmission, and recurrence). Mechanistic explanations or specific data on hemorrhagic transformation and blood\u2013brain barrier integrity are not provided.",
          "pmid": "30220102",
          "title": "Prevalence of diabetes and its effects on stroke\u00a0outcomes: A meta-analysis and literature review.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract concerns medical management and risk factors in peripheral artery disease and does not discuss acute ischemic stroke, hyperglycemia-related outcomes in stroke, hemorrhagic transformation, osmotic effects, or blood-brain barrier disruption. Therefore it neither supports nor contradicts the proposed mechanism.",
          "key_findings": "Peripheral artery disease is linked to systemic atherosclerosis and elevated risk of major adverse cardiovascular and limb events; therapies such as smoking cessation, lipid-lowering drugs, optimal glucose control, antithrombotics, exercise, and cilostazol improve outcomes in PAD. No mention is made of stroke hyperglycemia, hemorrhagic transformation, or blood-brain barrier mechanisms.",
          "pmid": "34110910",
          "title": "Contemporary Medical Management of Peripheral Artery Disease.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "medium",
          "reasoning": "The abstract discusses hyperglycemia after cerebral ischemia and notes that animals with protective ischemic preconditioning did not develop post-ischemic hyperglycemia and showed decreased metabolic damage and faster recovery. However, it does not examine hemorrhagic transformation outcomes nor specifically link hyperglycemia to blood-brain barrier disruption via osmotic effects. Thus it is related to glucose and ischemic injury but does not address the proposed mechanism involving hemorrhagic transformation and BBB disruption.",
          "key_findings": "Post-ischemic hyperglycemia is discussed as having a diverse impact depending on cause (experimentally induced, insulin resistance, stress response). Rats subjected to ischemic preconditioning did not develop post-ischemic hyperglycemia and showed decreased metabolic injury and faster metabolomic recovery, implying that absence of hyperglycemia may be beneficial, but no data are presented on hemorrhagic transformation or blood-brain barrier disruption.",
          "pmid": "38139131",
          "title": "Blood and Brain Metabolites after Cerebral Ischemia.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract discusses stress-induced hyperglycemia and the stress hyperglycemia ratio as prognostic markers in critical illness, including acute ischemic stroke, but it does not address hemorrhagic transformation, blood-brain barrier disruption, or osmotic mechanisms. It links hyperglycemia to adverse outcomes broadly, not specifically to hemorrhagic transformation via BBB effects.",
          "key_findings": "Stress-induced hyperglycemia is common in critical illness; the stress hyperglycemia ratio (admission glucose divided by estimated mean glucose from HbA1c) better reflects stress hyperglycemia than absolute glucose levels; SHR shows a U- or J-shaped association with morbidity and mortality; SHR has predictive value in cardiovascular diseases, cerebrovascular diseases (including acute ischemic stroke), and infectious diseases, but without mechanistic detail on hemorrhagic transformation or BBB disruption.",
          "pmid": "40317019",
          "title": "Relationship between stress hyperglycaemic ratio (SHR) and critical illness: a systematic review.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract discusses the effects of the SGLT2 inhibitor empagliflozin on heart failure outcomes and questions the dominance of diuresis as its main mechanism. It does not involve acute ischemic stroke, hyperglycemia, hemorrhagic transformation, or blood-brain barrier/osmotic effects, so it neither supports nor contradicts the proposed mechanism.",
          "key_findings": "Empagliflozin reduced cardiovascular death or hospitalization for heart failure and improved health status regardless of recent volume overload. The magnitude of benefit was not greater in patients with recent volume overload, and changes in body weight, hematocrit, and natriuretic peptides did not tightly track one another, arguing against a dominant diuretic mechanism in heart failure. No data are presented on stroke, hyperglycemia-related effects, hemorrhagic transformation, or blood-brain barrier disruption.",
          "pmid": "33736819",
          "title": "Empagliflozin in Patients With Heart\u00a0Failure, Reduced Ejection Fraction, and Volume Overload: EMPEROR-Reduced Trial.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract discusses endothelial function, insulin, inflammation, and atherosclerosis in the context of obesity and type 2 diabetes, and mentions stroke risk in general. It does not address acute ischemic stroke, hyperglycemia at stroke onset, hemorrhagic transformation, osmotic effects, or blood-brain barrier disruption, so it neither supports nor contradicts the specific proposed mechanism.",
          "key_findings": "Insulin and thiazolidinediones stimulate endothelial nitric oxide, act as vasodilators, have antiplatelet and anti-inflammatory effects, and may be antiatherogenic. Insulin resistance states such as obesity and type 2 diabetes are associated with increased atherosclerosis, coronary heart disease, and stroke in general.",
          "pmid": "12643190",
          "title": "Endothelium, inflammation, and diabetes.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract links hyperglycemia in acute ischemic stroke with worse outcomes and higher risk of intracerebral hemorrhage, especially in the context of tPA, but it explicitly states that the underlying mechanisms are not fully understood and does not specifically attribute the increased hemorrhagic transformation to osmotic blood\u2013brain barrier disruption.",
          "key_findings": "The review notes that: (1) acute hyperglycemia at stroke onset is associated with worse functional outcomes, longer hospital stay, and higher mortality; (2) tPA therapy, the main acute treatment, carries increased risk of intracerebral hemorrhage; (3) hyperglycemia and tPA together worsen neurovascular injury after stroke; (4) the mechanisms of this worsening are incompletely understood, and the article focuses broadly on potential mechanisms and therapeutic strategies, without detailing osmotic effects on the blood\u2013brain barrier.",
          "pmid": "24619488",
          "title": "Hyperglycemia, acute ischemic stroke, and thrombolytic therapy.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract states that hyperglycemia is associated with poor outcome after stroke but likely as a marker rather than a cause, and it does not discuss hemorrhagic transformation, osmotic effects, or blood\u2013brain barrier disruption. It focuses on risk, prognosis, and the limited benefit of glucose-lowering therapy, without addressing the specific mechanistic pathway proposed.",
          "key_findings": "Hyperglycemia is described as a risk factor for poor outcome following stroke, probably acting as a marker rather than a causal factor; lowering blood glucose has not been shown to improve prognosis or prevent stroke risk in diabetics. No mention is made of hemorrhagic transformation or blood\u2013brain barrier disruption mechanisms.",
          "pmid": "28203079",
          "title": "Role of prediabetes in stroke.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract discusses cardiovascular outcomes of various anti-hyperglycemic agents in diabetes, focusing on major adverse cardiac events (including stroke) and heart failure. It does not address acute ischemic stroke, hyperglycemia at stroke onset, hemorrhagic transformation, or blood-brain barrier disruption, nor any osmotic mechanisms. Therefore, it neither supports nor conflicts with the proposed mechanism.",
          "key_findings": "GLP-1 analogs (liraglutide, semaglutide) and some SGLT2 inhibitors (empagliflozin, canagliflozin) reduce major adverse cardiovascular events and heart failure hospitalizations in patients with diabetes and cardiovascular disease; DPP-4 inhibitors show mixed or neutral cardiovascular effects. No data are presented on acute stroke hyperglycemia, hemorrhagic transformation, or blood-brain barrier integrity.",
          "pmid": "30767126",
          "title": "Cardiovascular Protection with Anti-hyperglycemic Agents.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract links hyperglycemia in acute ischemic stroke to poor clinical outcome and reviews potential pathophysiological mechanisms in general, but it does not specifically discuss hemorrhagic transformation, osmotic effects, or blood\u2013brain barrier disruption as the mediating mechanism.",
          "key_findings": "Hyperglycemia is frequent in acute ischemic stroke and is associated with poor prognosis, particularly in persistent hyperglycemia, in patients without known diabetes, and in cortical infarction; one large trial of glycemic control showed no clinical benefit; the paper reviews mechanisms for deleterious effects of hyperglycemia and clinical management, but specific mention of hemorrhagic transformation or osmotic blood\u2013brain barrier disruption is absent in the abstract.",
          "pmid": "20157308",
          "title": "Hyperglycemia in acute ischemic stroke: pathophysiology and clinical management.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "low",
          "reasoning": "The abstract title indicates it concerns management after thrombectomy, but no details are provided about hyperglycemia, hemorrhagic transformation, or blood-brain barrier disruption, so it cannot be assessed for or against the proposed mechanism.",
          "key_findings": "No mechanism-relevant findings (hyperglycemia, osmotic effects, BBB disruption, or hemorrhagic transformation risk) are described in the provided text.",
          "pmid": "30355218",
          "title": "Care of the Post-Thrombectomy Patient.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract reports that elevated blood glucose (hyperglycemia) is statistically associated with hemorrhagic transformation after thrombolysis, which aligns with the epidemiologic aspect of the proposed mechanism (hyperglycemia \u2192 higher HT risk). However, it does not investigate or mention osmotic effects or blood-brain barrier disruption as the underlying cause, so it does not directly support or refute the specific mechanistic pathway proposed.",
          "key_findings": "In thrombolyzed acute ischemic stroke patients, hemorrhagic transformation was significantly associated with elevated blood glucose (p = 0.004), and the conclusions list hyperglycemia as a risk factor for hemorrhagic transformation and worse outcomes. No mechanistic analysis of osmotic effects or blood-brain barrier disruption is provided.",
          "pmid": "40283013",
          "title": "Risk Factors and Outcomes of Hemorrhagic Transformation in Acute Ischemic Stroke Following Thrombolysis: Analysis of a Single-Center Experience and Review of the Literature.",
          "analysis_method": "llm"
        }
      ]
    },
    {
      "feature_name": "glucose",
      "mechanism": {
        "mechanism_type": "biological",
        "description": "Elevated glucose levels can exacerbate excitotoxicity and oxidative stress in the ischemic penumbra, further damaging viable brain tissue.",
        "evidence_level": "moderate"
      },
      "query": "(stroke OR alteplase OR thrombolysis OR \"ischemic stroke\") AND \"glucose\" AND (\"pathophysiology\" OR \"mechanism\" OR \"causal\" OR \"etiology\" OR \"interaction\") AND (\"excitotoxicity\" OR \"exacerbate\" OR \"oxidative\") AND (Clinical Trial[PT] OR Review[PT] OR Meta-Analysis[PT])",
      "total_abstracts": 20,
      "support_count": 0,
      "conflict_count": 1,
      "neutral_count": 19,
      "support_percentage": 0.0,
      "conflict_percentage": 5.0,
      "support_ratio": 0.0,
      "abstracts_analyzed": [
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract discusses T2DM pathogenesis, oxidative stress in general, and chronic complications, but it does not mention stroke, ischemia, excitotoxicity, ischemic penumbra, or the impact of elevated glucose on acute brain tissue damage. Therefore it neither supports nor contradicts the specific proposed mechanism.",
          "key_findings": "Mentions oxidative stress as a mechanism in T2DM pathogenesis and describes diabetic complications (kidney disease, retinopathy, neuropathy), along with treatment strategies including lifestyle changes and modern antidiabetic drugs. No data or statements relate to glucose effects on excitotoxicity or oxidative stress in ischemic brain tissue.",
          "pmid": "39940862",
          "title": "Type 2 Diabetes Mellitus: New Pathogenetic Mechanisms, Treatment and the Most Important Complications.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract discusses complications of Cushing\u2019s syndrome, including impairment of glucose metabolism and increased risk of stroke, but it does not examine how elevated glucose affects excitotoxicity or oxidative stress in the ischemic penumbra, nor does it address mechanistic brain tissue damage pathways in ischemia.",
          "key_findings": "Cushing\u2019s syndrome leads to metabolic syndrome with impaired glucose metabolism and increases the risk of cardiovascular events such as stroke, but no data are provided on glucose-induced excitotoxicity, oxidative stress, or ischemic penumbra mechanisms.",
          "pmid": "27177728",
          "title": "Complications of Cushing's syndrome: state of the art.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract discusses diabetic complications and their vascular/microvascular mechanisms in broad terms but does not mention ischemic penumbra, excitotoxicity, oxidative stress in brain tissue specifically, or how elevated glucose modifies these processes in stroke or cerebral ischemia.",
          "key_findings": "The review outlines that diabetes leads to microvascular and macrovascular complications (kidney disease, blindness, amputations, heart attacks, strokes) and notes complex, interacting pathways underlying these complications, but it does not detail how hyperglycemia affects excitotoxicity or oxidative stress in ischemic brain regions.",
          "pmid": "23303908",
          "title": "Mechanisms of diabetic complications.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract links elevated glucose to mitochondrial dysfunction and increased ROS/oxidative stress in diabetes, but it does not address ischemic stroke, the ischemic penumbra, or excitotoxicity. Thus it supports a general hyperglycemia\u2013oxidative stress concept, but not specifically the penumbral excitotoxic/oxidative injury mechanism in brain tissue.",
          "key_findings": "Overloaded glucose levels in T2D are said to cause mitochondrial dysfunction and enhanced ROS production; oxidative stress and altered mitochondrial homeostasis contribute to cardiovascular complications; diabetes-associated hyperglycemia and dyslipidemia can directly damage vascular vessels and promote coronary artery disease or stroke. However, no mention is made of ischemic penumbra, neuronal excitotoxicity, or brain-specific oxidative mechanisms.",
          "pmid": "38220031",
          "title": "Cardiovascular benefits of SGLT2 inhibitors and GLP-1 receptor agonists through effects on mitochondrial function and oxidative stress.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract discusses smoking-related oxidative stress, vascular damage, and increased stroke and cardiovascular risk, but it does not mention glucose levels, ischemic penumbra, excitotoxicity, or glucose-mediated modulation of oxidative stress in ischemic brain tissue. Thus it does not directly address the proposed mechanism linking elevated glucose to exacerbated excitotoxicity and oxidative stress in the ischemic penumbra.",
          "key_findings": "Smoking causes oxidative stress, endothelial damage, plaque accumulation, increased risk of thrombotic events, and higher stroke risk; these risks are heightened when diabetes, hypertension, high cholesterol, and glucose intolerance are present. However, no mechanistic details are provided about how elevated glucose affects excitotoxicity or oxidative stress specifically in ischemic brain tissue.",
          "pmid": "37234135",
          "title": "A Systematic Review of the Effects of Smoking on the Cardiovascular System and General Health.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract discusses glycolipid metabolism disorders, their multi-omics study, and associated factors like oxidative stress and insulin resistance, but it does not address ischemic stroke, the ischemic penumbra, excitotoxicity, or the specific effect of elevated glucose on neuronal injury in that context.",
          "key_findings": "The review notes that oxidative stress, chronic inflammation, insulin resistance, and neuroendocrine dysfunction are core pathological links in glycolipid metabolism disorders, and that multi-omics approaches (genomics, transcriptomics, proteomics, metabolomics, gut microbiomics) are being used to identify biomarkers and clarify pathophysiology. No data or discussion is provided about elevated glucose exacerbating excitotoxicity or oxidative stress in ischemic brain tissue.",
          "pmid": "36382190",
          "title": "Advances in multi-omics study of biomarkers of glycolipid metabolism disorder.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract discusses SGLT2 inhibitors\u2019 glucose-lowering and cardiorenal protective effects, including reductions in oxidative stress and modulation of mitochondrial function, but it does not address cerebral ischemia, the ischemic penumbra, excitotoxicity, or how elevated glucose specifically affects neuronal injury in stroke. Therefore it neither supports nor contradicts the proposed brain-specific mechanism.",
          "key_findings": "SGLT2 inhibitors: (1) lower glucose via blocking renal proximal tubule glucose reabsorption; (2) reduce renal damage, chronic kidney disease, and cardiovascular events; (3) exert beneficial actions on heart and kidney through improved risk factors, diuresis/natriuresis, vascular effects, metabolic adjustments in myocardial substrate use; (4) have antifibrotic effects associated with correction of inflammation and oxidative stress, and modulate mitochondrial function and autophagy. No mention is made of cerebral ischemia, excitotoxicity, or glucose effects on brain tissue.",
          "pmid": "35409011",
          "title": "An Overview of the Cardiorenal Protective Mechanisms of SGLT2 Inhibitors.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract discusses insulin resistance, glucose metabolism disorders, and ischemic cerebrovascular disease at a high, bibliometric level but does not present mechanistic data or results showing that elevated glucose directly exacerbates excitotoxicity or oxidative stress in the ischemic penumbra. Mentions of oxidative stress are limited to keywords and research themes, not specific experimental or clinical evidence about this pathway.",
          "key_findings": "The study is a CiteSpace-based bibliometric analysis of 1,500 publications on insulin resistance and ischemic cerebrovascular disease. It reports that insulin resistance is strongly associated with ischemic stroke occurrence, early neurological deterioration, post-stroke depression, and cerebral small vessel disease, and suggests early treatment of insulin resistance to prevent stroke and improve prognosis. Oxidative stress appears only as a frequent keyword, without specific data on how elevated glucose levels affect excitotoxicity or oxidative stress in the ischemic penumbra.",
          "pmid": "36950100",
          "title": "Study on insulin resistance and ischemic cerebrovascular disease: A bibliometric analysis <i>via</i> CiteSpace.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract links stress hyperglycemia with worse outcomes and mentions that excessive hyperglycemia can exacerbate inflammation and oxidative stress in various critical illnesses, including cerebrovascular diseases. However, it does not specifically address mechanisms in the ischemic penumbra, nor does it discuss excitotoxicity or glucose-driven oxidative injury to viable penumbral brain tissue. Thus, it is related in theme but does not directly support or refute the proposed penumbra-specific mechanism.",
          "key_findings": "Prolonged or excessive hyperglycemia is described as exacerbating inflammation and oxidative stress and contributing to adverse outcomes in conditions including cerebrovascular diseases; the stress-hyperglycemia ratio is presented as a prognostic marker with a U- or J-shaped association with morbidity and mortality in acute ischemic stroke and intracerebral hemorrhage, but no mechanistic data on excitotoxicity or ischemic penumbra injury are provided.",
          "pmid": "40317019",
          "title": "Relationship between stress hyperglycaemic ratio (SHR) and critical illness: a systematic review.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract discusses endothelial dysfunction, oxidative stress, inflammation, and diabetes/obesity-related vascular mechanisms, but it does not address glucose levels in the context of cerebral ischemia, excitotoxicity, the ischemic penumbra, or neuronal injury. Therefore it neither supports nor refutes the specific mechanism that elevated glucose exacerbates excitotoxicity and oxidative stress in the ischemic penumbra.",
          "key_findings": "Obesity-associated perivascular adipose tissue increases oxidative stress and pro-inflammatory cytokines, contributing to endothelial dysfunction. Various therapies (liraglutide, RAAS blockade, SGLT2 inhibitor empagliflozin, metformin, GLP-1 receptor agonists, bariatric surgery) can improve endothelial dysfunction, oxidative stress, and cardiometabolic risk. The text mentions hyperinsulinemia, insulin resistance, and type 2 diabetes but does not examine how elevated glucose affects excitotoxicity or oxidative stress in ischemic brain tissue.",
          "pmid": "39287863",
          "title": "Endothelial Dysfunction in Obesity and Therapeutic Targets.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract discusses GLP-1 receptor agonists as glucose-lowering drugs with anti-inflammatory and anti-oxidative effects in heart failure with preserved ejection fraction, but it does not address cerebral ischemia, excitotoxicity, ischemic penumbra, or how elevated glucose affects neuronal injury. Therefore, it neither supports nor contradicts the specific mechanism about hyperglycemia exacerbating excitotoxicity and oxidative stress in ischemic brain tissue.",
          "key_findings": "GLP-1 receptor agonists (e.g., semaglutide) lower glucose and have pleiotropic effects including reduced inflammation and oxidative stress, vasodilation, decreased arterial stiffness, and reduced myocardial fibrosis in HFpEF; STEP-HFpEF trials show improved quality of life and reduced CRP in obese HFpEF patients.",
          "pmid": "39425816",
          "title": "GLP-1 receptor agonists as promising anti-inflammatory agents in heart failure with preserved ejection fraction.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract discusses astrocyte-neuron metabolic crosstalk and how astrocyte-derived metabolites (lactate, ketone bodies, glutamine, L-serine, and even mitochondria) support neuronal energy demands and redox balance in the peri-infarct zone. It does not address the impact of elevated glucose levels, excitotoxicity, or oxidative stress, nor does it relate hyperglycemia to additional neuronal damage in the ischemic penumbra. Therefore it neither supports nor contradicts the proposed glucose-exacerbated excitotoxic/oxidative mechanism.",
          "key_findings": "After ischemic stroke, astrocytes in the peri-infarct zone produce and shuttle lactate, ketone bodies, glutamine, L-serine, and mitochondria to neurons, helping to maintain neuronal energy requirements, preserve redox state, and regulate neurotransmitter receptor activity.",
          "pmid": "39988284",
          "title": "Astrocyte-neuron metabolic crosstalk in ischaemic stroke.",
          "analysis_method": "llm"
        },
        {
          "stance": "conflict",
          "confidence": "medium",
          "reasoning": "The proposed mechanism states that elevated glucose levels exacerbate excitotoxicity and oxidative stress, but the abstract describes ischemic injury as arising from limited delivery of oxygen and glucose leading to ATP reduction and energy depletion. This emphasizes damage due to insufficient, not elevated, glucose. While the abstract does not directly study hyperglycemia, its mechanistic framing of ischemic injury conflicts with the notion that higher glucose availability is a proximate exacerbating factor in this context.",
          "key_findings": "In both global and focal ischemia models, blood flow disruptions 'limit the delivery of oxygen and glucose to neurons causing ATP reduction and energy depletion, initiating excitotoxic mechanisms that are deleterious for neurons.' The text links excitotoxic neuronal death to reduced, not increased, glucose supply.",
          "pmid": "19075733",
          "title": "Ischemic neuronal damage.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract discusses endothelial function, nitric oxide, inflammation, insulin resistance, and risk of atherosclerosis, coronary heart disease, and stroke in diabetes, but it does not address glucose levels, excitotoxicity, oxidative stress, or ischemic penumbra brain injury. There is no mechanistic or experimental evidence about how elevated glucose affects excitotoxic or oxidative damage in ischemic brain tissue.",
          "key_findings": "Insulin and thiazolidinediones stimulate endothelial nitric oxide release, have vasodilatory, antiplatelet, and anti-inflammatory effects, and may be antiatherogenic. Obesity and type 2 diabetes (insulin-resistant states) are associated with increased atherosclerosis, coronary heart disease, and stroke. The focus is on vascular/endothelial mechanisms and atherosclerosis rather than on glucose-induced excitotoxicity or oxidative stress in ischemic brain tissue.",
          "pmid": "12643190",
          "title": "Endothelium, inflammation, and diabetes.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract discusses oxidative stress and excitotoxicity in ischemic stroke in general and focuses on the regulatory role of noncoding RNAs and glial cells. It does not mention glucose levels, hyperglycemia, or how elevated glucose might modulate excitotoxicity or oxidative stress in the ischemic penumbra, so it neither supports nor contradicts the specific proposed mechanism.",
          "key_findings": "The abstract states that oxidative stress and excitatory amino acid toxicity are key components of ischemic stroke pathophysiology; noncoding RNAs show altered expression in patients, animal models, and OGD cell models; ncRNAs and glial cells are involved in mediating oxidative stress and may serve as diagnostic biomarkers and therapeutic targets in ischemic stroke.",
          "pmid": "36132228",
          "title": "Pathophysiology of Ischemic Stroke: Noncoding RNA Role in Oxidative Stress.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract discusses ischemia-related insults including oxygen and glucose deprivation, glutamate excitotoxicity, and the role of NMDAR-activated pannexin-1 channels in anoxic depolarization and neuronal death. It does not address elevated glucose levels, nor how hyperglycemia might modulate excitotoxicity or oxidative stress in the ischemic penumbra. Therefore it is mechanistically related to excitotoxicity but does not provide evidence for or against the specific claim that elevated glucose exacerbates excitotoxicity and oxidative stress.",
          "key_findings": "Ischemic stroke involves oxygen and glucose deprivation, glutamate excitotoxicity, acidification/hypercapnia, and loss of shear forces. NMDAR activation during ischemia can activate pannexin-1 channels via Src family kinases. An interfering peptide corresponding to amino acids 305\u2013318 of Panx1 can antagonize Panx1 opening during ischemia and NMDAR overactivation, reducing anoxic depolarizations and neuronal death.",
          "pmid": "25384783",
          "title": "Pannexin channels and ischaemia.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract discusses hyperglycemia-induced kidney damage, oxidative stress, and autophagy in diabetic nephropathy, but it does not address brain ischemia, the ischemic penumbra, excitotoxicity, or how elevated glucose affects neuronal injury in stroke. Thus it neither supports nor contradicts the specific mechanism about elevated glucose exacerbating excitotoxicity and oxidative stress in ischemic brain tissue.",
          "key_findings": "Hyperglycemia contributes to diabetic kidney disease through mechanisms including chronic inflammation, increased oxidative stress, alterations in metabolism, RAAS overexpression, vitamin D\u2013klotho axis changes, and downregulation of protective autophagy in renal cells. Under normal glucose, autophagy is protective in renal epithelial cells, but in hyperglycemic conditions, reduced autophagy contributes to progression of diabetic kidney disease.",
          "pmid": "32661628",
          "title": "Autophagy in diabetic nephropathy: a review.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract discusses oxidative stress, excitotoxicity, neurotrophins, and astrocyte-mediated neurovascular coupling in ischemic stroke, but it does not address the role of elevated glucose levels or hyperglycemia in modulating excitotoxicity or oxidative stress in the ischemic penumbra. Therefore it neither supports nor contradicts the specific mechanism involving elevated glucose exacerbating these processes.",
          "key_findings": "Ischemic neuronal damage is linked to imbalance between metabolic needs and the ability of the vascular system to maintain glucose delivery and gas exchange; oxidative stress and excitotoxicity are identified as key triggers of neuroinflammation, necrosis, and apoptosis. The review emphasizes roles of neurotrophins (BDNF, NT-3, GDNF) and astrocytes in neuroprotection and neuroplasticity, including heterogeneous NT distribution in the penumbra and shifts in GDNF expression from neurons to glia over time. It notes that some early cytoprotective factors can later become neurotoxic, but does not mention elevated glucose levels or hyperglycemia as modulators of excitotoxicity or oxidative stress.",
          "pmid": "36603664",
          "title": "Neurotoxic and cytoprotective mechanisms in the ischemic neocortex.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract discusses chronic hyperglycemia and altered glucose metabolism as contributors to cognitive dysfunction in type 1 diabetes, but it does not address ischemic stroke, the ischemic penumbra, excitotoxicity, or oxidative stress in that context. There is no mention of how elevated glucose levels interact with excitotoxic or oxidative injury in ischemic brain tissue, so it neither supports nor contradicts the specific proposed mechanism.",
          "key_findings": "The review notes that mechanisms of diabetes-related cognitive dysfunction include chronic hyperglycemia, hypoglycemia, macro- and microvascular disease, and increased inflammatory cytokines, and that altered glucose metabolism may directly affect the brain. It also reports structural and white matter changes on neuroimaging in type 1 diabetes. However, the abstract does not examine ischemic penumbra physiology, excitotoxicity, or oxidative stress in relation to elevated glucose.",
          "pmid": "30657922",
          "title": "Cognitive Dysfunction in Type 1 Diabetes Mellitus.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract discusses oxidative stress and excitatory amino acid toxicity as general pathophysiologic processes in ischemic stroke and focuses on the regulatory role of long non-coding RNAs. It does not mention glucose levels, hyperglycemia, or how glucose might modulate excitotoxicity or oxidative stress in the ischemic penumbra, so it neither supports nor contradicts the proposed glucose-related mechanism.",
          "key_findings": "The abstract states that key processes in ischemic stroke include oxidative stress, excitatory amino acid toxicity, calcium overload, apoptosis, and inflammation, and that long non-coding RNAs may regulate these processes and serve as biomarkers or therapeutic targets. No data or claims are made about elevated glucose or its effect on excitotoxicity or oxidative stress.",
          "pmid": "29651234",
          "title": "Pathophysiology of Long Non-coding RNAs in Ischemic Stroke.",
          "analysis_method": "llm"
        }
      ]
    },
    {
      "feature_name": "glucose",
      "mechanism": {
        "mechanism_type": "biological",
        "description": "There is evidence that hyperglycemia suppresses fibrinolytic activity, which could directly interfere with the effectiveness of alteplase, a thrombolytic agent.",
        "evidence_level": "moderate"
      },
      "query": "(stroke OR alteplase OR thrombolysis OR \"ischemic stroke\") AND \"glucose\" AND (\"pathophysiology\" OR \"mechanism\" OR \"causal\" OR \"etiology\" OR \"interaction\") AND (\"hyperglycemia\" OR \"effectiveness\" OR \"fibrinolytic\") AND (Clinical Trial[PT] OR Review[PT] OR Meta-Analysis[PT])",
      "total_abstracts": 18,
      "support_count": 0,
      "conflict_count": 0,
      "neutral_count": 18,
      "support_percentage": 0.0,
      "conflict_percentage": 0.0,
      "support_ratio": 0.0,
      "abstracts_analyzed": [
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract discusses stress hyperglycaemia, its classification, associated risk, and the need for individualized glycaemic control in hospital inpatients, but it does not address fibrinolytic activity, alteplase, or any interaction between hyperglycaemia and thrombolytic effectiveness. Therefore, it neither supports nor contradicts the proposed mechanism.",
          "key_findings": "Stress hyperglycaemia is common in acute illness, may occur in patients with and without pre-existing diabetes, and is associated with higher risk of adverse outcomes compared with pre-existing diabetes; mechanisms of harm and management strategies are described in general terms, without reference to fibrinolysis or alteplase.",
          "pmid": "19465235",
          "title": "Stress hyperglycaemia.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract discusses hyperglycemia, vascular homeostasis, atherothrombotic progression, and myocardial dysfunction in diabetes, but does not mention fibrinolytic activity, alteplase, or how hyperglycemia might alter thrombolytic effectiveness. Therefore it neither supports nor contradicts the specific proposed mechanism.",
          "key_findings": "Hyperglycemia, hyperinsulinemia, and insulin resistance in diabetes lead to reduced nitric oxide, increased reactive oxygen species, inflammation, atherothrombotic progression, and myocardial dysfunction; the review focuses on heart failure epidemiology, pathophysiology, and treatment in diabetes without addressing fibrinolysis or alteplase response.",
          "pmid": "33813813",
          "title": "Epidemiology, Pathophysiology, Diagnosis and Treatment of Heart Failure in Diabetes.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract discusses diabetes epidemiology, diagnosis, complications, and general treatment approaches, but does not mention fibrinolytic activity, alteplase, thrombolysis, or the effect of hyperglycemia on fibrinolysis. Therefore it neither supports nor refutes the proposed mechanism.",
          "key_findings": "Describes prevalence and types of diabetes, diagnostic methods (FPG, OGTT, glucometers, novel sensors), general complications (microvascular and macrovascular), and the role of lifestyle interventions in preventing progression from pre-diabetes to type 2 diabetes. No data or statements about hyperglycemia\u2019s impact on fibrinolysis or alteplase effectiveness.",
          "pmid": "31470636",
          "title": "From Pre-Diabetes to Diabetes: Diagnosis, Treatments and Translational Research.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract discusses stress-induced hyperglycemia, its mechanisms (insulin resistance and decreased insulin secretion), its impact on outcomes (including in ischemic stroke), and its management. However, it does not mention fibrinolytic activity, alteplase, thrombolysis, or any interaction between hyperglycemia and fibrinolytic/thrombolytic efficacy. Thus it neither supports nor contradicts the specific proposed mechanism.",
          "key_findings": "Stress-induced hyperglycemia (blood glucose >180 mg/dL in non-diabetics) is common in hospitalized/critically ill patients, arises from illness-driven insulin resistance and reduced insulin secretion, is associated with increased mortality and worse outcomes in acute conditions such as myocardial infarction and ischemic stroke, and requires management with insulin and nutritional therapy; there is no discussion of fibrinolysis or alteplase effectiveness.",
          "pmid": "35959169",
          "title": "Stress-Induced Hyperglycemia: Consequences and Management.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract discusses hyperglycemia-induced oxidative stress, mitochondrial dysfunction, and cardiovascular damage, as well as benefits of SGLT2 inhibitors and GLP-1 receptor agonists. It does not address fibrinolytic activity, alteplase, or how hyperglycemia might alter thrombolysis effectiveness, so it neither supports nor contradicts the proposed mechanism.",
          "key_findings": "Overloaded glucose in T2D leads to mitochondrial dysfunction and increased ROS; hyperglycemia and dyslipidemia damage vasculature and contribute to coronary artery disease, stroke, and nephropathy; SGLT2 inhibitors and GLP-1 receptor agonists improve metabolic parameters and cardiovascular/cardiorenal outcomes, potentially via effects on oxidative stress and mitochondrial function. No mention of fibrinolysis or alteplase.",
          "pmid": "38220031",
          "title": "Cardiovascular benefits of SGLT2 inhibitors and GLP-1 receptor agonists through effects on mitochondrial function and oxidative stress.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract discusses peripheral artery disease management, including optimal glucose control and antithrombotic therapy in general, but it does not address hyperglycemia\u2019s effect on fibrinolytic activity, nor any interaction with alteplase or thrombolytic efficacy.",
          "key_findings": "Mentions diabetes and optimal glucose control as modifiable risk factors and components of PAD management, and refers broadly to antithrombotic medications, but provides no mechanistic or outcome data on hyperglycemia altering fibrinolysis or the effectiveness of alteplase.",
          "pmid": "34110910",
          "title": "Contemporary Medical Management of Peripheral Artery Disease.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract reports that diabetes and acute hyperglycemia are associated with poorer stroke outcomes, but it does not address fibrinolytic activity, alteplase use, or any interaction between hyperglycemia and thrombolytic effectiveness. Thus it is related to hyperglycemia and stroke prognosis but not to the specific mechanistic pathway involving suppression of fibrinolysis and alteplase efficacy.",
          "key_findings": "Meta-analysis of 39 studies (n=359,783) found diabetes prevalence of 28% among acute stroke patients, higher in ischemic than hemorrhagic stroke. Most included studies showed that acute hyperglycemia and diabetes are associated with poorer outcomes after stroke (higher mortality, worse neurological/functional outcomes, longer stay, higher readmissions, and recurrence). No data are presented on fibrinolytic activity, alteplase, or thrombolytic treatment response.",
          "pmid": "30220102",
          "title": "Prevalence of diabetes and its effects on stroke\u00a0outcomes: A meta-analysis and literature review.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "medium",
          "reasoning": "The abstract discusses hyperglycemia after cerebral ischemia and notes that animals with protective ischemic preconditioning did not develop post-ischemic hyperglycemia and had better metabolic recovery. However, it does not examine fibrinolytic activity, alteplase, or thrombolysis efficacy, nor does it link hyperglycemia mechanistically to suppressed fibrinolysis. Thus it is related to hyperglycemia in stroke but does not address the proposed mechanism involving interference with alteplase.",
          "key_findings": "Post-ischemic hyperglycemia is discussed as having diverse impacts depending on cause; rats with ischemic preconditioning did not develop post-ischemic hyperglycemia and showed decreased metabolic disturbance and faster metabolomic recovery after cerebral ischemia. No data are presented on fibrinolytic activity, plasminogen activation, or alteplase effectiveness.",
          "pmid": "38139131",
          "title": "Blood and Brain Metabolites after Cerebral Ischemia.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract discusses stress-induced hyperglycemia and the stress-hyperglycemia ratio as prognostic markers in critical illness but does not address fibrinolytic activity, alteplase, or how hyperglycemia might alter thrombolytic effectiveness. No mechanistic link between hyperglycemia and fibrinolysis or thrombolytic therapy is evaluated.",
          "key_findings": "The review describes SIH as a response to stress involving catecholamines, cortisol, and cytokines, and shows that both low and high stress-hyperglycemia ratios are associated with worse outcomes in various conditions including acute ischemic stroke. It emphasizes SHR as a predictor of morbidity and mortality, not as a modifier of fibrinolytic pathways or alteplase efficacy.",
          "pmid": "40317019",
          "title": "Relationship between stress hyperglycaemic ratio (SHR) and critical illness: a systematic review.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract discusses molecular mechanisms of ischemic neuronal death (excitotoxicity, apoptosis, autophagy) and neuroprotection in stroke models, but does not address blood glucose levels, hyperglycemia, fibrinolysis, or alteplase effectiveness. Therefore it neither supports nor contradicts the proposed mechanism involving hyperglycemia-suppressed fibrinolysis and thrombolytic response.",
          "key_findings": "Ischemic brain injury leads to ATP depletion, excitotoxic glutamate signaling, calcium overload, and activation of necrotic, apoptotic, and autophagic cell death pathways; various neuroprotective strategies targeting these death mechanisms show preclinical efficacy but have largely failed in clinical stroke trials.",
          "pmid": "19075733",
          "title": "Ischemic neuronal damage.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract discusses hyperglycemia, stroke outcomes, and interaction with tPA in general terms but does not mention fibrinolytic activity, plasminogen activation, or alteplase effectiveness being directly suppressed by hyperglycemia. It focuses on neurovascular injury and hemorrhage risk, not on hyperglycemia-mediated reduction of fibrinolysis or thrombolytic efficacy.",
          "key_findings": "Hyperglycemia at stroke onset is associated with worse outcomes and higher mortality; tPA is the only proven thrombolytic therapy but increases risk of intracerebral hemorrhage; the review addresses mechanisms of neurovascular injury and strategies to reduce hemorrhage risk in hyperglycemic settings, without specifying that hyperglycemia suppresses fibrinolytic activity or interferes with tPA efficacy.",
          "pmid": "24619488",
          "title": "Hyperglycemia, acute ischemic stroke, and thrombolytic therapy.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract discusses hyperglycemia and diabetes as risk factors for poor stroke outcome and the limited benefit of glucose-lowering on prognosis, but it does not address fibrinolytic activity, alteplase, or any interaction between hyperglycemia and thrombolytic efficacy. Therefore it neither supports nor contradicts the specific proposed mechanism.",
          "key_findings": "Hyperglycemia is described as a risk factor and probable marker of poor outcome after stroke; lowering blood glucose has not been shown to improve prognosis or stroke risk; prediabetes is a risk factor for type 2 diabetes and subsequently for stroke. No mention is made of fibrinolysis, plasminogen/alteplase activity, or thrombolytic treatment response.",
          "pmid": "28203079",
          "title": "Role of prediabetes in stroke.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract discusses the use of fibrinolytics for parapneumonic effusions and empyema but does not mention hyperglycemia, blood glucose levels (beyond pleural fluid glucose as a drainage criterion), systemic fibrinolytic activity, or alteplase effectiveness. It provides no data on how hyperglycemia might suppress fibrinolysis or alter thrombolytic drug action.",
          "key_findings": "Fibrinolytics are described as a controversial but potentially useful adjunct for complicated, loculated parapneumonic effusions and empyema; treatment decisions depend on effusion characteristics (including pleural fluid glucose threshold), local expertise, and surgical alternatives. No relationship is described between systemic hyperglycemia and fibrinolytic activity or alteplase efficacy.",
          "pmid": "18367849",
          "title": "Parapneumonic pleural effusion and empyema.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "medium",
          "reasoning": "The abstract reports that elevated blood glucose (hyperglycemia) is associated with a higher risk of hemorrhagic transformation after rt-PA, but it does not examine fibrinolytic activity, alteplase effectiveness, or any mediating effect of hyperglycemia on fibrinolysis. Thus, it is related to hyperglycemia in the thrombolysis context but does not provide mechanistic evidence about suppression of fibrinolysis or interference with alteplase action.",
          "key_findings": "In thrombolyzed acute ischemic stroke patients, elevated blood glucose (p = 0.004) is significantly associated with hemorrhagic transformation, but the study does not measure fibrinolytic markers or alteplase efficacy parameters, nor does it analyze how hyperglycemia might alter fibrinolysis.",
          "pmid": "40283013",
          "title": "Risk Factors and Outcomes of Hemorrhagic Transformation in Acute Ischemic Stroke Following Thrombolysis: Analysis of a Single-Center Experience and Review of the Literature.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract discusses hyperglycemia in acute ischemic stroke, its association with poor outcomes, and glycemic control strategies, but it does not mention fibrinolytic activity, alteplase, or any interaction between hyperglycemia and thrombolytic effectiveness. Therefore it neither supports nor contradicts the specific mechanism that hyperglycemia suppresses fibrinolysis and interferes with alteplase.",
          "key_findings": "Hyperglycemia is common in acute ischemic stroke and is associated with poor clinical outcomes, especially when persistent and in certain subgroups. One large trial of tight glycemic control did not show clinical benefit and had limitations. Guidelines still recommend treating hyperglycemia despite limited clinical evidence, and insulin treatment carries hypoglycemia risk. No data are presented on fibrinolytic pathways or alteplase response.",
          "pmid": "20157308",
          "title": "Hyperglycemia in acute ischemic stroke: pathophysiology and clinical management.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "low",
          "reasoning": "The provided abstract text contains only the title without methodological or result details, so it does not address whether hyperglycemia suppresses fibrinolytic activity or alters alteplase effectiveness.",
          "key_findings": "No mechanistic or outcome data related to hyperglycemia, fibrinolysis, or alteplase are available in the abstract fragment.",
          "pmid": "30355218",
          "title": "Care of the Post-Thrombectomy Patient.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract discusses associations between hyperglycemia, stroke outcomes, and response to tPA, and proposes that glucose normalization may reduce thrombolysis-induced hemorrhage. However, it does not mention suppression of fibrinolytic activity, alteplase pharmacodynamics, or any direct mechanistic interaction between hyperglycemia and fibrinolysis. It describes hypotheses and trial design rather than mechanistic or outcome data relevant to fibrinolytic activity.",
          "key_findings": "Hyperglycemia is associated with larger infarcts and enhanced cortical toxicity; initial blood glucose may influence response to tPA and risk of sICH; the SHINE trial will compare intensive vs. standard glucose control in hyperglycemic stroke patients and is hypothesized to show that glucose normalization reduces thrombolysis-induced sICH. No data or mechanistic evidence about hyperglycemia suppressing fibrinolytic activity or directly interfering with alteplase effectiveness are presented.",
          "pmid": "22994224",
          "title": "Considering hyperglycemia and thrombolysis in the Stroke Hyperglycemia Insulin Network Effort (SHINE) trial.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract discusses hyperglycemia as a contributor to neuronal apoptosis and diabetic encephalopathy, and highlights roles of insulin/C-peptide and IGF system in the brain, but it does not mention fibrinolytic activity, alteplase, thrombolysis, or how hyperglycemia might alter fibrinolysis or thrombolytic efficacy. Therefore it neither supports nor contradicts the proposed mechanism.",
          "key_findings": "Hyperglycemia, insulin/C-peptide deficiency, disturbed IGF system, and aging are implicated in neuronal apoptosis and diabetic encephalopathy; C-peptide administration improves IGF system status and reduces neuronal apoptosis in the hippocampus of diabetic patients. No data on fibrinolysis or alteplase are provided.",
          "pmid": "21703121",
          "title": "C-peptide and diabetic encephalopathy.",
          "analysis_method": "llm"
        }
      ]
    },
    {
      "feature_name": "nihss",
      "mechanism": {
        "mechanism_type": "biological",
        "description": "Patients with mild strokes (NIHSS \\( \\leq \\) 5) have functional impairments that reperfusion therapies can more easily alleviate, facilitating a return to baseline function.",
        "evidence_level": "moderate"
      },
      "query": "(stroke OR alteplase OR thrombolysis OR \"ischemic stroke\") AND (NIHSS OR \"stroke severity\" OR \"neurological deficit\" OR \"infarct volume\") AND (\"pathophysiology\" OR \"mechanism\" OR \"causal\" OR \"etiology\" OR \"interaction\") AND (\"facilitating\" OR \"impairments\" OR \"reperfusion\") AND (Clinical Trial[PT] OR Review[PT] OR Meta-Analysis[PT])",
      "total_abstracts": 20,
      "support_count": 0,
      "conflict_count": 1,
      "neutral_count": 19,
      "support_percentage": 0.0,
      "conflict_percentage": 5.0,
      "support_ratio": 0.0,
      "abstracts_analyzed": [
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The trial compares tenecteplase versus alteplase for acute ischaemic stroke and reports functional outcomes (mRS 0\u20131), but it does not stratify results by stroke severity (e.g., NIHSS \u22645), nor does it analyze whether patients with mild strokes have functional impairments that are more easily alleviated by reperfusion therapies. Therefore, it neither confirms nor refutes the specific mechanism about mild stroke patients\u2019 responsiveness to reperfusion.",
          "key_findings": "Intravenous tenecteplase (0.25 mg/kg) was non-inferior to alteplase (0.9 mg/kg) for achieving mRS 0\u20131 at 90\u2013120 days in a broad population of thrombolysis-eligible acute ischaemic stroke patients, with similar rates of symptomatic intracerebral haemorrhage and 90-day mortality. The abstract does not provide data specific to mild strokes (NIHSS \u22645) or differential functional recovery in that subgroup.",
          "pmid": "35779553",
          "title": "Intravenous tenecteplase compared with alteplase for acute ischaemic stroke in Canada (AcT): a pragmatic, multicentre, open-label, registry-linked, randomised, controlled, non-inferiority trial.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract discusses thrombolytic agents, recanalization strategies, and systems of care in acute ischaemic stroke in general terms, without addressing outcomes specifically in mild strokes (NIHSS \u2264 5) or whether reperfusion more easily restores baseline function in this subgroup.",
          "key_findings": "The abstract reviews alteplase as the current standard thrombolytic, emerging alternatives like tenecteplase, adjunct therapies to improve recanalization, strategies to reduce reocclusion, intra-arterial thrombolysis after thrombectomy, and the role of mobile stroke units and advanced neuroimaging in increasing thrombolysis rates. It does not report data stratified by stroke severity or NIHSS, nor functional outcome differences in mild vs more severe strokes.",
          "pmid": "36907201",
          "title": "Thrombolysis for acute ischaemic stroke: current status and future perspectives.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "medium",
          "reasoning": "The abstract shows that endovascular reperfusion therapy improves 90-day functional outcomes overall and that benefit does not significantly differ across stroke severity categories, but it does not specifically analyze or report outcomes limited to mild strokes (NIHSS \u2264 5) or demonstrate that such patients have impairments that are more easily alleviated or that they return to baseline more readily. Thus it does not directly test or validate the proposed mechanism regarding mild stroke patients.",
          "key_findings": "Meta-analysis of 5 RCTs (1,287 patients) found endovascular therapy increased odds of better functional outcome at 90 days versus medical management (OR 2.22, 95% CI 1.66\u20132.98) without increasing mortality or symptomatic intracerebral hemorrhage. Meta-regression indicated earlier treatment times were associated with better outcomes. No significant differences in treatment effect were observed across subgroups including stroke severity, but severity-specific data (e.g., NIHSS \u2264 5) were not provided.",
          "pmid": "26807742",
          "title": "Endovascular Treatment with Stent-Retriever Devices for Acute Ischemic Stroke: A Meta-Analysis of Randomized Controlled Trials.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "low",
          "reasoning": "The provided abstract text contains only the title and no substantive content about stroke severity, NIHSS scores, or the effect of reperfusion therapies on functional outcomes in mild stroke. Without data or statements related to these elements, the abstract cannot support or conflict with the proposed mechanism.",
          "key_findings": "No findings are available beyond the title; there is no information on mild strokes, NIHSS \u2264 5, reperfusion therapy, or functional recovery.",
          "pmid": "33130478",
          "title": "Stroke and Thromboprophylaxis in the Era of COVID-19.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The proposed mechanism concerns how baseline stroke severity (mild NIHSS \u22645) influences the ability of reperfusion therapies to restore function. This meta-analysis evaluates argatroban (a thrombin inhibitor) as mono- or adjunct therapy in acute ischemic stroke but does not stratify results by initial NIHSS severity, nor does it analyze outcomes specifically in mild strokes or discuss greater reversibility of deficits in that subgroup. Therefore, it neither supports nor contradicts the specific mechanistic claim about mild strokes and reperfusion benefit.",
          "key_findings": "Across eight RCTs (n=1393), argatroban alone or with r-tPA showed no significant differences vs controls in activities of daily living, NIHSS at 7 days, or proportions achieving mRS 0\u20131 or 0\u20132 at 90 days, and did not increase symptomatic intracranial hemorrhage or major bleeding. No analyses were reported by baseline NIHSS severity or restricted to mild stroke (NIHSS \u22645).",
          "pmid": "38176219",
          "title": "Efficacy and safety of argatroban in the management of acute ischemic stroke: A systematic literature review and meta-analysis.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract discusses cell adhesion molecules, inflammation, and anti-adhesion strategies in ischemic stroke and their interaction with thrombolytic therapy, but it does not address stroke severity (e.g., NIHSS \u2264 5), functional impairments, or the relative effectiveness of reperfusion therapies in mild versus more severe strokes. Thus it neither supports nor contradicts the specific mechanism about mild-stroke patients\u2019 functional recovery with reperfusion.",
          "key_findings": "Anti-adhesion strategies (e.g., targeting beta2-integrins, ICAM, P-selectin) reduce infarct volume, edema, behavioral deficits, and mortality in animal models of ischemic stroke and may widen the therapeutic window for thrombolytic therapy; however, clinical trials of anti-adhesion therapies have largely failed to show efficacy, partly due to immune reactions. Adhesion-blocking seems particularly effective at reperfusion, potentially in combination with thrombolytics, but no data are presented regarding mild stroke (NIHSS \u2264 5) or return to baseline function.",
          "pmid": "18826804",
          "title": "Cell adhesion molecules and ischemic stroke.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract discusses polymorphonuclear neutrophils, ischemic brain injury, reperfusion deficits, and recovery processes, but it does not address stroke severity stratified by NIHSS, the concept of \u201cmild stroke,\u201d nor the comparative effectiveness of reperfusion therapies in patients with mild deficits or their likelihood of returning to baseline. Therefore it neither supports nor contradicts the proposed mechanism about reperfusion benefit in mild strokes.",
          "key_findings": "PMNs exacerbate ischemic brain injury via ROS, proteases, cytokines, and capillary obstruction leading to reperfusion deficits. Experimental depletion or blockade of PMN entry reduces infarct volume and neurological deficits in animal models. Elevated PMN responses in humans correlate with larger infarcts and poorer outcomes, but clinical trials targeting PMN brain infiltration failed to improve or worsened outcomes. PMNs also contribute to post-ischemic angiogenesis and brain remodeling by promoting extracellular matrix degradation.",
          "pmid": "35087539",
          "title": "Roles of Polymorphonuclear Neutrophils in Ischemic Brain Injury and Post-Ischemic Brain Remodeling.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract evaluates endovascular revascularization strategies for tandem occlusions and reports angiographic and functional outcomes, but it does not stratify by stroke severity (e.g., NIHSS \u2264 5) or analyze whether milder strokes derive more easily reversible functional impairment from reperfusion. Thus it neither supports nor contradicts the specific mechanism about mild strokes and restoration to baseline.",
          "key_findings": "Among 790 patients with tandem occlusions, approximately 79% achieved TICI 2b or better reperfusion; one study reported better mRS outcomes in a thrombectomy-first versus stent-first approach; the illustrative case showed substantial NIHSS and mRS improvement after distal-to-proximal revascularization. No data addressed outcomes specifically in patients with mild stroke (NIHSS \u2264 5) or compared reperfusion benefit by baseline stroke severity.",
          "pmid": "28366063",
          "title": "Revascularization of tandem occlusions in acute ischemic stroke: review of the literature and illustrative case.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract discusses reperfusion therapy for acute ischemic stroke in general terms and its impact on disability and mortality but does not mention mild strokes, NIHSS scores, or differential functional recovery based on stroke severity. Therefore, it neither supports nor contradicts the specific mechanism about reperfusion being particularly effective in patients with NIHSS \u2264 5.",
          "key_findings": "Reperfusion therapy and organized stroke services improve chances of favorable outcomes and reduce disability and mortality in acute ischemic stroke patients in general, based on a review of scientific evidence and its implementation in Brazil.",
          "pmid": "38157871",
          "title": "Reperfusion therapy for acute ischemic stroke: where are we in 2023?",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract evaluates remote ischemic conditioning (RIC) as an adjunct or alternative therapy in acute ischemic stroke and summarizes its effects on mRS and NIHSS, but it does not stratify outcomes by initial stroke severity, NIHSS \u22645, or specifically address how reperfusion therapies perform in mild stroke patients. Thus, it does not provide direct evidence for or against the proposed mechanism about the particular responsiveness of mild strokes to reperfusion therapy.",
          "key_findings": "RIC reduced recurrent ischemic stroke (OR 0.67) and improved 90\u2011day functional outcomes (higher odds of mRS 0\u20131 and 0\u20132) and NIHSS scores, without increasing major adverse events, but the analysis was not focused on reperfusion therapies or on patients with mild strokes (NIHSS \u22645).",
          "pmid": "37183341",
          "title": "Efficacy and safety of remote ischemic conditioning for acute ischemic stroke: A comprehensive meta-analysis from randomized controlled trials.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract discusses white matter injury, its clinical manifestations, imaging, and need for therapies after ischemic stroke, but does not address stroke severity stratified by NIHSS, mild strokes specifically, functional impairment profiles, or the efficacy of reperfusion therapies in restoring baseline function. Therefore it neither supports nor contradicts the proposed mechanism about reperfusion benefits in mild stroke.",
          "key_findings": "Ischemic stroke causes significant white matter injury, often more severe than gray matter injury; white matter occupies nearly half of the average infarct volume; white matter injury is linked to cognitive, emotional, sensorimotor, urinary, and pain symptoms; MRI can noninvasively assess white matter structure and function; there is a need for therapies targeting white matter, and optimal protection should address both gray and white matter.",
          "pmid": "27090751",
          "title": "White matter injury in ischemic stroke.",
          "analysis_method": "llm"
        },
        {
          "stance": "conflict",
          "confidence": "high",
          "reasoning": "The mechanism proposes that in mild strokes (NIHSS \u22645), reperfusion therapies (here, EVT) should more easily alleviate functional impairments and facilitate return to baseline, implying superior or at least clear functional benefit. The meta-analysis in mild LVO stroke (NIHSS \u22646, with specific mention of NIHSS \u22645) found no improvement in favorable functional outcomes or functional independence with EVT compared to medical management, and instead showed higher 90\u2011day mortality and sICH risk with EVT, including in patients with NIHSS \u22645. This directly contradicts the expectation that reperfusion therapy more readily restores function in this population.",
          "key_findings": "In 22 studies (4,985 patients) with LVO mild stroke (NIHSS \u22646), EVT showed no significant difference in favorable functional outcome (mRS 0\u20131) or functional independence (mRS 0\u20132) versus medical management. For patients treated 2015\u20132023, EVT was associated with higher 90\u2011day mortality (OR 1.84, 95% CI 1.10\u20133.07) and increased symptomatic intracranial hemorrhage (OR 3.36, 95% CI 1.96\u20136.66), including in anterior circulation occlusions and in subgroups treated within 6 hours or with NIHSS \u22645. Overall, EVT and medical management did not differ in efficacy for mild LVO stroke, while EVT had worse safety outcomes.",
          "pmid": "38616013",
          "title": "A comparison of endovascular therapy and medical management in patients with large vessel occlusion mild stroke treated between 2015 and 2023: a systematic review and meta-analysis.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract discusses thrombo-inflammation and ischemia-reperfusion injury after revascularization in ischemic stroke in general, focusing on microcirculation dysfunction and infarct volume, and on pharmacologic modulation of thrombo-inflammation. It does not address stroke severity strata (e.g., mild strokes with NIHSS \u2264 5), functional impairments, or differential effectiveness of reperfusion therapies in relation to baseline NIHSS or return to baseline function.",
          "key_findings": "Reperfusion is an effective treatment for ischemic stroke but can cause ischemia-reperfusion injury characterized by microcirculation dysfunction and increased infarct volume, driven by thrombo-inflammation (platelet activation, endothelial injury, inflammatory cell infiltration). Various drugs (antiplatelet agents, anticoagulants, glucocorticoids, and newer agents) can modulate thrombo-inflammation and may mitigate ischemia-reperfusion injury, though most data are preclinical. No mention is made of NIHSS thresholds, mild stroke, or baseline functional recovery differences.",
          "pmid": "39107669",
          "title": "The Role of Thrombo-inflammation in Ischemic Stroke: Focus on the Manipulation and Clinical Application.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract focuses on the role of aquaporin-4 in stroke-related brain edema, its biphasic effects, regulation, and potential as a therapeutic target. It does not address stroke severity defined by NIHSS, does not distinguish mild strokes, and does not examine functional outcomes in relation to reperfusion therapies or their differential effectiveness by stroke severity. Therefore, it neither supports nor contradicts the proposed mechanism about reperfusion therapies more easily alleviating functional impairments in mild strokes.",
          "key_findings": "Aquaporin-4 exacerbates cytotoxic edema in acute ischemia and aids clearance in vasogenic edema; it is upregulated in infarcted regions and may serve as a biomarker of stroke severity and outcome; pharmacologic modulation of AQP4 is discussed as a therapeutic strategy. No data are provided on NIHSS scores, mild stroke subgroups, or the impact of reperfusion therapies on functional recovery.",
          "pmid": "40943104",
          "title": "Aquaporin-4 in Stroke and Brain Edema-Friend or Foe?",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract discusses memantine as a neuroprotective NMDA antagonist and reports improvements in NIHSS and functional indices after ischemic stroke, but it does not analyze outcomes specifically in patients with mild strokes (NIHSS \u2264 5), nor does it compare the ease or degree of functional restoration by reperfusion therapies across stroke severities. Thus, it neither supports nor contradicts the mechanism that mild-stroke patients have impairments more easily alleviated by reperfusion leading to return to baseline.",
          "key_findings": "Memantine, a non-competitive NMDA receptor antagonist, inhibits excitotoxic cascades in preclinical models and improves motor and sensory outcomes. Clinical trials of high-dose memantine in post-stroke patients report improvements in NIHSS, Barthel index, post-stroke aphasia, and intracranial hemorrhage outcomes, though limited by small sample sizes and methodological shortcomings. The abstract does not stratify by stroke severity (e.g., NIHSS \u2264 5) or focus on reperfusion therapies.",
          "pmid": "36743806",
          "title": "Memantine as a neuroprotective agent in ischemic stroke: Preclinical and clinical analysis.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract evaluates anesthesia type (general anesthesia vs conscious sedation) during endovascular treatment for acute posterior circulation stroke and its impact on functional independence and reperfusion success. It does not stratify by stroke severity, focus on mild strokes (NIHSS \u2264 5), or analyze how reperfusion therapies specifically affect functional impairments in mild stroke patients. Therefore, it neither supports nor contradicts the proposed mechanism about easier functional recovery in mild strokes with reperfusion therapies.",
          "key_findings": "In a randomized trial of 87 patients with acute posterior circulation stroke (median NIHSS 15), conscious sedation was not superior to general anesthesia for 90-day functional independence (mRS functional independence 48.8% vs 54.5%; adjusted OR 0.91, 95% CI 0.37-2.22). General anesthesia was associated with higher successful reperfusion rates (mTICI 2b-3: 95.3% vs 77.3%; adjusted OR 5.86, 95% CI 1.16-29.53). No data specific to mild strokes (NIHSS \u2264 5) or differential impact of reperfusion on such patients were reported.",
          "pmid": "36156704",
          "title": "General Anesthesia vs Conscious Sedation for Endovascular Treatment in Patients With Posterior Circulation Acute Ischemic Stroke: An Exploratory Randomized Clinical Trial.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract evaluates miRNA-modified exosomes in animal models of cerebral ischemia-reperfusion, focusing on infarct volume and neurobehavioral scores. It does not examine stroke severity stratified by NIHSS, mild stroke populations, or the comparative effectiveness of reperfusion therapies in relation to baseline functional impairment. Therefore, it neither supports nor contradicts the proposed mechanism about mild stroke patients and reperfusion therapies restoring baseline function.",
          "key_findings": "In preclinical middle cerebral artery occlusion models, miRNA-modified exosomes significantly reduced infarct volume and improved neurological scores, with higher injection frequency linked to greater infarct volume reduction. The study reports heterogeneity and potential publication bias but does not address patient NIHSS scores, mild vs severe stroke, or clinical reperfusion therapy outcomes.",
          "pmid": "36243363",
          "title": "Effects of miRNA-Modified Exosomes Alleviate Cerebral Ischemic Reperfusion Injury in Preclinical Studies: A Meta-Analysis.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract discusses potential cytoprotective and neuroprotective effects of statins and their possible impact on acute stroke severity in general, but it does not address mild strokes (NIHSS \u2264 5), differential responsiveness of mild versus more severe strokes to reperfusion therapies, or functional outcomes relative to baseline. Therefore it neither supports nor contradicts the specific proposed mechanism about reperfusion benefit in mild stroke.",
          "key_findings": "Statins have multiple experimental cytoprotective actions (angiogenesis promotion, reduced clot formation, facilitation of clot lysis, modulation of nitric oxide synthases, reduced excitotoxicity, and inflammatory modulation). Clinically, they appear to protect against vasospasm-related ischemic injury after subarachnoid hemorrhage. There are no prospective randomized trials showing statins reduce acute stroke severity, and observational data are inconsistent. The abstract does not examine stroke severity strata, NIHSS scores, or reperfusion therapy outcomes.",
          "pmid": "19500493",
          "title": "Statins and ischemic stroke severity: cytoprotection.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract notes that ischemic strokes occurring on NOAC treatment tend to have milder stroke severity and smaller infarct size, and that IV thrombolysis and endovascular therapy appear safe and effective, but it does not analyze outcomes stratified by mild stroke status (e.g., NIHSS \u2264 5) or demonstrate that reperfusion more easily restores patients with mild strokes to baseline function. Thus it neither directly supports nor contradicts the specific proposed mechanism.",
          "key_findings": "1) Existing data indicate milder stroke severity and smaller infarct size in patients who suffer acute ischemic stroke while on NOACs compared with VKAs. 2) Intravenous thrombolysis and endovascular therapy seem to be safe and effective in this population, but patient selection for recanalization therapies is challenging. 3) No data are provided on differential functional recovery or return to baseline specifically in mild strokes (e.g., NIHSS \u2264 5) after reperfusion.",
          "pmid": "30925155",
          "title": "Clinical presentation, diagnostic findings and management of cerebral ischemic events in patients on treatment with non-vitamin K antagonist oral anticoagulants - A systematic review.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The mechanism concerns functional outcomes in patients with mild strokes (NIHSS \u22645) and how reperfusion therapies may more easily restore baseline function. This abstract evaluates nerinetide\u2019s effect on final infarct volume (a surrogate imaging outcome) in thrombectomy patients without alteplase and notes that lower baseline NIHSS predicts smaller infarct volume, but it does not analyze treatment effects specifically in mild-stroke (NIHSS \u22645) subgroups, nor does it link these findings to functional recovery or ease of returning to baseline. Thus it neither directly supports nor contradicts the proposed mechanism.",
          "key_findings": "1) In ESCAPE-NA1 patients not receiving alteplase, nerinetide was associated with smaller final infarct volume (adjusted \u03b2 \u22120.35, 95% CI \u22120.67 to \u22120.02). 2) Lower baseline NIHSS score was an independent predictor of smaller infarct volume, along with factors such as good collateral status, MCA vs ICA occlusion, lower blood pressure and glucose, shorter onset-to-randomization time, and higher ASPECTS. 3) Interactions were observed between nerinetide treatment and systolic blood pressure, anesthesia use, and possibly reperfusion status with respect to infarct volume. 4) The study does not report NIHSS-stratified treatment effects, does not focus on NIHSS \u22645 specifically, and does not assess functional outcome or return to baseline function.",
          "pmid": "39648909",
          "title": "Factors Influencing Nerinetide Effect on Infarct Volume in Patients Without Alteplase in the Randomized ESCAPE-NA1 Trial.",
          "analysis_method": "llm"
        }
      ]
    },
    {
      "feature_name": "nihss",
      "mechanism": {
        "mechanism_type": "biological",
        "description": "A lower NIHSS score has been universally associated with better stroke recovery outcomes, suggesting that these patients have more neurological reserve to benefit from clot dissolution.",
        "evidence_level": "moderate"
      },
      "query": "(stroke OR alteplase OR thrombolysis OR \"ischemic stroke\") AND (NIHSS OR \"stroke severity\" OR \"neurological deficit\" OR \"infarct volume\") AND (\"pathophysiology\" OR \"mechanism\" OR \"causal\" OR \"etiology\" OR \"interaction\") AND (\"neurological\" OR \"dissolution\" OR \"universally\") AND (Clinical Trial[PT] OR Review[PT] OR Meta-Analysis[PT])",
      "total_abstracts": 19,
      "support_count": 0,
      "conflict_count": 0,
      "neutral_count": 19,
      "support_percentage": 0.0,
      "conflict_percentage": 0.0,
      "support_ratio": 0.0,
      "abstracts_analyzed": [
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract is a broad review of stroke pathophysiology, treatment, and research trends. It does not mention NIHSS scores, stroke severity scales, neurological reserve, or differential benefit from clot dissolution based on lower NIHSS. Therefore it neither supports nor conflicts with the proposed mechanism.",
          "key_findings": "Discusses general aspects of stroke as a leading cause of death and disability, focus on restoring blood flow and treating neurological damage, refinement of animal models, and trends in stroke research; no specific data or statements about NIHSS or its association with recovery outcomes.",
          "pmid": "33076218",
          "title": "Pathophysiology and Treatment of Stroke: Present Status and Future Perspectives.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract compares tenecteplase vs alteplase efficacy and safety in acute ischemic stroke and reports functional outcomes (mRS 0\u20131) and hemorrhage/mortality rates. It does not report NIHSS scores at baseline, outcomes stratified by NIHSS, or any analysis linking lower NIHSS to better recovery or to differential benefit from thrombolysis. Therefore, it neither supports nor contradicts the proposed mechanism about lower NIHSS reflecting greater neurological reserve and better response to clot dissolution.",
          "key_findings": "Tenecteplase was non-inferior to alteplase for achieving mRS 0\u20131 at 90\u2013120 days (36.9% vs 34.8%; risk difference 2.1% [95% CI \u22122.6 to 6.9]) with similar rates of symptomatic intracerebral hemorrhage (3.4% vs 3.2%) and 90-day mortality (15.3% vs 15.4%). No data on NIHSS severity distribution or NIHSS-outcome relationships are provided.",
          "pmid": "35779553",
          "title": "Intravenous tenecteplase compared with alteplase for acute ischaemic stroke in Canada (AcT): a pragmatic, multicentre, open-label, registry-linked, randomised, controlled, non-inferiority trial.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract discusses thrombolytic agents, delivery strategies, and systems of care in acute ischaemic stroke but does not mention NIHSS scores, stroke severity, neurological reserve, or differential benefit of thrombolysis by baseline NIHSS. Therefore it neither supports nor contradicts the proposed mechanism.",
          "key_findings": "Alteplase is currently the only approved thrombolytic; tenecteplase is emerging as a potential alternative, especially in large vessel occlusion. Research focuses on new thrombolytics, adjunct therapies, intra-arterial thrombolysis after thrombectomy, and improving treatment access via mobile stroke units and advanced imaging. No data are presented on NIHSS or its relation to recovery or response to clot dissolution.",
          "pmid": "36907201",
          "title": "Thrombolysis for acute ischaemic stroke: current status and future perspectives.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract discusses post-stroke cognitive impairment, its epidemiology, risk factors, and management in broad terms. It does not mention NIHSS scores, baseline stroke severity measures, or their relationship to recovery or benefit from clot dissolution, so it neither supports nor contradicts the proposed mechanism.",
          "key_findings": "The review covers heterogeneity in definitions of post-stroke cognitive impairment, variability in prevalence estimates, potential predictors of PSCI, and prevention/treatment strategies, but provides no data or statements about NIHSS scores or their association with stroke recovery outcomes or response to clot dissolution.",
          "pmid": "35147548",
          "title": "Post-Stroke Cognitive Impairment: Epidemiology, Risk Factors, and Management.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract mentions only an inclusion criterion of NIHSS \u22652 but does not analyze outcomes stratified by NIHSS score, does not examine the relationship between lower NIHSS and stroke recovery, and does not discuss \u2018neurological reserve\u2019 or differential benefit from clot dissolution based on baseline NIHSS. Therefore it neither supports nor contradicts the proposed mechanism.",
          "key_findings": "MR CLEAN-LATE showed that in patients with anterior circulation large-vessel occlusion 6\u201324 hours after onset and with collateral flow on CTA, endovascular treatment improved 90-day mRS distribution compared with no endovascular treatment. All participants had NIHSS \u22652, but no data are provided on how different NIHSS levels relate to treatment benefit or recovery.",
          "pmid": "37003289",
          "title": "Endovascular treatment versus no endovascular treatment after 6-24 h in patients with ischaemic stroke and collateral flow on CT angiography (MR CLEAN-LATE) in the Netherlands: a multicentre, open-label, blinded-endpoint, randomised, controlled, phase 3 trial.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract mentions NIHSS only as a variable used in the randomization/minimisation algorithm but does not analyze or report outcomes stratified by baseline NIHSS score, nor does it evaluate any relationship between lower NIHSS and stroke recovery or benefit from thrombolysis. Therefore, it neither supports nor contradicts the proposed mechanism.",
          "key_findings": "NIHSS score was included in the randomisation/minimisation algorithm, but no results are presented linking NIHSS level to functional or imaging outcomes, thrombolytic benefit, or neurological reserve. The main findings concern comparative efficacy and safety (penumbra salvage, hemorrhage rates, adverse events, and neurological/radiological outcomes) of tenecteplase vs alteplase, without mechanistic analysis based on baseline stroke severity.",
          "pmid": "25726502",
          "title": "Alteplase versus tenecteplase for thrombolysis after ischaemic stroke (ATTEST): a phase 2, randomised, open-label, blinded endpoint study.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The proposed mechanism is about lower NIHSS being universally associated with better recovery and implying greater neurological reserve to benefit from clot dissolution. This trial only includes patients with low NIHSS (0\u20135) and compares alteplase vs aspirin; it does not examine outcome across different NIHSS levels, nor does it test whether lower NIHSS predicts greater benefit from alteplase. It therefore neither supports nor contradicts the specific mechanistic claim about NIHSS-related reserve or benefit from clot dissolution.",
          "key_findings": "All enrolled patients had minor nondisabling strokes (NIHSS 0\u20135; median 2). At 90 days, favorable functional outcome (mRS 0\u20131) occurred in 78.2% of alteplase-treated vs 81.5% of aspirin-treated patients (adjusted risk difference \u22121.1%; 95% CI \u22129.4% to 7.3%), with higher sICH in the alteplase group (3.2% vs 0%). The trial does not compare outcomes between low vs higher NIHSS groups and thus does not directly address the relationship between NIHSS level and recovery or benefit from alteplase.",
          "pmid": "29998337",
          "title": "Effect of Alteplase vs Aspirin on Functional Outcome for Patients With Acute Ischemic Stroke and Minor Nondisabling Neurologic Deficits: The PRISMS Randomized Clinical Trial.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract reports NIHSS scores at 72 hours as an efficacy endpoint and shows better outcomes with ApTOLL, but it does not analyze the relationship between baseline NIHSS and stroke recovery, nor does it discuss neurological reserve or differential benefit from clot dissolution in patients with lower NIHSS. Therefore, it neither supports nor contradicts the proposed mechanism.",
          "key_findings": "ApTOLL 0.2 mg/kg, given with endovascular treatment within 6 hours of ischemic stroke onset, was associated with lower NIHSS scores at 72 hours, smaller final infarct volume, and better 90-day mRS outcomes versus placebo, but no data are presented on how baseline NIHSS stratifies outcomes or treatment benefit.",
          "pmid": "37338893",
          "title": "Safety and Efficacy of ApTOLL in Patients With Ischemic Stroke Undergoing Endovascular Treatment: A Phase 1/2 Randomized Clinical Trial.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The mechanism concerns the relationship between lower NIHSS (baseline stroke severity) and better recovery and benefit from clot dissolution. This meta-analysis adjusted treatment effect for baseline stroke severity and reports no heterogeneity of thrombectomy effect across baseline stroke severity subgroups, but it does not present or analyze outcomes specifically as a function of NIHSS level nor claim that lower NIHSS patients derive more benefit. Thus it neither supports nor contradicts the proposed mechanism.",
          "key_findings": "In this individual patient data meta-analysis of thrombectomy 6\u201324 hours after last known well, thrombectomy improved 90-day mRS outcomes versus medical therapy, with adjusted common OR 2.54. Safety outcomes (mortality, symptomatic intracerebral hemorrhage) did not differ significantly between groups. Subgroup analyses found no heterogeneity of treatment effect across age, gender, baseline stroke severity, vessel occlusion site, ASPECTS, or mode of presentation; stronger treatment effect was observed in the 12\u201324 h vs 6\u201312 h window. No specific relationship between lower NIHSS and better outcome or greater benefit from therapy is reported.",
          "pmid": "34774198",
          "title": "Thrombectomy for anterior circulation stroke beyond 6 h from time last known well (AURORA): a systematic review and individual patient data meta-analysis.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract reports that personalized music listening improved NIHSS scores compared with control, but it does not analyze outcomes stratified by baseline NIHSS, nor does it address the concept of neurological reserve or its interaction with clot dissolution. The proposed mechanism is about the prognostic significance of lower NIHSS for recovery, particularly via benefit from clot dissolution, which is not examined here.",
          "key_findings": "In a randomized controlled trial of 34 patients with post-stroke cognitive impairment, those receiving a 3\u2011month personalized music listening intervention showed significantly higher MoCA scores and better NIHSS, Barthel Index, and Zarit Caregiver Burden scores than controls listening to white noise. Mood measures (HAMA, HAMD) showed no significant effects.",
          "pmid": "39098085",
          "title": "Effects of personalized music listening on post-stroke cognitive impairment: A randomized controlled trial.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract reports perioperative stroke and death rates and identifies baseline clinical and anatomical predictors of surgical risk, but it does not mention NIHSS scores, quantify initial stroke severity on that scale, or relate any measure of initial neurological deficit to recovery or benefit from clot dissolution. Thus it neither supports nor contradicts the proposed mechanism regarding lower NIHSS and better stroke recovery.",
          "key_findings": "In 1415 NASCET patients undergoing carotid endarterectomy, perioperative stroke/death rate was 6.5% with 1.1% death, 1.8% disabling stroke, and 3.7% nondisabling stroke at 30 days; at 90 days this shifted to 1.1% death, 0.9% disabling stroke, and 4.5% nondisabling stroke due to neurological improvement. Predictors of increased surgical risk included hemispheric vs retinal TIA, left-sided procedure, contralateral carotid occlusion, ipsilateral ischemic CT lesion, and irregular/ulcerated ipsilateral plaque. History of coronary artery disease with prior cardiac procedure was associated with reduced risk. No data are reported linking initial NIHSS or quantified stroke severity to outcomes or to benefit from clot-related interventions.",
          "pmid": "10471419",
          "title": "The North American Symptomatic Carotid Endarterectomy Trial : surgical results in 1415 patients.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract discusses ischemic stroke epidemiology, risk factors, and general advances in acute and endovascular therapies but does not mention NIHSS scores, stroke severity scales, or relationships between baseline NIHSS and recovery or benefit from clot dissolution.",
          "key_findings": "The abstract notes that ischemic stroke is common, that there are modifiable risk factors, and that acute ischemic stroke is now amenable to medical and endovascular therapies which can reduce infarct volume, with anticipated advances in prevention and recovery. No data or statements are provided regarding NIHSS, neurological reserve, or how initial stroke severity relates to treatment benefit or recovery outcomes.",
          "pmid": "28800170",
          "title": "Ischaemic stroke.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract reports baseline NIHSS scores but does not analyze or discuss the relationship between lower NIHSS and stroke recovery outcomes, nor does it address neurological reserve or response to clot dissolution. It focuses on the effect of intravenous glibenclamide on outcomes after large hemispheric infarction, not on outcome stratification by stroke severity.",
          "key_findings": "Median NIHSS was 19 in both placebo and glibenclamide groups; intravenous glibenclamide did not improve 90-day functional outcomes or mortality. No analysis is presented relating NIHSS level to recovery or treatment benefit.",
          "pmid": "39577921",
          "title": "Intravenous glibenclamide for cerebral oedema after large hemispheric stroke (CHARM): a phase 3, double-blind, placebo-controlled, randomised trial.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract discusses COVID-19\u2013related coagulopathy, endothelial dysfunction, and general issues in stroke care, but does not mention NIHSS, stroke severity scoring, neurological reserve, or differential recovery outcomes based on initial NIHSS. Therefore it neither supports nor contradicts the proposed mechanism.",
          "key_findings": "SARS-CoV-2 infection induces coagulopathy and endothelial dysfunction leading to a hypercoagulable state and predisposition to cerebrovascular events; stroke care has been compromised during the pandemic; mechanisms linking COVID-19 and stroke and effective interventions require further study.",
          "pmid": "33225251",
          "title": "COVID-19 and stroke: A review.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract discusses epidemiology, natural history, risk factors for hemorrhage, and treatment modalities for brain arteriovenous malformations, but does not mention NIHSS scores, stroke recovery outcomes, clot dissolution, or neurological reserve. Therefore it neither supports nor contradicts the proposed mechanism.",
          "key_findings": "Describes AVMs as congenital vascular lesions with typical presentations (hemorrhage, seizures, progressive neurological deficit, headache), reports annual hemorrhage and rebleeding rates, notes factors that increase hemorrhage risk, and summarizes advances in endovascular, radiosurgical, and microsurgical treatments; no data on NIHSS, stroke severity scales, or outcomes related to clot dissolution.",
          "pmid": "11897302",
          "title": "Arteriovenous malformations.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract evaluates intrathecal therapies for vasospasm after aneurysmal subarachnoid hemorrhage and their effects on vasospasm, delayed cerebral ischemia, infarction, and functional outcome. It does not mention NIHSS scores, baseline stroke severity, or how lower NIHSS might relate to neurological reserve or benefit from clot dissolution. Therefore, it neither supports nor contradicts the proposed mechanism about NIHSS and recovery.",
          "key_findings": "Intrathecal treatments (CSF drainage via lumbar drain, intraventricular nimodipine, cisternal magnesium) are reported to reduce vasospasm, delayed cerebral ischemia, and cerebral infarction, and improve functional outcomes after aSAH. No data are provided on NIHSS scores, clot dissolution, or the relationship between initial stroke severity and recovery.",
          "pmid": "35231885",
          "title": "Update on intrathecal management of cerebral vasospasm: a systematic review and meta-analysis.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract focuses on incidence, precipitating events, and sport-related mechanisms of stroke in athletes. It does not mention NIHSS scores, stroke severity scales, or comparative recovery outcomes, nor does it address neurological reserve or response to clot dissolution. Therefore, it neither supports nor contradicts the proposed mechanism.",
          "key_findings": "In athletes aged 14\u201356, 39 reported stroke cases were identified; major precipitating events included headaches (38.4%), head trauma (30.7%), and neck injury/vertebral artery dissection (20.5%). Sports involving impact, collision, or microtrauma were associated with subsequent stroke, often with delayed ischemia and diagnostic difficulty. No data are provided on initial NIHSS scores, stroke severity, or recovery outcomes.",
          "pmid": "34639349",
          "title": "Stroke and Athletes: A Scoping Review.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract discusses poststroke dementia risk in relation to stroke severity, location, and inflammatory mechanisms, but does not mention NIHSS scores, neurological reserve, or response to clot dissolution. It focuses on inflammation-driven neurodegeneration rather than acute stroke severity scales or treatment benefit stratified by initial deficit.",
          "key_findings": "Poststroke dementia risk within the first year is associated with stroke severity and location; later risk relates to traditional dementia risk factors. Proposed mechanism centers on chronic brain inflammation from inefficient myelin debris clearance and prolonged immune responses, potentially modulated by peripheral immune state. No data are presented on NIHSS values or their relationship to recovery outcomes or benefit from clot dissolution therapies.",
          "pmid": "31789707",
          "title": "Immunological mechanisms in poststroke dementia.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract discusses general management of ischemic stroke (thrombolysis, antiplatelets, anticoagulation, secondary prevention) but does not mention NIHSS scores, initial stroke severity, or any relationship between baseline NIHSS and recovery or benefit from clot dissolution.",
          "key_findings": "Intravenous thrombolysis within 4.5 hours is described as the only proven therapy to improve functional outcome, and antiplatelet therapy is noted to prevent early stroke recurrence. No data or statements are provided regarding NIHSS, neurological reserve, or differential outcomes based on stroke severity.",
          "pmid": "25007216",
          "title": "[Ischemic stroke--diagnosis and treatment].",
          "analysis_method": "llm"
        }
      ]
    },
    {
      "feature_name": "nihss",
      "mechanism": {
        "mechanism_type": "biological",
        "description": "Reperfusion therapies like alteplase are most effective when administered early and in cases where the damage is not extensive, potentially translating to a higher relative benefit in patients with lower initial NIHSS scores.",
        "evidence_level": "moderate"
      },
      "query": "(stroke OR alteplase OR thrombolysis OR \"ischemic stroke\") AND (NIHSS OR \"stroke severity\" OR \"neurological deficit\" OR \"infarct volume\") AND (\"pathophysiology\" OR \"mechanism\" OR \"causal\" OR \"etiology\" OR \"interaction\") AND (\"administered\" OR \"translating\" OR \"potentially\") AND (Clinical Trial[PT] OR Review[PT] OR Meta-Analysis[PT])",
      "total_abstracts": 20,
      "support_count": 1,
      "conflict_count": 1,
      "neutral_count": 18,
      "support_percentage": 5.0,
      "conflict_percentage": 5.0,
      "support_ratio": 0.05,
      "abstracts_analyzed": [
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract is a broad review of post-stroke cognitive impairment epidemiology, risk factors, and management, and does not mention reperfusion therapies (e.g., alteplase), treatment timing, NIHSS scores, or differential treatment benefit by stroke severity. Therefore it neither supports nor contradicts the proposed mechanism.",
          "key_findings": "Discusses prevalence, definitions, predictors, and management strategies for post-stroke cognitive impairment in general terms, emphasizing modifiable risk factors and preventive strategies, without specific data on reperfusion therapy timing or effectiveness by initial stroke severity.",
          "pmid": "35147548",
          "title": "Post-Stroke Cognitive Impairment: Epidemiology, Risk Factors, and Management.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract evaluates ApTOLL (a TLR4 antagonist) as an adjunct to endovascular treatment and reports outcomes like NIHSS, infarct volume, and mRS, but it does not analyze how timing of reperfusion or baseline NIHSS severity modifies the effectiveness of alteplase or other reperfusion therapies. There is no comparison of benefit across different initial NIHSS strata or explicit examination of earlier vs later treatment effects.",
          "key_findings": "ApTOLL 0.2 mg/kg given within 6 hours in combination with EVT (and IV thrombolysis if indicated) was associated with lower NIHSS at 72 hours, smaller final infarct volume, and better 90-day mRS compared with placebo, without major safety concerns. The study population had large vessel occlusions with ASPECTS 6\u201310 and core volumes 5\u201370 mL, but no data are provided on differential benefit according to baseline NIHSS or extent of initial damage in relation to alteplase or reperfusion efficacy.",
          "pmid": "37338893",
          "title": "Safety and Efficacy of ApTOLL in Patients With Ischemic Stroke Undergoing Endovascular Treatment: A Phase 1/2 Randomized Clinical Trial.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The proposed mechanism concerns time- and severity-dependent effectiveness of reperfusion therapy (alteplase) with greater relative benefit in patients with lower NIHSS scores. This trial studies intravenous glibenclamide for cerebral edema after large hemispheric stroke, not reperfusion therapy or alteplase, and does not compare outcomes by lower versus higher NIHSS levels in relation to reperfusion benefit. Therefore it neither supports nor contradicts the specific mechanism.",
          "key_Findings": "Phase 3 double-blind RCT of IV glibenclamide vs placebo in large hemispheric infarction (median NIHSS 19, treatment within ~9 hours); no favorable shift in 90-day mRS (common OR 1.17, 95% CI 0.80\u20131.71) and similar mortality (29% vs 32%). The trial is about edema-targeting therapy, not reperfusion or alteplase efficacy by NIHSS or timing.",
          "pmid": "39577921",
          "title": "Intravenous glibenclamide for cerebral oedema after large hemispheric stroke (CHARM): a phase 3, double-blind, placebo-controlled, randomised trial.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract focuses on treatment and prevention of post-stroke depression, antidepressant efficacy, psychotherapy, and neuromodulation. It does not discuss reperfusion therapies (e.g., alteplase), timing of such therapies, infarct extent, or outcomes stratified by NIHSS or any stroke severity measure in relation to reperfusion. Therefore it neither supports nor contradicts the proposed mechanism about early reperfusion benefit being greater in patients with lower NIHSS scores.",
          "key_findings": "The review reports that: (1) post-stroke depression is influenced by stroke severity, early physical disability, and functional loss; (2) antidepressants, especially escitalopram and paroxetine, and cognitive behavioral therapy are effective for post-stroke depression; (3) neuromodulation (rTMS, tDCS) and psychosocial interventions may be useful; and (4) antidepressant treatment may reduce mortality after stroke. No data are presented regarding reperfusion therapies, alteplase, or differential benefit by initial NIHSS.",
          "pmid": "31236751",
          "title": "Treatment of Post-Stroke Depression.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract focuses on IL-17\u2013mediated inflammatory mechanisms and post-stroke neurodegeneration, not on reperfusion therapies, alteplase, treatment timing, or differential benefit by initial NIHSS score. It does not address clinical efficacy of reperfusion or stratification of benefit by stroke severity.",
          "key_findings": "The review describes: (1) IL-17 and related cytokines (IL-23, IL-21) as mediators of delayed inflammatory tissue damage after stroke; (2) roles of specific T-lymphocyte subsets (CD4+ \u03b1\u03b2 and CD4\u2212 \u03b3\u03b4 T cells) in propagating IL-17 release; and (3) potential therapeutic targeting of IL-17 pathways to improve post-stroke outcomes. No data on alteplase, reperfusion timing, or interaction with initial NIHSS severity are provided.",
          "pmid": "23370232",
          "title": "Interleukin-17 in post-stroke neurodegeneration.",
          "analysis_method": "llm"
        },
        {
          "stance": "conflict",
          "confidence": "medium",
          "reasoning": "The proposed mechanism suggests that reperfusion therapies confer relatively greater benefit in patients with lower initial NIHSS scores. This meta-analysis of endovascular thrombectomy found no significant differences in the beneficial effects of treatment across categories of stroke severity, implying that benefit does not preferentially accrue to those with lower baseline severity. Although it concerns endovascular therapy rather than alteplase, it directly examines effect modification by stroke severity for a reperfusion therapy and reports no differential benefit by severity, which conflicts with the proposed mechanism.",
          "key_findings": "Meta-regression showed that shorter time from stroke onset to groin puncture/reperfusion was associated with better functional outcomes. However, the analysis found no significant differences in the beneficial effects of endovascular treatment on functional outcomes across categories of stroke severity, indicating no detected greater relative benefit in patients with less severe strokes.",
          "pmid": "26807742",
          "title": "Endovascular Treatment with Stent-Retriever Devices for Acute Ischemic Stroke: A Meta-Analysis of Randomized Controlled Trials.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "medium",
          "reasoning": "The abstract supports the importance of early thrombolytic/reperfusion therapy in acute ischemic stroke but does not address how treatment effect varies by initial stroke severity (e.g., NIHSS level or extent of damage). It focuses on time-to-treatment windows and experimental occlusion duration, without stratifying benefit by baseline neurological deficit or infarct size in a way that maps to the proposed mechanism of greater relative benefit in patients with lower initial NIHSS scores.",
          "key_findings": "1) Experimental models (reversible MCA occlusion in animals) show that reperfusion within 2\u20133 hours can lead to survival without neurological deficit, while longer occlusion (beyond ~4\u20136 hours) is unlikely to allow salvage of ischemic brain. 2) The usefulness of tPA is stated to depend in part on how quickly it can be initiated and on side-effect risk. 3) At least one-third of ischemic stroke patients reperfuse spontaneously within 48 hours, but too late to be beneficial. 4) No data are presented regarding differential efficacy of thrombolysis by initial stroke severity, NIHSS scores, or degree of existing damage.",
          "pmid": "1728786",
          "title": "Thrombolytic therapy in cerebrovascular disorders.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract evaluates argatroban (a direct thrombin inhibitor) alone or with r-tPA for acute ischemic stroke, focusing on overall efficacy and safety outcomes. It does not analyze time-to-treatment, extent of brain damage, baseline NIHSS strata, or differential benefit by initial stroke severity. Therefore, it neither supports nor contradicts the specific mechanism that earlier reperfusion (e.g., alteplase) confers greater relative benefit in patients with lower initial NIHSS scores.",
          "key_findings": "In a meta-analysis of eight RCTs (1393 patients), argatroban\u2014alone or with r-tPA\u2014did not significantly improve activities of daily living, NIHSS at 7 days, or 90-day mRS (0\u20131 or 0\u20132) compared with control or r-tPA alone, and did not significantly increase symptomatic intracranial hemorrhage or major systemic bleeding. No data on timing of reperfusion therapy or interaction with baseline NIHSS were reported.",
          "pmid": "38176219",
          "title": "Efficacy and safety of argatroban in the management of acute ischemic stroke: A systematic literature review and meta-analysis.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "medium",
          "reasoning": "The abstract confirms that earlier thrombolysis (both onset-to-needle and door-to-needle) yields better functional outcomes, but it does not analyze whether the relative benefit of reperfusion therapy is greater in patients with lower versus higher baseline NIHSS scores. Although it reports that patients treated in the later 3\u20134.5 hour window had lower baseline NIHSS, it does not stratify treatment effect by NIHSS or examine an interaction between stroke severity and benefit, which is the core of the proposed mechanism.",
          "key_findings": "1) In this AcT trial analysis (tenecteplase vs alteplase), each 30-minute reduction in onset-to-needle time was associated with a 1.8% absolute increase in probability of achieving mRS 0\u20131 at 90 days; each 10-minute reduction in door-to-needle time with a 0.2% increase, independent of thrombolytic agent.\n2) Type of thrombolytic (tenecteplase vs alteplase) did not modify the association between treatment time metrics and outcomes (no significant interaction).\n3) Patients treated in the 3\u20134.5 hour window had lower median baseline NIHSS and lower rates of large-vessel occlusion than those treated in the 0\u20133 hour window, but no analysis is presented on whether lower NIHSS patients derived a relatively greater benefit from thrombolysis.\n4) Overall conclusion: faster administration of either alteplase or tenecteplase results in better outcomes; no specific evidence is provided about differential benefit by baseline NIHSS severity.",
          "pmid": "37800372",
          "title": "Effect of Time to Thrombolysis on Clinical Outcomes in Patients With Acute Ischemic Stroke Treated With Tenecteplase Compared to Alteplase: Analysis From the AcT Randomized Controlled Trial.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "medium",
          "reasoning": "The abstract confirms that earlier thrombolysis (within three hours) is more effective overall, but it does not analyze treatment effect by initial stroke severity or NIHSS strata. Although it notes heterogeneity partly attributable to stroke severity, it does not specify that patients with lower initial NIHSS derive greater relative benefit, so it neither supports nor contradicts the proposed mechanism about higher relative benefit in milder strokes.",
          "key_findings": "Thrombolytic therapy up to six hours after ischemic stroke reduced death or dependency (mRS 3\u20136) at 3\u20136 months (OR 0.81), at the cost of increased symptomatic intracranial hemorrhage (OR 3.49) and increased mortality (OR 1.31). Treatment within three hours appeared more effective in reducing death or dependency (OR 0.71) without a statistically significant increase in death (OR 1.13). Heterogeneity between trials was partly attributable to stroke severity and time to treatment, but no outcome data are presented stratified by baseline severity (e.g., NIHSS) to show differential benefit in lower versus higher severity strokes.",
          "pmid": "19821269",
          "title": "Thrombolysis for acute ischaemic stroke.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract discusses cerebrovascular manifestations of SARS-CoV-2, reports typical NIHSS ranges, and states that large-vessel ischemic stroke patients meeting criteria are treated with intravenous thrombolysis per guidelines. However, it does not examine how timing of alteplase or initial stroke severity (low vs high NIHSS) modifies treatment effectiveness or relative benefit, so it neither supports nor contradicts the proposed mechanism.",
          "key_findings": "1) Most COVID-19\u2013related stroke patients had NIHSS scores within 5\u201315. 2) Patients with large-vessel ischemic stroke fulfilling intravenous thrombolysis criteria are managed successfully according to existing guidelines. 3) No data or statements are provided on differential efficacy of reperfusion therapy by NIHSS level or by early vs late administration.",
          "pmid": "36950279",
          "title": "Cerebrovascular Manifestations of SARS-CoV-2: A Comprehensive Review.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract evaluates bumetanide in animal models of ischemic stroke and does not involve reperfusion therapies such as alteplase, nor does it examine treatment effectiveness stratified by initial NIHSS score or stroke severity. Therefore it neither supports nor conflicts with the proposed mechanism about time-dependent and severity-dependent efficacy of reperfusion therapy.",
          "key_findings": "Bumetanide reduced infarct volume and brain edema and improved neurobehavioral outcomes in animal models of cerebral ischemia, with greater effect in transient (vs. permanent) ischemia and when administered after (vs. before) stroke, but no data are presented on alteplase or other reperfusion therapies, nor on NIHSS-based subgroups.",
          "pmid": "38850525",
          "title": "Efficacy of bumetanide in animal models of ischemic stroke: a systematic review and meta-analysis.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract focuses on post-stroke epilepsy, its risk factors, mechanisms, and prevention. It discusses initial stroke severity as a risk factor for developing epilepsy but does not address reperfusion therapies (e.g., alteplase), treatment timing, or differential benefit based on NIHSS scores. Thus, it neither supports nor contradicts the proposed mechanism concerning early reperfusion efficacy relative to initial stroke severity.",
          "key_findings": "PSE occurs in about 6% of stroke patients; main risk factors include cortical lesion, initial stroke severity, young age, and early post-stroke seizures. Potential mechanisms involve gliosis, scarring, and altered synaptic plasticity. Statins may have a preventive role; antiepileptic monotherapy is generally sufficient for seizure prevention. No mention is made of alteplase, reperfusion timing, or treatment effect stratified by NIHSS.",
          "pmid": "38134643",
          "title": "Post-stroke epilepsy: From clinical predictors to possible mechanisms.",
          "analysis_method": "llm"
        },
        {
          "stance": "support",
          "confidence": "high",
          "reasoning": "The abstract explicitly states that thrombolytic therapy (rt-PA) is more beneficial when given earlier within the 3\u2011hour window and notes that greater neurological deficit and more advanced infarct evolution are associated with higher risk of hemorrhagic complications. This aligns with the proposed mechanism that reperfusion therapies are most effective when administered early and in cases with less extensive damage (i.e., lower initial NIHSS/less severe deficits), implying relatively greater benefit in less severe strokes.",
          "key_findings": "1) Thrombolytic therapy with rt-PA is an accepted treatment if the patient can be treated within 3 hours of symptom onset. 2) \"The later the patient is treated, within the 3-hour therapeutic window, the less likely there is to be clinical benefit of the treatment and the greater risk of hemorrhagic transformation.\" 3) There is about a 30% greater chance of full recovery at 3 months with rt-PA versus no rt-PA. 4) \"The greater the neurological deficit at the time of presentation and the greater the evolution of the infarct by the admission CT brain scan, the greater the risk of intracerebral hemorrhage complicating the use of rt-PA.\" These findings together indicate that earlier treatment and less extensive initial damage are associated with better net outcomes, supporting the proposed mechanism.",
          "pmid": "10875215",
          "title": "Thrombolytic therapy for acute ischemic stroke.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract discusses stroke severity, infarct size, and the safety/effectiveness of thrombolysis and endovascular therapy in NOAC-treated patients, but it does not analyze treatment effect as a function of time-to-treatment or baseline NIHSS, nor does it compare relative benefit across NIHSS strata. Therefore, it neither supports nor contradicts the mechanism that earlier reperfusion and lower initial NIHSS correspond to higher relative benefit of alteplase.",
          "key_findings": "Existing data indicates milder stroke severity and smaller infarct size in acute ischemic stroke occurring on NOACs compared with VKAs; intravenous thrombolysis and endovascular therapy in this population seem safe and effective, though patient selection is challenging. No data are presented on differential treatment benefit by baseline NIHSS or timing of reperfusion therapy.",
          "pmid": "30925155",
          "title": "Clinical presentation, diagnostic findings and management of cerebral ischemic events in patients on treatment with non-vitamin K antagonist oral anticoagulants - A systematic review.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract studies dual antiplatelet regimens (indobufen+clopidogrel vs aspirin+clopidogrel) in minor ischemic stroke/high\u2011risk TIA and reports clinical outcomes and NIHSS changes, but it does not involve reperfusion therapy (e.g., alteplase), treatment timing relative to onset in the context of thrombolysis, or differential benefit by baseline NIHSS. Thus it neither supports nor contradicts the proposed mechanism about early reperfusion efficacy and initial stroke severity.",
          "key_findings": "In patients with minor ischemic stroke or high\u2011risk TIA treated within 72 hours (or up to 1 month with intracranial stenosis), the indobufen+clopidogrel group had no endpoint events (stroke/TIA recurrence, MI, or death) vs 6.5% in the aspirin+clopidogrel group, lower mRS scores, a nonsignificant trend to greater NIHSS improvement, and fewer bleeding events. No reperfusion therapies or analyses of thrombolysis benefit by baseline NIHSS were evaluated.",
          "pmid": "38429754",
          "title": "Clopidogrel with indobufen or aspirin in minor ischemic stroke or high-risk transient ischemic attack: a randomized controlled clinical study.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract evaluates salvianolic acid B as a neuroprotective agent in animal models of acute ischemic stroke, focusing on oxidative stress, inflammation, apoptosis, energy metabolism, and ion balance. It does not involve reperfusion therapies such as alteplase, does not analyze treatment timing relative to stroke onset, and does not stratify effects by stroke severity (e.g., NIHSS) or extent of damage. Therefore it neither supports nor contradicts the proposed mechanism about early alteplase efficacy and greater relative benefit in patients with lower initial NIHSS scores.",
          "key_findings": "Salvianolic acid B in animal models of acute ischemic stroke reduced infarct size, neurological deficit scores, brain edema, and brain water content, and modulated oxidative stress (\u2191SOD, \u2193MDA), inflammation (\u2193IL-1\u03b2), apoptosis (\u2193TUNEL-positive cells), and energy/ion homeostasis (\u2191energy charge, \u2191phosphocreatine, maintained Na+/K+ ATPase activity). No data on alteplase, reperfusion timing, or interaction with initial stroke severity are provided.",
          "pmid": "39776581",
          "title": "Role of salvianolic acid B in the treatment of acute ischemic stroke: a systematic review and meta-analysis of animal models.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract evaluates clazosentan, an endothelin receptor antagonist for preventing vasospasm-related morbidity and mortality after aneurysmal subarachnoid hemorrhage. It does not involve reperfusion therapies like alteplase, does not analyze treatment timing in relation to onset, and does not examine outcomes stratified by initial NIHSS or baseline stroke severity. Therefore it neither supports nor contradicts the proposed mechanism about early reperfusion benefit being greater in patients with lower NIHSS scores.",
          "key_findings": "Clazosentan, started within 48 hours after aneurysmal subarachnoid hemorrhage and continued up to 15 days, significantly reduced vasospasm-related morbidity and all-cause mortality after both coiling and clipping in Japanese patients; all-cause morbidity/mortality and poor outcome were also reduced after pooling. No data are presented on alteplase or other reperfusion therapies, NIHSS scores, or differential benefit by baseline neurological severity.",
          "pmid": "35364589",
          "title": "Effects of clazosentan on cerebral vasospasm-related morbidity and all-cause mortality after aneurysmal subarachnoid hemorrhage: two randomized phase 3 trials in Japanese patients.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract discusses DWI lesion size as a prognostic marker and introduces mismatch concepts (perfusion\u2013diffusion and clinical\u2013DWI mismatch), but it does not analyze the relative efficacy of reperfusion therapies (like alteplase) by baseline NIHSS or extent of damage. There is no comparison of treatment effect by initial stroke severity or timing of reperfusion, so it neither supports nor contradicts the proposed mechanism about higher relative benefit in lower NIHSS patients treated early.",
          "key_findings": "1) DWI lesion size is a prognostic marker of stroke outcome, but cannot replace clinical outcome scores in a mixed stroke population. 2) The perfusion\u2013diffusion mismatch is hypothesized to indicate potentially salvageable tissue for early reperfusion, but newer data indicate DWI lesions are not always irreversible and perfusion may overestimate penumbra. 3) A mismatch between clinical stroke severity (NIHSS) and DWI lesion volume has been introduced as a concept, but no data are provided about treatment benefit stratified by NIHSS or extent of damage.",
          "pmid": "19130326",
          "title": "The clinical significance of diffusion-weighted MR imaging in stroke and TIA patients.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract discusses cell therapy and mechanisms of brain repair after stroke, not reperfusion therapies like alteplase, timing of reperfusion, or the relationship between treatment effect and baseline NIHSS severity. It provides no data on early vs late reperfusion, infarct extent, or differential benefit by initial stroke severity, so it neither supports nor contradicts the proposed mechanism.",
          "key_findings": "Animal models show mesenchymal and neural stem cells can improve functional recovery and, when MSCs are given acutely, reduce infarct volume. The paper focuses on endogenous and exogenous cell-based repair processes, angiogenesis, neurogenesis, immunomodulation, and trophic factor secretion. It also notes logistical and ethical issues of different stem cell sources and mentions early clinical trials of NSCs and MSCs, but does not address reperfusion therapies, alteplase, or outcome differences by initial NIHSS score.",
          "pmid": "24627643",
          "title": "Brain repair: cell therapy in stroke.",
          "analysis_method": "llm"
        }
      ]
    },
    {
      "feature_name": "atrialfib_rand",
      "mechanism": {
        "mechanism_type": "biological",
        "description": "Thrombi in non-atrial fibrillation strokes are more fibrin-rich and might be more susceptible to fibrinolysis by alteplase compared to platelet-rich thrombi from atrial fibrillation strokes.",
        "evidence_level": "moderate"
      },
      "query": "(stroke OR alteplase OR thrombolysis OR \"ischemic stroke\") AND \"atrialfib_rand\" AND (\"pathophysiology\" OR \"mechanism\" OR \"causal\" OR \"etiology\" OR \"interaction\") AND (\"fibrinolysis\" OR \"fibrillation\" OR \"susceptible\") AND (Clinical Trial[PT] OR Review[PT] OR Meta-Analysis[PT])",
      "total_abstracts": 3,
      "support_count": 0,
      "conflict_count": 0,
      "neutral_count": 3,
      "support_percentage": 0.0,
      "conflict_percentage": 0.0,
      "support_ratio": 0.0,
      "abstracts_analyzed": [
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract evaluates apixaban versus aspirin for stroke prevention in patients with subclinical atrial fibrillation. It does not examine thrombus composition (fibrin-rich vs platelet-rich), differences between atrial fibrillation\u2013related and non\u2013atrial fibrillation strokes, nor response to alteplase or fibrinolysis. Therefore, it neither supports nor contradicts the proposed mechanism about thrombus composition and alteplase susceptibility.",
          "key_findings": "In patients with subclinical atrial fibrillation, apixaban reduced stroke or systemic embolism compared to aspirin (HR 0.63) but increased major bleeding (HR 1.80). No data are presented on thrombus histology or differential fibrinolytic response of AF vs non-AF stroke thrombi.",
          "pmid": "37952132",
          "title": "Apixaban for Stroke Prevention in Subclinical Atrial Fibrillation.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract evaluates timing of DOAC initiation after ischemic stroke in patients with atrial fibrillation, with subgroup analysis by chronic kidney disease status. It does not examine thrombus composition (fibrin-rich vs platelet-rich), response to alteplase, or differential fibrinolysis between AF-related and non-AF-related strokes. Thus it neither supports nor contradicts the proposed mechanism.",
          "key_findings": "Early (\u22644 days) vs delayed (7\u201314 days) DOAC initiation after ischemic stroke with atrial fibrillation showed no difference in the composite primary outcome or key secondary outcomes, and chronic kidney disease did not modify this treatment effect.",
          "pmid": "40402086",
          "title": "Anticoagulation Timing in Acute Stroke With Atrial Fibrillation According to Chronic Kidney Disease: The OPTIMAS Trial.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract discusses incidence of arterial thromboembolism and the role of anticoagulation in heart failure with sinus rhythm, but it does not describe thrombus composition, differentiate atrial fibrillation\u2013related vs non\u2013atrial fibrillation stroke thrombi, nor assess response to alteplase or fibrinolysis. Therefore it neither supports nor conflicts with the proposed mechanism about fibrin-rich vs platelet-rich thrombi and alteplase susceptibility.",
          "key_findings": "In patients with heart failure and sinus rhythm not receiving anticoagulants, arterial thromboembolism incidence ranged from 0.9 to 5.5 events per 100 patient-years; large studies reported 2.0% and 2.4%. Data on the relationship between severity of ventricular dysfunction and thromboembolic events were contradictory. No controlled trials have evaluated efficacy or risks of anticoagulation in this population, and reported efficacy in case series varied widely. The article advises against routine anticoagulation in heart failure patients who are in sinus rhythm.",
          "pmid": "7966873",
          "title": "Management of heart failure. IV. Anticoagulation for patients with heart failure due to left ventricular systolic dysfunction.",
          "analysis_method": "llm"
        }
      ]
    },
    {
      "feature_name": "atrialfib_rand",
      "mechanism": {
        "mechanism_type": "biological",
        "description": "Cardioembolic strokes related to atrial fibrillation often have clot characteristics that can hinder the effectiveness of thrombolytic therapy, such as being more platelet-rich.",
        "evidence_level": "moderate"
      },
      "query": "(stroke OR alteplase OR thrombolysis OR \"ischemic stroke\") AND \"atrialfib_rand\" AND (\"pathophysiology\" OR \"mechanism\" OR \"causal\" OR \"etiology\" OR \"interaction\") AND (\"characteristics\" OR \"effectiveness\" OR \"cardioembolic\") AND (Clinical Trial[PT] OR Review[PT] OR Meta-Analysis[PT])",
      "total_abstracts": 7,
      "support_count": 0,
      "conflict_count": 0,
      "neutral_count": 7,
      "support_percentage": 0.0,
      "conflict_percentage": 0.0,
      "support_ratio": 0.0,
      "abstracts_analyzed": [
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract evaluates a cognitive and functional occupational therapy intervention for individuals with mild stroke, focusing on daily functioning, participation, and satisfaction. It does not address clot composition, cardioembolic vs. other stroke etiologies, atrial fibrillation, or response to thrombolytic therapy, so it neither supports nor contradicts the proposed mechanism about clot characteristics in AF-related cardioembolic stroke.",
          "key_findings": "FaCoT, a cognitive and functional occupational therapy program, improved Canadian Occupational Performance Measure performance and satisfaction scores and Reintegration to Normal Living scores compared with standard care in people with mild stroke, with large effect sizes and clinically important differences. No data are presented on stroke mechanism, clot characteristics, or thrombolytic effectiveness.",
          "pmid": "34360299",
          "title": "Effectiveness of the Functional and Cognitive Occupational Therapy (FaC<sub>o</sub>T) Intervention for Improving Daily Functioning and Participation of Individuals with Mild Stroke: A Randomized Controlled Trial.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract evaluates calcium intake and overall cardiovascular disease and stroke risk in generally healthy adults but does not examine atrial fibrillation, cardioembolic stroke subtypes, clot composition, or response to thrombolytic therapy. Therefore it neither supports nor contradicts the proposed mechanism about clot characteristics in AF-related cardioembolic strokes.",
          "key_findings": "Calcium intake (dietary or supplemental, within tolerable upper intake levels of 2000\u20132500 mg/d) was not associated with increased cardiovascular disease events, cardiovascular mortality, or consistent changes in stroke risk in generally healthy adults. No data were presented on atrial fibrillation, cardioembolic stroke, clot composition, or thrombolytic efficacy.",
          "pmid": "27776363",
          "title": "Calcium Intake and Cardiovascular Disease Risk: An Updated Systematic Review and Meta-analysis.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract evaluates the association of antiplatelet agent use with mortality and heart failure hospitalization in patients with left ventricular systolic dysfunction and its interaction with enalapril. It does not address cardioembolic stroke, atrial fibrillation, thrombolytic therapy, clot composition, or platelet-rich thrombi, so it neither supports nor refutes the proposed mechanism about clot characteristics in cardioembolic strokes.",
          "key_findings": "In 6,797 patients with LV systolic dysfunction from the SOLVD trial, antiplatelet agent use (46.3% of patients) was associated with reduced all-cause mortality (adjusted HR 0.82, 95% CI 0.73\u20130.92) and reduced risk of death or hospital admission for heart failure (adjusted HR 0.81, 95% CI 0.74\u20130.89). The benefit was independent of gender, LV ejection fraction, NYHA class, trial assignment, or etiology. A strong interaction was noted between antiplatelet use and enalapril: survival benefit from antiplatelets was not seen in the enalapril group, and enalapril survival benefit was not detectable in baseline antiplatelet users, though enalapril reduced the combined endpoint in antiplatelet users.",
          "pmid": "9462588",
          "title": "Antiplatelet agents and survival: a cohort analysis from the Studies of Left Ventricular Dysfunction (SOLVD) trial.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract focuses on unilateral spatial neglect and upper extremity motor recovery after stroke, without mentioning atrial fibrillation, cardioembolic stroke, clot composition, or thrombolytic therapy. It does not address any aspect of clot characteristics or treatment response relevant to the proposed mechanism.",
          "key_findings": "USN is associated with poor upper extremity motor capacity and less recovery poststroke, and there is limited evidence on sensorimotor interventions for patients with USN; no data are provided on stroke etiology, clot biology, or thrombolysis outcomes.",
          "pmid": "30784364",
          "title": "Is Unilateral Spatial Neglect Associated With Motor Recovery of the Affected Upper Extremity Poststroke? A Systematic Review.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract studies kinematic properties of multi-segment arm movements and how task difficulty (per Fitts' law) affects movement planning and execution. It does not involve stroke, atrial fibrillation, clot composition, thrombolysis, or any hemostatic/vascular mechanisms, so it neither supports nor contradicts the proposed mechanism about clot characteristics in cardioembolic stroke.",
          "key_findings": "Changing the index of difficulty for the second segment of a two-part arm movement altered kinematic features of the first segment, including movement duration, peak velocity, and intersegment interval, indicating that complex movement planning incorporates accuracy demands of multiple movement segments.",
          "pmid": "9224841",
          "title": "The influence of movement segment difficulty on movements with two-stroke sequence.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract studies the effect of a mobility intervention on functional outcomes in patients with intracerebral and subarachnoid hemorrhage. It does not address atrial fibrillation, cardioembolic stroke, clot composition, or thrombolytic therapy effectiveness, so it neither supports nor contradicts the proposed mechanism.",
          "key_findings": "Daily, evidence-based mobility intervention in a neurointensive care unit was associated with a 2.3-fold increase in hemorrhagic stroke patients achieving a higher level of function (walking >15.24m) by discharge; factors such as intervention exposure, initial functional level, stroke type (SAH), longer ICU stay, and absence of aphasia/hemiplegia were associated with better walking outcomes.",
          "pmid": "25701637",
          "title": "Effect of an evidence-based mobility intervention on the level of function in acute intracerebral and subarachnoid hemorrhagic stroke patients on a neurointensive care unit.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract focuses on botulinum toxin treatment for post-stroke lower limb spasticity, gait, and quality of life outcomes. It does not discuss atrial fibrillation, cardioembolic stroke, clot composition, platelet-rich thrombi, or thrombolytic therapy, so it neither supports nor contradicts the proposed mechanism.",
          "key_findings": "The study is a randomized double-blind placebo-controlled trial assessing botulinum toxin A versus placebo in 94 patients with post-stroke lower limb spasticity. Outcomes include spasticity reduction (Modified Ashworth Scale), gait velocity, mobility, balance, activities of daily living, goal attainment, and quality of life. The abstract notes existing evidence for improved mobility with botulinum toxin is not robust and aims to clarify this, but it does not address clot characteristics or thrombolysis in cardioembolic stroke.",
          "pmid": "31078139",
          "title": "Efficacy of botulinum toxin in modifying spasticity to improve walking and quality of life in post-stroke lower limb spasticity - a randomized double-blind placebo controlled study.",
          "analysis_method": "llm"
        }
      ]
    },
    {
      "feature_name": "atrialfib_rand",
      "mechanism": {
        "mechanism_type": "biological",
        "description": "Studies have highlighted variability in alteplase response based on clot composition, with fibrin-rich clots responding more favorably (Marder et al., 2008).",
        "evidence_level": "moderate"
      },
      "query": "(stroke OR alteplase OR thrombolysis OR \"ischemic stroke\") AND \"atrialfib_rand\" AND (\"pathophysiology\" OR \"mechanism\" OR \"causal\" OR \"etiology\" OR \"interaction\") AND (\"highlighted\" OR \"variability\" OR \"composition\") AND (Clinical Trial[PT] OR Review[PT] OR Meta-Analysis[PT])",
      "total_abstracts": 1,
      "support_count": 0,
      "conflict_count": 0,
      "neutral_count": 1,
      "support_percentage": 0.0,
      "conflict_percentage": 0.0,
      "support_ratio": 0.0,
      "abstracts_analyzed": [
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract concerns the development of quality indicators for heart failure care in general practice and does not address thrombolysis, alteplase, clot composition, or fibrin-rich versus other clot types. Therefore, it neither supports nor conflicts with the proposed mechanism about variability in alteplase response based on clot composition.",
          "key_findings": "Nineteen electronic health record\u2013based quality indicators for heart failure care in Belgian general practice were identified and prioritized using a RAND/UCLA modified Delphi process; top indicators involved identifying heart failure etiology, distinguishing preserved vs reduced ejection fraction, and appropriate ACE inhibitor and beta-blocker treatment.",
          "pmid": "30261830",
          "title": "Defining quality indicators for heart failure in general practice.",
          "analysis_method": "llm"
        }
      ]
    },
    {
      "feature_name": "stroketype_3.0",
      "mechanism": {
        "mechanism_type": "biological",
        "description": "Certain secondary prevention medications, such as antiplatelets or anticoagulants, started immediately post-stroke may interfere with the thrombolytic action of alteplase, potentially reducing its efficacy.",
        "evidence_level": "moderate"
      },
      "query": "(stroke OR alteplase OR thrombolysis OR \"ischemic stroke\") AND \"stroketype_3.0\" AND (\"pathophysiology\" OR \"mechanism\" OR \"causal\" OR \"etiology\" OR \"interaction\") AND (\"anticoagulants\" OR \"antiplatelets\" OR \"thrombolytic\") AND (Clinical Trial[PT] OR Review[PT] OR Meta-Analysis[PT])",
      "total_abstracts": 0,
      "support_count": 0,
      "conflict_count": 0,
      "neutral_count": 0,
      "abstracts_analyzed": []
    },
    {
      "feature_name": "stroketype_3.0",
      "mechanism": {
        "mechanism_type": "biological",
        "description": "The inflammatory environment of a recurrent stroke, occurring shortly after the initial, may be less receptive to thrombolysis due to altered coagulation pathways.",
        "evidence_level": "moderate"
      },
      "query": "(stroke OR alteplase OR thrombolysis OR \"ischemic stroke\") AND \"stroketype_3.0\" AND (\"pathophysiology\" OR \"mechanism\" OR \"causal\" OR \"etiology\" OR \"interaction\") AND (\"thrombolysis\" OR \"inflammatory\" OR \"environment\") AND (Clinical Trial[PT] OR Review[PT] OR Meta-Analysis[PT])",
      "total_abstracts": 0,
      "support_count": 0,
      "conflict_count": 0,
      "neutral_count": 0,
      "abstracts_analyzed": []
    },
    {
      "feature_name": "stroketype_3.0",
      "mechanism": {
        "mechanism_type": "biological",
        "description": "Patients who experience a stroke recurrence soon after treatment initiation may be predisposed to a less favorable response due to underlying pathophysiological factors not addressed by thrombolysis alone.",
        "evidence_level": "moderate"
      },
      "query": "(stroke OR alteplase OR thrombolysis OR \"ischemic stroke\") AND \"stroketype_3.0\" AND (\"pathophysiology\" OR \"mechanism\" OR \"causal\" OR \"etiology\" OR \"interaction\") AND (\"pathophysiological\" OR \"thrombolysis\" OR \"predisposed\") AND (Clinical Trial[PT] OR Review[PT] OR Meta-Analysis[PT])",
      "total_abstracts": 0,
      "support_count": 0,
      "conflict_count": 0,
      "neutral_count": 0,
      "abstracts_analyzed": []
    },
    {
      "feature_name": "weight",
      "mechanism": {
        "mechanism_type": "biological",
        "description": "High body weight is associated with increased adipose tissue, which can affect drug distribution and metabolism, potentially reducing the efficacy of alteplase.",
        "evidence_level": "moderate"
      },
      "query": "(stroke OR alteplase OR thrombolysis OR \"ischemic stroke\") AND (weight OR BMI OR obesity OR \"body mass\" OR \"pharmacokinetics\") AND (\"pathophysiology\" OR \"mechanism\" OR \"causal\" OR \"etiology\" OR \"interaction\") AND (\"distribution\" OR \"potentially\" OR \"associated\") AND (Clinical Trial[PT] OR Review[PT] OR Meta-Analysis[PT])",
      "total_abstracts": 20,
      "support_count": 0,
      "conflict_count": 0,
      "neutral_count": 20,
      "support_percentage": 0.0,
      "conflict_percentage": 0.0,
      "support_ratio": 0.0,
      "abstracts_analyzed": [
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract evaluates the effect of semaglutide on cardiovascular outcomes in patients with overweight/obesity, but it does not examine alteplase, drug distribution, pharmacokinetics, or how increased adipose tissue alters drug metabolism or efficacy. Therefore, it neither supports nor contradicts the proposed mechanism about high body weight affecting alteplase efficacy.",
          "key_findings": "In 17,604 patients with preexisting cardiovascular disease and BMI \u226527 without diabetes, once-weekly subcutaneous semaglutide 2.4 mg reduced the composite endpoint of cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke compared with placebo (HR 0.80, 95% CI 0.72\u20130.90). Adverse events leading to discontinuation were more frequent with semaglutide. No data on alteplase or weight-related changes in its distribution or metabolism are provided.",
          "pmid": "37952131",
          "title": "Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract discusses obesity, gut microbiota, and the gut-brain axis in relation to body weight regulation and potential anti-obesity therapies. It does not mention alteplase, drug distribution, or drug metabolism, nor does it address how increased adipose tissue in high body weight individuals might alter pharmacokinetics or efficacy of alteplase or any thrombolytic drugs.",
          "key_findings": "Obesity is linked to alterations in gut microbiota and gut-brain axis signaling, which influence metabolism, adiposity, energy balance, appetite, and food reward. Modulation of the gut microbiome (e.g., via fecal microbiota transplantation, probiotics, and prebiotics) is proposed as a potential treatment for obesity. No data or discussion is provided about drug distribution, metabolism, or alteplase efficacy.",
          "pmid": "35421277",
          "title": "Obesity and gut-microbiota-brain axis: A narrative review.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract discusses obesity as a risk factor for atrial fibrillation and its role in atrial remodeling, but it does not mention alteplase, thrombolytic therapy, or how high body weight/adipose tissue affects drug distribution, metabolism, or treatment efficacy. Therefore it neither supports nor contradicts the proposed pharmacologic mechanism.",
          "key_findings": "Obesity is identified as a modifiable risk factor for atrial fibrillation that contributes to structural and electrical atrial remodeling; no data are presented on alteplase pharmacokinetics, pharmacodynamics, or clinical efficacy in relation to body weight or adipose tissue.",
          "pmid": "36434795",
          "title": "Atrial fibrillation: Epidemiology, pathophysiology, and clinical complications (literature review).",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract examines associations and causal relationships between adiposity and cardiovascular disease and mortality, but does not address drug distribution, metabolism, or the efficacy of alteplase or any other medication. Therefore it neither supports nor contradicts the proposed mechanism about adiposity altering alteplase efficacy.",
          "key_findings": "Increased BMI/adiposity is associated with higher risks of multiple cardiovascular outcomes (e.g., coronary heart disease, heart failure, various stroke types, hypertension, thrombo-embolic events), with Mendelian randomization suggesting a causal role for obesity in most CVD outcomes but not stroke or all-cause mortality. No data are presented on pharmacokinetics, pharmacodynamics, or treatment response to alteplase.",
          "pmid": "34333589",
          "title": "Association between adiposity and cardiovascular outcomes: an umbrella review and meta-analysis of observational and Mendelian randomization studies.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract discusses hypertension risk factors in low- and middle-income countries, including obesity, but does not address drug distribution, metabolism, or the efficacy of alteplase or any thrombolytic therapy. There is no mechanistic or pharmacologic evidence related to how high body weight or adipose tissue affects alteplase action.",
          "key_findings": "Obesity is listed as an established risk factor for hypertension among others (unhealthy diet, physical inactivity, tobacco, alcohol). The abstract focuses on epidemiology, awareness, control rates, health system challenges, and population-level interventions for hypertension in LMICs, without mentioning alteplase, pharmacokinetics, or treatment efficacy modulation by body weight.",
          "pmid": "33793340",
          "title": "Hypertension in Low- and Middle-Income Countries.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract discusses cancer-associated stroke, thrombolysis, and rTPA use in cancer patients but does not address body weight, adipose tissue, pharmacokinetics, or altered efficacy of alteplase. Therefore it neither supports nor contradicts the proposed mechanism about high body weight affecting alteplase distribution and metabolism.",
          "key_findings": "Cancer is associated with increased risk of stroke; cancer is not a contraindication to thrombolysis with rTPA, and hemorrhage risk is reported as similar to the general population. No mention is made of obesity, adiposity, body weight, or altered alteplase efficacy related to these factors.",
          "pmid": "30628661",
          "title": "Cancer-associated stroke: Pathophysiology, detection and management (Review).",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract evaluates the impact of bariatric surgery on cardiovascular outcomes and mortality in patients with obesity but does not discuss alteplase, thrombolytic therapy, or how high body weight/adipose tissue affects drug distribution, metabolism, or efficacy. Therefore, it neither supports nor contradicts the specific pharmacokinetic/pharmacodynamic mechanism proposed for alteplase.",
          "key_findings": "Bariatric surgery in obese patients is associated with reduced all-cause mortality (HR 0.55), cardiovascular mortality (HR 0.59), and incidence of heart failure (HR 0.50), myocardial infarction (HR 0.58), and stroke (HR 0.64), with no significant association with atrial fibrillation. No information is provided on alteplase use, dosing, or efficacy, nor on drug distribution/metabolism related to adipose tissue.",
          "pmid": "35243488",
          "title": "Bariatric surgery and cardiovascular disease: a systematic review and meta-analysis.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract examines childhood BMI as a predictor of adult obesity-related morbidity (diabetes, CHD, cancers). It does not address drug pharmacokinetics, adipose effects on drug distribution or metabolism, nor alteplase efficacy. Therefore, it neither supports nor contradicts the proposed mechanism about high body weight altering alteplase effectiveness.",
          "key_findings": "High childhood BMI is associated with increased incidence of adult diabetes (OR 1.70), coronary heart disease (OR 1.20), and some cancers, but not stroke or breast cancer. Childhood BMI has low accuracy for predicting adult obesity-related morbidity overall, as most adult morbidity occurs in people who had normal weight in childhood.",
          "pmid": "26440472",
          "title": "Childhood obesity as a predictor of morbidity in adulthood: a systematic review and meta-analysis.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract examines the effects of tirzepatide-induced weight loss on left ventricular mass and paracardiac adipose tissue in obesity-related HFpEF. It does not involve alteplase, thrombolytic therapy, or any assessment of how increased adipose tissue or high body weight affects drug distribution, metabolism, or efficacy. Therefore it neither supports nor contradicts the proposed mechanism about alteplase effectiveness in high body weight.",
          "key_findings": "Tirzepatide treatment in patients with obesity-related HFpEF reduced LV mass by 11 g versus placebo and reduced paracardiac adipose tissue by 45 mL versus placebo over 52 weeks, with LV mass changes correlating with changes in body weight and cardiac volumes.",
          "pmid": "39566869",
          "title": "Tirzepatide Reduces LV Mass and Paracardiac Adipose Tissue in Obesity-Related Heart\u00a0Failure: SUMMIT CMR Substudy.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract evaluates the clinical effectiveness of endovascular thrombectomy with or without weight-based intravenous alteplase but does not analyze how body weight or adipose tissue influences alteplase distribution, metabolism, or efficacy. There are no subgroup analyses or mechanistic data related to high body weight or adiposity, so it neither supports nor contradicts the proposed mechanism.",
          "key_findings": "Alteplase was dosed by body weight (0.9 mg/kg), and thrombectomy alone was noninferior to thrombectomy plus alteplase for functional outcome at 90 days. Differences in reperfusion rates and mortality between groups were reported, but no data were presented on the impact of high body weight, adiposity, or altered pharmacokinetics on alteplase efficacy.",
          "pmid": "32374959",
          "title": "Endovascular Thrombectomy with or without Intravenous Alteplase in Acute Stroke.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract examines long-term cardiometabolic risks in women with PCOS (hypertension, diabetes, lipid levels, cardiovascular events). It does not assess alteplase, drug distribution, or how high body weight or adipose tissue affect drug metabolism or efficacy. While obesity and metabolic risk are implicit in PCOS, there is no mechanistic or pharmacologic data relevant to alteplase or its effectiveness.",
          "key_findings": "Women with PCOS have increased risks of hypertension (RR 1.75), type 2 diabetes (RR 3.00), higher total cholesterol, lower HDL-C, and increased non-fatal cerebrovascular events compared with women without PCOS; no clear differences for LDL-C, triglycerides, or coronary events. No mention of alteplase, drug distribution, or treatment response by body weight.",
          "pmid": "32995872",
          "title": "Long-term cardiometabolic disease risk in women with PCOS: a systematic review and meta-analysis.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract evaluates how the magnitude of weight loss and changes in fitness affect long-term cardiovascular outcomes in overweight or obese people with type 2 diabetes. It does not measure or discuss alteplase, drug distribution, pharmacokinetics, or treatment efficacy as related to body weight or adipose tissue. Therefore it neither supports nor conflicts with the proposed mechanism about high body weight altering alteplase distribution/metabolism and efficacy.",
          "key_findings": "Greater weight loss (\u226510% in the first year) and increases in fitness were associated with reduced risk of composite cardiovascular outcomes over ~10 years in overweight/obese adults with type 2 diabetes. No data on alteplase or drug pharmacokinetics were presented.",
          "pmid": "27595918",
          "title": "Association of the magnitude of weight loss and changes in physical fitness with long-term cardiovascular disease outcomes in overweight or obese people with type 2 diabetes: a post-hoc analysis of the Look AHEAD randomised clinical trial.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract discusses how obesity and adipose tissue dysfunction contribute to various cardiometabolic and obesity-related diseases through inflammatory, metabolic, and fat-distribution mechanisms, but it does not mention alteplase or drug distribution/metabolism, nor does it address how high body weight or adipose tissue affects thrombolytic efficacy. Thus it is related to adipose-tissue mechanisms in general but does not provide evidence for or against altered alteplase efficacy.",
          "key_findings": "Obesity is linked epidemiologically to many adverse health outcomes; adipose tissue dysfunction (hypertrophy, ectopic fat, inflammation, altered signaling) is proposed as a mechanistic link between obesity and its complications; risk is not explained by fat mass alone but by qualitative aspects of adipose tissue; weight loss improves obesity-related complications. No data or discussion are provided regarding drug pharmacokinetics, pharmacodynamics, or specifically alteplase efficacy in individuals with high body weight.",
          "pmid": "40069923",
          "title": "An overview of obesity-related complications: The epidemiological evidence linking body weight and other markers of obesity to adverse health outcomes.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract evaluates the causal association between obesity and cardiovascular outcomes via Mendelian randomization but does not address drug pharmacokinetics, alteplase, adipose-related drug distribution, or treatment efficacy. Therefore, it neither supports nor contradicts the proposed mechanism about obesity altering alteplase effectiveness.",
          "key_findings": "Genetically instrumented obesity was associated with increased risk of type 2 diabetes (OR 1.67) and coronary artery disease (OR 1.20), but not stroke (OR 1.02). No data on drug metabolism, distribution, or alteplase response are presented.",
          "pmid": "30646365",
          "title": "Association Between Obesity and Cardiovascular Outcomes: A Systematic Review and Meta-analysis of Mendelian Randomization Studies.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract evaluates endovascular thrombectomy versus medical care for large ischemic strokes and reports functional outcomes and complications. It does not examine body weight, adipose tissue, pharmacokinetics, or alteplase efficacy, nor does it stratify results by weight or discuss drug distribution/metabolism.",
          "key_findings": "Endovascular thrombectomy within 24 hours in patients with large ischemic-core strokes improved 90-day functional outcomes versus medical care alone, with similar mortality and low rates of symptomatic intracranial hemorrhage. No data on body weight, adiposity, or alteplase pharmacodynamics or pharmacokinetics are presented.",
          "pmid": "36762865",
          "title": "Trial of Endovascular Thrombectomy for Large Ischemic Strokes.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract evaluates effects of semaglutide-induced weight loss on cardiac structure and function in obesity-related HFpEF. It does not involve alteplase, thrombolytic therapy, or drug distribution/metabolism in relation to body weight or adipose tissue, so it neither supports nor contradicts the proposed mechanism about altered alteplase efficacy in high body weight.",
          "key_findings": "Semaglutide vs placebo in patients with obesity-related HFpEF reduced left atrial volume and right ventricular size and improved several diastolic function parameters over 52 weeks, with greater weight loss associated with greater reduction in left atrial volume. No effects were seen on left ventricular dimensions, mass, or systolic function. The study did not assess alteplase, pharmacokinetics, or drug efficacy as a function of adiposity.",
          "pmid": "39217567",
          "title": "Effect of Semaglutide on Cardiac Structure and Function in Patients With Obesity-Related\u00a0Heart\u00a0Failure.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract examines how baseline BMI, adiposity distribution, and weight loss modify clinical responses to tirzepatide in HFpEF, not how high body weight or adipose tissue alters pharmacokinetics, distribution, or metabolism of alteplase or any thrombolytic. It does not assess drug levels, metabolic handling, or efficacy of alteplase across weight or adiposity strata, so it neither supports nor contradicts the proposed mechanism.",
          "key_findings": "In obese patients with HFpEF, higher BMI and higher waist-height ratio were associated with worse baseline clinical status. Tirzepatide reduced the risk of cardiovascular death or worsening heart failure consistently across BMI and WHR tertiles, with greater improvements in 6-minute walk distance, body weight, and blood pressure at higher BMI. Greater weight loss on tirzepatide was linked to larger improvements in functional capacity, symptoms, inflammation, and blood pressure. No data on alteplase, its pharmacokinetics, or BMI-related differences in alteplase efficacy were reported.",
          "pmid": "40701669",
          "title": "Impact of Body Mass Index, Central Adiposity, and Weight Loss on the Benefits of Tirzepatide in HFpEF: The SUMMIT Trial.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract discusses obesity as a modifiable risk factor for obstructive sleep apnea and the benefits of weight loss, but it does not address pharmacokinetics, drug distribution, metabolism, or alteplase efficacy. Therefore it neither supports nor contradicts the specific mechanism about high body weight altering alteplase effectiveness.",
          "key_findings": "Obstructive sleep apnea is common and associated with significant morbidity; overweight and obesity are identified as modifiable risk factors; weight loss is the only intervention with adequate evidence to reduce obstructive sleep apnea risk. No mention is made of drug distribution, metabolism, or alteplase.",
          "pmid": "11991871",
          "title": "Epidemiology of obstructive sleep apnea: a population health perspective.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract examines associations between artificially sweetened beverage consumption and various health outcomes (including obesity, diabetes, and cardiovascular disease), but does not address body weight as it relates to adipose tissue effects on drug distribution or metabolism, nor does it mention alteplase or any drug efficacy. Thus, it neither supports nor contradicts the proposed pharmacokinetic mechanism.",
          "key_findings": "Artificially sweetened beverages were associated with higher risk of obesity, type 2 diabetes, all-cause mortality, hypertension, and cardiovascular disease incidence, based on an umbrella review of observational meta-analyses; no data on drug metabolism, distribution, or response (including alteplase) are reported.",
          "pmid": "37187453",
          "title": "Artificially Sweetened Beverages and Health Outcomes: An Umbrella Review.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract examines genetic determinants of mitochondrial DNA copy number and cardiometabolic diseases, including obesity, but does not address drug pharmacokinetics, alteplase, or how adipose tissue affects drug distribution or metabolism. Therefore it neither supports nor refutes the proposed mechanism about high body weight altering alteplase efficacy.",
          "key_findings": "Genetically predicted mtDNA copy number was not causally associated with obesity or other cardiometabolic diseases; in reverse analyses, dyslipidemia and possibly coronary artery disease were associated with decreased mtDNA copy number. No data on drug response, pharmacokinetics, or alteplase efficacy are presented.",
          "pmid": "38282013",
          "title": "The role of mitochondrial DNA copy number in cardiometabolic disease: a bidirectional two-sample mendelian randomization study.",
          "analysis_method": "llm"
        }
      ]
    },
    {
      "feature_name": "weight",
      "mechanism": {
        "mechanism_type": "biological",
        "description": "Elevated glucose levels, common in overweight individuals, have been associated with worse neurological outcomes in stroke patients, possibly due to hyperglycemia-induced secondary injury.",
        "evidence_level": "moderate"
      },
      "query": "(stroke OR alteplase OR thrombolysis OR \"ischemic stroke\") AND (weight OR BMI OR obesity OR \"body mass\" OR \"pharmacokinetics\") AND (\"pathophysiology\" OR \"mechanism\" OR \"causal\" OR \"etiology\" OR \"interaction\") AND (\"hyperglycemia\" OR \"neurological\" OR \"individuals\") AND (Clinical Trial[PT] OR Review[PT] OR Meta-Analysis[PT])",
      "total_abstracts": 20,
      "support_count": 1,
      "conflict_count": 0,
      "neutral_count": 19,
      "support_percentage": 5.0,
      "conflict_percentage": 0.0,
      "support_ratio": 0.05,
      "abstracts_analyzed": [
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract focuses on cross-ancestry genome-wide association studies for stroke risk, identification of genetic loci, putative drug targets, and polygenic risk scores. It does not mention blood glucose, hyperglycemia, overweight/obesity, or secondary neurological injury mechanisms after stroke, so it neither supports nor contradicts the proposed hyperglycemia-related mechanism.",
          "key_findings": "Identification of 89 stroke-associated loci across ancestries; replication of most loci; fine-mapping and multi-omics analyses revealing putative causal genes (e.g., SH3PXD2A, FURIN, GRK5, NOS3); genetic evidence for drug targets (e.g., F11, KLKB1, PROC, GP1BA, LAMC2, VCAM1); development of integrative polygenic scores predictive of ischemic stroke independent of clinical risk factors. No findings related to glucose levels or hyperglycemia-induced secondary injury.",
          "pmid": "36180795",
          "title": "Stroke genetics informs drug discovery and risk prediction across ancestries.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract focuses on obesity, heart failure, the obesity paradox, and cardiorespiratory fitness. It does not discuss stroke, neurological outcomes, glucose levels, or hyperglycemia-induced secondary injury, so it neither supports nor contradicts the proposed mechanism.",
          "key_findings": "Obesity is a major risk factor for heart failure and is highly prevalent, especially in HFpEF. An obesity paradox is described in which obese patients with established heart failure have better short- and mid-term survival but more hospitalizations. Cardiorespiratory fitness appears to modify risk, and when it is accounted for, the obesity paradox disappears. BMI is criticized as an imperfect measure of body composition in heart failure.",
          "pmid": "38199320",
          "title": "Update on obesity, the obesity paradox, and obesity management in heart failure.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract focuses on weight loss, fitness change, and long-term cardiovascular outcomes in overweight/obese adults with type 2 diabetes. It does not measure glucose levels, hyperglycemia severity, stroke outcomes, or mechanisms of secondary neurological injury. Therefore it neither supports nor contradicts the proposed mechanism about elevated glucose worsening neurological outcomes after stroke.",
          "key_findings": "In the Look AHEAD post-hoc analysis, overweight/obese adults with type 2 diabetes who lost at least 10% of their bodyweight in the first year had a 21% lower risk of a composite primary cardiovascular outcome (CV death, non-fatal MI, non-fatal stroke, or hospitalization for angina) and a 24% lower risk of a broader secondary cardiovascular outcome over a median 10.2 years. Increased fitness was associated with reduced risk of the secondary but not primary cardiovascular outcome. The study did not report effects of glucose levels or hyperglycemia on stroke-specific neurological outcomes.",
          "pmid": "27595918",
          "title": "Association of the magnitude of weight loss and changes in physical fitness with long-term cardiovascular disease outcomes in overweight or obese people with type 2 diabetes: a post-hoc analysis of the Look AHEAD randomised clinical trial.",
          "analysis_method": "llm"
        },
        {
          "stance": "support",
          "confidence": "high",
          "reasoning": "The abstract explicitly states that hyperglycemia (elevated glucose), commonly occurring in diabetes and obesity, is associated with increased stroke risk and poorer clinical outcomes, including higher mortality, especially following ischemic stroke. This directly supports the proposed mechanism that elevated glucose is linked to worse neurological outcomes after stroke, consistent with hyperglycemia-induced secondary injury.",
          "key_findings": "The abstract notes: (1) Hyperglycemia confers greater risk of stroke occurrence; (2) This increased risk is seen in individuals with diabetes; (3) Hyperglycemia is associated with poorer clinical outcomes, including higher mortality, especially following ischemic stroke.",
          "pmid": "27079344",
          "title": "Diabetes and Stroke: Epidemiology, Pathophysiology, Pharmaceuticals and Outcomes.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract evaluates the clinical efficacy and safety of endovascular thrombectomy versus medical care in large ischemic strokes and reports functional outcomes, mortality, and vascular/hemorrhagic complications. It does not assess glucose levels, weight/overweight status, hyperglycemia, or any metabolic factors, nor does it analyze their relationship to neurological outcomes or secondary brain injury.",
          "key_findings": "Endovascular thrombectomy within 24 hours for large ischemic-core strokes improved 90-day functional outcomes and functional independence compared with medical care alone, with similar mortality and low rates of symptomatic intracranial hemorrhage in both groups. No data on blood glucose, hyperglycemia, overweight status, or glucose-related mechanisms are presented.",
          "pmid": "36762865",
          "title": "Trial of Endovascular Thrombectomy for Large Ischemic Strokes.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract discusses epigenetic/epitranscriptomic mechanisms, gut microbiota, and their roles in post-stroke depression, including mention of fat mass and obesity-associated protein. However, it does not address blood glucose levels, hyperglycemia, stroke outcomes, or hyperglycemia-induced secondary injury, so it neither supports nor contradicts the proposed glucose-related mechanism.",
          "key_findings": "The review focuses on how gut microbiota interacts with epigenetic and epitranscriptomic pathways (DNA methylation, histone modifications, RNA methylation such as m6A) to modulate candidate genes (BDNF, TET family proteins, FTO) implicated in post-stroke depression, and highlights these as potential molecular targets. No data on elevated glucose, overweight status, or their effects on neurological outcomes after stroke are presented.",
          "pmid": "37188778",
          "title": "Post-stroke depression: epigenetic and epitranscriptomic modifications and their interplay with gut microbiota.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract discusses optimal glucose control as part of guideline-recommended therapy in peripheral artery disease and notes that such management lowers major adverse cardiovascular and limb events, including stroke. However, it does not address how elevated glucose or hyperglycemia specifically affects neurological outcomes after stroke, nor does it discuss hyperglycemia-induced secondary brain injury. Thus it neither supports nor contradicts the proposed mechanism.",
          "key_findings": "In patients with peripheral artery disease, treatment with guideline-recommended therapies, including optimal glucose control, lowers the incidence of major adverse cardiovascular events (which include stroke) and major adverse limb events. No data or discussion is provided on post-stroke neurological outcomes or hyperglycemia-related secondary injury in the brain.",
          "pmid": "34110910",
          "title": "Contemporary Medical Management of Peripheral Artery Disease.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract discusses migraine as a risk factor for stroke, overlapping risk factors such as obesity, and that migraine is linked to worse ischemic stroke outcomes, but it does not mention hyperglycemia, glucose levels, or mechanisms of hyperglycemia-induced secondary injury in stroke. Therefore, it neither supports nor contradicts the specific mechanism involving elevated glucose and post-stroke neurological outcome.",
          "key_findings": "Migraine, particularly migraine with aura, is an independent risk factor for stroke and is associated with worse outcomes after ischemic stroke, including larger infarct volumes and poorer functional outcomes. Shared processes and risk factors between migraine and stroke include cortical spreading depression, endothelial dysfunction, vasculopathy, microRNAs, genetic links, and comorbid conditions such as PFO, atrial fibrillation, carotid artery dissection, platelet dysfunction, dyslipidemia, obesity, hyperhomocysteinemia, and elevated estrogen levels. Glucose levels or hyperglycemia are not discussed.",
          "pmid": "39979846",
          "title": "Migraine and stroke: correlation, coexistence, dependence - a modern perspective.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract compares aquatic versus land-based rehabilitation exercises in chronic hemiplegic stroke patients, focusing on spasticity, balance, postural control, and functional scales. It does not measure glucose levels, hyperglycemia, weight status, or neurological outcomes in relation to blood glucose, nor does it discuss hyperglycemia-induced secondary injury. Therefore it neither supports nor contradicts the proposed glucose-related mechanism.",
          "key_findings": "Aquatic therapy and land-based exercises both improved outcomes in chronic hemiplegic stroke patients, with land-based therapy showing greater benefit for spasticity and some postural sway parameters. No data on blood glucose, overweight status, or hyperglycemia-related neurological injury are reported.",
          "pmid": "38954645",
          "title": "Comparative Study Between Aquatic Therapy and Land-Based Exercises in Hemiplegic Patients After Stroke: A Randomized Controlled Trial.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract focuses on dietary salt intake, hypertension, and related cardiovascular and metabolic outcomes. It does not discuss blood glucose levels, hyperglycemia, overweight-related elevated glucose, stroke outcomes, or hyperglycemia-induced secondary neurological injury. Therefore, it neither supports nor contradicts the proposed glucose\u2013stroke outcome mechanism.",
          "key_findings": "Excessive salt intake is associated with increased hypertension risk and thereby increased risk of stroke and other cardiovascular and kidney diseases; salt reduction lowers blood pressure, especially in hypertensives. Salt sensitivity is more common in individuals with metabolic syndrome or obesity. Recommended strategies include reducing salt intake, increasing potassium intake, normalizing body weight, and engaging in physical activity. No findings address glucose levels or hyperglycemia-related stroke injury.",
          "pmid": "27757935",
          "title": "Impact of Salt Intake on the Pathogenesis and Treatment of Hypertension.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract focuses on defining transient ischemic attack, risk stratification for early stroke, and diagnostic/imaging recommendations. It does not discuss blood glucose levels, overweight status, hyperglycemia, or their impact on neurological outcomes after stroke or TIA, so it neither supports nor contradicts the proposed mechanism.",
          "key_findings": "Provides a tissue-based definition of TIA; emphasizes high early stroke risk after TIA; describes use of clinical scales (e.g., ABCD2), vessel imaging, and diffusion MRI for risk stratification; and outlines diagnostic and hospitalization recommendations. No mention of glucose, hyperglycemia, metabolic factors, or secondary injury mechanisms.",
          "pmid": "19423857",
          "title": "Definition and evaluation of transient ischemic attack: a scientific statement for healthcare professionals from the American Heart Association/American Stroke Association Stroke Council; Council on Cardiovascular Surgery and Anesthesia; Council on Cardiovascular Radiology and Intervention; Council on Cardiovascular Nursing; and the Interdisciplinary Council on Peripheral Vascular Disease. The American Academy of Neurology affirms the value of this statement as an educational tool for neurologists.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract evaluates the efficacy and safety of the neuroprotectant nerinetide in acute ischaemic stroke patients undergoing endovascular thrombectomy. It does not mention glucose levels, hyperglycemia, overweight status, or secondary injury mechanisms related to elevated glucose. Therefore, it neither supports nor contradicts the proposed mechanism regarding hyperglycemia-induced worse neurological outcomes.",
          "key_findings": "Nerinetide did not improve functional outcomes (mRS 0\u20132 at 90 days) compared with placebo in patients with acute ischaemic stroke treated with endovascular thrombectomy. Outcomes and serious adverse events were similar between groups, with a noted treatment effect modification by alteplase use. No data on blood glucose, hyperglycemia, or weight-related metabolic status are reported.",
          "pmid": "32087818",
          "title": "Efficacy and safety of nerinetide for the treatment of acute ischaemic stroke (ESCAPE-NA1): a multicentre, double-blind, randomised controlled trial.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract discusses obesity, endothelial dysfunction, cardiovascular risk, and effects of antidiabetic/anti-obesity therapies on vascular function, but it does not examine stroke outcomes, acute neurological injury, or the specific role of elevated glucose/hyperglycemia in worsening neurological outcome after stroke. Therefore, it neither supports nor contradicts the proposed mechanism about hyperglycemia-induced secondary injury in stroke.",
          "key_findings": "Obesity-related endothelial dysfunction is linked to cardiovascular disease and type 2 diabetes; mechanisms include chronic inflammation, reduced NO bioavailability, insulin resistance, oxidized LDL, and PVAT dysfunction. Various therapies (liraglutide, RAAS-targeted drugs, SGLT2 inhibitor empagliflozin, metformin, bariatric surgery, GLP-1 analogs) are reported to improve endothelial dysfunction, oxidative stress, and cardiometabolic risk. No data are presented on stroke, neurological outcomes, or direct effects of elevated glucose levels on secondary brain injury.",
          "pmid": "39287863",
          "title": "Endothelial Dysfunction in Obesity and Therapeutic Targets.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract discusses obesity, metabolic syndrome, and increased risk of stroke and other cardiovascular diseases, but it does not address glucose levels, hyperglycemia, or neurological outcomes after stroke, nor does it discuss secondary injury mechanisms. Therefore it neither supports nor contradicts the specific proposed mechanism linking elevated glucose in overweight individuals to worse neurological outcomes in stroke.",
          "key_findings": "Obesity is common and contributes to cardiovascular disease mainly via metabolic syndrome (insulin resistance, dyslipidemia, hypertension). Obesity is associated with accelerated atherosclerosis, ventricular remodeling, and increased risk of stroke, myocardial infarction, and heart failure. Overweight and class I obesity may be associated with improved survival in patients with existing chronic cardiovascular disease. Lifestyle interventions, particularly diet and exercise, are effective at reversing cardiovascular risk factors related to obesity. No data are provided on glucose levels, hyperglycemia, or post-stroke neurological outcomes.",
          "pmid": "28150485",
          "title": "Obesity and cardiovascular diseases.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract discusses ischemic encephalopathy, its association with chronic diseases including obesity and diabetes, and the potential protective effects and signaling pathways of heat-clearing herbs. However, it does not analyze or report data on blood glucose levels, hyperglycemia, or glucose-related secondary injury after stroke. No causal or correlative evidence is presented regarding elevated glucose worsening neurological outcomes, so it neither supports nor contradicts the proposed mechanism.",
          "key_findings": "Ischemic encephalopathy is linked with chronic diseases such as obesity, hypertension, and diabetes; heat-clearing Chinese herbs and their bioactive components (e.g., quercetin, beta-sitosterol, stigmasterol) may exert cerebroprotective effects via multiple signaling pathways (Calcium, PI3K-Akt, MAPK, cAMP, IL-17, HIF-1, TNF, T-cell receptor, NF-\u03baB, JAK-STAT). The work is a systematic review and network pharmacology analysis of herbal components and targets, without specific examination of hyperglycemia or glucose-mediated secondary injury in stroke.",
          "pmid": "38285889",
          "title": "Substance basis and pharmacological mechanism of heat-clearing herbs in the treatment of ischaemic encephalopathy: a systematic review and network pharmacology.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract studies semaglutide\u2019s effects on symptoms, weight, and hypoglycemia in obese HFpEF patients with type 2 diabetes, stratified by baseline HbA1c. It does not examine stroke, neurological outcomes, or hyperglycemia-induced secondary brain injury, nor does it link elevated glucose levels to neurological prognosis after stroke. Therefore it neither supports nor contradicts the proposed mechanism.",
          "key_findings": "Semaglutide 2.4 mg weekly improved Kansas City Cardiomyopathy Questionnaire scores and reduced body weight across low, medium, and high baseline HbA1c groups, with no significant interaction by HbA1c level. Hypoglycemia event rates were similar or lower with semaglutide versus placebo despite broad use of concomitant glucose-lowering drugs. No data on stroke or neurological outcomes are presented.",
          "pmid": "39848268",
          "title": "Semaglutide in obesity-related heart failure with preserved ejection fraction and type 2 diabetes across baseline HbA<sub>1c</sub> levels (STEP-HFpEF DM): a prespecified analysis of heart failure and metabolic outcomes from a randomised, placebo-controlled trial.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract studies acetazolamide plus a low-sodium weight-reduction diet for idiopathic intracranial hypertension and visual outcomes. It reports weight loss and visual improvements but does not measure glucose levels, hyperglycemia, stroke, or neurological outcomes related to elevated glucose. Therefore it neither supports nor contradicts the proposed mechanism about hyperglycemia-induced secondary injury in stroke.",
          "key_findings": "Acetazolamide added to a low-sodium weight-reduction diet in IIH patients with mild visual loss led to modestly greater improvement in visual field function, papilledema grade, and vision-related quality of life versus placebo, and produced greater weight loss. No data on blood glucose, hyperglycemia, or stroke-related neurological outcomes are presented.",
          "pmid": "24756514",
          "title": "Effect of acetazolamide on visual function in patients with idiopathic intracranial hypertension and mild visual loss: the idiopathic intracranial hypertension treatment trial.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract discusses secondary stroke prevention and lists diabetes and obesity as modifiable risk factors, but it does not address acute hyperglycemia at the time of stroke, its relationship to neurological outcomes, or any mechanism of hyperglycemia-induced secondary injury.",
          "key_findings": "Identifies diabetes mellitus and obesity among modifiable risk factors for recurrent stroke and summarizes that guidelines exist for secondary prevention, without mechanistic detail on elevated glucose and neurological outcomes after stroke.",
          "pmid": "18158505",
          "title": "Secondary stroke prevention.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract evaluates intravenous glibenclamide for cerebral edema and functional outcome after large hemispheric stroke. It does not assess patients\u2019 glucose levels, effects of hyperglycemia, or secondary injury mechanisms related to elevated glucose. Hypoglycemia is mentioned only as a safety outcome of the drug, not as a mechanistic exploration of how glucose levels influence neurological outcomes.",
          "key_findings": "Intravenous glibenclamide vs placebo showed no significant improvement in 90-day modified Rankin Scale distribution (OR 1.17, 95% CI 0.80\u20131.71, p=0.42) or mortality (29% vs 32%, HR 1.20, 95% CI 0.85\u20131.70, p=0.30) after large hemispheric infarction. Hypoglycemia occurred more often in the glibenclamide group (6% vs 2%). No data are provided on baseline glucose, hyperglycemia, or the relationship between elevated glucose and stroke outcomes.",
          "pmid": "39577921",
          "title": "Intravenous glibenclamide for cerebral oedema after large hemispheric stroke (CHARM): a phase 3, double-blind, placebo-controlled, randomised trial.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract discusses obesity as a risk factor for various diseases including stroke and cancer, but does not mention glucose levels, hyperglycemia, or neurological outcomes after stroke. It provides no mechanistic or outcome data about elevated glucose causing secondary neurological injury in stroke patients.",
          "key_findings": "Obesity and increased body fat are associated with multiple health risks such as type 2 diabetes, coronary heart disease, stroke, and several cancers, with a focus on cancer risk; no details are given about post-stroke neurological outcomes or the role of elevated glucose levels.",
          "pmid": "12939106",
          "title": "Obesity and cancer.",
          "analysis_method": "llm"
        }
      ]
    },
    {
      "feature_name": "weight",
      "mechanism": {
        "mechanism_type": "biological",
        "description": "Obesity is linked to a pro-inflammatory state, which could interfere with thrombolytic therapy effectiveness by promoting clot persistence.",
        "evidence_level": "moderate"
      },
      "query": "(stroke OR alteplase OR thrombolysis OR \"ischemic stroke\") AND (weight OR BMI OR obesity OR \"body mass\" OR \"pharmacokinetics\") AND (\"pathophysiology\" OR \"mechanism\" OR \"causal\" OR \"etiology\" OR \"interaction\") AND (\"effectiveness\" OR \"inflammatory\" OR \"thrombolytic\") AND (Clinical Trial[PT] OR Review[PT] OR Meta-Analysis[PT])",
      "total_abstracts": 20,
      "support_count": 0,
      "conflict_count": 0,
      "neutral_count": 20,
      "support_percentage": 0.0,
      "conflict_percentage": 0.0,
      "support_ratio": 0.0,
      "abstracts_analyzed": [
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract evaluates the efficacy and safety of tenecteplase versus standard medical treatment in ischemic stroke but does not assess obesity, inflammatory status, or their impact on thrombolytic effectiveness. No data on BMI, adiposity, inflammatory markers, or subgroup analyses by obesity are presented, so the proposed mechanism about obesity-related pro-inflammatory interference with thrombolysis is neither supported nor contradicted.",
          "key_findings": "Tenecteplase given 4.5\u201324 hours after stroke onset in patients with large-vessel occlusion without thrombectomy access increased the proportion with good functional outcome (mRS 0\u20131 at 90 days: 33.0% vs 24.2%) compared with standard medical treatment, with similar mortality (13.3% vs 13.1%) but higher symptomatic intracranial hemorrhage (3.0% vs 0.8%). No mention is made of obesity, body weight beyond dosing, or inflammatory/prothrombotic states.",
          "pmid": "38884324",
          "title": "Tenecteplase for Ischemic Stroke at 4.5 to 24 Hours without Thrombectomy.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract discusses obesity, inflammation, and vascular complications in diabetes, but it does not mention thrombolytic therapy, clot persistence, or treatment response. Therefore it neither supports nor contradicts the specific mechanism that obesity-related pro-inflammatory state interferes with thrombolytic therapy effectiveness.",
          "key_findings": "Obesity is noted as the most prominent risk factor for type 2 diabetes and is more common in women; sex hormones influence energy metabolism, body composition, vascular function, and inflammatory responses; women with diabetes have greater increases in cardiovascular risk, myocardial infarction, and stroke mortality compared with men. No data are presented on thrombolytic therapy outcomes or clot persistence.",
          "pmid": "27159875",
          "title": "Sex and Gender Differences in Risk, Pathophysiology and Complications of Type 2 Diabetes Mellitus.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract focuses on tirzepatide\u2019s effects on glycemic control, body weight reduction, and cardiovascular safety, but does not discuss inflammatory status, thrombolytic therapy, clot persistence, or any interaction between obesity-related inflammation and thrombolysis. Therefore, it neither supports nor contradicts the proposed mechanism about a pro-inflammatory state impairing thrombolytic effectiveness.",
          "key_findings": "Tirzepatide, a dual GIP/GLP-1 receptor agonist, substantially lowers HbA1c and body weight in type 2 diabetes, is more effective than semaglutide and basal insulin for these outcomes, shows acceptable gastrointestinal side effects, and appears cardiovascularly safe with a tendency toward reduced MACE-4 events. Mechanistic discussion is limited to incretin signaling, insulin secretion/sensitivity, appetite, and weight loss, with no data on inflammation or thrombolytic response.",
          "pmid": "36050763",
          "title": "Tirzepatide, a dual GIP/GLP-1 receptor co-agonist for the treatment of type 2 diabetes with unmatched effectiveness regrading glycaemic control and body weight reduction.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract reports stroke epidemiology, risk factor prevalence (including obesity), utilization and outcomes of thrombolytic therapy, but does not analyze the relationship between obesity (or obesity-related inflammation) and thrombolytic effectiveness, clot persistence, or treatment outcomes. No mechanistic or outcome data are stratified by obesity or inflammatory status.",
          "key_findings": "Obesity prevalence in China was 37.4% in 2018; large numbers of stroke cases and thrombolytic treatments (IVT, MT, bridging) are described with overall rates of intracranial hemorrhage and in-hospital death, but there is no assessment of how obesity or pro-inflammatory state affects thrombolytic therapy response or clot persistence.",
          "pmid": "37468952",
          "title": "China stroke surveillance report 2021.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract discusses obstructive sleep apnea, its cardiovascular associations, and recommends weight loss as part of OSA management. It does not address thrombolytic therapy, clot persistence, or inflammatory effects of obesity on thrombolysis, so it neither supports nor contradicts the proposed mechanism.",
          "key_findings": "OSA is prevalent, especially in cardiovascular disease; obesity is mentioned as related to OSA prevalence; weight loss is recommended as a treatment component, but there is no discussion of pro-inflammatory states, thrombolytic therapy effectiveness, or clot persistence.",
          "pmid": "34148375",
          "title": "Obstructive Sleep Apnea and Cardiovascular Disease: A Scientific Statement From the American Heart Association.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract discusses myocardial infarction symptoms, general treatments (including thrombolytic therapy), and lifestyle measures such as weight loss, but it does not address obesity-related inflammation, pro-inflammatory states, or any impact of obesity on the effectiveness of thrombolytic therapy or clot persistence.",
          "key_findings": "The article describes that MI is treated with thrombolytic (clot-dissolving) drugs such as tissue plasminogen activator, streptokinase, or urokinase within 3 hours of onset, and mentions weight loss as a preventive lifestyle measure; however, it does not analyze or report any relationship between obesity, inflammation, and thrombolytic effectiveness.",
          "pmid": "25638347",
          "title": "Myocardial Infarction: Symptoms and Treatments.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract links obesity and PCOS to a chronic low-grade inflammatory and pro-thrombotic state (elevated inflammatory markers, PAI-1, thrombosis-related markers), but it does not mention thrombolytic therapy, clot persistence, or treatment efficacy. Thus it neither supports nor contradicts the specific mechanism that obesity-related inflammation interferes with thrombolytic therapy effectiveness.",
          "key_findings": "PCOS is associated with low-grade chronic inflammation, with elevated CRP, IL-18, TNF-\u03b1, IL-6, WBC, MCP-1, MIP-1\u03b1, AGEs/RAGE, and markers related to oxidative stress, inflammation, and thrombosis such as ADMA, CRP, homocysteine, and plasminogen activator inhibitor-1 (PAI-1). This inflammatory state is aggravated by obesity and hyperinsulinemia and is linked to endothelial dysfunction and cardiovascular risk in PCOS.",
          "pmid": "33917519",
          "title": "Chronic Low Grade Inflammation in Pathogenesis of PCOS.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract evaluates antithrombotic regimens (oral anticoagulation alone vs anticoagulation plus single antiplatelet therapy) in atrial fibrillation with stable coronary disease, focusing on ischemic and bleeding outcomes. It does not examine obesity, inflammatory status, thrombolytic therapy, or clot persistence, nor does it analyze how obesity-related inflammation might alter response to thrombolysis.",
          "key_findings": "In 4 RCTs including 4,092 patients with AF and stable CAD, oral anticoagulation monotherapy compared with anticoagulation plus single antiplatelet therapy showed no significant differences in composite ischemic outcomes, myocardial infarction, ischemic stroke, systemic embolism, or death, but did reduce major bleeding risk. Subgroup analyses suggested greater bleeding reduction in men and in patients with diabetes, without significant interaction for effectiveness outcomes.",
          "pmid": "39918465",
          "title": "Anticoagulation and Antiplatelet Therapy\u00a0for Atrial Fibrillation and Stable Coronary Disease: Meta-Analysis of Randomized Trials.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract discusses disseminated intravascular coagulation, focusing on inflammatory cytokine-driven coagulation activation and suppression of fibrinolysis, but does not address obesity, obesity-related chronic inflammation, or the effectiveness of thrombolytic therapy or clot persistence in obese versus non-obese states.",
          "key_findings": "DIC is characterized by inflammatory cytokine-initiated activation of tissue factor-dependent coagulation, inadequate anticoagulant control, and plasminogen activator inhibitor-1\u2013mediated suppression of fibrinolysis, leading to endothelial dysfunction, microvascular thrombosis, and organ dysfunction. Management is based on treating the underlying condition and following ISTH guidance. No mention is made of obesity or its impact on thrombolytic therapy effectiveness.",
          "pmid": "27250996",
          "title": "Disseminated intravascular coagulation.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract discusses glycolipid metabolism disorders, their multifactorial pathogenesis, and the role of chronic inflammatory response and multi-omics in identifying biomarkers. It does not address obesity specifically, thrombolytic therapy, clot persistence, or how inflammation might affect thrombolytic effectiveness, so it neither supports nor contradicts the proposed mechanism.",
          "key_findings": "The review notes that glycolipid metabolism disorders involve factors such as neuroendocrine axis dysfunction, insulin resistance, oxidative stress, chronic inflammatory response, and gut microbiota dysbiosis, and that multi-omics approaches (genomics, transcriptomics, proteomics, metabolomics, gut microbiomics) can help identify biomarkers. No mention is made of obesity-related effects on thrombolytic therapy or clot persistence.",
          "pmid": "36382190",
          "title": "Advances in multi-omics study of biomarkers of glycolipid metabolism disorder.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract links obesity to adipose tissue dysfunction and a pro-inflammatory, atherogenic, diabetogenic signaling milieu, but it does not discuss thrombolytic therapy, clot persistence, or treatment response. Thus it is mechanistically consistent with a pro-inflammatory state in obesity but provides no direct evidence about interference with thrombolytic effectiveness.",
          "key_findings": "Obesity is associated with adipose tissue dysfunction characterized by adipocyte hypertrophy, hypoxia, inflammatory processes, and release of pro-inflammatory, diabetogenic, and atherogenic signals. These inflammatory and vascular effects are proposed as mechanisms linking obesity to cardiometabolic diseases, but no data or discussion is provided on thrombolysis, clot dissolution, or therapy outcomes.",
          "pmid": "40069923",
          "title": "An overview of obesity-related complications: The epidemiological evidence linking body weight and other markers of obesity to adverse health outcomes.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract examines associations between diabetes, fasting glucose, and vascular disease risk, adjusted for BMI and inflammatory markers, but does not address obesity-related pro-inflammatory states, thrombolytic therapy, or clot persistence. It provides outcome risk data, not mechanistic or treatment-response evidence relevant to how obesity-related inflammation might alter thrombolysis effectiveness.",
          "key_findings": "Diabetes approximately doubles risk of coronary heart disease and increases risk of multiple stroke subtypes and other vascular deaths. These associations are largely independent of conventional risk factors, and additional adjustment for lipid, inflammatory, or renal markers does not materially change hazard ratios. Fasting blood glucose is non-linearly and modestly associated with vascular risk, and adding fasting glucose or impaired fasting glucose status does not substantially improve vascular risk prediction beyond conventional factors.",
          "pmid": "20609967",
          "title": "Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract evaluates exoskeleton-assisted gait training versus conventional therapy on balance, gait, function, and cortical activation in subacute stroke patients. It does not measure obesity, inflammatory state, thrombolytic therapy, or clot persistence, nor does it analyze how inflammation might alter thrombolytic effectiveness.",
          "key_findings": "Robot-assisted gait training led to greater improvements in Berg Balance Scale, lower-limb Fugl-Meyer scores, functional ambulation category, modified Barthel index, and certain gait parameters compared with conventional training, alongside increased cortical activity in ipsilesional motor and bilateral prefrontal areas. No data relate to obesity, systemic inflammation, or thrombolysis outcomes.",
          "pmid": "39639336",
          "title": "Effectiveness of unilateral lower-limb exoskeleton robot on balance and gait recovery and neuroplasticity in patients with subacute stroke: a randomized controlled trial.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract discusses salt intake, hypertension, cardiovascular risk, and notes that salt sensitivity is increased in obesity, but it does not address inflammatory states in obesity, thrombolytic therapy, clot persistence, or any treatment response related to thrombosis. Therefore it neither supports nor contradicts the proposed mechanism about obesity-related inflammation impairing thrombolysis.",
          "key_findings": "High salt intake increases risk of hypertension and related cardiovascular diseases; salt reduction lowers blood pressure. Salt sensitivity is more common in people with obesity and metabolic syndrome. No data are presented on inflammation, coagulation, thrombolytic therapy, or clot persistence.",
          "pmid": "27757935",
          "title": "Impact of Salt Intake on the Pathogenesis and Treatment of Hypertension.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract discusses venous leg ulcers, chronic venous disease, inflammation, and lists obesity as a risk factor for recalcitrant ulcers, but it does not examine obesity-related systemic inflammation in relation to thrombolytic therapy effectiveness or clot persistence. There is no mention of thrombolytic treatment, response to such therapy, or mechanistic links between obesity-induced inflammation and thrombolysis.",
          "key_findings": "Obesity is cited as a factor associated with prolonged healing time of venous leg ulcers. The pathophysiology of venous leg ulcers is described as involving endothelial injury, leukocyte infiltration, inflammatory cytokines, MMPs, and oxidative stress. Treatments discussed include compression, endovenous ablation, surgery, biologics, and other wound-healing adjuncts. Thrombolytic therapy and its effectiveness are not addressed.",
          "pmid": "33374372",
          "title": "Why Venous Leg Ulcers Have Difficulty Healing: Overview on Pathophysiology, Clinical Consequences, and Treatment.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract discusses post-stroke depression mechanisms, neuroinflammation, HPA axis activation, mitochondrial dysfunction, and SSRI effects, but it does not address obesity, pro-inflammatory states in obesity, thrombolytic therapy, or clot persistence. Therefore it neither supports nor contradicts the proposed obesity\u2013inflammation\u2013thrombolysis mechanism.",
          "key_findings": "Post-stroke depression is common and involves multifactorial mechanisms including neuroinflammatory responses to acute ischemic stroke, HPA axis activation, impaired neurogenesis, and altered energy metabolism. SSRIs may help via serotonergic, anti-inflammatory, and neurotrophic mechanisms but can increase bleeding risk. Depression is both a consequence of and an independent risk factor for stroke. No mention is made of obesity, thrombolytic therapy effectiveness, or clot persistence.",
          "pmid": "29128343",
          "title": "Post-stroke depression: Mechanisms and pharmacological treatment.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract discusses hypoalbuminemia as a cardiovascular risk factor via its anti-inflammatory, anticoagulant, and antiplatelet properties, but it does not address obesity, obesity-related pro-inflammatory states, or the effectiveness of thrombolytic therapy or clot persistence. Therefore it neither supports nor contradicts the proposed mechanism linking obesity-induced inflammation to impaired thrombolysis.",
          "key_findings": "Low serum albumin levels are associated with higher risk and worse prognosis in multiple cardiovascular diseases, independent of BMI and inflammation; serum albumin has anti-inflammatory, antioxidant, anticoagulant, and antiplatelet aggregation activities, and hypoalbuminemia may be a modifiable cardiovascular risk factor.",
          "pmid": "29680174",
          "title": "Human serum albumin in cardiovascular diseases.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract links obesity to a systemic pro-inflammatory state and describes inflammation-driven cardiac pathology in HFpEF, but it does not address thrombolytic therapy, clot behavior, or thrombus persistence. Therefore, it neither supports nor refutes the specific claim that obesity-related inflammation interferes with thrombolytic effectiveness.",
          "key_findings": "Obesity and aging promote systemic inflammation integral to cardiometabolic HFpEF; immune cell accumulation in the heart, driven by an altered metabolome, contributes to cardiac inflammation and fibrosis; broad anti-inflammatory therapy has not shown significant benefit in HFpEF outcomes.",
          "pmid": "39357068",
          "title": "Contributions of Inflammation to Cardiometabolic Heart Failure with Preserved Ejection Fraction.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract mentions obesity as a shared risk factor for migraine and stroke but does not discuss obesity-induced pro-inflammatory states, thrombolytic therapy, or clot persistence. There is no evidence provided about how obesity-related inflammation might affect thrombolytic effectiveness.",
          "key_findings": "Obesity is listed among several conditions linked to both migraine and stroke, but no mechanisms involving inflammation, thrombosis, or response to thrombolytic therapy are described.",
          "pmid": "39979846",
          "title": "Migraine and stroke: correlation, coexistence, dependence - a modern perspective.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract reviews treatments for cerebral venous thrombosis and briefly mentions thrombolysis and fibrinolysis but does not discuss obesity, pro-inflammatory states, or how such states might alter thrombolytic effectiveness or clot persistence. No mechanistic or clinical data are provided that relate inflammation, obesity, or pro-thrombotic milieu to thrombolytic therapy outcomes.",
          "key_findings": "The review concludes that low-molecular-weight heparin and unfractionated heparin are safe and effective first-line treatments for acute CVT; warfarin has weak evidence for secondary prevention; DOACs may be safe alternatives but guidelines still recommend warfarin; antiplatelets have little evidence; endovascular therapy and fibrinolysis are reserved for complex cases. Obesity or inflammatory status and their impact on thrombolytic effectiveness are not addressed.",
          "pmid": "39492709",
          "title": "Treatment of cerebral venous thrombosis: a review.",
          "analysis_method": "llm"
        }
      ]
    },
    {
      "feature_name": "gcs_score_rand",
      "mechanism": {
        "mechanism_type": "biological",
        "description": "A low initial GCS score (< 8) suggests extensive cerebral damage, which may not be reversible by reperfusion therapy alone.",
        "evidence_level": "moderate"
      },
      "query": "(stroke OR alteplase OR thrombolysis OR \"ischemic stroke\") AND \"gcs_score_rand\" AND (\"pathophysiology\" OR \"mechanism\" OR \"causal\" OR \"etiology\" OR \"interaction\") AND (\"reperfusion\" OR \"reversible\" OR \"extensive\") AND (Clinical Trial[PT] OR Review[PT] OR Meta-Analysis[PT])",
      "total_abstracts": 0,
      "support_count": 0,
      "conflict_count": 0,
      "neutral_count": 0,
      "abstracts_analyzed": []
    },
    {
      "feature_name": "gcs_score_rand",
      "mechanism": {
        "mechanism_type": "biological",
        "description": "Rapid clinical improvement might indicate significant early spontaneous recanalization, reducing the marginal benefit provided by alteplase.",
        "evidence_level": "moderate"
      },
      "query": "(stroke OR alteplase OR thrombolysis OR \"ischemic stroke\") AND \"gcs_score_rand\" AND (\"pathophysiology\" OR \"mechanism\" OR \"causal\" OR \"etiology\" OR \"interaction\") AND (\"recanalization\" OR \"significant\" OR \"spontaneous\") AND (Clinical Trial[PT] OR Review[PT] OR Meta-Analysis[PT])",
      "total_abstracts": 0,
      "support_count": 0,
      "conflict_count": 0,
      "neutral_count": 0,
      "abstracts_analyzed": []
    },
    {
      "feature_name": "gcs_score_rand",
      "mechanism": {
        "mechanism_type": "biological",
        "description": "Patients with severe strokes (GCS < 8) likely have larger infarct volumes, which correlates with a reduced likelihood of achieving independence regardless of treatment.",
        "evidence_level": "moderate"
      },
      "query": "(stroke OR alteplase OR thrombolysis OR \"ischemic stroke\") AND \"gcs_score_rand\" AND (\"pathophysiology\" OR \"mechanism\" OR \"causal\" OR \"etiology\" OR \"interaction\") AND (\"independence\" OR \"regardless\" OR \"correlates\") AND (Clinical Trial[PT] OR Review[PT] OR Meta-Analysis[PT])",
      "total_abstracts": 0,
      "support_count": 0,
      "conflict_count": 0,
      "neutral_count": 0,
      "abstracts_analyzed": []
    },
    {
      "feature_name": "systolic blood pressure",
      "mechanism": {
        "mechanism_type": "biological",
        "description": "Blood pressure fluctuations may lead to compromised cerebral autoregulation, disrupting optimal perfusion necessary for the efficacy of thrombolytic treatment.",
        "evidence_level": "moderate"
      },
      "query": "(stroke OR alteplase OR thrombolysis OR \"ischemic stroke\") AND \"systolic blood pressure\" AND (\"pathophysiology\" OR \"mechanism\" OR \"causal\" OR \"etiology\" OR \"interaction\") AND (\"autoregulation\" OR \"fluctuations\" OR \"thrombolytic\") AND (Clinical Trial[PT] OR Review[PT] OR Meta-Analysis[PT])",
      "total_abstracts": 20,
      "support_count": 1,
      "conflict_count": 1,
      "neutral_count": 18,
      "support_percentage": 5.0,
      "conflict_percentage": 5.0,
      "support_ratio": 0.05,
      "abstracts_analyzed": [
        {
          "stance": "neutral",
          "confidence": "medium",
          "reasoning": "The abstract mentions blood pressure control after endovascular thrombectomy and notes that intensive systolic blood pressure control acutely post thrombectomy is associated with harm and worse outcomes, but it does not discuss blood pressure fluctuations, cerebral autoregulation, or how altered perfusion specifically affects the efficacy of thrombolytic treatment. The mechanistic pathway proposed (BP fluctuations \u2192 impaired autoregulation \u2192 suboptimal perfusion \u2192 altered thrombolytic efficacy) is not directly addressed.",
          "key_findings": "The review reports that intensive systolic blood pressure control acutely after thrombectomy is associated with harm and worse outcomes, and it discusses blood pressure control as part of stroke management, but it does not examine cerebral autoregulation, perfusion changes linked to BP fluctuations, or their specific impact on thrombolytic treatment efficacy.",
          "pmid": "40797003",
          "title": "Advances in Ischemic Stroke Treatment: Current and Future Therapies.",
          "analysis_method": "llm"
        },
        {
          "stance": "support",
          "confidence": "medium",
          "reasoning": "The proposed mechanism centers on blood pressure fluctuations compromising cerebral autoregulation and thereby affecting thrombolytic efficacy. This study shows that greater systolic blood pressure variability in the first 24 hours after thrombolysis is associated with worse functional outcomes and higher intracranial hemorrhage risk, while more consistent (less variable) and lower attained SBP is associated with better outcomes. Although the abstract does not directly measure cerebral autoregulation, the link between BP variability and outcomes in thrombolyzed patients is consistent with the proposed idea that unstable blood pressure can impair optimal perfusion necessary for effective thrombolysis.",
          "key_findings": "In 4511 thrombolyzed acute ischemic stroke patients, lower attained SBP and smaller SBP variability over 1\u201324 hours were associated with favorable shift on the modified Rankin Scale (per 10 mm Hg increase in mean SBP: OR 0.76, 95% CI 0.71\u20130.82; per higher SD of SBP: OR 0.86, 95% CI 0.76\u20130.98). Higher attained SBP and greater SBP variability were associated with increased odds of intracranial hemorrhage (attained SBP OR 1.18, 95% CI 1.06\u20131.31; SBP variability OR 1.34, 95% CI 1.11\u20131.62). Magnitude of SBP reduction at 1 hour was not associated with functional outcome or intracranial hemorrhage. Early and consistent low SBP (<140 mm Hg, even 110\u2013120 mm Hg) over 24 hours was associated with better outcomes.",
          "pmid": "34702064",
          "title": "Associations of Early Systolic Blood Pressure Control and Outcome After Thrombolysis-Eligible Acute Ischemic Stroke: Results From the ENCHANTED Study.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract examines associations between admission systolic blood pressure and overall functional outcome, and whether blood pressure modifies the effect of endovascular thrombectomy. It does not investigate blood pressure fluctuations, cerebral autoregulation, or perfusion mechanisms underlying thrombolytic treatment efficacy, nor does it provide mechanistic data about autoregulatory failure as a mediator. Therefore it neither supports nor contradicts the proposed mechanism.",
          "key_findings": "High admission systolic blood pressure (\u2265140 mm Hg) was associated with worse functional outcome after ischaemic stroke (acOR 0.86 per 10 mm Hg increase), while no association was found below 140 mm Hg. There was no significant interaction between admission systolic blood pressure and the effect of endovascular thrombectomy on outcome (p=0.96). The results suggest admission SBP should not be used to withhold or delay endovascular thrombectomy.",
          "pmid": "36931806",
          "title": "Admission systolic blood pressure and effect of endovascular treatment in patients with ischaemic stroke: an individual patient data meta-analysis.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract links higher systolic blood pressure and hypertension with the development of new cerebral microbleeds and subsequent hemorrhagic complications after intravenous thrombolysis, but it does not assess blood pressure fluctuations, cerebral autoregulation, or how perfusion dynamics influence thrombolytic efficacy. Thus, it neither supports nor contradicts the specific mechanism of BP fluctuations impairing autoregulation and thrombolytic effectiveness.",
          "key_findings": "In patients with acute ischemic stroke undergoing intravenous thrombolysis, the pooled prevalence of new cerebral microbleeds (CMBs) was 7.6%. Patients with new CMBs were older, more often hypertensive, and had higher systolic blood pressure and greater baseline CMB burden compared with those without new CMBs. New CMBs were associated with a markedly increased risk of remote intracerebral hemorrhage (OR 28.75) and symptomatic intracerebral hemorrhage (OR 15.49), but not with functional outcomes or hemorrhagic transformation. The study does not evaluate blood pressure variability, cerebral autoregulation, or perfusion-dependent thrombolytic efficacy.",
          "pmid": "37857916",
          "title": "Prevalence, Risk Factors, and Clinical Outcomes of New Cerebral Microbleeds After Intravenous Thrombolysis in Acute Ischemic Stroke: a\u00a0Systematic Review and Meta-analysis.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "medium",
          "reasoning": "The abstract notes that high systolic blood pressure is an independent risk factor for symptomatic intracerebral hemorrhage after thrombolysis, but it does not examine blood pressure fluctuations, cerebral autoregulation, or how perfusion dynamics affect thrombolytic efficacy. It focuses on risk factors for hemorrhagic complications, not on the proposed mechanism of compromised autoregulation altering treatment effectiveness.",
          "key_findings": "High systolic blood pressure is identified as an independent risk factor for thrombolysis-associated symptomatic intracerebral hemorrhage in one study; other risk factors include extent of hypoattenuation on CT, elevated serum glucose/diabetes, symptom severity, advanced age, increased time to treatment, low platelets, history of congestive heart failure, and low plasminogen activator inhibitor levels.",
          "pmid": "17519538",
          "title": "Symptomatic intracerebral hemorrhage following thrombolytic therapy for acute ischemic stroke: a review of the risk factors.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract discusses imaging, thrombolysis, thrombectomy, general stroke management, and a blood pressure target for hemorrhagic stroke, but it does not address blood pressure fluctuations, cerebral autoregulation, or how these might influence the efficacy of thrombolytic treatment in ischemic stroke.",
          "key_findings": "Recommends rt-PA within 4.5 hours and mechanical thrombectomy within 6 hours for acute ischemic stroke; advises lowering systolic blood pressure to <140 mm Hg within 1 hour in hemorrhagic stroke; no discussion of cerebral autoregulation or of how blood pressure variability impacts thrombolysis outcomes.",
          "pmid": "26633844",
          "title": "[State-of-the-art Treatment of Acute Stroke].",
          "analysis_method": "llm"
        },
        {
          "stance": "conflict",
          "confidence": "medium",
          "reasoning": "The proposed mechanism suggests that blood pressure fluctuations compromise cerebral autoregulation and thereby alter the efficacy of thrombolytic treatment (IVT). This study examined admission systolic blood pressure and its association with outcomes and explicitly tested whether prior IV thrombolysis modifies these blood pressure\u2013outcome relationships in acute ischaemic stroke patients undergoing EVT. They found a J-shaped association of SBP with functional outcome, but no effect modification by IVT on functional outcome, sICH, or reperfusion. This indicates that within the studied BP range, the impact of BP on clinical outcomes does not differ by thrombolytic treatment status, which argues against the idea that BP-related autoregulatory disturbances specifically alter the efficacy of IV thrombolysis.",
          "key_findings": "1) Admission SBP showed a J-shaped association with 90-day mRS, with worse outcomes for SBP >150 mmHg (adjusted common OR 1.23 per 10 mmHg, 95% CI 1.09\u20131.38) compared with 150 mmHg, while lower SBP was not clearly associated with outcome. 2) Higher SBP was not associated with risk of symptomatic intracranial haemorrhage (aOR 1.09, 95% CI 0.93\u20131.27) or probability of successful reperfusion (aOR 1.00, 95% CI 0.91\u20131.10). 3) There was no effect modification by prior IV alteplase on the relationships between SBP and mRS, sICH, or reperfusion (interaction p-values: mRS=0.94; sICH=0.26; successful reperfusion=0.58). 4) Authors conclude that, for SBP \u2264185/110 mmHg, SBP level should not guide IVT decisions in patients eligible for both IVT and EVT.",
          "pmid": "37641554",
          "title": "Admission blood pressure and clinical outcomes in patients with acute ischaemic stroke treated with intravenous alteplase and endovascular treatment versus endovascular treatment alone: A MR CLEAN-NO IV substudy.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "medium",
          "reasoning": "The abstract shows that high baseline blood pressure and greater blood pressure variability are associated with worse outcomes, and that blood pressure lowering is associated with better long\u2011term outcome in acute ischemic stroke patients considered for thrombolysis. However, it does not assess cerebral autoregulation, cerebral perfusion metrics, or the specific interaction between blood pressure fluctuations, autoregulatory failure, and the efficacy of thrombolytic treatment. The proposed mechanism is about impaired cerebral autoregulation and perfusion as the pathway by which BP fluctuations influence thrombolytic efficacy, which is not directly examined.",
          "key_findings": "1) High baseline systolic blood pressure and higher blood pressure variability within the first 24 hours after stroke onset were associated with more early adverse events and early deaths.\n2) Greater decline in systolic blood pressure over 24 hours and use of blood pressure\u2013lowering treatment were associated with reduced risk of poor functional outcome at 6 months, with similar effects regardless of recombinant tissue-type plasminogen activator use (no significant interaction).\n3) The study did not measure or report cerebral autoregulation or perfusion parameters, nor did it directly test how BP fluctuations alter the mechanistic efficacy of thrombolysis.",
          "pmid": "26486868",
          "title": "Effects of Blood Pressure and Blood Pressure-Lowering Treatment During the First 24 Hours Among Patients in the Third International Stroke Trial of Thrombolytic Treatment for Acute Ischemic Stroke.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "medium",
          "reasoning": "The abstract discusses blood pressure management, cerebral autoregulation, and perfusion in acute cerebrovascular disease, and notes that certain drugs (e.g., sodium nitroprusside) have adverse effects on cerebral autoregulation. However, it does not address blood pressure fluctuations per se, does not describe compromised autoregulation as a result of such fluctuations, and does not link these changes specifically to the efficacy of thrombolytic treatment. Therefore it neither directly supports nor contradicts the proposed mechanism.",
          "key_findings": "1) Overly aggressive treatment of hypertension in acute ischemic stroke can compromise collateral perfusion of the ischemic penumbra. 2) Sodium nitroprusside is not recommended because of adverse effects on cerebral autoregulation and intracranial pressure. 3) Hypoperfusion of the injured brain should be avoided. 4) The abstract does not mention thrombolytic therapy or how blood pressure variability affects its efficacy.",
          "pmid": "21366852",
          "title": "Blood pressure control in acute cerebrovascular disease.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "medium",
          "reasoning": "The abstract discusses that very low systolic and diastolic blood pressure may not be sustainable by cerebral blood flow autoregulation and could lead to cerebral ischemia, particularly when treating isolated diastolic hypertension in older adults. However, it does not address blood pressure *fluctuations* nor link such fluctuations or impaired autoregulation specifically to the *efficacy of thrombolytic treatment*. Thus, while it touches on cerebral autoregulation and ischemia risk, it does not provide direct evidence for or against the proposed mechanism involving thrombolysis outcomes.",
          "key_findings": "1) Treatment of isolated diastolic hypertension in older subjects could increase cardiovascular complications via a J-curve effect and may increase stroke incidence by further lowering normal systolic blood pressure. 2) Very low systolic and diastolic blood pressure cannot be sustained by cerebral blood flow autoregulation and could lead to cerebral ischemia. 3) Isolated diastolic hypertension is associated with adverse cardiovascular events in younger persons and should be treated, whereas in older subjects its prevalence is low and generally not associated with adverse events, so further lowering should be avoided.",
          "pmid": "32594846",
          "title": "The clinical significance of isolated diastolic hypertension.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The trial evaluates different targets for blood pressure lowering during and after alteplase treatment and reports clinical and hemorrhagic outcomes, but it does not measure or analyze cerebral autoregulation, blood pressure variability/fluctuations, or perfusion dynamics as mechanistic mediators of thrombolytic efficacy. Therefore, it neither supports nor contradicts the specific proposed mechanism about BP fluctuations compromising cerebral autoregulation and altering thrombolysis effectiveness.",
          "key_findings": "In alteplase-treated acute ischaemic stroke patients with baseline systolic BP \u2265150 mm Hg, intensive BP lowering (target 130\u2013140 mm Hg within 1 h, 72 h duration) achieved a modestly lower mean 24 h systolic BP than guideline management (<180 mm Hg) but did not improve 90-day functional outcome (mRS shift OR 1.01, 95% CI 0.87\u20131.17). Intensive BP lowering reduced the rate of any intracranial haemorrhage (14.8% vs 18.7%; OR 0.75, 95% CI 0.60\u20130.94) without increasing serious adverse events. The study does not assess cerebral autoregulation or BP fluctuations, nor does it link mechanistic changes in perfusion to thrombolytic efficacy.",
          "pmid": "30739745",
          "title": "Intensive blood pressure reduction with intravenous thrombolysis therapy for acute ischaemic stroke (ENCHANTED): an international, randomised, open-label, blinded-endpoint, phase 3 trial.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract evaluates alteplase outcomes across multiple clinical subgroups, including baseline systolic and diastolic blood pressure, but it does not investigate blood pressure fluctuations over time, cerebral autoregulation, or how such fluctuations might alter thrombolytic efficacy. It reports no significant interaction of blood pressure subgroups with alteplase effect across outcomes, but this is about static baseline BP levels, not dynamic BP variability or autoregulatory compromise, so it neither supports nor contradicts the proposed mechanistic pathway.",
          "key_findings": "In the Third International Stroke Trial (3035 patients), alteplase was compared with control and outcomes were analyzed in prespecified subgroups including systolic and diastolic blood pressure at randomization. No consistent significant interactions in treatment effect were found across subgroups for 6\u2011month functional outcome, early death, or symptomatic intracranial hemorrhage, except for higher symptomatic intracranial hemorrhage risk in patients on prior antiplatelets without worse functional outcome. The authors found no clear evidence to avoid alteplase treatment in patients with hypertension, but dynamic BP fluctuations and cerebral autoregulation were not assessed.",
          "pmid": "25613308",
          "title": "Alteplase for acute ischemic stroke: outcomes by clinically important subgroups in the Third International Stroke Trial.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "medium",
          "reasoning": "The abstract shows that higher post-thrombolysis blood pressure is associated with increased risk of hemorrhagic transformation after t-PA, but it does not assess cerebral autoregulation, perfusion adequacy, or thrombolytic efficacy (e.g., recanalization, reperfusion, or functional response to t-PA). Thus, it links BP elevation to a complication (hemorrhage), not to impaired perfusion mechanisms underlying thrombolytic effectiveness, so it neither directly supports nor contradicts the proposed mechanism.",
          "key_findings": "In ischemic stroke patients from a randomized t-PA vs placebo trial, parenchymal hematoma was more common with t-PA. Patients with parenchymal hematoma had significantly higher 24-hour weighted average systolic BP (159.4\u00b118.8 mm Hg) than those without hemorrhagic transformation (143.1\u00b120.0 mm Hg), while baseline BP did not differ. Multinomial logistic regression identified larger DWI lesion volume, atrial fibrillation, and higher 24-hour BP as independent predictors of parenchymal hematoma. The study concludes that post-thrombolysis BP and baseline lesion size predict hemorrhagic transformation and suggests stricter BP control, but does not examine cerebral autoregulation or perfusion-related determinants of thrombolytic efficacy.",
          "pmid": "19926841",
          "title": "Postthrombolysis blood pressure elevation is associated with hemorrhagic transformation.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract evaluates associations between baseline arterial blood pressure and risks of stroke, intracranial hemorrhage, and mortality in patients receiving thrombolysis for acute myocardial infarction. It does not assess cerebral autoregulation, cerebral perfusion, or how blood pressure fluctuations might alter the efficacy of thrombolytic treatment via perfusion-related mechanisms. The findings concern risk/benefit (stroke vs death) at different static blood pressure levels rather than mechanistic changes in cerebral autoregulation or treatment efficacy.",
          "key_findings": "Higher systolic blood pressure at study entry was associated with increased incidence of total stroke and intracranial hemorrhage during thrombolysis for acute myocardial infarction, particularly at systolic pressures \u2265175 mm Hg. Despite higher stroke and hemorrhagic stroke rates at very elevated systolic pressures, patients treated with accelerated alteplase had lower 30\u2011day mortality and lower combined death plus disabling stroke compared with streptokinase. The study suggests a tradeoff between bleeding risk and mortality benefit at different blood pressure levels but does not investigate cerebral autoregulation or perfusion-dependent efficacy of thrombolysis.",
          "pmid": "8967669",
          "title": "Relation of increased arterial blood pressure to mortality and stroke in the context of contemporary thrombolytic therapy for acute myocardial infarction. A randomized trial. GUSTO-I Investigators.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "medium",
          "reasoning": "The abstract examines clinical effects of pharmacologic blood pressure lowering with candesartan in acute ischemic stroke patients with carotid stenosis, but it does not measure or discuss cerebral autoregulation, cerebral perfusion, or how BP fluctuations might compromise autoregulation specifically in relation to thrombolytic efficacy. It shows signals of worse stroke progression and possibly poorer outcome with BP lowering in severe stenosis, which is compatible with the proposed mechanism in a broad sense, but the study does not involve thrombolytic treatment as an efficacy endpoint nor mechanistic assessments of autoregulatory function. Therefore it neither directly supports nor directly contradicts the specific mechanistic claim.",
          "key_findings": "In acute ischemic stroke patients with carotid artery stenosis, randomized to candesartan vs placebo: (1) No clear difference in composite vascular endpoint or functional outcome overall; (2) Among those with severe stenosis, there were signals of higher risk of poor functional outcome (aOR 2.24, 95% CI 0.71\u20137.09) and increased progressive stroke with candesartan (11.5% vs 4.0%), with a linear trend of higher progression risk with increasing stenosis severity (P=0.04); (3) The trial did not assess cerebral autoregulation, perfusion parameters, or the impact of BP fluctuations on thrombolytic treatment efficacy.",
          "pmid": "25472578",
          "title": "Effects of blood pressure lowering in patients with acute ischemic stroke and carotid artery stenosis.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The study tests remote ischemic perconditioning in acute ischemic stroke and reports effects on infarct growth and clinical outcomes. Although the perconditioning protocol uses cuff inflation at a pressure relative to systolic blood pressure, the abstract does not assess blood pressure fluctuations, cerebral autoregulation, or how these might influence thrombolytic efficacy. No measurements or analyses link hemodynamic variability or autoregulatory status to treatment response, so it neither supports nor contradicts the proposed mechanism.",
          "key_findings": "Remote ischemic perconditioning (4 cycles of 5-minute leg cuff inflation/deflation at 110 mm Hg above systolic blood pressure) added to standard care, including intravenous thrombolysis and mechanical thrombectomy, did not significantly reduce brain infarction volume growth at 24 hours compared with standard care alone (mean between-group difference on log-transformed change \u22120.07; 95% CI, \u22120.33 to 0.18; P = .57). No significant differences were observed in excellent 90-day functional outcome, mortality, or symptomatic intracerebral hemorrhage. The abstract does not report data on blood pressure fluctuations, cerebral autoregulation, or their interaction with thrombolytic treatment.",
          "pmid": "32227157",
          "title": "Effect of In-Hospital Remote Ischemic Perconditioning on Brain Infarction Growth and Clinical Outcomes in Patients With Acute Ischemic Stroke: The RESCUE BRAIN Randomized Clinical Trial.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract compares long-term mortality between tenecteplase and alteplase in STEMI and notes that baseline systolic blood pressure did not significantly interact with treatment effect. It does not examine blood pressure fluctuations, cerebral autoregulation, cerebral perfusion, or the mechanistic efficacy of thrombolytics in the brain, so it neither supports nor contradicts the proposed mechanism.",
          "key_findings": "In 16,949 STEMI patients, 1-year mortality was similar for alteplase (9.1%) and tenecteplase (9.2%; RR 1.01, 95% CI 0.91\u20131.12). No significant interaction was found between treatment and baseline systolic blood pressure in a Cox regression model. The study did not assess blood pressure variability, cerebral autoregulation, or cerebral perfusion in relation to thrombolytic efficacy.",
          "pmid": "12851604",
          "title": "One-year follow-up of the ASSENT-2 trial: a double-blind, randomized comparison of single-bolus tenecteplase and front-loaded alteplase in 16,949 patients with ST-elevation acute myocardial infarction.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract examines how increasing systemic/aortic blood pressure in cardiogenic shock improves delivery and efficacy of intravenous tPA for myocardial infarction. It does not address cerebral circulation, cerebral autoregulation, or the impact of blood pressure fluctuations on brain perfusion or thrombolytic efficacy in the cerebral context. Thus it neither supports nor contradicts the proposed mechanism about compromised cerebral autoregulation affecting thrombolysis.",
          "key_findings": "In patients with acute myocardial infarction and profound hypotension or cardiogenic shock, pharmacologic increase of systolic aortic pressure from about 64 to 102 mmHg combined with rapid tPA infusion was associated with early reperfusion, patent infarct-related coronary arteries, and 30-day survival in 6 of 8 patients, whereas the 2 patients whose blood pressure did not increase had persistent artery occlusion and died.",
          "pmid": "7850662",
          "title": "Thrombolytic therapy in cardiogenic shock: effect of increased aortic pressure and rapid tPA administration.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract discusses blood pressure levels, hypertension management, and impaired cerebral autoregulation in acute stroke, and notes that autoregulation impairment plus inadequate BP control may worsen brain damage. However, it does not examine how BP fluctuations specifically affect cerebral autoregulation in the context of thrombolytic therapy efficacy, nor does it link BP-related autoregulatory compromise to outcomes of thrombolysis. Thus it neither supports nor refutes the proposed mechanism about thrombolytic treatment effectiveness.",
          "key_findings": "1) Acute elevation of blood pressure after stroke is common and its management varies. 2) In chronic hypertension, the lower limit of cerebral autoregulation is shifted to higher pressures, and impaired autoregulation due to acute stroke may increase risk of further brain damage if BP is inadequately controlled. 3) Guidelines for BP targets differ between intracerebral hemorrhage and ischemic stroke, with relatively permissive targets in acute ischemic stroke. 4) The ACCESS trial suggests candesartan after acute ischemic stroke improves cardiovascular morbidity and mortality. None of these findings address how BP fluctuations impact cerebral autoregulation in relation to thrombolytic efficacy.",
          "pmid": "19579664",
          "title": "[Hypertension and its therapy in the acute phase of stroke].",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract examines associations between creatine kinase levels and major bleeding risk in non-ST-elevation acute coronary syndrome, including patients treated with thrombolytics, but does not address blood pressure fluctuations, cerebral autoregulation, cerebral perfusion, or thrombolytic efficacy in the brain. Thus it neither supports nor contradicts the proposed mechanism about BP-related cerebral autoregulation affecting thrombolysis.",
          "key_findings": "In NSTE-ACS patients from the TIMI 3B trial, higher peak plasma creatine kinase (CKmax) was independently associated with increased odds of major bleeding (adjusted OR per log CK increase 3.1, 95% CI 1.6\u20135.9) and with a combined outcome of major bleeding, stroke, and hospital death (adjusted OR 3.9, 95% CI 2.5\u20136.1), with C-index 0.8. The association between CK and bleeding was independent of thrombolytic therapy use. The proposed mechanism involving blood pressure fluctuations and cerebral autoregulation is not addressed.",
          "pmid": "33262195",
          "title": "Creatine kinase during non-ST-segment elevation acute coronary syndromes is associated with major bleeding.",
          "analysis_method": "llm"
        }
      ]
    },
    {
      "feature_name": "systolic blood pressure",
      "mechanism": {
        "mechanism_type": "biological",
        "description": "High blood pressure variability is associated with increased risk of hemorrhagic transformation, a known complication of alteplase therapy and a negative prognostic indicator.",
        "evidence_level": "moderate"
      },
      "query": "(stroke OR alteplase OR thrombolysis OR \"ischemic stroke\") AND \"systolic blood pressure\" AND (\"pathophysiology\" OR \"mechanism\" OR \"causal\" OR \"etiology\" OR \"interaction\") AND (\"transformation\" OR \"complication\" OR \"variability\") AND (Clinical Trial[PT] OR Review[PT] OR Meta-Analysis[PT])",
      "total_abstracts": 20,
      "support_count": 1,
      "conflict_count": 0,
      "neutral_count": 19,
      "support_percentage": 5.0,
      "conflict_percentage": 0.0,
      "support_ratio": 0.05,
      "abstracts_analyzed": [
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract discusses lifestyle management for hypertension and general cardiovascular risk, but does not mention blood pressure variability, alteplase therapy, hemorrhagic transformation, or their interrelationships. Therefore it neither supports nor contradicts the proposed mechanism.",
          "key_findings": "The paper defines hypertension, outlines its association with increased cardiovascular disease and mortality, and provides lifestyle recommendations (weight control, physical activity, diet, smoking/alcohol avoidance, stress/sleep management) as first-line strategies for prevention and control; no data or discussion on BP variability or hemorrhagic transformation in the context of thrombolysis are provided.",
          "pmid": "37712135",
          "title": "Lifestyle management of hypertension: International Society of Hypertension position paper endorsed by the World Hypertension League and European Society of Hypertension.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "medium",
          "reasoning": "The abstract notes that blood pressure is the most important risk factor for intracerebral hemorrhage and recommends carefully titrated blood pressure lowering to avoid peaks and large variability, but it does not discuss alteplase therapy, hemorrhagic transformation of ischemic stroke, or outcomes specifically linked to blood pressure variability in that context. Thus it is related to blood pressure variability and hemorrhage risk in general, but does not directly support or refute the proposed mechanism involving hemorrhagic transformation after alteplase.",
          "key_findings": "Blood pressure is described as the most important risk factor for intracerebral hemorrhage; medical treatment should aim for carefully titrated blood pressure lowering to ensure smooth and sustained control, explicitly avoiding peaks and large variability in systolic blood pressure.",
          "pmid": "39557033",
          "title": "Intracerebral Hemorrhage.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract evaluates the blood pressure\u2013lowering efficacy and general safety (vascular complications, renal artery stenosis, hypertensive crisis, mortality, renal function) of renal denervation in hypertension. It does not assess blood pressure variability, alteplase therapy, hemorrhagic transformation, or their inter-relationships, so it neither supports nor contradicts the proposed mechanism.",
          "key_findings": "Renal denervation reduced 24\u2011hour and office systolic and diastolic blood pressure versus sham with no significant differences in major vascular complications, renal artery stenosis, hypertensive crisis, all\u2011cause death, or changes in renal function; blood pressure variability and alteplase-related outcomes were not measured or discussed.",
          "pmid": "39355923",
          "title": "Effects of Catheter-Based Renal Denervation in Hypertension: A Systematic Review and Meta-Analysis.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract evaluates the effects of high-intensity exercise on integrated cardiovascular regulation (Starling mechanism, arterial elastance, baroreflex) in healthy adults and discusses heart rate variability, but it does not examine blood pressure variability, alteplase therapy, hemorrhagic transformation, or stroke outcomes. Therefore, it neither supports nor contradicts the proposed link between blood pressure variability and hemorrhagic transformation risk after alteplase.",
          "key_findings": "Two years of high-intensity exercise in previously sedentary, healthy middle-aged adults increased dynamic Starling mechanism gain, arterial-cardiac baroreflex gain, and integrated cardiovascular regulation gain, without changing dynamic arterial elastance, compared with controls. The study focuses on cardiovascular variability and regulation metrics but does not measure blood pressure variability in the context of stroke or alteplase treatment, nor does it assess hemorrhagic transformation.",
          "pmid": "30387144",
          "title": "The impact of 2\u00a0years of high-intensity exercise training on a model of integrated cardiovascular regulation.",
          "analysis_method": "llm"
        },
        {
          "stance": "support",
          "confidence": "high",
          "reasoning": "The abstract directly reports that greater systolic blood pressure variability in the first 24 hours after alteplase treatment is associated with higher odds of intracranial hemorrhage (a category that includes hemorrhagic transformation) and with worse functional outcome. This aligns with the proposed mechanism that high blood pressure variability increases risk of hemorrhagic complications following alteplase.",
          "key_findings": "In 4511 alteplase-treated acute ischemic stroke patients, higher early SBP variability (SD over 1\u201324 hours) was associated with increased odds of intracranial hemorrhage (OR 1.34, 95% CI 1.11\u20131.62; P=0.002) and with less favorable functional outcome (per higher variability, OR 0.86, 95% CI 0.76\u20130.98; P=0.025). Lower attained SBP and smaller SBP variability were associated with better functional outcomes, while magnitude of initial SBP reduction was not associated with either outcome.",
          "pmid": "34702064",
          "title": "Associations of Early Systolic Blood Pressure Control and Outcome After Thrombolysis-Eligible Acute Ischemic Stroke: Results From the ENCHANTED Study.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The proposed mechanism concerns blood pressure *variability* increasing the risk of hemorrhagic transformation after alteplase. The abstract examines new cerebral microbleeds after intravenous thrombolysis, noting higher systolic blood pressure and hypertension prevalence in patients with new CMBs, and relates new CMBs to remote and symptomatic intracerebral hemorrhage. However, it does not analyze blood pressure variability, nor does it link BP patterns to hemorrhagic transformation specifically. Thus it neither supports nor contradicts the proposed mechanism.",
          "key_findings": "1) New cerebral microbleeds occurred in 7.6% of patients after IV thrombolysis. 2) Patients with new CMBs were older, had more hypertension, higher systolic blood pressure, and higher baseline CMB burden. 3) New CMBs were strongly associated with remote intracerebral hemorrhage (OR 28.75) and symptomatic intracerebral hemorrhage (OR 15.49). 4) New CMBs were not related to functional outcomes or hemorrhagic transformation. 5) The study did not assess blood pressure variability.",
          "pmid": "37857916",
          "title": "Prevalence, Risk Factors, and Clinical Outcomes of New Cerebral Microbleeds After Intravenous Thrombolysis in Acute Ischemic Stroke: a\u00a0Systematic Review and Meta-analysis.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract examines long-term systolic blood pressure variability and its association with mortality and broad cardiovascular outcomes, including stroke, in the general population. It does not address hemorrhagic transformation, alteplase therapy, or post-thrombolysis complications, nor does it analyze BP variability specifically in the acute stroke/thrombolysis setting. Therefore, it neither supports nor contradicts the proposed mechanism.",
          "key_findings": "Long-term systolic blood pressure variability, adjusted for mean blood pressure, is associated with increased risk of all-cause mortality, cardiovascular mortality, major adverse cardiovascular events, stroke, and myocardial infarction, with stronger effects for cerebrovascular than coronary events.",
          "pmid": "38103812",
          "title": "Long-term systolic blood pressure variability independent of mean blood pressure is associated with mortality and cardiovascular events: A systematic review and meta-analysis.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract discusses absolute blood pressure levels and their prognostic value after acute stroke, describing a U-shaped relationship between systolic BP and outcome. It does not address blood pressure variability, nor does it examine hemorrhagic transformation or alteplase-related complications, so it neither supports nor contradicts the proposed mechanism.",
          "key_findings": "Acute hypertensive response occurs in over 50% of acute stroke patients and is associated with poor prognosis; the relationship between outcome and systolic blood pressure is U-shaped, with best outcomes at 140\u2013180 mm Hg; the benefit of actively lowering or raising blood pressure in acute ischemic or hemorrhagic stroke remains unproven.",
          "pmid": "19747655",
          "title": "Blood pressure as a prognostic factor after acute stroke.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract links blood pressure variability with overall stroke incidence but does not address hemorrhagic transformation, alteplase therapy, or post-thrombolysis outcomes. Therefore it neither supports nor contradicts the specific mechanism that BP variability increases risk of hemorrhagic transformation after alteplase.",
          "key_findings": "In Asian populations, systolic blood pressure, diastolic blood pressure, and blood pressure variability are positively correlated with stroke incidence; hypertension is highlighted as the most prevalent risk factor for stroke.",
          "pmid": "33190399",
          "title": "Hypertension and stroke in Asia: A comprehensive review from HOPE Asia.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract shows that different antihypertensive drug classes affect blood pressure variability and that changes in variance and mean systolic blood pressure are associated with stroke risk. However, it does not address alteplase therapy, hemorrhagic transformation, or specifically link blood pressure variability to hemorrhagic transformation risk. Therefore, it neither directly supports nor contradicts the proposed mechanism about BP variability and hemorrhagic transformation after alteplase.",
          "key_findings": "Calcium-channel blockers and non-loop diuretics reduced interindividual variation in systolic blood pressure, while ACE inhibitors, ARBs, and beta blockers increased it. Changes in variance and mean systolic blood pressure together accounted for differences in stroke risk across antihypertensive classes. The study did not evaluate alteplase use or hemorrhagic transformation as outcomes.",
          "pmid": "20226989",
          "title": "Effects of antihypertensive-drug class on interindividual variation in blood pressure and risk of stroke: a systematic review and meta-analysis.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The proposed mechanism concerns blood pressure variability as a risk factor for hemorrhagic transformation after alteplase, whereas the abstract studies absolute post-thrombolysis blood pressure levels (24-hour weighted average SBP) and their association with parenchymal hematoma. It does not measure or analyze BP variability (e.g., fluctuations, SD, CV, visit-to-visit variability), so it neither supports nor contradicts the specific role of BP variability.",
          "key_findings": "In ischemic stroke patients from a randomized t-PA vs placebo trial, parenchymal hematoma was more frequent in t-PA\u2013treated patients (11/49) than in placebo (4/48). Patients with parenchymal hematoma had higher 24-hour weighted average systolic blood pressure (159.4\u00b118.8 mm Hg) than those without hemorrhagic transformation (143.1\u00b120.0 mm Hg). Multinomial logistic regression showed that parenchymal hematoma was predicted by larger DWI lesion volume, presence of atrial fibrillation, and higher 24-hour weighted average SBP. Baseline SBP did not differ between patients with and without hemorrhage.",
          "pmid": "19926841",
          "title": "Postthrombolysis blood pressure elevation is associated with hemorrhagic transformation.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract examines variability and discordance in systolic blood pressure and albuminuria responses to ARB therapy and their association with long-term cardiovascular outcomes in diabetic nephropathy. It does not address blood pressure variability in the context of acute stroke, alteplase therapy, or the risk of hemorrhagic transformation, nor does it examine short-term BP fluctuations or bleeding complications. Therefore it neither supports nor contradicts the proposed mechanism.",
          "key_findings": "In combined RENAAL and IDNT trial data, reductions in systolic blood pressure and albuminuria over 6 months independently correlated with lower cardiovascular risk (HR per 5 mmHg SBP reduction 0.97; HR per decrement log albuminuria 0.87). Response in SBP and albuminuria to ARBs was variable and often discordant between patients, and lower albuminuria was associated with lower cardiovascular risk across SBP categories. No data were presented on hemorrhagic transformation, thrombolysis (alteplase), or short-term BP variability in acute stroke.",
          "pmid": "21421598",
          "title": "Albuminuria and blood pressure, independent targets for cardioprotective therapy in patients with diabetes and nephropathy: a post hoc analysis of the combined RENAAL and IDNT trials.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract examines the relationship between blood pressure variability and new-onset atrial fibrillation and its possible role in mediating stroke risk, not hemorrhagic transformation after alteplase therapy. It does not assess alteplase use, hemorrhagic transformation, or BP variability in that specific context, so it neither supports nor contradicts the proposed mechanism.",
          "key_findings": "In a systematic review of randomized antihypertensive trials, effects of treatment on blood pressure variability were unrelated to risk of new-onset atrial fibrillation (meta-analysis OR 1.02, 95% CI 0.90\u20131.15). Angiotensin receptor blockers tended to reduce new-onset AF without a consistent effect on BP variability. Authors conclude that mechanisms other than AF likely explain the association between BP variability and stroke risk.",
          "pmid": "20651263",
          "title": "Blood pressure variability and risk of new-onset atrial fibrillation: a systematic review of randomized trials of antihypertensive drugs.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "medium",
          "reasoning": "The abstract shows that high baseline blood pressure and greater blood pressure variability in the first 24 hours after ischemic stroke are associated with more early adverse events, early deaths, and poor prognosis, and that BP-lowering/greater BP decline is associated with better 6\u2011month outcome. However, it does not specifically examine hemorrhagic transformation as an outcome, nor does it separate alteplase-related complications from other adverse events. Therefore it cannot be said to directly support or refute the specific mechanism that BP variability increases the risk of hemorrhagic transformation after alteplase.",
          "key_findings": "1) In IST-3, high baseline systolic blood pressure and high BP variability (SD and range over first 24 hours) were associated with higher numbers of early adverse events and early deaths; several of these associations were statistically significant. 2) A larger decline in systolic BP and the use of BP-lowering treatment in the first 24 hours were associated with reduced risk of poor functional outcome at 6 months (OR 0.93 per greater decline, 95% CI 0.89\u20130.97; OR 0.78 for BP-lowering treatment, 95% CI 0.65\u20130.93), regardless of rtPA use. 3) Authors conclude that high baseline BP and large BP variability may be associated with poor prognosis, and that lowering BP or reducing variability may be beneficial, but specific data on hemorrhagic transformation are not reported.",
          "pmid": "26486868",
          "title": "Effects of Blood Pressure and Blood Pressure-Lowering Treatment During the First 24 Hours Among Patients in the Third International Stroke Trial of Thrombolytic Treatment for Acute Ischemic Stroke.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract discusses chronic hypotension in hemodialysis patients, its hemodynamic characteristics, possible pathophysiology, and treatment. It does not address blood pressure variability, alteplase therapy, hemorrhagic transformation, or stroke outcomes, so it neither supports nor contradicts the proposed mechanism.",
          "key_findings": "Chronic hypotension in hemodialysis patients (SBP < 100 mmHg interdialytically) affects 5\u201310% of patients, is more prevalent with long-term hemodialysis, is characterized by preserved cardiac index with reduced total peripheral vascular resistance, may involve reduced responses to vasopressors and increased vasodilators, and has limited treatment options such as midodrine and limb contention.",
          "pmid": "12243360",
          "title": "Chronic hypotension in the dialysis patient.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract links higher systolic blood pressure variability with increased stroke risk, especially with nonselective \u03b2-blockers, but it does not address alteplase therapy, hemorrhagic transformation, or this complication as a prognostic indicator. Therefore, it neither supports nor contradicts the specific mechanism involving blood pressure variability and hemorrhagic transformation after alteplase.",
          "key_findings": "Nonselective \u03b2-blockers increase systolic blood pressure variability more than \u03b21-selective agents (VR=1.34 vs 1.09 vs other antihypertensives; and lower variability with \u03b21-selective vs nonselective \u03b2-blockers, VR=0.81). Nonselective \u03b2-blockers are associated with a higher increase in stroke risk compared with other antihypertensives (OR=2.29) than \u03b21-selective agents (OR=1.24). No data are presented on alteplase, hemorrhagic transformation, or post-thrombolysis outcomes.",
          "pmid": "21795649",
          "title": "Effects of \u03b2-blocker selectivity on blood pressure variability and stroke: a systematic review.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract concerns individualized intraoperative blood pressure targets and postoperative acute kidney injury in surgical patients. It does not involve alteplase therapy, stroke, hemorrhagic transformation, or blood pressure variability as a predictor of hemorrhagic transformation risk. Thus it neither supports nor contradicts the proposed mechanism.",
          "key_findings": "In older patients undergoing major abdominal surgery, individualized blood pressure management reduced intraoperative hypotension and showed a non\u2011significant reduction in postoperative AKI, along with more urine output and faster recovery parameters. No data on blood pressure variability, hemorrhagic transformation, or alteplase-related complications are reported.",
          "pmid": "39878550",
          "title": "Individualized blood pressure regulation and acute kidney injury in older patients having major abdominal surgery: a pilot randomized trial.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract examines associations between blood pressure variability and risks of recurrent ischemic and hemorrhagic stroke in a chronic secondary-prevention cohort, not in the context of alteplase therapy or hemorrhagic transformation after thrombolysis. It reports no significant association with hemorrhagic stroke overall, but does not assess hemorrhagic transformation as a complication of alteplase, so it neither supports nor contradicts the proposed mechanism.",
          "key_findings": "In patients with prior stroke from the PRoFESS trial, higher systolic and diastolic blood pressure variability were associated with increased risk of recurrent ischemic stroke, major cardiovascular events, and all-cause death. The association with stroke was significant for ischemic but not hemorrhagic stroke. Alteplase use and hemorrhagic transformation were not studied.",
          "pmid": "31537194",
          "title": "Blood Pressure Variability and Cardiovascular Outcomes in Patients With Prior Stroke: A Secondary Analysis of PRoFESS.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract discusses intradialytic hypotension, its risk factors, and its association with mortality and organ damage, but does not address blood pressure variability, alteplase therapy, hemorrhagic transformation, or any interaction between BP variability and thrombolysis-related complications.",
          "key_findings": "Intradialytic hypotension (nadir systolic BP <90 mm Hg on >30% of treatments) is associated with increased mortality, myocardial stunning, negative brain and gut effects, and higher risk of stroke and endotoxin-related inflammation; high ultrafiltration rates predict cardiovascular and all-cause mortality.",
          "pmid": "28661565",
          "title": "A brief review of intradialytic hypotension with a focus on survival.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract evaluates effects of intensive versus standard blood pressure lowering on cerebral perfusion and brain structure in hypertensive patients with and without early CKD. It does not assess blood pressure variability, alteplase use, hemorrhagic transformation, or related complications, nor does it analyze variability as a predictor of hemorrhagic events. Therefore it neither supports nor contradicts the proposed mechanism linking high BP variability to hemorrhagic transformation risk in the context of alteplase therapy.",
          "key_findings": "In a SPRINT MRI substudy of 716 hypertensive adults (mean age 68), intensive BP treatment (SBP <120 mm Hg) versus standard treatment (SBP <140 mm Hg) over ~3.9 years did not show detrimental effects on global cerebral blood flow, white matter lesion volume, or total brain volume in participants with primarily early CKD, as defined by eGFR <60 mL/min/1.73 m\u00b2 or UACR >30 mg/g. The study focuses on long-term effects of BP target intensity on brain perfusion and structure, not on BP variability, alteplase treatment, or hemorrhagic transformation.",
          "pmid": "34543687",
          "title": "Kidney Disease, Hypertension Treatment, and Cerebral Perfusion and Structure.",
          "analysis_method": "llm"
        }
      ]
    },
    {
      "feature_name": "systolic blood pressure",
      "mechanism": {
        "mechanism_type": "biological",
        "description": "Previous studies have demonstrated that stable blood pressure following stroke is linked with improved clinical outcomes and prevents further ischemic damage.",
        "evidence_level": "moderate"
      },
      "query": "(stroke OR alteplase OR thrombolysis OR \"ischemic stroke\") AND \"systolic blood pressure\" AND (\"pathophysiology\" OR \"mechanism\" OR \"causal\" OR \"etiology\" OR \"interaction\") AND (\"demonstrated\" OR \"following\" OR \"previous\") AND (Clinical Trial[PT] OR Review[PT] OR Meta-Analysis[PT])",
      "total_abstracts": 20,
      "support_count": 2,
      "conflict_count": 2,
      "neutral_count": 16,
      "support_percentage": 10.0,
      "conflict_percentage": 10.0,
      "support_ratio": 0.1,
      "abstracts_analyzed": [
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract evaluates the effect of tranexamic acid on mortality, bleeding, and vascular occlusive events in trauma patients. Although blood pressure and systolic blood pressure are mentioned as stratification variables, the study does not examine whether stable blood pressure after stroke is linked to improved outcomes or prevention of ischemic damage. It focuses on trauma, not stroke, and does not analyze blood pressure stability as a mechanistic factor in outcomes.",
          "key_findings": "Early administration of tranexamic acid (within 3 hours of injury) reduced all-cause mortality and deaths due to bleeding in trauma patients, with time-to-treatment modifying effectiveness. No evidence was found that the effect of tranexamic acid on death due to bleeding varied by systolic blood pressure, Glasgow Coma Scale score, or type of injury. The trial deals with trauma-related bleeding, not post-stroke blood pressure stability or ischemic damage.",
          "pmid": "23477634",
          "title": "The CRASH-2 trial: a randomised controlled trial and economic evaluation of the effects of tranexamic acid on death, vascular occlusive events and transfusion requirement in bleeding trauma patients.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The proposed mechanism concerns the effect of stable blood pressure following stroke on stroke outcomes. This abstract examines how dietary fibre and whole grain intake affect incident stroke risk, all-cause and cardiovascular mortality, and systolic blood pressure in generally healthy adults. It does not involve stroke patients, post-stroke blood pressure stability, or clinical outcomes after stroke, so it neither supports nor contradicts the specific mechanistic claim.",
          "key_findings": "Higher dietary fibre intake is associated with a 15\u201330% decreased incidence of stroke and stroke mortality, among other outcomes, and clinical trials show significantly lower systolic blood pressure, bodyweight, and total cholesterol with higher fibre intakes. However, these findings relate to primary prevention and risk factor modification in the general population, not to blood pressure stability or clinical outcomes after an acute stroke.",
          "pmid": "30638909",
          "title": "Carbohydrate quality and human health: a series of systematic reviews and meta-analyses.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract evaluates the blood pressure\u2013lowering efficacy and safety of renal denervation in hypertension but does not involve stroke patients, does not assess post-stroke outcomes, and does not examine whether stable blood pressure after stroke improves clinical outcomes or prevents further ischemic damage. Thus, it does not directly address the proposed post-stroke mechanism.",
          "key_findings": "Catheter-based renal denervation, compared with sham, reduced 24-hour systolic BP by 4.4 mmHg and office systolic BP by 6.6 mmHg, with parallel reductions in diastolic BP, without significant differences in vascular complications, renal artery stenosis, hypertensive crisis, all-cause death, or change in eGFR. Trials included hypertensive patients on or off medication but did not involve stroke-specific populations or outcomes.",
          "pmid": "39355923",
          "title": "Effects of Catheter-Based Renal Denervation in Hypertension: A Systematic Review and Meta-Analysis.",
          "analysis_method": "llm"
        },
        {
          "stance": "conflict",
          "confidence": "medium",
          "reasoning": "The proposed mechanism claims that stable blood pressure following stroke is linked with improved outcomes and prevention of further ischemic damage. This review in older adults with hypertension (not specifically post-stroke patients) shows that more aggressive blood pressure lowering (to <140/90 or 110\u2013130 mmHg) reduces incident stroke and serious cardiovascular events compared with higher targets (150\u2013160/95\u2013105 mmHg), with no clear mortality benefit or increase in withdrawals. It does not address blood pressure stability or post-stroke populations, and instead focuses on primary/secondary prevention via target levels. Because it shows benefit of more intensive BP lowering rather than emphasizing stability as the key determinant, it does not support the specific stability-based mechanism and is somewhat misaligned with it; however, the population and question differ, so the contradiction is indirect.",
          "key_findings": "\u2022 In adults \u226565 years, lower BP targets (<140/90 or 110\u2013130 mmHg) vs higher targets (150\u2013160/95\u2013105 mmHg) over 2\u20134 years: little to no difference in all-cause mortality (RR 1.14, 95% CI 0.95\u20131.37; low-certainty).\n\u2022 Lower BP targets reduce stroke (RR 1.33, 95% CI 1.06\u20131.67; high-certainty) and likely reduce total serious cardiovascular adverse events (RR 1.25, 95% CI 1.09\u20131.45; moderate-certainty).\n\u2022 Lower BP targets likely do not increase withdrawals due to adverse effects (RR 0.99, 95% CI 0.74\u20131.33; moderate-certainty).\n\u2022 The review does not specifically examine post-stroke patients or blood pressure stability; it evaluates different BP target levels in older hypertensive adults.",
          "pmid": "39688187",
          "title": "Higher blood pressure targets for hypertension in older adults.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The proposed mechanism concerns stable blood pressure after stroke and its impact on post-stroke ischemic damage and clinical outcomes. This meta-analysis evaluates intensive versus less intensive blood pressure lowering in high-risk patients broadly (cardiovascular disease, renal disease, diabetes), not specifically in the post-stroke setting, does not assess blood pressure stability/variability, and does not analyze secondary ischemic damage after stroke. Thus, it neither directly supports nor contradicts the specific mechanistic claim about stable post-stroke blood pressure.",
          "key_findings": "Intensive blood pressure lowering (mean 133/76 mm Hg vs 140/81 mm Hg) reduced risk of major cardiovascular events by 14%, stroke by 22%, myocardial infarction by 13%, albuminuria by 10%, and retinopathy progression by 19%. There were no clear effects on heart failure, cardiovascular death, total mortality, or end-stage kidney disease. Serious adverse events were slightly more frequent, including increased severe hypotension, but absolute excess was small. These results relate to intensity of BP lowering in high-risk populations, not to stability of blood pressure following stroke or prevention of further ischemic brain damage.",
          "pmid": "26559744",
          "title": "Effects of intensive blood pressure lowering on cardiovascular and renal outcomes: updated systematic review and meta-analysis.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract evaluates the relationship between lipoprotein(a) levels, statin therapy, and risk of cardiovascular events. It does not assess blood pressure levels, blood pressure stability after stroke, ischemic damage, or post-stroke clinical outcomes, and therefore does not provide evidence for or against the proposed blood-pressure-related mechanism.",
          "key_findings": "In statin-treated patients, elevated baseline and on-treatment lipoprotein(a) levels show an approximately linear, independent association with increased cardiovascular disease risk, with no significant statin effect on lipoprotein(a) levels themselves. These findings concern lipoprotein(a) and statin therapy, not post-stroke blood pressure stability or ischemic damage.",
          "pmid": "30293769",
          "title": "Baseline and on-statin treatment lipoprotein(a) levels for prediction of cardiovascular events: individual patient-data meta-analysis of statin outcome trials.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The proposed mechanism concerns the clinical impact of stable blood pressure after stroke on outcomes and prevention of further ischemic damage. This abstract examines genetic and modifiable risk factors (including genetically predicted higher systolic and diastolic blood pressure) for intracerebral hemorrhage using GWAS and Mendelian randomization. It addresses baseline/elevated blood pressure as a causal risk factor for ICH, not the stability of blood pressure following a stroke, nor post-stroke outcomes or ischemic damage. Therefore, it neither validates nor refutes the specific mechanism about stable post-stroke blood pressure and clinical outcomes.",
          "key_findings": "Genetically predicted higher systolic and diastolic blood pressure are associated with increased odds of intracerebral hemorrhage. Excess adiposity, elevated blood pressure, type 2 diabetes, and smoking are identified as key modifiable risk factors for ICH, and an APOE locus is associated with ICH susceptibility.",
          "pmid": "38716647",
          "title": "Risk Factors for Intracerebral Hemorrhage: Genome-Wide Association Study and Mendelian Randomization Analyses.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The proposed mechanism concerns stability of blood pressure after stroke and its impact on clinical outcomes and ischemic damage. The abstract analyzes baseline cholesterol and blood pressure as joint risk factors for future vascular mortality (including stroke) in largely healthy adults, without examining post-stroke blood pressure behavior, stability over time, or stroke outcomes conditional on post-event hemodynamics. Thus, it neither supports nor contradicts the specific mechanistic claim about stable blood pressure following stroke.",
          "key_findings": "The meta-analysis of 61 prospective studies (\u223c900,000 adults without prior disease) found that: (1) Lower total cholesterol is strongly associated with reduced ischemic heart disease mortality across age groups; (2) The absolute effects of cholesterol and blood pressure on IHD mortality are approximately additive, and the proportional benefit of lower cholesterol diminishes at higher blood pressure; (3) Total cholesterol shows complex, age- and blood-pressure\u2013dependent relationships with stroke mortality, with weak positive associations in middle age and some negative associations with hemorrhagic and total stroke at older ages and higher blood pressures; (4) These findings relate to baseline risk and not to the stability of blood pressure after a stroke event.",
          "pmid": "18061058",
          "title": "Blood cholesterol and vascular mortality by age, sex, and blood pressure: a meta-analysis of individual data from 61 prospective studies with 55,000 vascular deaths.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The proposed mechanism concerns stable blood pressure after stroke and its effect on post-stroke outcomes and ischemic damage. The abstract focuses on GLP-1 receptor agonists in nondiabetic obese individuals, reporting reductions in cardiovascular events and some blood pressure lowering, but it does not involve stroke patients, post-stroke period, blood pressure stability after stroke, or subsequent ischemic injury. Therefore it neither supports nor contradicts the specific post-stroke blood pressure mechanism.",
          "key_findings": "GLP-1RA therapies in nondiabetic overweight/obese adults reduce total cardiovascular events, major adverse cardiovascular events, myocardial infarction, and all-cause mortality, with no significant effect on stroke incidence; some agents reduce systolic blood pressure and improve cardiometabolic markers. No data are presented on post-stroke patients, blood pressure stability following stroke, or prevention of further ischemic damage after stroke.",
          "pmid": "40207414",
          "title": "Efficacy of GLP-1 Receptor Agonist-Based Therapies on Cardiovascular Events and Cardiometabolic Parameters in Obese Individuals Without Diabetes: A Meta-Analysis of Randomized Controlled Trials.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract discusses hypertension, the benefits of treating elevated systolic blood pressure, and combination therapy, but it does not address blood pressure stability after stroke, stroke patients specifically, or the relationship between post-stroke blood pressure stability and prevention of further ischemic damage or improved outcomes. Therefore it neither supports nor contradicts the proposed mechanism.",
          "key_findings": "Large clinical trials show that treating isolated systolic and systolic/diastolic hypertension reduces total mortality, cardiovascular mortality, and stroke in older adults; combination therapy with calcium-channel blockers and ACE inhibitors may improve tolerability and cognitive function.",
          "pmid": "17184139",
          "title": "Systolic hypertension.",
          "analysis_method": "llm"
        },
        {
          "stance": "support",
          "confidence": "medium",
          "reasoning": "The proposed mechanism states that maintaining appropriate post-stroke blood pressure is associated with better clinical outcomes and less ischemic damage. This meta-analysis directly examines blood pressure targets after endovascular therapy for acute ischemic stroke and reports that more intensive systolic blood pressure control (especially SBP < 140 mmHg) is associated with improved functional outcome (higher 90-day mRS 0\u20132 rate in subgroup), lower symptomatic intracranial hemorrhage, and lower hemicraniectomy rates, implying protection from further brain injury. These findings align with the mechanism that controlled/stable blood pressure post-stroke improves outcomes, even though the abstract focuses on specific SBP thresholds rather than explicit \u201cstability.\u201d",
          "key_findings": "1) Subgroup analysis showed that targeting SBP < 140 mmHg was associated with a higher incidence of favorable 90-day functional outcome (mRS 0\u20132) compared with higher BP targets (OR=1.73, 95% CI [1.04, 2.90], p=0.04). 2) SBP < 140 mmHg was associated with a lower incidence of symptomatic intracranial hemorrhage (OR=0.49, 95% CI [0.28, 0.87], p=0.02). 3) SBP < 140 mmHg was associated with a lower incidence of hemicraniectomy (OR=0.30, 95% CI [0.15, 0.58], p<0.001). 4) Authors conclude that more intensive BP treatment after EVT, particularly reducing SBP to <140 mmHg, confers the greatest clinical benefit.",
          "pmid": "37354634",
          "title": "Blood pressure targets for acute ischemic stroke patients following endovascular thrombectomy: A meta-analysis.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The proposed mechanism is about stable blood pressure after stroke improving outcomes and preventing ischemic damage. The abstract discusses sleep-disordered breathing causing blood pressure swings and CPAP producing mild blood pressure reductions, and notes an association of SDB with early neurological worsening, but it does not directly examine whether maintaining stable blood pressure post-stroke improves outcomes or prevents further ischemic injury. Thus it is related to blood pressure and stroke, but does not provide mechanism-specific evidence for or against the stated claim.",
          "key_findings": "Sleep-disordered breathing (SDB) may increase stroke risk via mechanisms including blood pressure swings; CPAP treatment in SDB patients leads to mild reductions in systolic and diastolic blood pressure; one study in acute stroke patients found SDB associated with early neurological worsening but not with final stroke outcome.",
          "pmid": "12544862",
          "title": "Sleep-disordered breathing and stroke.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The proposed mechanism concerns stable blood pressure after stroke and its impact on post\u2011stroke outcomes and ischemic damage. This abstract evaluates whether reducing alcohol intake lowers blood pressure and affects cardiovascular outcomes in hypertensive adults in general, not in stroke patients or in the post\u2011stroke period, and does not examine blood pressure stability or ischemic brain injury. Therefore, it neither supports nor contradicts the specific post\u2011stroke mechanistic claim.",
          "key_findings": "In a single RCT (269 participants, 2\u2011year follow\u2011up), a cognitive\u2011behavioural intervention significantly reduced alcohol intake compared with control, but produced no statistically significant differences in systolic or diastolic blood pressure, the proportion achieving BP <140/90 mmHg, overall mortality, cardiovascular mortality, or cardiovascular events. Stroke-specific outcomes, post\u2011stroke status, and blood pressure stability after stroke were not assessed.",
          "pmid": "32960976",
          "title": "Alcohol intake reduction for controlling hypertension.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract mentions blood pressure as one of several risk-factor targets in an aggressive medical management strategy that reduced recurrent stroke risk, but it does not isolate the effect of stable or controlled blood pressure, nor does it link blood pressure stability specifically to prevention of further ischemic damage or improved clinical outcomes after stroke. The evidence is about a multifactorial management bundle, not the specific mechanistic role of stable blood pressure.",
          "key_findings": "Aggressive medical management, including risk factor control with a target systolic blood pressure <140 mmHg, LDL <70 mg/dL, HbA1c <7.0%, lifestyle changes, and antithrombotics, was associated with about half the risk of stroke compared to patients in a previous trial. The contribution of blood pressure control per se, or of blood pressure stability, is not separately evaluated.",
          "pmid": "27443379",
          "title": "Management of Symptomatic Intracranial Stenosis.",
          "analysis_method": "llm"
        },
        {
          "stance": "support",
          "confidence": "medium",
          "reasoning": "The proposed mechanism is that stable blood pressure after stroke is linked with improved outcomes and prevents further ischemic damage. The abstract reports that high systolic blood pressure is an independent risk factor for symptomatic intracerebral hemorrhage following thrombolytic therapy, a serious complication associated with high morbidity and mortality. While the abstract does not directly study \u2018stability\u2019 of blood pressure or overall ischemic damage, it does show that elevated blood pressure worsens clinical safety outcomes after stroke, which is directionally consistent with the idea that better-controlled (i.e., not high) blood pressure is beneficial.",
          "key_findings": "In a systematic review of 12 studies on risk factors for symptomatic intracerebral hemorrhage after thrombolysis for acute ischemic stroke, high systolic blood pressure was identified in one study as an independent risk factor for thrombolysis-associated symptomatic intracerebral hemorrhage, a complication linked to high morbidity and mortality.",
          "pmid": "17519538",
          "title": "Symptomatic intracerebral hemorrhage following thrombolytic therapy for acute ischemic stroke: a review of the risk factors.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract examines risk factors and outcomes related to new cerebral microbleeds after intravenous thrombolysis, noting higher systolic blood pressure and hypertension in patients with new CMBs, but it does not evaluate whether maintaining stable blood pressure after stroke improves clinical outcomes or prevents further ischemic damage. No intervention or analysis of blood pressure stability or its direct impact on ischemic injury is reported.",
          "key_findings": "New cerebral microbleeds occurred in 7.6% of patients after IV thrombolysis; patients with new CMBs were older, more often hypertensive, and had higher systolic blood pressure and greater baseline CMB burden. New CMBs were associated with higher odds of remote and symptomatic intracerebral hemorrhage but not with functional outcome or hemorrhagic transformation. The study does not assess the effect of stable vs unstable blood pressure on post-stroke outcomes or ischemic damage.",
          "pmid": "37857916",
          "title": "Prevalence, Risk Factors, and Clinical Outcomes of New Cerebral Microbleeds After Intravenous Thrombolysis in Acute Ischemic Stroke: a\u00a0Systematic Review and Meta-analysis.",
          "analysis_method": "llm"
        },
        {
          "stance": "conflict",
          "confidence": "high",
          "reasoning": "The proposed mechanism claims that stable blood pressure following stroke is linked with improved outcomes and prevention of further ischemic damage in general. This meta-analysis shows that in non-reperfused patients, blood pressure lowering has no significant effect on mortality or dependency, and very intensive BP lowering after successful reperfusion actually worsens dependency. Benefits are context-specific (pre-reperfusion only) rather than showing a general protective effect of achieving stability. Overall, these findings challenge a simple, broadly beneficial role of post-stroke BP control as described in the mechanism.",
          "key_findings": "In acute ischemic stroke patients not treated with reperfusion, BP lowering did not significantly change short- or long-term mortality or dependency. BP lowering before reperfusion reduced dependency, but intensive BP lowering to systolic <120 mmHg after successful reperfusion increased dependency risk. BP reduction had no significant effect on recurrent strokes or combined vascular events.",
          "pmid": "38021612",
          "title": "Antihypertensive Interventions in Acute Ischemic Stroke: A Systematic Review and Meta-Analysis Evaluating Clinical Outcomes Through an Emergency Medicine Paradigm.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The proposed mechanism concerns stable blood pressure following stroke and its association with post-stroke outcomes and ischemic damage. The abstract evaluates target systolic blood pressure levels in patients with type 2 diabetes for prevention of major cardiovascular events and death, not post-stroke management or blood pressure stability after stroke. It does not address stroke survivors, infarct progression, or stability of blood pressure following stroke, so it neither supports nor contradicts the specific mechanistic claim.",
          "key_findings": "In patients with type 2 diabetes, achieved systolic BP of 120\u2013124 mm Hg was associated with the lowest risk of major cardiovascular events compared with higher SBP categories; all-cause mortality was reduced below 140 mm Hg, with no further mortality benefit at lower SBP. These results relate to primary/secondary prevention in diabetes, not to blood pressure stability or outcomes specifically after stroke.",
          "pmid": "37254768",
          "title": "Systolic Blood Pressure Control Targets to Prevent Major Cardiovascular Events and Death in Patients With Type 2 Diabetes: A Systematic Review and Network Meta-Analysis.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The proposed mechanism concerns *stable* blood pressure after stroke and its relation to preventing further ischemic damage and improving outcomes. This abstract examines a single admission systolic blood pressure value (with a J-shaped association to functional outcome) and whether this relationship is modified by prior IV thrombolysis; it does not assess BP stability over time, BP variability, or its role in preventing additional ischemic damage. Thus, it neither supports nor contradicts the specific mechanistic claim about stable blood pressure.",
          "key_findings": "In acute ischemic stroke patients treated with endovascular therapy (with or without IV alteplase), admission systolic blood pressure showed a J-shaped relationship with 90-day functional outcome, with an inflection around 150 mmHg. Higher SBP above 150 mmHg was associated with poorer functional outcome, while lower SBP was not clearly associated. Higher admission SBP was not associated with symptomatic intracranial hemorrhage or successful reperfusion, and IV thrombolysis did not modify the association between SBP and outcomes. The study did not measure or analyze blood pressure stability/variability over time.",
          "pmid": "37641554",
          "title": "Admission blood pressure and clinical outcomes in patients with acute ischaemic stroke treated with intravenous alteplase and endovascular treatment versus endovascular treatment alone: A MR CLEAN-NO IV substudy.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "medium",
          "reasoning": "The proposed mechanism concerns stable blood pressure *after stroke* and its association with improved outcomes and reduced further ischemic damage. The abstract only states that trials have shown systolic blood pressure lower than 140 mmHg \"may be better for the brain\" and discusses stroke/dementia prevention and vascular risk factor control in general populations. It does not address post-stroke blood pressure stability, post-stroke clinical outcomes, or prevention of further ischemic damage in stroke survivors, so it neither directly supports nor contradicts the specific mechanistic claim.",
          "key_findings": "The abstract reports: (1) population-level evidence that lower vascular risk factor profiles, including reduced stroke incidence, are associated with better cognitive function and lower dementia rates; (2) trial data that anticoagulation for atrial fibrillation can reduce dementia risk by 48%; and (3) that systolic blood pressure lower than 140 mmHg may be better for the brain. None of these findings are specific to blood pressure stability following stroke or its impact on subsequent ischemic damage and clinical outcomes in stroke patients.",
          "pmid": "31327392",
          "title": "Preventing dementia by preventing stroke: The Berlin Manifesto.",
          "analysis_method": "llm"
        }
      ]
    },
    {
      "feature_name": "antiplat_rand",
      "mechanism": {
        "mechanism_type": "biological",
        "description": "Antiplatelet therapy affects platelet aggregation pathways, thereby potentially altering the efficacy of alteplase, which targets fibrin clot dissolution.",
        "evidence_level": "moderate"
      },
      "query": "(stroke OR alteplase OR thrombolysis OR \"ischemic stroke\") AND (antiplatelet OR aspirin OR clopidogrel OR \"platelet inhibition\") AND (\"pathophysiology\" OR \"mechanism\" OR \"causal\" OR \"etiology\" OR \"interaction\") AND (\"antiplatelet\" OR \"potentially\" OR \"dissolution\") AND (Clinical Trial[PT] OR Review[PT] OR Meta-Analysis[PT])",
      "total_abstracts": 20,
      "support_count": 0,
      "conflict_count": 0,
      "neutral_count": 20,
      "support_percentage": 0.0,
      "conflict_percentage": 0.0,
      "support_ratio": 0.0,
      "abstracts_analyzed": [
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract evaluates the clinical efficacy and bleeding risk of dual antiplatelet therapy (clopidogrel plus aspirin) versus aspirin alone in patients who did NOT receive thrombolysis or thrombectomy. It does not involve alteplase use, does not analyze interactions between antiplatelet-induced changes in platelet aggregation pathways and fibrinolytic therapy, and provides no mechanistic or clinical data on how antiplatelet therapy might alter alteplase efficacy.",
          "key_findings": "In patients with mild ischemic stroke or high-risk TIA of presumed atherosclerotic cause, all without thrombolysis or thrombectomy, clopidogrel plus aspirin started within 72 hours reduced new stroke at 90 days compared with aspirin alone (7.3% vs. 9.2%; HR 0.79, 95% CI 0.66\u20130.94) but increased moderate-to-severe bleeding (0.9% vs. 0.4%; HR 2.08, 95% CI 1.07\u20134.04). Alteplase or fibrin clot dissolution mechanisms were not studied.",
          "pmid": "38157499",
          "title": "Dual Antiplatelet Treatment up to 72 Hours after Ischemic Stroke.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract compares durations and compositions of antiplatelet regimens (short DAPT then clopidogrel vs 12-month DAPT) on clinical cardiovascular and bleeding outcomes after PCI in ACS. It does not involve alteplase use, fibrin clot dissolution, or any assessment of how antiplatelet-induced changes in platelet aggregation modify alteplase efficacy. Therefore it neither supports nor contradicts the proposed interaction mechanism between antiplatelet therapy and alteplase.",
          "key_findings": "In ACS patients post-PCI, 1\u20132 months of DAPT followed by clopidogrel monotherapy was not noninferior to 12 months of DAPT for a composite cardiovascular/bleeding endpoint (HR 1.14, 95% CI 0.80\u20131.62). Cardiovascular events were numerically higher with short DAPT (HR 1.50, 95% CI 0.99\u20132.26), while bleeding events were lower (HR 0.46, 95% CI 0.23\u20130.94). No data were presented on thrombolytic (alteplase) therapy or its interaction with antiplatelet therapy.",
          "pmid": "35234821",
          "title": "Comparison of Clopidogrel Monotherapy After 1 to 2 Months of Dual Antiplatelet Therapy With 12 Months of Dual Antiplatelet Therapy in Patients With Acute Coronary Syndrome: The STOPDAPT-2 ACS Randomized Clinical Trial.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract discusses mechanisms and clinical effects of various antiplatelet agents in ischemic stroke prevention and post-stroke management, but it does not address their interaction with alteplase or how antiplatelet-induced changes in platelet aggregation pathways might alter alteplase efficacy on fibrin clot dissolution.",
          "key_findings": "Evidence supports aspirin and clopidogrel for secondary prevention; dual antiplatelet therapy has higher efficacy in the first 21 days post-stroke but higher long-term hemorrhage risk; treatment failure is influenced by adherence and genetic polymorphisms; cilostazol may offer extra benefit in certain racial groups; future research should examine platelet polymorphisms and diverse populations. No mention is made of alteplase, thrombolysis, or modification of alteplase efficacy by antiplatelet therapy.",
          "pmid": "35094598",
          "title": "Antiplatelet Use in Ischemic Stroke.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract mentions dual antiplatelet therapy as standard secondary prevention for intracranial atherosclerotic stenosis but does not discuss alteplase use, fibrinolysis, or any interaction between antiplatelet therapy and alteplase\u2019s efficacy or mechanisms. It provides no mechanistic or outcome data on how antiplatelet agents might alter alteplase-mediated fibrin clot dissolution.",
          "key_findings": "Patients with ICAS are treated with intensive risk factor management and dual antiplatelet therapy transitioning to aspirin alone; the optimal regimen and duration of dual antiplatelet therapy are uncertain and under investigation. No information is provided about thrombolysis with alteplase or its interaction with antiplatelet therapy.",
          "pmid": "35143758",
          "title": "Intracranial atherosclerotic stenosis: risk factors, diagnosis, and treatment.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract evaluates clinical outcomes (death, MI, stroke, revascularization, bleeding) of dual vs single antiplatelet therapy after CABG and does not involve alteplase use, fibrinolysis, or any assessment of how antiplatelet-induced changes in platelet aggregation pathways might alter alteplase efficacy. It is about antiplatelet strategy post-surgery, not interaction with thrombolytic therapy.",
          "key_findings": "Ticagrelor plus aspirin vs aspirin alone after CABG for acute coronary syndrome showed no reduction in the composite of death, MI, stroke, or repeat revascularization at 1 year (HR 1.06, 95% CI 0.72\u20131.56) but increased major bleeding (4.9% vs 2.0%; HR 2.50, 95% CI 1.52\u20134.11). No data on alteplase, fibrin clot dissolution, or pharmacodynamic interaction between antiplatelets and thrombolytic therapy are reported.",
          "pmid": "40888737",
          "title": "Ticagrelor and Aspirin or Aspirin Alone after Coronary Surgery for Acute Coronary Syndrome.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract evaluates rivaroxaban with or without aspirin versus aspirin alone in stable peripheral/carotid artery disease and reports effects on cardiovascular and limb outcomes and bleeding. It does not involve alteplase, fibrinolysis, or thrombolytic therapy, nor does it examine how antiplatelet therapy might alter alteplase efficacy or its fibrin-targeted action. Thus it neither supports nor contradicts the proposed mechanism.",
          "key_findings": "In patients with peripheral artery disease, rivaroxaban 2.5 mg twice daily plus aspirin reduced cardiovascular death, myocardial infarction, or stroke and major adverse limb events compared with aspirin alone, at the cost of increased major (mostly gastrointestinal) bleeding. Rivaroxaban 5 mg twice daily alone did not significantly reduce the primary composite cardiovascular endpoint versus aspirin but reduced major adverse limb events and increased major bleeding. No data are presented on alteplase, fibrin clot dissolution, or interactions between antiplatelet therapy and alteplase efficacy.",
          "pmid": "29132880",
          "title": "Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract evaluates clinical outcomes of different antiplatelet strategies (P2Y12 monotherapy vs DAPT) after PCI and their effects on ischemic events and bleeding. It does not involve alteplase use, fibrinolysis, or any assessment of how antiplatelet-induced changes in platelet aggregation pathways might alter alteplase efficacy or fibrin clot dissolution. Therefore, it neither supports nor contradicts the proposed mechanism.",
          "key_findings": "Ticagrelor monotherapy after a short course of DAPT was noninferior to continued DAPT for composite death, MI, or stroke and reduced major bleeding and net adverse clinical events; clopidogrel monotherapy reduced major bleeding but was not noninferior to DAPT for the primary composite outcome, largely due to noncardiovascular deaths in one East Asian trial. No data on alteplase, fibrinolysis, or interaction between antiplatelet therapy and thrombolytic efficacy are presented.",
          "pmid": "38506796",
          "title": "Ticagrelor or Clopidogrel Monotherapy vs Dual Antiplatelet Therapy After Percutaneous Coronary Intervention: A Systematic Review and Patient-Level Meta-Analysis.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract compares clinical outcomes of low-dose DOAC versus dual antiplatelet therapy after LAAO, without involving alteplase use, fibrin clot dissolution, or how antiplatelet-modulated platelet aggregation pathways might alter alteplase efficacy. It addresses antithrombotic regimen efficacy and safety, not the mechanistic interaction between antiplatelet therapy and alteplase\u2019s fibrinolytic action.",
          "key_findings": "In 90 patients post-LAAO, low-dose apixaban (2.5 mg bid) for 3 months reduced the composite endpoint of major bleeding and thromboembolic events (including device-related thrombosis) compared with dual antiplatelet therapy (aspirin plus clopidogrel): 4.5% vs 21.7% (HR 0.19, 95% CI 0.04\u20130.88). Device-related thrombosis was 0% with low-dose DOAC vs 8.7% with DAPT. Major bleeding tended to be lower with DOAC (4.6% vs 13.0%), with no strokes or systemic emboli in either group. No data involve alteplase or its interaction with antiplatelet therapy.",
          "pmid": "39110427",
          "title": "Low-Dose Direct Oral Anticoagulation vs Dual Antiplatelet Therapy After Left Atrial Appendage Occlusion: The ADALA Randomized Clinical Trial.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract compares NOACs to aspirin in ESUS and notes that neither was superior overall, with some subgroups possibly benefiting more from one or the other. However, it does not discuss how antiplatelet therapy mechanistically affects platelet aggregation pathways in relation to alteplase\u2019s fibrin-targeted thrombolysis, nor any interaction between antiplatelets and alteplase efficacy.",
          "key_findings": "The abstract reports that in ESUS patients, dabigatran and rivaroxaban were not superior to aspirin, though certain subgroups might specifically benefit from anticoagulation or antiplatelet therapy. It focuses on treatment comparisons and ESUS classification rather than on mechanistic interactions between antiplatelet therapy and alteplase-mediated fibrin clot dissolution.",
          "pmid": "35538232",
          "title": "Review and update of the concept of embolic stroke of undetermined source.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract evaluates aggressive medical management (which includes antiplatelet therapy) versus stenting for intracranial stenosis in terms of clinical outcomes (stroke, death, haemorrhage), but it does not involve alteplase use, does not study fibrinolysis, and does not examine how antiplatelet therapy might alter alteplase efficacy or platelet aggregation pathways in the context of thrombolysis. Therefore it neither supports nor contradicts the proposed mechanism.",
          "key_findings": "Aggressive medical management with antiplatelet therapy and risk-factor control was superior to stenting with the Wingspan system for preventing stroke or death over a median 32.4-month follow-up in patients with high-grade intracranial stenosis; the stenting group had higher rates of any stroke (26% vs 19%) and major haemorrhage (13% vs 4%). Alteplase or interactions between antiplatelet therapy and fibrinolytic treatment were not assessed.",
          "pmid": "24168957",
          "title": "Aggressive medical treatment with or without stenting in high-risk patients with intracranial artery stenosis (SAMMPRIS): the final results of a randomised trial.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract evaluates clinical efficacy and bleeding risk of dual vs single antiplatelet therapy after mild ischemic stroke/TIA, stratified by time from symptom onset, but it does not involve alteplase use, fibrinolysis, or any interaction between antiplatelet-induced changes in platelet aggregation pathways and alteplase\u2019s fibrin clot dissolution. Thus it neither supports nor contradicts the proposed mechanism about antiplatelet\u2013alteplase interaction.",
          "key_findings": "Dual antiplatelet therapy with clopidogrel plus aspirin, initiated within 72 hours after mild ischemic stroke or TIA, reduced 90-day new stroke risk compared with aspirin alone, with a similar relative increase in moderate-to-severe bleeding across time-to-initiation subgroups. Alteplase use, fibrin clot dissolution mechanisms, or modification of alteplase efficacy by antiplatelet therapy were not studied or reported.",
          "pmid": "39240565",
          "title": "Clopidogrel and Aspirin Initiated Between 24 to 72 Hours for Mild Ischemic Stroke: A Subgroup Analysis of the INSPIRES Randomized Clinical Trial.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract discusses how antiplatelet and anticoagulant therapies are used for secondary stroke prevention, including efficacy and bleeding risks, but it does not address their interaction with alteplase or whether modifying platelet aggregation pathways alters alteplase\u2019s fibrin-based thrombolytic efficacy. No data or claims are made about treatment response to alteplase or mechanistic interplay between antiplatelet therapy and fibrinolysis.",
          "key_findings": "Single and dual antiplatelet therapy reduce recurrent ischemic stroke risk in specific populations; short-term DAPT (21\u201330 days) is more effective than single therapy for minor non-cardioembolic stroke or high-risk TIA but longer DAPT increases bleeding risk; DOACs are preferred over warfarin in many cardioembolic stroke patients due to lower bleeding risk. None of these findings mention alteplase use or its efficacy.",
          "pmid": "37037980",
          "title": "Contemporary Antiplatelet and Anticoagulant Therapies for Secondary Stroke Prevention: A Narrative Review of Current Literature and Guidelines.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract evaluates clinical outcomes of clopidogrel plus omeprazole versus clopidogrel plus placebo in coronary artery disease and assesses gastrointestinal and cardiovascular events. It does not involve alteplase, fibrin clot dissolution, or how antiplatelet-induced changes in platelet aggregation pathways might modify alteplase efficacy. Thus, it neither supports nor contradicts the proposed mechanism.",
          "key_findings": "In patients on aspirin and clopidogrel, omeprazole significantly reduced upper gastrointestinal events (HR 0.34 for GI composite, HR 0.13 for overt upper GI bleeding) without a detectable difference in cardiovascular outcomes (HR 0.99 for CV composite). No data are presented on thrombolytic therapy or alteplase response.",
          "pmid": "20925534",
          "title": "Clopidogrel with or without omeprazole in coronary artery disease.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract compares two antiplatelet regimens (indobufen+clopidogrel vs aspirin+clopidogrel) after PCI and reports clinical ischemic and bleeding outcomes. It does not involve alteplase use, fibrinolytic therapy, or assessment of how antiplatelet-mediated changes in platelet aggregation alter alteplase efficacy or fibrin clot dissolution. Thus it neither supports nor contradicts the proposed mechanism.",
          "key_findings": "Indobufen-based DAPT (indobufen 100 mg BID + clopidogrel 75 mg daily) was noninferior to aspirin-based DAPT (aspirin 100 mg daily + clopidogrel 75 mg daily) over 1 year in patients with negative troponin undergoing DES implantation, with similar rates of cardiovascular death, MI, ischemic stroke, and stent thrombosis, and lower rates of BARC 2\u20135 bleeding, mainly due to fewer BARC 2 events. No data on alteplase, fibrinolysis, or interaction with fibrin clot dissolution pathways are presented.",
          "pmid": "36335890",
          "title": "Indobufen or Aspirin on Top of Clopidogrel After Coronary Drug-Eluting Stent Implantation (OPTION): A Randomized, Open-Label, End Point-Blinded, Noninferiority Trial.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract compares rivaroxaban (an anticoagulant) with acetylsalicylic acid (an antiplatelet agent) for stroke prevention after AF ablation, but it does not involve alteplase use, fibrinolysis, or how antiplatelet-induced changes in platelet aggregation might alter alteplase efficacy. No platelet aggregation pathways or interactions with fibrin clot dissolution therapy are discussed.",
          "key_findings": "The OCEAN trial is a randomized, multicenter study testing whether rivaroxaban is superior to aspirin for preventing overt and covert stroke/systemic embolism in post\u2013AF ablation patients with stroke risk factors. Patients without recurrent AF for at least 12 months are randomized to rivaroxaban 15 mg daily or aspirin 75\u2013160 mg daily and followed for 3 years. Primary and secondary outcomes include stroke/systemic embolism, covert stroke on MRI, bleeding, and quality of life. The abstract describes trial design and hypothesis only, with no mechanistic data on platelet aggregation pathways or alteplase interaction.",
          "pmid": "29447772",
          "title": "The Optimal Anti-Coagulation for Enhanced-Risk Patients Post-Catheter Ablation for Atrial Fibrillation (OCEAN) trial.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract compares clinical outcomes of antiplatelet versus anticoagulant therapy in cervical artery dissection but does not involve alteplase use, fibrinolysis, or how antiplatelet-induced changes in platelet aggregation might alter alteplase efficacy or mechanism. It addresses treatment strategies for preventing recurrent stroke, not interactions between antiplatelets and fibrin clot dissolution by alteplase.",
          "key_findings": "In 250 patients with extracranial carotid or vertebral artery dissection randomized to antiplatelet or anticoagulant therapy, recurrent stroke rate at 1 year was low (2.4%) with no significant difference between groups for stroke, death, or recanalization. Imaging showed no difference in residual narrowing or occlusion between antiplatelet and anticoagulant groups. Alteplase or fibrinolytic mechanisms were not studied.",
          "pmid": "30801621",
          "title": "Antiplatelet Therapy vs Anticoagulation Therapy in Cervical Artery Dissection: The Cervical Artery Dissection in Stroke Study (CADISS) Randomized Clinical Trial Final Results.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract compares long-term outcomes of clopidogrel vs aspirin monotherapy after PCI, focusing on thrombotic and bleeding clinical endpoints. It does not involve alteplase use, fibrinolytic therapy, or evaluate how antiplatelet-induced changes in platelet aggregation pathways might alter alteplase efficacy. Therefore, it neither supports nor contradicts the proposed mechanism about interaction between antiplatelet therapy and alteplase-mediated fibrin clot dissolution.",
          "key_findings": "Clopidogrel monotherapy was associated with lower thrombotic and bleeding event rates than aspirin monotherapy in patients post-PCI, with consistent benefit regardless of high bleeding risk or PCI complexity. No data on alteplase, fibrinolysis, or modifications of alteplase efficacy are reported.",
          "pmid": "39602157",
          "title": "Long-Term Aspirin vs Clopidogrel After Coronary Stenting by Bleeding Risk and Procedural Complexity.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract evaluates early aspirin and heparin in acute ischemic stroke, but it does not involve alteplase, fibrinolysis, or how antiplatelet-induced changes in platelet aggregation pathways might alter alteplase efficacy. It focuses on clinical outcomes of antithrombotic therapy alone, not on interactions with fibrin clot dissolution by alteplase.",
          "key_findings": "Aspirin started within 48 hours of stroke onset produced a small reduction in death or non-fatal recurrent stroke and slightly increased extracranial bleeding; heparin reduced recurrent ischemic stroke but increased hemorrhagic stroke and extracranial bleeding, with no net clinical benefit at 6 months. No thrombolytic (alteplase) therapy or its efficacy is discussed.",
          "pmid": "9174558",
          "title": "The International Stroke Trial (IST): a randomised trial of aspirin, subcutaneous heparin, both, or neither among 19435 patients with acute ischaemic stroke. International Stroke Trial Collaborative Group.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract evaluates combination antithrombotic therapy (low-dose rivaroxaban plus aspirin vs aspirin alone) for secondary stroke prevention in intracranial atherosclerotic disease, focusing on safety and recurrent ischemic outcomes. It does not involve alteplase use, thrombolysis, or any interaction between antiplatelet therapy and alteplase-mediated fibrin clot dissolution, nor does it analyze platelet aggregation pathways in that context. Therefore it neither supports nor contradicts the proposed mechanism.",
          "key_findings": "In 101 patients with recent ischemic stroke or TIA due to intracranial atherosclerotic disease, low-dose rivaroxaban plus aspirin showed no increase in hemorrhagic stroke versus aspirin alone and a nonsignificant numerical reduction in the composite of ischemic stroke or covert brain infarct (15.7% vs 24.0%; HR 0.78, 95% CI 0.32\u20131.93, P=0.59). The study concludes that a larger trial of this combination is feasible and appears safe, but it does not address alteplase efficacy or mechanisms involving fibrin clot dissolution.",
          "pmid": "39781748",
          "title": "Combination Antithrombotic Therapy for Reduction of Recurrent Ischemic Stroke in Intracranial Atherosclerotic Disease.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The trial compares different antiplatelet regimens (early aspirin discontinuation with ticagrelor monotherapy vs 12-month DAPT) in ACS patients after stenting and reports clinical outcomes (ischemic and bleeding events). It does not involve alteplase use, fibrinolytic therapy, or any assessment of how antiplatelet therapy modifies the efficacy or mechanism of alteplase-mediated fibrin clot dissolution. Therefore, it does not directly support or refute the proposed interaction between antiplatelet therapy and alteplase.",
          "key_findings": "Early discontinuation of aspirin (median 16 days) with ticagrelor monotherapy after DES implantation in ACS patients was noninferior and statistically superior to 12 months of ticagrelor-based DAPT for a 1-year composite endpoint (all-cause death, MI, stent thrombosis, stroke, and major bleeding), driven mainly by reduced major bleeding (1.2% vs 3.4%). No data are presented on thrombolytic therapy or alteplase efficacy.",
          "pmid": "37878786",
          "title": "Stopping Aspirin Within 1 Month After Stenting for Ticagrelor Monotherapy in Acute Coronary Syndrome: The T-PASS Randomized Noninferiority Trial.",
          "analysis_method": "llm"
        }
      ]
    },
    {
      "feature_name": "antiplat_rand",
      "mechanism": {
        "mechanism_type": "biological",
        "description": "Observational data indicate a trend where patients on antiplatelet therapy have a higher rate of hemorrhagic complications, which could negate the benefits of thrombolytic therapy.",
        "evidence_level": "moderate"
      },
      "query": "(stroke OR alteplase OR thrombolysis OR \"ischemic stroke\") AND (antiplatelet OR aspirin OR clopidogrel OR \"platelet inhibition\") AND (\"pathophysiology\" OR \"mechanism\" OR \"causal\" OR \"etiology\" OR \"interaction\") AND (\"complications\" OR \"observational\" OR \"thrombolytic\") AND (Clinical Trial[PT] OR Review[PT] OR Meta-Analysis[PT])",
      "total_abstracts": 20,
      "support_count": 4,
      "conflict_count": 3,
      "neutral_count": 13,
      "support_percentage": 20.0,
      "conflict_percentage": 15.0,
      "support_ratio": 0.2,
      "abstracts_analyzed": [
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The mechanism is about antiplatelet therapy in patients receiving thrombolytic therapy and whether increased hemorrhagic complications could negate thrombolytic benefit. This trial studies dual versus single antiplatelet therapy in patients who explicitly did NOT undergo thrombolysis or thrombectomy. Although it shows that dual antiplatelet therapy increases moderate-to-severe bleeding while reducing recurrent stroke, it does not address patients on thrombolysis or whether bleeding risk negates thrombolytic benefits.",
          "key_findings": "In 6100 patients with mild ischemic stroke or high-risk TIA who had not undergone thrombolysis or thrombectomy, clopidogrel plus aspirin started within 72 hours reduced new stroke at 90 days (7.3% vs. 9.2%; HR 0.79, 95% CI 0.66\u20130.94) but increased moderate-to-severe bleeding (0.9% vs. 0.4%; HR 2.08, 95% CI 1.07\u20134.04). The study excluded thrombolysed patients and does not evaluate whether antiplatelet-associated bleeding offsets benefits of thrombolytic therapy.",
          "pmid": "38157499",
          "title": "Dual Antiplatelet Treatment up to 72 Hours after Ischemic Stroke.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract discusses antiplatelet therapy as standard secondary prevention in intracranial atherosclerotic stenosis and mentions uncertainty about the optimal duration and combination, but it does not report data on hemorrhagic complication rates, nor on how these might offset benefits of thrombolytic therapy. Therefore, it neither supports nor contradicts the proposed mechanism.",
          "key_findings": "Dual antiplatelet therapy followed by aspirin alone is the current secondary prevention strategy for ICAS; the optimal regimen is unclear and under investigation. The abstract does not mention hemorrhagic complications or outcomes specifically related to antiplatelet use in the context of thrombolytic therapy.",
          "pmid": "35143758",
          "title": "Intracranial atherosclerotic stenosis: risk factors, diagnosis, and treatment.",
          "analysis_method": "llm"
        },
        {
          "stance": "support",
          "confidence": "high",
          "reasoning": "The mechanism posits that antiplatelet therapy is associated with a higher rate of hemorrhagic complications that may negate benefits of thrombolytic/antithrombotic therapy. This trial directly compares more intensive antiplatelet therapy (ticagrelor + aspirin) versus aspirin alone and shows substantially higher major bleeding with dual therapy, without any reduction in ischemic outcomes. Thus, the added antiplatelet intensity increases hemorrhagic complications and negates net clinical benefit, aligning with the proposed mechanism.",
          "key_findings": "In 2201 post-CABG ACS patients, ticagrelor plus aspirin vs aspirin alone yielded: (1) similar rates of the primary ischemic composite (death, MI, stroke, repeat revascularization: 4.8% vs 4.6%; HR 1.06, 95% CI 0.72\u20131.56); (2) higher net adverse clinical events with dual therapy (9.1% vs 6.4%; HR 1.45, 95% CI 1.07\u20131.97); (3) markedly increased major bleeding with dual therapy (4.9% vs 2.0%; HR 2.50, 95% CI 1.52\u20134.11). These results show that intensified antiplatelet therapy increases hemorrhagic complications and worsens net outcomes without added ischemic benefit.",
          "pmid": "40888737",
          "title": "Ticagrelor and Aspirin or Aspirin Alone after Coronary Surgery for Acute Coronary Syndrome.",
          "analysis_method": "llm"
        },
        {
          "stance": "support",
          "confidence": "medium",
          "reasoning": "The proposed mechanism is that antiplatelet therapy is associated with higher rates of hemorrhagic complications, potentially offsetting benefits of other therapies. The abstract states that routine perioperative use of low-dose aspirin (an antiplatelet agent) does not decrease cardiovascular events but does increase surgical bleeding. This directly supports the component of the mechanism that antiplatelet therapy is linked to increased hemorrhagic (bleeding) complications, although it does not specifically address thrombolytic therapy or net benefit tradeoffs.",
          "key_findings": "Routine perioperative use of low-dose aspirin (100 mg/d) does not decrease cardiovascular events but does increase surgical bleeding.",
          "pmid": "32692391",
          "title": "Perioperative Cardiovascular Risk Assessment and Management for Noncardiac Surgery: A Review.",
          "analysis_method": "llm"
        },
        {
          "stance": "conflict",
          "confidence": "medium",
          "reasoning": "The proposed mechanism suggests that antiplatelet therapy is associated with higher hemorrhagic complications that could negate thrombolytic (or more generally antithrombotic) benefits. In this trial, dual antiplatelet therapy (DAPT) was compared with low-dose anticoagulation (DOAC) after LAA occlusion. DAPT showed a numerically higher rate of major bleeding (13.0% vs 4.6%) and a higher composite of safety/efficacy events (21.7% vs 4.5%). These data indicate that antiplatelet therapy here was not safer but instead associated with worse overall outcomes and at least a trend toward more major bleeding, contradicting the notion that antiplatelet therapy necessarily offers a favorable hemorrhagic profile that might negate thrombolytic/antithrombotic benefits.",
          "key_findings": "In 90 post-LAAO patients randomized to low-dose DOAC vs DAPT for 3 months, the primary composite safety/efficacy endpoint occurred less often with DOAC (4.5%) than with DAPT (21.7%; HR 0.19, 95% CI 0.04\u20130.88). Major bleeding was numerically lower with DOAC (4.6%) than with DAPT (13.0%; P=0.17). Device-related thrombosis was 0% in DOAC vs 8.7% in DAPT. There were no strokes or systemic emboli in either group.",
          "pmid": "39110427",
          "title": "Low-Dose Direct Oral Anticoagulation vs Dual Antiplatelet Therapy After Left Atrial Appendage Occlusion: The ADALA Randomized Clinical Trial.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract compares NOAC anticoagulants with aspirin for ESUS and reports no overall superiority of NOACs, but it does not report hemorrhagic complication rates or how antiplatelet therapy might affect bleeding risk or net benefit of thrombolysis. Thus it neither supports nor contradicts the specific mechanism about higher hemorrhagic complications on antiplatelet therapy negating thrombolytic benefits.",
          "key_findings": "In ESUS patients, large randomized trials found that dabigatran and rivaroxaban were not superior to aspirin for preventing secondary ischemic events overall, though some ESUS subgroups appeared to benefit more from anticoagulation or antiplatelet therapy. The abstract does not provide data on hemorrhagic complications or interaction with thrombolytic therapy.",
          "pmid": "35538232",
          "title": "Review and update of the concept of embolic stroke of undetermined source.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "medium",
          "reasoning": "The abstract compares aggressive medical management (which includes antiplatelet therapy) versus the same medical management plus stenting, and reports higher major haemorrhage rates in the stenting group. However, both arms receive antiplatelet therapy, and the trial does not isolate or compare outcomes based on antiplatelet use vs non-use, nor does it relate antiplatelet therapy specifically to hemorrhagic complications of thrombolytic therapy. Therefore it does not directly test or quantify the proposed mechanism.",
          "key_findings": "In high-risk patients with intracranial stenosis, aggressive medical management alone had fewer primary endpoint events than stenting plus medical therapy (15% vs 23%). Major hemorrhage occurred more often in the PTAS (stenting) group than in the medical group (13% vs 4%; p=0.0009). Both groups received aggressive medical management including antiplatelet therapy, so the abstract does not isolate the effect of antiplatelet therapy on hemorrhagic complications or its interaction with thrombolytic therapy.",
          "pmid": "24168957",
          "title": "Aggressive medical treatment with or without stenting in high-risk patients with intracranial artery stenosis (SAMMPRIS): the final results of a randomised trial.",
          "analysis_method": "llm"
        },
        {
          "stance": "support",
          "confidence": "high",
          "reasoning": "The abstract explicitly states that extended or prolonged dual antiplatelet therapy increases bleeding risk, including major hemorrhagic complications such as intracranial bleeding, and emphasizes the need to balance benefit with bleeding risk. This directly supports the mechanistic claim that antiplatelet therapy is associated with higher rates of hemorrhagic complications that can offset therapeutic benefit, consistent with the proposed mechanism, even though it is discussed in the context of secondary prevention rather than acute thrombolysis.",
          "key_findings": "1) The review notes that while short-term dual antiplatelet therapy (DAPT) is effective in preventing recurrent stroke, a more prolonged course 'can increase bleeding risks without additional benefit.' 2) It specifies the need to monitor for both minor (e.g., bruising) and major (e.g., intracranial) bleeding complications in patients on DAPT. 3) It highlights that direct oral anticoagulants may be preferred over warfarin due to decreased bleeding risks, including intracranial hemorrhage. 4) The authors conclude that clinicians must weigh each patient's bleeding risk against benefits when selecting antiplatelet/anticoagulant regimens, underscoring the clinically significant hemorrhagic risk from these therapies.",
          "pmid": "37037980",
          "title": "Contemporary Antiplatelet and Anticoagulant Therapies for Secondary Stroke Prevention: A Narrative Review of Current Literature and Guidelines.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The proposed mechanism concerns whether antiplatelet therapy increases hemorrhagic complications enough to negate thrombolytic benefit. This trial evaluates gastrointestinal bleeding risk and cardiovascular events in patients on dual antiplatelet therapy with or without a proton-pump inhibitor; it does not involve thrombolytic therapy, nor does it assess whether bleeding complications offset benefits of thrombolysis. Thus it neither supports nor contradicts the specific mechanism.",
          "key_findings": "In patients on aspirin plus clopidogrel, adding omeprazole reduced gastrointestinal events (1.1% vs 2.9%; HR 0.34, 95% CI 0.18\u20130.63) and overt upper GI bleeding (HR 0.13, 95% CI 0.03\u20130.56) without a significant difference in composite cardiovascular events (4.9% vs 5.7%; HR 0.99, 95% CI 0.68\u20131.44). No thrombolytic therapy or its benefit-risk balance was evaluated.",
          "pmid": "20925534",
          "title": "Clopidogrel with or without omeprazole in coronary artery disease.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract is a general primer on atrial fibrillation epidemiology, pathophysiology, and management. It does not mention antiplatelet therapy, hemorrhagic complications, or interactions with thrombolytic therapy, so it provides no direct evidence for or against the proposed mechanism.",
          "key_findings": "Describes atrial fibrillation as a common arrhythmia associated with increased stroke risk and outlines broad management strategies (stroke prevention, rate and rhythm control) without specific discussion of antiplatelet therapy\u2013related bleeding risks or thrombolysis outcomes.",
          "pmid": "27159789",
          "title": "Atrial fibrillation.",
          "analysis_method": "llm"
        },
        {
          "stance": "support",
          "confidence": "high",
          "reasoning": "The proposed mechanism suggests that antiplatelet-related bleeding risk could negate the benefits of thrombolytic therapy. In this trial, alteplase (thrombolytic) was compared with aspirin (antiplatelet) in minor nondisabling stroke. Alteplase did not improve functional outcomes compared with aspirin but did increase symptomatic intracranial hemorrhage. This directly supports the idea that hemorrhagic complications associated with thrombolytic therapy, in a context of antiplatelet comparison, can negate its net clinical benefit.",
          "key_findings": "In 313 patients with minor nondisabling ischemic stroke (NIHSS 0\u20135) treated within 3 hours, favorable 90-day functional outcome occurred in 78.2% of alteplase-treated vs 81.5% of aspirin-treated patients (adjusted risk difference \u22121.1%; 95% CI, \u22129.4% to 7.3%), showing no functional benefit of alteplase over aspirin. Symptomatic intracranial hemorrhage occurred in 3.2% (5/156) of alteplase patients vs 0% (0/157) of aspirin patients (risk difference 3.3%; 95% CI, 0.8%\u20137.4%). Thus, increased hemorrhagic complications with thrombolysis were observed without offsetting improvement in outcomes, indicating that bleeding risk can negate the benefit of thrombolytic therapy in this population.",
          "pmid": "29998337",
          "title": "Effect of Alteplase vs Aspirin on Functional Outcome for Patients With Acute Ischemic Stroke and Minor Nondisabling Neurologic Deficits: The PRISMS Randomized Clinical Trial.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract compares antiplatelet vs anticoagulant therapy for cervical artery dissection in terms of recurrent stroke, death, and arterial recanalization. It does not report on hemorrhagic complication rates or whether antiplatelet therapy increases hemorrhage enough to negate thrombolytic benefits, so it neither supports nor contradicts the proposed mechanism.",
          "key_findings": "In 250 patients with extracranial carotid/vertebral dissection, randomized to antiplatelet or anticoagulant therapy, recurrent stroke at 1 year was low (2.4% ITT) with no significant difference between groups and no difference in recanalization rates; hemorrhagic complications or interactions with thrombolytic therapy were not reported.",
          "pmid": "30801621",
          "title": "Antiplatelet Therapy vs Anticoagulation Therapy in Cervical Artery Dissection: The Cervical Artery Dissection in Stroke Study (CADISS) Randomized Clinical Trial Final Results.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract describes the design of a trial comparing rivaroxaban with aspirin after AF ablation and notes that major bleeding and intracranial hemorrhage are secondary outcomes, but it does not provide any results or observational data on hemorrhagic complication rates with antiplatelet therapy, nor does it assess whether such complications negate thrombolytic benefits.",
          "key_findings": "The OCEAN trial is an ongoing randomized, open-label trial comparing rivaroxaban 15 mg vs acetylsalicylic acid 75\u2013160 mg in post\u2013AF ablation patients with stroke risk factors, with a primary composite outcome of stroke/systemic embolism/covert stroke and key secondary outcomes including major bleeding and intracranial hemorrhage. No outcome data or comparative bleeding rates are reported in this abstract.",
          "pmid": "29447772",
          "title": "The Optimal Anti-Coagulation for Enhanced-Risk Patients Post-Catheter Ablation for Atrial Fibrillation (OCEAN) trial.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The proposed mechanism concerns hemorrhagic complications from antiplatelet therapy potentially negating benefits of thrombolytic therapy. The abstract compares apixaban (an anticoagulant) with aspirin (an antiplatelet) in subclinical atrial fibrillation, reporting stroke/embolism reduction and increased major bleeding with apixaban. It does not study thrombolytic therapy, nor does it assess hemorrhagic complications specifically attributable to antiplatelet therapy; instead, aspirin is the comparator and apixaban is the cause of increased bleeding. Thus it neither supports nor contradicts the specific mechanism.",
          "key_findings": "In ARTESiA, apixaban vs aspirin reduced stroke/systemic embolism but increased major bleeding across CHA2DS2-VASc strata. For CHA2DS2-VASc >4, apixaban prevented 1.28 strokes/SE and caused 0.68 major bleeds per 100 patient-years; for lower scores, net clinical benefit was smaller or unfavorable. These data relate to anticoagulation vs antiplatelet therapy, not to increased hemorrhagic complications from antiplatelet therapy negating thrombolytic benefit.",
          "pmid": "39019530",
          "title": "Apixaban vs Aspirin According to CHA<sub>2</sub>DS<sub>2</sub>-VASc Score in Subclinical Atrial\u00a0Fibrillation: Insights From ARTESiA.",
          "analysis_method": "llm"
        },
        {
          "stance": "conflict",
          "confidence": "high",
          "reasoning": "The proposed mechanism suggests that antiplatelet (or more broadly, antithrombotic) therapy is associated with higher hemorrhagic complications that could offset benefits. In this ICAD trial, adding low-dose rivaroxaban to aspirin (intensified antithrombotic therapy) resulted in no hemorrhagic strokes in either arm and was explicitly described as appearing safe without increased hemorrhagic stroke risk. Thus, within this studied context, the data contradict the expectation of increased hemorrhagic complications negating benefit.",
          "key_findings": "In 101 ICAD patients randomized to low-dose rivaroxaban plus aspirin versus aspirin alone and followed for a median of 20 months, there were no hemorrhagic strokes in either treatment arm. The investigators conclude that the combination therapy 'appears safe without an increased risk of hemorrhagic stroke,' with a numerical trend toward improved ischemic outcomes in the combination arm.",
          "pmid": "39781748",
          "title": "Combination Antithrombotic Therapy for Reduction of Recurrent Ischemic Stroke in Intracranial Atherosclerotic Disease.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract reports on pharmacological interventions for asymptomatic carotid stenosis and includes limited data on antiplatelet therapy (aspirin) and major bleeding, but it does not analyze hemorrhagic complications in the context of thrombolytic therapy or assess whether antiplatelet-related bleeding negates thrombolytic benefits. The proposed mechanism concerns interaction between antiplatelet therapy and thrombolysis, which is not addressed.",
          "key_findings": "In one RCT of acetylsalicylic acid versus placebo (372 participants), the effect on major bleeding was very uncertain (RR 0.98, 95% CI 0.06 to 15.53; very low-certainty evidence). The trial did not involve thrombolytic therapy, and no conclusions were drawn about how antiplatelet-related hemorrhagic complications might impact the benefits of thrombolysis.",
          "pmid": "37565307",
          "title": "Pharmacological interventions for asymptomatic carotid stenosis.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract discusses the role of antiplatelet and antithrombotic drugs in stroke prevention but does not address hemorrhagic complication rates, their interaction with thrombolytic therapy, or whether bleeding risk negates thrombolytic benefit.",
          "key_findings": "Antiplatelet agents (aspirin, aspirin/dipyridamole, clopidogrel) are recommended for secondary prevention in noncardioembolic ischemic stroke; warfarin is effective for cardioembolic stroke and several other indications. No data or statements are provided about hemorrhagic complications or their impact on thrombolytic therapy outcomes.",
          "pmid": "14579620",
          "title": "[Stroke prevention].",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract discusses sex differences in stroke etiology, presentation, treatment, and outcomes but does not mention antiplatelet therapy, hemorrhagic complications, or how prior antiplatelet use might modify risks or benefits of thrombolytic therapy. Therefore it neither supports nor conflicts with the proposed mechanism.",
          "key_findings": "Evidence for sex differences in stroke risk factors, pathophysiology, and treatment response is reviewed, with an emphasis on clinical and experimental data; no specific data on antiplatelet therapy or hemorrhagic complications in the context of thrombolysis are provided.",
          "pmid": "18810232",
          "title": "Sex differences in stroke.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract discusses indications for thrombolytic therapy and antithrombotic therapy in different stroke subtypes but does not provide any data or statements about hemorrhagic complication rates in patients on antiplatelet therapy, nor about how such complications might negate thrombolytic benefits.",
          "key_findings": "The abstract notes that alteplase is indicated for hyper-acute ischemic stroke within 3 hours, and that antiplatelet therapy is used for secondary prevention in non-cardioembolic stroke while anticoagulants are used for cardioembolic stroke. It does not quantify hemorrhagic risks associated with antiplatelet therapy or its interaction with thrombolytic therapy.",
          "pmid": "17087294",
          "title": "[Cerebral infarction].",
          "analysis_method": "llm"
        },
        {
          "stance": "conflict",
          "confidence": "medium",
          "reasoning": "The proposed mechanism suggests that antiplatelet therapy (e.g., aspirin) is associated with a higher rate of hemorrhagic complications that could negate benefits of thrombolytic/antithrombotic therapy. In this network meta-analysis of Fontan patients, aspirin, warfarin, and NOACs all reduced thromboembolic events compared with no thromboprophylaxis, and there were no statistically significant increases in major bleeding for any therapy versus no prophylaxis. This finding conflicts with the notion that antiplatelet therapy is clearly associated with higher hemorrhagic complication rates that would offset benefit, at least in this population.",
          "key_findings": "1) Compared with no thromboprophylaxis, aspirin (IRR 0.24; 95% CI 0.15\u20130.39), warfarin (IRR 0.23; 95% CI 0.14\u20130.37), and NOACs (IRR 0.11; 95% CI 0.03\u20130.40) significantly lowered thromboembolic events. 2) For major bleeding, there were no significant differences versus no thromboprophylaxis: aspirin IRR 0.72 (95% CI 0.20\u20132.58), warfarin IRR 1.38 (95% CI 0.41\u20134.69), NOAC IRR 1.45 (95% CI 0.28\u20137.43). 3) Aspirin was noted to tend toward the most favorable overall profile, implying benefit without a clear excess of major hemorrhage.",
          "pmid": "36697138",
          "title": "Thromboprophylaxis in Patients With\u00a0Fontan Circulation.",
          "analysis_method": "llm"
        }
      ]
    },
    {
      "feature_name": "antiplat_rand",
      "mechanism": {
        "mechanism_type": "biological",
        "description": "Clinical trials have shown variability in alteplase efficacy, with some evidence suggesting pre-treatment with antiplatelet agents might diminish expected therapeutic outcomes.",
        "evidence_level": "moderate"
      },
      "query": "(stroke OR alteplase OR thrombolysis OR \"ischemic stroke\") AND (antiplatelet OR aspirin OR clopidogrel OR \"platelet inhibition\") AND (\"pathophysiology\" OR \"mechanism\" OR \"causal\" OR \"etiology\" OR \"interaction\") AND (\"antiplatelet\" OR \"variability\" OR \"therapeutic\") AND (Clinical Trial[PT] OR Review[PT] OR Meta-Analysis[PT])",
      "total_abstracts": 20,
      "support_count": 0,
      "conflict_count": 0,
      "neutral_count": 20,
      "support_percentage": 0.0,
      "conflict_percentage": 0.0,
      "support_ratio": 0.0,
      "abstracts_analyzed": [
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The proposed mechanism concerns how pre-treatment with antiplatelet agents might alter the efficacy of alteplase (thrombolytic therapy). This trial explicitly excluded patients who had undergone thrombolysis or thrombectomy and evaluates dual antiplatelet therapy versus aspirin alone for prevention of recurrent stroke, not its interaction with alteplase efficacy. Therefore, it does not provide evidence for or against the specific effect of antiplatelet pre-treatment on alteplase outcomes.",
          "key_findings": "In patients with mild ischemic stroke or high-risk TIA who did NOT receive thrombolysis or thrombectomy, clopidogrel plus aspirin initiated within 72 hours reduced new stroke at 90 days compared with aspirin alone (7.3% vs 9.2%, HR 0.79) but increased moderate-to-severe bleeding (0.9% vs 0.4%, HR 2.08). No data are presented on alteplase use or how antiplatelet therapy modifies alteplase efficacy.",
          "pmid": "38157499",
          "title": "Dual Antiplatelet Treatment up to 72 Hours after Ischemic Stroke.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract reviews antiplatelet use for primary and secondary stroke prevention and discusses antiplatelet treatment failure, but it does not address alteplase (tPA) at all, nor does it examine how pre-treatment with antiplatelets might alter alteplase efficacy or outcomes. Therefore it neither supports nor contradicts the proposed mechanism.",
          "key_findings": "Evidence supports aspirin and clopidogrel for secondary stroke prevention; short-term dual antiplatelet therapy post-stroke reduces recurrence but long-term use increases hemorrhage risk; antiplatelet treatment failure is linked to poor adherence and genetic polymorphisms; potential differential benefits of cilostazol in certain racial groups; calls for personalized therapies based on platelet polymorphisms and more diverse trials. No mention of alteplase or interaction between antiplatelets and thrombolytic efficacy.",
          "pmid": "35094598",
          "title": "Antiplatelet Use in Ischemic Stroke.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract discusses intracranial atherosclerotic stenosis management, including use and optimization of dual antiplatelet therapy, but does not mention alteplase, thrombolysis, or how antiplatelet pretreatment might influence alteplase efficacy or outcomes. Therefore, it neither supports nor contradicts the proposed mechanism.",
          "key_findings": "Secondary stroke prevention for ICAS includes intensive risk factor management and dual antiplatelet therapy transitioning to aspirin alone; the optimal duration and combination of dual antiplatelet therapy is uncertain and under investigation. No data are provided on alteplase or on interactions between antiplatelet therapy and thrombolytic efficacy.",
          "pmid": "35143758",
          "title": "Intracranial atherosclerotic stenosis: risk factors, diagnosis, and treatment.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract compares tirofiban versus aspirin in ischemic stroke patients without large or medium vessel occlusion and includes subgroups with various relationships to thrombolysis, but it does not evaluate alteplase efficacy itself nor the impact of pre-treatment antiplatelet agents on alteplase outcomes. No data are presented on how antiplatelet use modifies alteplase response, so it neither supports nor contradicts the proposed mechanism.",
          "key_findings": "In a multicenter trial of 1177 patients with acute ischemic stroke and nonoccluded large/medium vessels, tirofiban for 2 days followed by aspirin was associated with a higher rate of excellent functional outcome at 90 days (mRS 0\u20131: 29.1% vs 22.2% with aspirin alone; adjusted RR 1.26, 95% CI 1.04\u20131.53, P=0.02). Symptomatic intracranial hemorrhage was 1.0% with tirofiban and 0% with aspirin; mortality was similar. Some enrolled patients had early neurologic deterioration after thrombolysis or lack of improvement after thrombolysis, but the study does not analyze whether pre-treatment with antiplatelet agents alters alteplase efficacy.",
          "pmid": "37256974",
          "title": "Tirofiban for Stroke without Large or Medium-Sized Vessel Occlusion.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The proposed mechanism concerns variability in alteplase efficacy potentially affected by pre-treatment with antiplatelet agents. This trial compares low-dose apixaban versus dual antiplatelet therapy after left atrial appendage occlusion and does not involve alteplase, its thrombolytic efficacy, or how prior antiplatelet therapy modifies alteplase response. While it addresses antithrombotic regimens, it does not test or comment on alteplase efficacy or platelet-related modulation of thrombolysis.",
          "key_findings": "In patients after LAAO, low-dose apixaban for 3 months reduced the composite primary endpoint (safety and efficacy) compared with dual antiplatelet therapy, driven by lower device-related thrombosis and a trend toward less major bleeding, with no difference in stroke or systemic embolism. No alteplase use or its interaction with antiplatelet pretreatment was studied.",
          "pmid": "39110427",
          "title": "Low-Dose Direct Oral Anticoagulation vs Dual Antiplatelet Therapy After Left Atrial Appendage Occlusion: The ADALA Randomized Clinical Trial.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract discusses anticoagulation (NOACs) versus aspirin for secondary prevention in embolic stroke of undetermined source and notes that NOACs were not superior overall, with some ESUS subgroups possibly benefiting from anticoagulation or antiplatelet therapy. It does not mention alteplase, thrombolysis, or any interaction between antiplatelet pretreatment and alteplase efficacy, so it neither supports nor contradicts the proposed mechanism.",
          "key_findings": "Two large RCTs in ESUS compared dabigatran or rivaroxaban with aspirin and found neither NOAC was superior to aspirin overall, though some ESUS subgroups appeared to benefit more from anticoagulation or antiplatelet therapy. The results prompted reassessment of the ESUS construct and its treatment strategies. No data are presented on alteplase or on how prior antiplatelet therapy affects alteplase outcomes.",
          "pmid": "35538232",
          "title": "Review and update of the concept of embolic stroke of undetermined source.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract evaluates aggressive medical management (which includes antiplatelet therapy) versus stenting for intracranial arterial stenosis, but it does not involve alteplase use, thrombolysis outcomes, or any interaction between antiplatelet pretreatment and alteplase efficacy. Therefore it neither supports nor contradicts the proposed mechanism about antiplatelet agents diminishing alteplase\u2019s therapeutic effect.",
          "key_findings": "Aggressive medical management (antiplatelet therapy plus risk factor control) resulted in fewer primary endpoint events and lower rates of any stroke and major hemorrhage compared with stenting in high-risk intracranial stenosis patients, over a median 32.4-month follow-up. Alteplase or thrombolytic therapy is not discussed.",
          "pmid": "24168957",
          "title": "Aggressive medical treatment with or without stenting in high-risk patients with intracranial artery stenosis (SAMMPRIS): the final results of a randomised trial.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The proposed mechanism concerns how pre-treatment with antiplatelet agents may alter the efficacy of alteplase (a thrombolytic). This trial evaluates efficacy and safety of dual antiplatelet therapy (clopidogrel plus aspirin) versus aspirin alone in mild ischemic stroke/TIA without involving alteplase use or its interaction with prior antiplatelet therapy. Therefore, it neither supports nor contradicts the specific mechanism about alteplase efficacy modulation.",
          "key_findings": "In 6100 patients with mild ischemic stroke/TIA randomized within 72 hours of symptom onset, dual antiplatelet therapy with clopidogrel plus aspirin reduced 90-day new stroke risk compared with aspirin alone, consistently across initiation windows (\u226424h, >24\u201348h, >48\u201372h), with a similar relative increase in moderate-to-severe bleeding across subgroups. Alteplase use or its efficacy was not evaluated.",
          "pmid": "39240565",
          "title": "Clopidogrel and Aspirin Initiated Between 24 to 72 Hours for Mild Ischemic Stroke: A Subgroup Analysis of the INSPIRES Randomized Clinical Trial.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The proposed mechanism concerns variability in alteplase efficacy and possible diminution of its therapeutic effect by prior antiplatelet therapy. This trial evaluates cardiovascular and gastrointestinal outcomes in patients on clopidogrel plus aspirin, with or without omeprazole, and does not involve alteplase use, thrombolytic efficacy, or how antiplatelet pre-treatment might alter alteplase outcomes. Therefore it neither supports nor contradicts the specific alteplase-related mechanism.",
          "key_findings": "In patients receiving dual antiplatelet therapy (aspirin + clopidogrel), addition of omeprazole reduced gastrointestinal events (HR 0.34; 95% CI 0.18\u20130.63) without an apparent increase in cardiovascular events (HR 0.99; 95% CI 0.68\u20131.44). The study does not assess alteplase or effects of antiplatelet pre-treatment on thrombolytic efficacy.",
          "pmid": "20925534",
          "title": "Clopidogrel with or without omeprazole in coronary artery disease.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract discusses antiplatelet and anticoagulant therapy for secondary stroke prevention, but does not address alteplase use, its efficacy, or how pre-treatment with antiplatelet agents might modify alteplase outcomes. Therefore it neither supports nor contradicts the proposed mechanism.",
          "key_findings": "Short-term dual antiplatelet therapy (aspirin with clopidogrel or ticagrelor) for 21\u201330 days is more effective than single antiplatelet therapy in minor non-cardioembolic stroke or high-risk TIA; longer DAPT increases bleeding without added benefit; DOACs are preferred over warfarin in non-valvular cardioembolic stroke due to lower bleeding risk. No data on alteplase interaction with antiplatelet pretreatment are provided.",
          "pmid": "37037980",
          "title": "Contemporary Antiplatelet and Anticoagulant Therapies for Secondary Stroke Prevention: A Narrative Review of Current Literature and Guidelines.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract compares intracranial stenting versus aggressive medical therapy for intracranial arterial stenosis and reports overall clinical outcomes (stroke and death). It does not mention alteplase use, thrombolysis, or the impact of antiplatelet pre-treatment on alteplase efficacy. Therefore, it neither supports nor contradicts the proposed mechanism about antiplatelet agents diminishing alteplase efficacy.",
          "key_findings": "Aggressive medical management alone was superior to PTAS with the Wingspan stent system for preventing stroke or death in patients with 70\u201399% intracranial arterial stenosis. The 30-day stroke or death rate was 14.7% in the PTAS group vs 5.8% in the medical-management group, and 1-year primary end point rates were 20.0% vs 12.2%, respectively. No data on alteplase or the interaction between antiplatelet therapy and alteplase efficacy are provided.",
          "pmid": "21899409",
          "title": "Stenting versus aggressive medical therapy for intracranial arterial stenosis.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The proposed mechanism concerns how pre-treatment with antiplatelet agents may alter alteplase efficacy. This trial compares alteplase to aspirin started at the time of stroke (not prior antiplatelet exposure) and does not analyze outcomes by prior antiplatelet use or its interaction with alteplase. Therefore, it does not address whether antecedent antiplatelet therapy diminishes alteplase\u2019s therapeutic effect.",
          "key_findings": "In patients with minor, nondisabling acute ischemic stroke (NIHSS 0\u20135) treated within 3 hours, alteplase showed no improvement in favorable 90-day functional outcome compared with aspirin (78.2% vs 81.5%; adjusted risk difference \u22121.1%, 95% CI \u22129.4% to 7.3%), but had higher symptomatic intracranial hemorrhage (3.2% vs 0%). Early trial termination limits definitive conclusions. No data are reported on pre-treatment with antiplatelet agents or its influence on alteplase efficacy.",
          "pmid": "29998337",
          "title": "Effect of Alteplase vs Aspirin on Functional Outcome for Patients With Acute Ischemic Stroke and Minor Nondisabling Neurologic Deficits: The PRISMS Randomized Clinical Trial.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The proposed mechanism concerns how pre-treatment with antiplatelet agents might alter the efficacy of alteplase (a thrombolytic). This trial compares two dual antiplatelet regimens (indobufen+clopidogrel vs aspirin+clopidogrel) after coronary stenting and reports ischemic and bleeding outcomes, but it does not involve alteplase use, thrombolytic therapy, or how prior antiplatelet exposure affects alteplase efficacy. Therefore, it neither supports nor contradicts the specific alteplase-focused mechanism.",
          "key_findings": "In patients with negative troponin undergoing drug-eluting stent implantation, indobufen+clopidogrel was noninferior (and statistically superior for the composite net clinical outcome) to aspirin+clopidogrel at 1 year, mainly by reducing BARC 2\u20135 bleeding without increasing ischemic events (cardiovascular death, MI, ischemic stroke, stent thrombosis). No data on alteplase or thrombolytic therapy were presented.",
          "pmid": "36335890",
          "title": "Indobufen or Aspirin on Top of Clopidogrel After Coronary Drug-Eluting Stent Implantation (OPTION): A Randomized, Open-Label, End Point-Blinded, Noninferiority Trial.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The study compares antiplatelet vs anticoagulant therapy in cervical artery dissection and finds no difference in stroke recurrence or recanalization, but it does not involve alteplase use, alteplase efficacy, or the impact of prior antiplatelet therapy on thrombolytic response. Therefore it neither supports nor contradicts the proposed mechanism about antiplatelet pre-treatment modifying alteplase outcomes.",
          "key_findings": "In 250 patients with extracranial carotid or vertebral artery dissection randomized to antiplatelet or anticoagulant therapy for 3 months, recurrent stroke at 1 year was low (~2.4\u20132.5%) with no significant difference between groups in clinical outcomes or arterial recanalization; the trial does not assess alteplase treatment or its interaction with antiplatelet agents.",
          "pmid": "30801621",
          "title": "Antiplatelet Therapy vs Anticoagulation Therapy in Cervical Artery Dissection: The Cervical Artery Dissection in Stroke Study (CADISS) Randomized Clinical Trial Final Results.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract compares long-term clopidogrel vs aspirin monotherapy after PCI and reports thrombotic and bleeding outcomes by bleeding risk and procedural complexity. It does not involve alteplase use, alteplase efficacy, or how prior antiplatelet therapy might modify alteplase\u2019s therapeutic effect. Therefore it neither supports nor contradicts the proposed mechanism regarding antiplatelet pre-treatment diminishing alteplase efficacy.",
          "key_findings": "In a post hoc analysis of the HOST-EXAM Extended trial (3974 patients post-PCI, event-free on DAPT for 6\u201318 months), clopidogrel monotherapy was associated with lower thrombotic and bleeding events compared with aspirin monotherapy, and these benefits were consistent irrespective of high bleeding risk status or PCI complexity.",
          "pmid": "39602157",
          "title": "Long-Term Aspirin vs Clopidogrel After Coronary Stenting by Bleeding Risk and Procedural Complexity.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract evaluates safety and preliminary efficacy of low-dose rivaroxaban plus aspirin versus aspirin alone for secondary prevention in intracranial atherosclerotic disease. It does not involve alteplase use, does not examine variability in alteplase efficacy, and does not assess how pre-treatment with antiplatelet agents might modify alteplase\u2019s therapeutic effect. Therefore it neither supports nor conflicts with the proposed mechanism.",
          "key_findings": "In a pilot RCT of 101 patients with recent ischemic stroke or TIA due to intracranial atherosclerotic disease, low-dose rivaroxaban plus aspirin was compared with aspirin alone. No hemorrhagic strokes occurred in either arm, and there was a non-significant numerical reduction in the composite outcome of ischemic stroke or covert brain infarct in the combination arm (15.7% vs 24.0%; HR 0.78, 95% CI 0.32\u20131.93, P=0.59). The study concluded that a larger phase III trial is feasible and that the combination appears safe without increased hemorrhagic stroke risk.",
          "pmid": "39781748",
          "title": "Combination Antithrombotic Therapy for Reduction of Recurrent Ischemic Stroke in Intracranial Atherosclerotic Disease.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract discusses antiplatelet agents for stroke prevention but does not mention alteplase, thrombolysis, or how prior antiplatelet therapy affects alteplase efficacy or outcomes. Therefore, it neither supports nor contradicts the proposed mechanism.",
          "key_findings": "Antiplatelet agents (aspirin, aspirin/dipyridamole, clopidogrel) are recommended for secondary prevention of noncardioembolic ischemic stroke; warfarin is used for various cardioembolic and other indications. No data are given on interaction between antiplatelet therapy and alteplase efficacy.",
          "pmid": "14579620",
          "title": "[Stroke prevention].",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract discusses aspirin and its drug-drug interactions in the context of stroke prevention, but does not mention alteplase, thrombolytic therapy, or how pre-treatment with antiplatelet agents might alter alteplase efficacy. It therefore neither supports nor contradicts the proposed mechanism about antiplatelet pre-treatment diminishing alteplase therapeutic outcomes.",
          "key_findings": "Low-dose aspirin is recommended for secondary prevention after non-cardioembolic ischemic stroke or TIA; certain NSAIDs can interfere with aspirin\u2019s antiplatelet effect via cyclooxygenase-1 competition; aspirin has limited clinically relevant pharmacokinetic drug-drug interactions; co-administration with SSRIs may produce synergistic platelet inhibition; aspirin remains a cornerstone in cerebrovascular disease management due to straightforward pharmacokinetics.",
          "pmid": "27765537",
          "title": "Aspirin, stroke and drug-drug interactions.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract evaluates the benefits and harms of chronic antiplatelet and anticoagulant therapy in patients with hypertension for prevention of cardiovascular events. It does not involve alteplase use, thrombolytic therapy, or the impact of prior antiplatelet exposure on alteplase efficacy or outcomes. Therefore, it neither supports nor contradicts the specific mechanism about antiplatelet pretreatment diminishing alteplase therapeutic effect.",
          "key_findings": "In hypertensive patients, acetylsalicylic acid (ASA) showed no effect on all-cause or cardiovascular mortality but reduced non-fatal and total cardiovascular events while increasing major bleeding risk; clopidogrel had different bleeding and event profiles compared with ASA; warfarin showed no mortality effect. No data were presented on alteplase or on how prior antiplatelet therapy modifies response to thrombolytic treatment.",
          "pmid": "35900898",
          "title": "Antiplatelet agents and anticoagulants for hypertension.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract discusses pediatric stroke management, noting lack of consensus on antiplatelet (aspirin) therapy and stating that thrombolysis with recombinant tissue plasminogen activator (alteplase) is not advised in children outside trials. It does not examine or report data on how pre-treatment with antiplatelet agents affects alteplase efficacy, nor on variability in alteplase outcomes. Thus it neither supports nor contradicts the proposed mechanism.",
          "key_findings": "1) Thrombolysis using recombinant tissue plasminogen activator is not advised in pediatric stroke outside clinical trials and guidelines provide no indication for its use in children. 2) Antithrombotic therapy is recommended, but there is no consensus on antiplatelet (aspirin) therapy regarding dose, use, or duration. 3) The recommendations are largely extrapolated from adult data and remain controversial, with no specific data on interactions between antiplatelet therapy and alteplase efficacy.",
          "pmid": "23129344",
          "title": "Therapy in pediatric stroke.",
          "analysis_method": "llm"
        }
      ]
    },
    {
      "feature_name": "stroke type",
      "mechanism": {
        "mechanism_type": "biological",
        "description": "Gender-specific differences in platelet reactivity and coagulation cascades may alter the responsiveness to thrombolytic therapy.",
        "evidence_level": "moderate"
      },
      "query": "(stroke OR alteplase OR thrombolysis OR \"ischemic stroke\") AND \"stroke type\" AND (\"pathophysiology\" OR \"mechanism\" OR \"causal\" OR \"etiology\" OR \"interaction\") AND (\"responsiveness\" OR \"thrombolytic\" OR \"differences\") AND (Clinical Trial[PT] OR Review[PT] OR Meta-Analysis[PT])",
      "total_abstracts": 15,
      "support_count": 0,
      "conflict_count": 0,
      "neutral_count": 15,
      "support_percentage": 0.0,
      "conflict_percentage": 0.0,
      "support_ratio": 0.0,
      "abstracts_analyzed": [
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract compares rESWT and TENS for post-stroke upper limb spasticity and reports overall outcomes, including stratification by gender in the sample description, but it does not analyze or report any gender-specific differences in treatment response, platelet reactivity, or coagulation, nor does it involve thrombolytic therapy. Thus it neither supports nor contradicts the proposed mechanism.",
          "key_findings": "Randomized controlled trial of 106 chronic post-stroke patients (62 males, 44 females) comparing rESWT vs TENS for upper limb spasticity. rESWT showed greater reductions in spasticity and better improvements in voluntary control and hand function than TENS at 4 weeks. No data or subgroup analysis on gender-specific differences in response, no measures of platelet function or coagulation, and no use of thrombolytic therapy.",
          "pmid": "37235581",
          "title": "The effectiveness of radial extracorporeal shock wave therapy vs transcutaneous electrical nerve stimulation in the management of upper limb spasticity in chronic-post stroke hemiplegia-A randomized controlled trial.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract analyzes clinical symptoms and signs that differentiate ischemic from hemorrhagic stroke, without examining platelet reactivity, coagulation cascades, sex/gender differences, or responsiveness to thrombolytic therapy. Therefore it neither supports nor contradicts the proposed gender-specific biological mechanism.",
          "key_findings": "Systematic review of 60 studies (n\u224812.9 million) identified presenting features with higher odds of hemorrhagic vs ischemic stroke (e.g., coma, neck stiffness, low GCS, vomiting, altered consciousness, headache, syncope, seizure, abnormal plantar response, vertigo/dizziness) and features with lower odds of hemorrhagic stroke (morning onset, facial weakness, hemiplegia, ataxia). Mean age and proportion of women are reported, but no sex-stratified analyses or thrombolytic response data are provided.",
          "pmid": "40759192",
          "title": "Discrimination of ischemic versus hemorrhagic stroke type by presenting symptoms or signs: A systematic review and meta-analysis.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract focuses on apathy after stroke, its prevalence, and associated factors such as age, depression, and cognitive impairment. It notes no gender differences in apathy rates, but does not examine platelet reactivity, coagulation cascades, thrombolytic therapy, or treatment responsiveness by sex. Therefore, it neither supports nor conflicts with the proposed mechanism about gender-specific differences in thrombolytic responsiveness.",
          "key_findings": "Apathy after stroke has a pooled rate of 36.3%; it is more common in older patients and is associated with higher rates and severity of depression and cognitive impairment. No gender differences in apathy were found. The study does not evaluate thrombolytic therapy, platelet function, or coagulation-related treatment response.",
          "pmid": "23428994",
          "title": "Apathy secondary to stroke: a systematic review and meta-analysis.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract examines prevalence and risk factors for post-stroke delirium and notes that female percentage in samples had no significant effect on delirium prevalence, but it does not investigate platelet reactivity, coagulation cascades, or responsiveness to thrombolytic therapy, nor gender-specific biological mechanisms related to these. Thus it neither supports nor contradicts the proposed mechanism.",
          "key_findings": "Overall post-stroke delirium prevalence in acute settings was 25%; prevalence increased with age and varied by assessment duration, initial screening, and involvement of nurses. Meta-regression found higher delirium prevalence associated with increased age. No significant effects were detected for female percentage, economic status, publication year, onset-to-admission time, stroke type, or assessment frequency.",
          "pmid": "38552472",
          "title": "Prevalence of post-stroke delirium in acute settings: A systematic review and meta-analysis.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract compares endovascular therapy plus conventional medical treatment versus conventional medical treatment alone for symptomatic intracranial artery stenosis and reports overall clinical outcomes (stroke, death, TIA). It does not analyze or stratify results by gender, nor does it evaluate platelet reactivity or coagulation cascade differences, nor responsiveness to thrombolytic therapy. Therefore it neither supports nor contradicts the proposed gender-specific biological mechanism.",
          "key_findings": "Endovascular therapy plus conventional medical treatment was associated with higher rates of 30-day and one-year death or stroke, and higher rates of ipsilateral, ischemic, and hemorrhagic stroke compared with conventional medical treatment alone. No data were presented on sex-specific responses, platelet function, coagulation differences, or thrombolytic therapy responsiveness.",
          "pmid": "32789891",
          "title": "Endovascular therapy versus medical treatment for symptomatic intracranial artery stenosis.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract studies repetitive transcranial magnetic stimulation for post-stroke upper limb spasticity and its effects on motor function and nerve excitability. It does not measure or discuss platelet reactivity, coagulation cascades, gender differences, or thrombolytic therapy responsiveness, so it neither supports nor contradicts the proposed mechanism.",
          "key_findings": "rTMS plus conventional rehabilitation reduced upper limb spasticity (lower MAS scores) and improved motor function (higher FM-UE scores) compared to sham; subgroup analyses by stroke type showed no significant differences, and the authors attribute this to small intracerebral hemorrhage sample size.",
          "pmid": "40399427",
          "title": "Clinical efficacy observation of repetitive magnetic stimulation for treating upper limb spasticity after stroke.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract discusses ethnic (black-white) differences in stroke frequency, stroke subtypes, risk factors, and possible roles of genetics, lifestyle, and access to care. It does not address gender, platelet reactivity, coagulation cascades, or responsiveness to thrombolytic therapy, so it neither supports nor contradicts the proposed gender-specific biological mechanism.",
          "key_findings": "Blacks have a disproportionately higher burden of strokes than whites; hypertension is more common in blacks; stroke types differ between blacks and whites (whites: more large-vessel and embolic strokes; blacks: more small-vessel and hemorrhagic strokes); potential roles of access to care, treatment compliance, and genetic differences in drug responsiveness are mentioned but not specified for thrombolytics or gender.",
          "pmid": "7800109",
          "title": "Black-white differences in stroke frequency: challenges for research.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract compares stroke types, diabetes prevalence, and prognosis between Chinese and non-Chinese Canadians with type 2 diabetes. It does not examine gender-specific biology, platelet reactivity, coagulation cascades, or responsiveness to thrombolytic therapy, nor does it report sex-stratified treatment response outcomes. Therefore it neither supports nor contradicts the proposed gender-specific thrombolytic response mechanism.",
          "key_findings": "Chinese Canadians with stroke had a higher frequency of diabetes than non-Chinese Canadians; Chinese Canadians with diabetes were more likely to have lacunar (small vessel) stroke and intracranial small vessel disease; stroke risk factor prevalence and stroke types differed between Chinese and non-Chinese Canadians, with a trend toward poorer prognosis in high-risk Chinese Canadians.",
          "pmid": "28549667",
          "title": "Epidemiology of Cerebrovascular Disease Among Chinese Canadian Adults With Type 2 Diabetes.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract evaluates blood pressure manipulation after stroke and its impact on mortality and neurological deterioration but does not analyze or report any gender-specific differences, platelet reactivity, coagulation parameters, or responsiveness to thrombolytic therapy. Therefore it neither supports nor contradicts the proposed mechanism about sex-related differences in thrombolytic responsiveness.",
          "key_findings": "In acute stroke patients, active BP-lowering treatment with lisinopril or labetalol reduced blood pressure more than placebo without increasing early neurological deterioration; no significant difference in death or dependency at 2 weeks; possible lower 3\u2011month mortality with active treatment (p = 0.05). The study did not address gender differences, platelet/coagulation biology, or thrombolytic therapy response.",
          "pmid": "19208305",
          "title": "Controlling hypertension and hypotension immediately post stroke (CHHIPS)--a randomised controlled trial.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract evaluates robot-assisted gait training versus conventional physical therapy in subacute hemiparetic stroke patients and reports outcomes on gait independence. It does not assess thrombolytic therapy, platelet reactivity, coagulation pathways, or gender-specific differences, so it provides no direct evidence for or against the proposed mechanism.",
          "key_findings": "Robot-assisted gait training with Welwalk plus conventional physical therapy was not significantly more effective than conventional physical therapy alone for achieving gait independence in subacute hemiparetic stroke patients. A non-significant trend toward earlier gait independence was observed in patients with cerebral infarction. No measurements or analyses related to thrombolytic therapy, platelet function, coagulation cascades, or gender-specific responses were reported.",
          "pmid": "38745235",
          "title": "Effects of robot-assisted gait training using the Welwalk on gait independence for individuals with hemiparetic stroke: an assessor-blinded, multicenter randomized controlled trial.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract discusses nitric oxide\u2019s dual roles in stroke pathophysiology, vasodilation, anti-thrombotic effects, and timing/concentration-dependent outcomes of NO-donor therapy, but it does not mention gender/sex differences, platelet reactivity by gender, coagulation differences by gender, or gender-specific responsiveness to thrombolytic therapy.",
          "key_findings": "Nitric oxide and its donors have neuroprotective vasodilatory and anti-thrombotic effects as well as potential neurotoxic effects depending on concentration, timing, and source; NO-based interventions\u2019 efficacy varies by stroke type and timing; optimal timing and dosing of NO donors remain unclear; clinical translation is limited and more trials are needed. No sex- or gender-specific platelet or coagulation data, nor effects on thrombolytic responsiveness by gender, are reported.",
          "pmid": "41496301",
          "title": "Therapeutic potential of nitric oxide and its donors in hemorrhagic and ischemic stroke: a systematic review.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract investigates citicoline\u2019s effects on post-stroke cognitive outcomes and safety but does not evaluate thrombolytic therapy, platelet reactivity, or coagulation differences by gender. There is no analysis of sex-specific treatment response, nor any mechanistic data regarding platelet or coagulation pathways, so it neither supports nor contradicts the proposed mechanism.",
          "key_findings": "Citicoline (1 g/day for 12 months) after first-ever ischemic stroke was associated with improved attention-executive function and temporal orientation compared with controls, with similar safety profiles between groups. Patients were randomized by gender, but no gender-stratified results or measurements of platelet function, coagulation, or thrombolytic responsiveness were reported.",
          "pmid": "23406981",
          "title": "Long-term treatment with citicoline may improve poststroke vascular cognitive impairment.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract concerns stroke rehabilitation using tDCS and robot-assisted therapy and examines effect modification by stroke duration and stroke type. It does not assess thrombolytic therapy, platelet reactivity, coagulation cascades, or gender-specific differences. Therefore, it neither supports nor contradicts the proposed mechanism.",
          "key_findings": "The study found that both real and sham tDCS groups improved in upper extremity motor function, and that stroke duration (acute vs. chronic) and stroke type (cortical vs. subcortical) modified the effect of tDCS plus robotics. No data were presented regarding thrombolysis, platelet function, coagulation, or gender-related differences.",
          "pmid": "27123448",
          "title": "tDCS and Robotics on Upper Limb Stroke Rehabilitation: Effect Modification by Stroke Duration and Type of Stroke.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract discusses insulin resistance syndrome in children, its cardiovascular risk factors, obesity, inflammation, and potential lifestyle interventions. It does not mention platelet reactivity, coagulation cascades, thrombolytic therapy, or gender-specific differences in these processes, so it neither supports nor contradicts the proposed mechanism.",
          "key_findings": "Insulin resistance syndrome in children is associated with obesity (particularly visceral fat), impaired glucose metabolism, hypertension, dyslipidemia, inflammatory factors, oxidative stress, ethnic differences, familial factors, and is linked to future cardiovascular disease and type 2 diabetes. No data are presented regarding platelets, coagulation, gender differences in hemostasis, or thrombolytic responsiveness.",
          "pmid": "16489322",
          "title": "Insulin resistance (metabolic) syndrome in children.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract evaluates nortriptyline for poststroke generalized anxiety disorder and depression, focusing on psychiatric outcomes and functional status. It does not mention platelet reactivity, coagulation cascades, thrombolytic therapy, or gender-specific differences in these biological pathways. Therefore, it neither supports nor contradicts the proposed mechanism.",
          "key_findings": "Nortriptyline treatment in poststroke patients with comorbid generalized anxiety disorder and depression led to significantly greater improvement in anxiety (Ham-A), depression (Ham-D), and activities of daily living (JHFI) compared to placebo, with anxiety symptoms improving earlier than depressive symptoms.",
          "pmid": "12724111",
          "title": "Treatment of poststroke generalized anxiety disorder comorbid with poststroke depression: merged analysis of nortriptyline trials.",
          "analysis_method": "llm"
        }
      ]
    },
    {
      "feature_name": "stroke type",
      "mechanism": {
        "mechanism_type": "biological",
        "description": "Previous studies have identified sex-specific responses to pharmacologic interventions, suggesting biological variability that could influence outcomes.",
        "evidence_level": "moderate"
      },
      "query": "(stroke OR alteplase OR thrombolysis OR \"ischemic stroke\") AND \"stroke type\" AND (\"pathophysiology\" OR \"mechanism\" OR \"causal\" OR \"etiology\" OR \"interaction\") AND (\"pharmacologic\" OR \"interventions\" OR \"variability\") AND (Clinical Trial[PT] OR Review[PT] OR Meta-Analysis[PT])",
      "total_abstracts": 9,
      "support_count": 0,
      "conflict_count": 1,
      "neutral_count": 8,
      "support_percentage": 0.0,
      "conflict_percentage": 11.11111111111111,
      "support_ratio": 0.0,
      "abstracts_analyzed": [
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract discusses maternal obesity and its impact on offspring health and mechanisms such as epigenetic changes and gut microbiome alterations, but it does not address sex-specific differences in pharmacologic responses or biological variability by sex in treatment outcomes. Therefore, it neither supports nor contradicts the proposed mechanism about sex-specific pharmacologic responses.",
          "key_findings": "Maternal obesity is linked to increased risks in offspring for obesity, cardiovascular disease, type 2 diabetes, asthma, poorer cognitive performance, neurodevelopmental disorders, and possibly immune/infectious outcomes. Experimental data suggest causal effects mediated in part by epigenetic changes and gut microbiome alterations, and weight loss before pregnancy reduces offspring obesity risk. No sex-specific or pharmacologic response data are described.",
          "pmid": "27743978",
          "title": "Influence of maternal obesity on the long-term health of offspring.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract evaluates sensory-based rehabilitation after stroke and its effect on sensation and sensorimotor function, but it does not analyze or report sex-specific responses or biological variability by sex to these interventions. Therefore, it neither supports nor contradicts the proposed mechanism about sex-specific pharmacologic responses.",
          "key_findings": "The systematic review and meta-analysis of 38 RCTs (n=1,093) found moderate evidence that passive sensory training improves upper and lower limb activity and some support for effects on sensory impairment and motor function after stroke, while evidence for active sensory training remains limited. No sex-stratified analyses or sex-related differential responses are mentioned.",
          "pmid": "31114472",
          "title": "Does Sensory Retraining Improve Sensation and Sensorimotor Function Following Stroke: A Systematic Review and Meta-Analysis.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The proposed mechanism concerns sex-specific biological responses to pharmacologic interventions. The abstract, while mentioning female-specific risk factors for cerebral venous thrombosis, does not present data on sex-differentiated responses to anticoagulation or other pharmacologic treatments, nor does it analyze outcomes by sex. Therefore, it neither supports nor contradicts the specific mechanism.",
          "key_findings": "The review notes that CVT risk factors include female-specific conditions and discusses the effectiveness of anticoagulation therapy and endovascular interventions in general, but it does not evaluate treatment responses or outcomes separately by sex.",
          "pmid": "40923133",
          "title": "Cerebral Venous Thrombosis:Current Status and Challenges.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract examines prevalence and predictors of post-stroke delirium, including age, assessment duration, and involvement of nurses, but does not evaluate sex-specific responses to pharmacologic interventions or any sex-based biological variability in treatment effects. It reports that female percentage had no significant effect on delirium prevalence, but this is an observational prevalence association, not a test of sex-specific pharmacologic response, so it neither supports nor contradicts the proposed mechanism.",
          "key_findings": "Overall post-stroke delirium prevalence in acute settings was 25%. Delirium prevalence increased with age and varied by assessment duration and involvement of nurses. Meta-regression showed a borderline association between higher age and higher delirium prevalence. No significant effects were detected for female percentage or other factors, but no pharmacologic interventions or sex-specific treatment responses were analyzed.",
          "pmid": "38552472",
          "title": "Prevalence of post-stroke delirium in acute settings: A systematic review and meta-analysis.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The proposed mechanism concerns sex-specific (male vs female) differences in pharmacologic responses, whereas the abstract discusses ethnic (black vs white) differences in stroke frequency and possible contributors such as hypertension prevalence, access to care, lifestyle, socioeconomic factors, and potential genetic differences, including responsiveness to certain drugs. It does not analyze or present data on sex-specific pharmacologic responses, so it neither supports nor conflicts with the specific mechanism.",
          "key_findings": "The abstract reports that blacks have a higher burden of stroke than whites and different distributions of stroke subtypes. It reviews possible explanations, including higher prevalence of hypertension, unclear roles of access to care, treatment compliance, lifestyle and socioeconomic factors, and genetic differences including responsiveness to certain drugs, but does not address sex-specific pharmacologic effects.",
          "pmid": "7800109",
          "title": "Black-white differences in stroke frequency: challenges for research.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The proposed mechanism concerns sex-specific biological responses to pharmacologic interventions. This trial reports overall effects and safety of acute blood pressure manipulation after stroke but does not mention patient sex, conduct sex-stratified analyses, or discuss sex-related variability in treatment response. Therefore, it neither supports nor contradicts sex-specific pharmacologic responses.",
          "key_findings": "In acute stroke patients, active BP-lowering treatment with lisinopril or labetalol versus placebo produced greater BP reductions at 24 hours and 2 weeks without increasing early neurological deterioration or 2-week death/dependency; there was a lower 3\u2011month mortality in the active treatment group (p = 0.05). The pressor arm was under-recruited, and the study was underpowered for the primary endpoint. No sex-specific analyses or outcomes were reported.",
          "pmid": "19208305",
          "title": "Controlling hypertension and hypotension immediately post stroke (CHHIPS)--a randomised controlled trial.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract discusses nitric oxide\u2019s dual neuroprotective/neurotoxic roles and timing/concentration-dependent effects in stroke, but it does not examine or compare responses by sex, nor mention sex-specific pharmacologic responses or biological variability between males and females. Therefore it neither supports nor contradicts the proposed sex-specific response mechanism.",
          "key_findings": "Nitric oxide has dual roles in stroke pathophysiology (neuroprotective via vasodilation/anti-thrombotic effects and neurotoxic via oxidative stress and excitotoxicity), with efficacy of NO-based interventions depending on concentration, timing, source, stroke subtype, and temporal dynamics after stroke onset. The review highlights limited clinical translation, need for optimization of timing and dosing, and lack of large-scale clinical data, but does not address sex differences or sex-specific outcomes.",
          "pmid": "41496301",
          "title": "Therapeutic potential of nitric oxide and its donors in hemorrhagic and ischemic stroke: a systematic review.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract discusses pharmacologic treatments for obesity and summarizes that it reviews recent clinical trials and future directions, but it does not mention sex-specific responses, biological sex differences, or differential outcomes by sex for any pharmacologic interventions.",
          "key_findings": "The abstract notes that several obesity medications (phentermine/topiramate ER, lorcaserin, naltrexone SR/bupropion SR, liraglutide 3.0 mg) have been approved and that recent literature and clinical trials in obesity pharmacotherapy are reviewed, including agents that promote weight loss and reduce cardiovascular mortality; however, it provides no data or statements about sex-specific variability in responses.",
          "pmid": "27181165",
          "title": "Pharmacologic Approaches to Weight Management: Recent Gains and Shortfalls in Combating Obesity.",
          "analysis_method": "llm"
        },
        {
          "stance": "conflict",
          "confidence": "medium",
          "reasoning": "The proposed mechanism posits sex-specific variability in response to pharmacologic interventions. While this study is not pharmacologic, it directly tests whether presence of incomplete bladder emptying after stroke is related to sex and finds no association. This provides evidence against sex-based biological variability in this specific post-stroke urinary outcome, which conflicts with the suggested broad mechanism of sex-specific treatment-related differences, at least in this context.",
          "key_findings": "In this cohort of acute stroke inpatients, the presence of incomplete bladder emptying (IBE) was not related to sex (P > 0.05), nor to diabetes, stroke type, or stroke location. Electroacupuncture treatment improved spontaneous voiding volume and decreased postvoid residual urine volume in patients with IBE, but no sex-specific differences in response were reported.",
          "pmid": "23152677",
          "title": "Effects of electroacupuncture on recent stroke inpatients with incomplete bladder emptying: a preliminary study.",
          "analysis_method": "llm"
        }
      ]
    },
    {
      "feature_name": "stroke type",
      "mechanism": {
        "mechanism_type": "biological",
        "description": "Stroke type categorization is often associated with the anatomical location and underlying vascular pathophysiology, which may differ in women due to hormonal or genetic factors.",
        "evidence_level": "moderate"
      },
      "query": "(stroke OR alteplase OR thrombolysis OR \"ischemic stroke\") AND \"stroke type\" AND (\"pathophysiology\" OR \"mechanism\" OR \"causal\" OR \"etiology\" OR \"interaction\") AND (\"pathophysiology\" OR \"categorization\" OR \"anatomical\") AND (Clinical Trial[PT] OR Review[PT] OR Meta-Analysis[PT])",
      "total_abstracts": 3,
      "support_count": 0,
      "conflict_count": 0,
      "neutral_count": 3,
      "support_percentage": 0.0,
      "conflict_percentage": 0.0,
      "support_ratio": 0.0,
      "abstracts_analyzed": [
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract discusses stroke pathophysiology, stroke type (ischemic vs hemorrhagic), risk factors, and management in the context of sickle cell disease, but it does not address sex-specific differences, hormonal or genetic sex-related factors, or how stroke type categorization might differ between women and men. Therefore it neither supports nor contradicts the proposed mechanism about sex-related differences in stroke type categorization.",
          "key_findings": "The review reports that sickle cell disease alters red blood cells, leading to vascular obstruction, altered cerebral blood flow, and vessel wall damage, resulting in ischemic and hemorrhagic strokes, more common in childhood with ischemic stroke predominance. It identifies risk factors such as prior TIA, low hemoglobin, and high leukocyte count, and emphasizes neuroimaging for stroke type determination and blood transfusions/hydroxyurea for primary prevention. No sex- or gender-specific analyses or hormonal/genetic sex differences are mentioned.",
          "pmid": "38107212",
          "title": "Overview of the Association Between the Pathophysiology, Types, and Management of Sickle Cell Disease and Stroke.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract discusses microRNAs as diagnostic and therapeutic tools in ischemic stroke and their roles in various stroke-related pathophysiologic processes, but it does not address sex differences, hormonal or genetic sex-specific factors, nor stroke type categorization by anatomical location or vascular pathophysiology in women versus men.",
          "key_findings": "miRNAs are implicated in ischemic stroke risk factors (hypertension, metabolic disorders, atherosclerosis) and in processes such as excitotoxicity, oxidative stress, inflammation, apoptosis, angiogenesis, neurogenesis, and Alzheimer\u2019s disease. miRNAs may serve as biomarkers to identify stroke type and evaluate severity of brain injury, but no mention is made of sex-specific differences or female-specific hormonal/genetic influences on stroke type categorization.",
          "pmid": "32937836",
          "title": "Can miRNAs Be Considered as Diagnostic and Therapeutic Molecules in Ischemic Stroke Pathogenesis?-Current Status.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract discusses nitric oxide\u2019s dual roles and therapeutic potential in different stroke subtypes (hemorrhagic vs ischemic) and timing-related pathophysiology, but it does not address sex-based differences, hormonal or genetic factors, or how stroke type categorization may differ in women. Thus it does not provide evidence for or against the proposed sex-specific mechanistic variation in stroke type categorization.",
          "key_findings": "Nitric oxide acts as both neuroprotective (via vasodilation and anti-thrombotic effects) and neurotoxic (via oxidative stress and glutamate excitotoxicity) in stroke, depending on concentration, timing, and source. The efficacy of NO-based interventions varies by stroke type (hemorrhagic vs ischemic, including subarachnoid and intracerebral hemorrhage) and timing of administration. The review highlights the need to optimize timing and dosing of NO donors for different stroke subtypes and notes limited clinical translation, but does not mention sex, hormonal, or genetic differences.",
          "pmid": "41496301",
          "title": "Therapeutic potential of nitric oxide and its donors in hemorrhagic and ischemic stroke: a systematic review.",
          "analysis_method": "llm"
        }
      ]
    }
  ]
}